



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
G01N 33/68, 33/53, C07K 16/00, C12N
15/11, 15/12, 15/00, 15/63, A61K 38/17,
38/16, C12P 21/02

A1

(11) International Publication Number: **WO 99/22243**
(43) International Publication Date: 6 May 1999 (06.05.99)

(21) International Application Number: PCT/US98/22376
(22) International Filing Date: 23 October 1998 (23.10.98)

(30) Priority Data:

60/063,099 24 October 1997 (24.10.97) US
60/063,088 24 October 1997 (24.10.97) US
60/063,100 24 October 1997 (24.10.97) US
60/063,387 24 October 1997 (24.10.97) US
60/063,148 24 October 1997 (24.10.97) US
60/063,386 24 October 1997 (24.10.97) US
60/062,784 24 October 1997 (24.10.97) US
60/063,091 24 October 1997 (24.10.97) US
60/063,090 24 October 1997 (24.10.97) US
60/063,089 24 October 1997 (24.10.97) US
60/063,092 24 October 1997 (24.10.97) US
60/063,111 24 October 1997 (24.10.97) US
60/063,101 24 October 1997 (24.10.97) US
60/063,109 24 October 1997 (24.10.97) US
60/063,110 24 October 1997 (24.10.97) US
60/063,098 24 October 1997 (24.10.97) US
60/063,097 24 October 1997 (24.10.97) US

(71) Applicant (for all designated States except US): HUMAN
GENOME SCIENCES, INC. (USUS); 9410 Key West
Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(72) Inventors; and
(72) Applicants (for US only): FENG, Ping (CNUS); 4
Reid Court, Gaithersburg, MD 20878 (US); ROSEN, Craig,
A. (USUS); 2240 Rolling Hill Road, Laytonville, MD
20882 (US); RUBEN, Steven, M. (USUS); 18328 Heritage
Hills Drive, Olney, MD 20832 (US); NI, Jian (CNUS);
5502 Manofield Road, Rockville, MD 20853 (US); WEI,
Ying-Pei (CNUS); 1714-C Marina Court, San Mateo, CA
94403 (US); SOPPET, Daniel, R. (USUS); 15050 Still-
field Place, Centerville, VA 22020 (US); MOORE, Paul,
A. (GBUS); 19055 Leatherbark Drive, Germantown, MD
20874 (US); KATYV, Hla (MMUS); 520 Sugarbush Cir-
cle, Frederick, MD 21703 (US); LAFLURE, David, W.,
(USUS); 3142 Quenada Street, N.W., Washington, DC
20015 (US); OLSEN, Henrik, S. (DKUS); 182 Kandtek

Place #24, Gaithersburg, MD 20878 (US); BREWER, Lau-
rie, A. (USUS); Apartment 115, 410 Van Dye Street, St.
Paul, MN 55119-4321 (US); SHI, Yanguo (CNUS); Apart-
ment 102, 437 West Side Drive, Gaithersburg, MD 20878
(US); EBNER, Reinhard (DEUS); 9905 Shelburne Ter-
race #316, Gaithersburg, MD 20878 (US); YOUNG, Paul
(USUS); 122 Beckwith Street, Gaithersburg, MD 20878
(US); GREENE, John, M. (USUS); 872 Diamond Drive,
Gaithersburg, MD 20878 (US); FLORENCE, Kimberly, A.
(USUS); 12805 Atlantic Avenue, Rockville, MD 20851
(US); FLORENCE, Charles (USUS); 12805 Atlantic Av-
enue, Rockville, MD 20851 (US); DUAN, D., Roxanne
(USUS); 5315 Northfield Road, Bethesda, MD 20817 (US);
JANAT, Fouad (USUS); 140 High Street #202, Westbury,
RI 02891 (US); ENDRESS, Gregory, A. (USUS); 9729
Cragg Farm Drive, Potomac, MD 20854 (US); CARTER,
Kenneth, C. (USUS); 11601 Brandy Hall Lane, North Po-
tomac, MD 20878 (US).

(74) Agents: BROOKES, A., Anders et al.; Human Genome
Sciences, Inc., 9410 Key West Avenue, Rockville, MD
20850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,
GE, GH, GM, GR, HU, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TH, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW,
ARPO patent (GM, AM, AZ, BY, BG, CZ, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN,
TD, TG).

Published

With an indication in relation to deposited biological
material, furnished under Rule 13bis separately from the
description.

(54) Title: 148 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing International applications under the PCT.

FOR THE PURPOSES OF INFORMATION ONLY

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Switzerland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GR	Greece	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BG	Bulgaria	HU	Hungary	ML	Mali	TR	Turkey
BJ	Benin	IE	Ireland	MN	Mongolia	TT	Trinidad and Tobago
BR	Brazil	IL	Israel	MR	Mauritania	UA	Ukraine
BY	Belarus	IS	Iceland	MW	Malawi	UG	Uganda
CA	Canada	IT	Italy	MX	Mexico	US	United States of America
CF	Central African Republic	JP	Japan	NE	Niger	UZ	Uzbekistan
CG	Congo	KE	Kenya	NL	Netherlands	VN	Viet Nam
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CI	Cote d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CN	China	KR	Republic of Korea	PL	Poland		
CU	Cuba	KZ	Republic of Kazakhstan	PT	Portugal		
CZ	Czech Republic	LC	Saint Lucia	RO	Romania		
DE	Germany	LI	Liechtenstein	RU	Russian Federation		
DK	Denmark	LK	Sri Lanka	SD	Sudan		
EE	Estonia	LR	Liberia	SE	Sweden		
				SG	Singapore		

148 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO. X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO. X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions; or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA, followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polynucleotide or polynucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, uridyated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS -

STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Scifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

25 Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

30

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

MRFISQQSCECVRPCMDVYVCVYISHVYMDAHVYLCRICKTNMR (SEQ ID NO:309), RLRWNVNCMACDLYLNKAVSVAHVWCMCVYISLYMYTWP
 MCYVEYVKQT (SEQ ID NO:310), NPENQLEISFFPRRQMKMLTLDLQVSQS
 SLVHSLSSDFFSVSKEGCLWKPILLPSHF (SEQ ID NO:311), LQTQISN
 YLMFVLHILHRYTWTWASMYTCIEIYTHYTSIHGRTHSQC (SEQ ID NO:312),

IHMGIHVYMYRDIYTHIHHTWAHTLTALLRYKSHAIQLTHLNIR (SEQ ID NO:313), and/or MKWIFTVLILTSCTTAGICEDGICSRQL RDKIVQSAFRQ (SEQ ID NO:314). Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly neutropenia and related conditions.

10 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. More specifically, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 812 of SEQ ID NO:11, b is an integer of 15 to 826, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

KPCPSVSNRSSVQMHQLPIQLGQFEAHGICGRSFLETFTYHDPAMHSFL
SSISPSLPFGFSRMTSQINHLHPSPLC (SEQ ID NO:315). Polynucleotides

encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:161 as residues: Asp-15 to Tyr-21, Pro-29 to Asn-39.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. Moreover,

the expression of this gene product indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 510 of SEQ ID NO:12, b is an integer of 15 to 524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SYFKINLKSFKQHEWVWPRRS (SEQ ID NO:316).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, including neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:162 as residues: Met-1 to Arg-8, Leu-35 to Glu-41.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. More specifically, expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may also be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 477 of SEQ ID NO:13, b is an integer of 15 to 491, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

15 This gene is expressed primarily in IL-1 and LPS induced neutrophils. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, including neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:163 as residues: Asn-45 to Thr-58.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or prevention of a variety of immune disorders. In particular, this gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by

11

boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lensc tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 389 of SEQ ID NO:14, b is an integer of 15 to 403, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

30

GTRSFSPVSYRLTGSLMICYLLLLIQTALLIHPOGLQAVSNGESALKGTPTF
SSPFLVTEGRKEWEGVFLSSGWKGNTLSNYIYSLVFYYSRILQPYFYCLWGWK
LEMVTLIRSVWRGINGGDKSVGFQKC (SEQ ID NO:317). WMERKHTVKLL
YLLGFLQNSPAIFLLSMGEVGDGLD (SEQ ID NO:318) SNGESALKGTPTF

35

TFSSPFLVTE (SEQ ID NO:319), and/or LSNYIYSLVFYYSRILQPYFYCLW (SEQ
ID NO:320). Polynucleotides encoding these polypeptides are also encompassed by the
invention. The gene encoding the disclosed cDNA is believed to reside on chromosome

12

17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in the breast and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, reproductive, or neural disorders, such as cancers of the breast, lymph system and brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune, and central nervous systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, neural, breast, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, breast milk, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:164 as residues: Leu-31 to Phe-38, Glu-47 to Trp-52.

20

The tissue distribution in breast and brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancers in the breast, lymph system, and brain. Moreover, the protein product of this gene may be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the
developing embryo, sexually-linked disorders, or disorders of the cardiovascular

30

35

system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 799 of SEQ ID NO:15, b is an integer of 15 to 813, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:165 as residues: Ser-49 to Leu-54.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of a variety of immune disorders. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product

may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin,

the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia,

neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 250 of SEQ ID NO:16, b is an integer of 15 to 264, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares sequence homology with neurotoxin which is thought to be important in neural diseases. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

EKDFMQSDAGHGTHYRALVQWPLAWVFLSHAKTHWGEELRFSRRKN
LRLREAMRHETCOVTLVA GKADSNLCIRDSETFWPPLWAACSSLQATA
35 CRLSSPSKGLGASRECPWLASGRAALVSFL (SEQ ID NO:321), SLRVKGRKPR
LLYHSPARGTLWMLPGLCDCLICRQWLVERSLPRVGARTRFQSPSDTGWS

15

QLQLPAV (SEQ ID NO:322), and/or ERSRLPRVGARTRFQSPSDTGWSQLC (SEQ ID NO:323). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and neural diseases, particularly neurodegenerative disorders, such as Alzheimers or Parkinson's. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hemopoietic, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

20 NO:166 as residues: Gln-2 to Gly-10, Asp-77 to Phe-82.

The tissue distribution in neutrophils combined with the homology to the conserved neurotoxin protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune and neural diseases. Similarly, the protein product of this gene may be useful for the detection/treatment of

25 neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
30 compulsive disorder, panic disorder, learning disabilities, A.L.S, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a
35 role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular

16

system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 506 of SEQ ID NO:17, b is an integer of 15 to 520, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 8

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KHAFLMAHQFCVLSLAMQWSSCFQLVALPTYSL (SEQ ID NO:324). Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hemopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
30 sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders. Furthermore, this gene product may be involved in the

regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 979 of SEQ ID NO:18. b is an integer of 15 to 993, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

When tested against Jurket and PC12 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) and EGR1 (early growth response gene 1) promoter elements. Thus, it is likely that this gene activates T-cells and sensory neurons through the JAK-STAT and EGR1 signal transduction pathways. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MRPLCVLLPWCWQWGLGSGASPIRPQAPPGQAHAHP LPRAQHLAGRSRQ (SEQ ID NO:325). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in breast, lymph nodes, spleen, and to a lesser extent, in liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, immune, or hepatic disorders, particularly cancers of the breast, liver, and lymph system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast, liver and lymph system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, breast, immune hematopoietic, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, breast milk, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:168 as residues: Pro-54 to Gly-67.

The tissue distribution in breast and immune tissues combined with the detected EGR1 and GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancers of the breast and lymph systems. Moreover, the GAS and EGR1 activity strongly indicates that the protein product of this gene may play an integral role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, such proliferative tissues rely on finely regulated

19

decisions involving cell differentiation and/or apoptosis. Thus this protein may also be involved in regulating apoptosis or tissue differentiation and, thus could be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 445 of SEQ ID NO:19, b is an integer of 15 to 459, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARGLRSPHGAAGVVRGDGGKKGEDPYSPILFQ SERIPRLIYLPVISSEENS (SEQ ID NO:326). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in an LPS induced neutrophil cDNA library.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35

20

1

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders, for example, in ameliorating an aberrant neutrophil response to infectious agents. Similarly, the expression of this gene product may suggest a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may also be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lensc tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 541 of SEQ ID NO:20, b is an integer of 15 to 555, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

30

35

21

22

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed primarily in prostate cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or immune system disorders, particularly prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, prostate, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:170 as residues: Pro-14 to Asp-25, Leu-51 to Val-63.

The tissue distribution in prostate tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive system disorders such as cancer, particularly prostate cancer. Similarly, the expression within prostate cancer tissue, a cellular source marked by proliferating cells, indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders not limited to prostate tissue. Further, such tissues rely on decisions involving cell differentiation and/or apoptosis. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 651 of SEQ ID NO:21, b is an integer of 15 to 665, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The polynucleotide sequence of this gene may have a frame shift. Therefore the preferred signal peptide may reside in a frame other than the associated polynucleotides of this gene. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

KSLSCSFLFLAFWLRMGQTMVCVCVCVCTWVYL YEPVKF RSPLYV
NLPTS (SEQ ID NO:327), and/or KLGFTMLARLVSNSXTSGDLPSSASQNAIGI
KGMYSYRWPYSYFLIRKNKQT NKQTKTNPOLGENKHCRNLKVSWSKNYFL
(SEQ ID NO:328). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, particularly immunodeficiencies such as lupus and AIDS, or inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Moreover, this gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may

23

also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 763 of SEQ ID NO:22, b is an integer of 15 to 777, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO. 13

When tested against Jurket and U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates T-cells and promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the

24

proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
 ERGQGGSSRNVAAGSDLVPPAVFVFXSLC (SEQ ID NO:329),
 GSPQGPSVALGSRQCWSPRLRRGGGAIVEMWRGPTWCFRPSLCLCCVCGV
 SFGLYYPHGFSLSMCVSAPGSAWLSLYSICLARGSMSXRSRXXSLV
 ASGASVLLVCFWVXADPGVGVSPRAXYVSGLWWCVSPSACLXLAPTKPP
 XLSFSLIFPSSNPSK (SEQ ID NO:330), and/or TIASLQPTALNHLIWRGW
 KRKGRRLRERKRGXGGAWLGPXRGQRMDSTTRDQRQLGEQRHPLGLXA
 PRSKPTKQMPQMOPGXPEKXXLTWNHGLDRWNTQGTARQSLGQK
 HTWRD (SEQ ID NO:331). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adipose tissue and the brain. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic or neural disorders, particularly obesity, and neurodegenerative or central nervous system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. adipose, neural, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in adipose and neural tissues, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of obesity and disorders of the brain and central nervous system. Similarly, the protein product of this gene may be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, A.L.S, psychoses, autism, and altered behaviors, including disorders in

5 feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. In addition, the protein product of this gene may also be beneficial in detecting, treating, or preventing neural disorders which occur secondary to aberrant fatty acid metabolism in neural tissues, such as for aberrations in myelin sheath development, or associated autoimmune disorders of neural tissue or the overlying integument. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 526 of SEQ ID NO:23, b is an integer of 15 to 540, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARGPGTEGCEPWLQLQDRRER (SEQ ID NO:332), and/or MSSGTNSFFTLMALNSPTGDSGRITVSPRVHPVKSGRGRASDLLLTRFLAPR SALWS (SEQ ID NO:333). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in a cDNA library from IL-1 and LPS induced neutrophils.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, immune system disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of conditions where lymphocytes show aberrant response to an infectious agent. Similarly, this gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

27

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 470 of SEQ ID NO:24, b is an integer of 15 to 484, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

10 This gene is expressed primarily in ovaries, tonsils, and CD34 positive bone marrow stem cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, immune, developmental, or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., reproductive, ovarian, immune, tonsil, umbilical, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in ovarian and tonsil tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune and reproductive system disorders. Similarly, expression of this gene product in tonsils indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia,

28

neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 693 of SEQ ID NO:25, b is an integer of 15 to 707, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

25 When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HEYHLSSRHLSGVRLDVC SALWS (SEQ ID NO:334). Polynucleotides encoding these polypeptides are also encompassed by the invention.

35 This gene is expressed primarily in IL-1 and LPS induced neutrophils. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of immune disorders.

Specifically, the expression of this gene product in neutrophils indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 779 of SEQ ID NO:26, b is an integer of 15 to 793, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed primarily in the spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, any of a variety of nervous system and neuromuscular disorders, particularly amyotrophic lateral sclerosis, muscular dystrophy, and inherited and non-inherited forms of chorea. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and neuromuscular systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, neuromuscular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord tissue indicates that this gene could be used for the treatment of spinal cord and related injuries. The protein product of this gene could be injected into the spinal cord to promote or control growth following injuring or degeneration. Alternatively cells expressing this gene could be injected or transferred into the spinal cord by other means as a treatment promoting the regulation of growth following spinal cord injury or degeneration. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction,

31

aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 624 of SEQ ID NO:27, b is an integer of 15 to 638, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large-signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FLFLLEYDMLWKSLEYTNSSAYGYVIASFCLLGIKLLVKQKKKKKTRGAR

32

XPIRPXVESYYSKXAVLQRRGLGKNLGG (SEQ ID NO:335). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the adrenal gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine disorders, particularly disorders of the adrenal gland. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adrenal gland, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endocrine, adrenal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in adrenal tissue, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 514 of SEQ ID NO:28, b is an integer of 15 to 528, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is expressed primarily in the placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. placental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 178 as residues: His-15 to Trp-20, Pro-48 to Ala-54.

The tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of reproductive disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 905 of SEQ ID NO:29, b is an integer of 15 to 919, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene shares sequence homology with human erythrocyte membrane anion-transport protein which is thought to be important in autoimmune diseases. Furthermore, the translation product of this gene also has homology to a human gallPIDid1026838 (AB012130) sodium bicarbonate cotransporter2 which is thought to be important in maintaining cellular homeostasis. Contact of cells with supernatant expressing the product of this gene was found to increase the permeability of the plasma membrane of enterocytes and renal mesangial cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the enterocytes and renal mesangial cells. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating cellular processes within enterocytes and renal mesangial cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

RVSSHLFRLFGGLLDIKRKAPFLSDFKDALSLQCLASILFLYCACMSPVITFG
GLLGEATEG RIVSTKIGSQAFSSSEASVCMHLSHYFYFLKSLPTA (SEQ ID
NO:336), FRLFGGLLDIKRKAPFLSDFKD (SEQ ID NO:337), FLYCACMSPV
ITFGGLLGEATEG (SEQ ID NO:338), and/or SSSEASVCMHLSHYFYFLKSL
(SEQ ID NO:339). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in human testes tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or reproductive disorders, particularly autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

35

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in testis, the homology to an erythrocyte membrane anion-transport protein, in addition to, the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of autoimmune diseases and other immune diseases such as cancer, particularly in, but not limited to, testicular tissue. Similarly, the translation product of this gene may be important in maintaining normal, cellular homeostasis. Therefore, the protein, as well as antibodies directed to the invention, is beneficial as a therapeutic in order to ameliorate conditions related to aberrant cellular pH regulation (for example, use antibodies to decrease the presence of the protein, or possibly in gene therapy applications in order to replace a defective form, or alternatively, increase the expression of either the endogenous or modified form of the invention). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 850 of SEQ ID NO:30, b is an integer of 15 to 864, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

30 This gene is expressed primarily in the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, which include, but are not limited to, disorders of the brain and central nervous system, such as neurodegenerative conditions and/or depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)

36

5 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:180 as residues: His-13 to Leu-18.

10 The tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the brain and central nervous system. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, A.L.S, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 905 of SEQ ID NO:31, b is an integer of 15 to

919, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 22

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

10 PCLQVIGIDFCRLMLCLVLKRNLTVPFSSYSPLKTTTCTITSEQIAVVSNFRQKL
GVRAK FFQGACLHTSKVVICLNLPISIQRADIRMWL VVNTPYARGVNN
(SEQ ID NO:340). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the spinal cord.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, any of a variety of nervous system and neuromuscular disorders including, but not limited to, amyotrophic lateral sclerosis, muscular dystrophy, and inherited and non-inherited forms of chorea. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and neuromuscular systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in spinal cord indicates that this gene could be used for the treatment of spinal cord injuries. The protein product of this gene could be injected into the spinal cord to promote or control growth following injuring or degeneration. Alternatively cells expressing this gene could be injected or transferred into the spinal cord by other means as a treatment promoting the growth or regulation of growth following spinal cord injury or degeneration. This gene may also be useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases,

peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 942 of SEQ ID NO:32, b is an integer of 15 to 956, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VVSVCVLETQQLGPAALCRSV (SEQ ID NO:341).

30 Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, which include, but are not limited to, inflammatory diseases or neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification

of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of the inflammatory conditions. Moreover, This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 552 of SEQ ID NO:33, b is an integer of 15 to 566, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

```

NISVHGFPVPCLRQRLQGCPCHKCCPHXISSGKPRSSPSSYHCKSRNATLL
VVPNIFSYMQSSFLPQTSKYILXPYAXTXRPKIXIFKQAKQ (SEQ ID NO:342),
IYNDMMMEKKKTEVYQKRSGDNTWGGKQLVAFVSSMEQGIHVQRCFIANL
KESSPGV (SEQ ID NO: 343), YDDGEKEDRQLPEEMXWGQHLGWQGPCSL
CLKHGTGNPCTEMFYCQFKIFSWCLIPLVEARLGDFRDRPGWIFSWR YLKH
TWGGVNIIML (SEQ ID NO: 344), TPGDENFKLAIKHLCTWIPCS (SEQ ID NO:
345), IRHEIFLTIESFCPSAPRGEDDDNLLRTSRVPDI (SEQ ID NO:346), IRGSIP
GHKKMHLISFNVAQWSLLKPLVIREGALFLTHDQLESKNWSLISGPRV
PYTYVVVTWSSALWDLPNQPLAGRKESGGSYGRISVTSQSPHQAALKWFAKK
KKGQSHSTVQLANILHVFAXPDXYHFVNTSLQLFLEYVMCMLCENK QKT
LGR (SEQ ID NO:347), EPEVTQVXSXELTFQPKKAGAKVTAGKSHHQVHWE
FEIMLSSYSTDYVPLWFLKFFSSNLPTQTFPHSGVKKKWGSCFSLPWRDSPPLT
FISLLSSHLLTFHLVYHLHHGIICLGFSVYFHKAYTSLCILETAVGSSY (SEQ ID
NO:348), WSLKPLVIREGALFLTHDQLESK (SEQ ID NO:349), WFAKKK
GKQSHSTVQLANILHV (SEQ ID NO:350), AGKSHHQVHWEFEIMLSSYSTDYV
(SEQ ID NO:351), and/or HGIICLGFSVYFHKAYTSLCILETAV (SEQ ID NO:352).
Polynucleotides encoding these polypeptides are also encompassed by the invention.

```

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular or vascular disorders, which include, but are not limited to defective organ innervation, deficiencies in neuronal survival, peristaltic abnormalities; digestive disorders; perturbations of the vasculature. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the smooth muscle, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in smooth muscle tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders that result from failures of normal smooth muscle function. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it may be involved in controlling the digestive process, and such actions as peristalsis. Similarly, it may be involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO:34, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KRLTINARVHLWTLKSVPL (SEQ ID NO:353), EYVFNMX XYSKRAISPLSGPYPRGTTPLPIPEPGARQRDHPAS LKYAKUQTKLFAL PYPKETSMAVA (SEQ ID NO:354), and/or ETVPRSSQFLKTXGPARMSLIX XAIQNPEPYLLYLALIQEALLLYLSSQSQVPGNETTPPV (SEQ ID NO:355).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, which include, but are not limited to lupus,

inflammatory conditions, and immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:184 as residues: Ser-21 to Thr-34, Thr-38 to Glu-43.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1021 of SEQ ID NO:35, b is an integer of 15 to 1035, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

The translation product of this gene was determined to have homology to the human IB3089A protein which is thought to play an important role in tumor suppression (See Genbank Accession No. gi3041877 (AF027734)). In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NEVSFSLGSPREFARWKVNNLAL ERKDFSLPLAPEFIRNI RLLGRPPNLQVYTENLIKKGTHLLSATLGKQHNPKLGCQTIGNNV KTRVA (SEQ ID NO:356), VPYFLRFSVTCCLGLLPRRMFRIN SGARGNG KLKKSFLSRAK LFTFQRANSLGEKPRDKEKLTSFQSKRHKI (SEQ ID NO:357), and/or EMSAVLNFQFCNLLQIGSPSKKANVPDKLWGKRQWQTEEVLPQSQV VHLPTGKLPGCKAKG (SEQ ID NO:358). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human fibrosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders afflicting endothelial, muscular, and extracellular matrix tissues, which include, but are not limited to fibrosarcomas and bladder cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumentary system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endothelial, urogenital, renal, muscular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:185 as residues: Pro-49 to Asp-68.

The tissue distribution in human fibrosarcoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of various cancers, particularly fibrosarcomas and fibroids. Moreover, the expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 606 of SEQ ID NO:36, b is an integer of 15 to 620, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

This gene is expressed primarily in human tonsil.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, which include, but are not limited to inflammation and infectious diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types

(e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tonsils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of inflammation and infectious diseases. Moreover, this gene product may play a role in regulating the proliferation, survival, differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 959 of SEQ ID NO:37, b is an integer of 15 to 973, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

HYHSGFLIKEFGSLLLCMLSCPYYVFCGHMLEQVEPSSVSPSTLDFPTSR
TVNKFLLKLPSTWYSVIATQNLKQKIRETFLFVQFSQMPRWHKLE (SEQ ID
NO:359). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adipose and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic or neural conditions, which include but are not limited to obesity and disorders of the brain and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, metabolic tissues, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neural and adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of obesity and disorders of brain and central system. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain

indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. In addition, considering the expression within both adipose tissue and brain indicates that the protein may be beneficial either as a target for gene therapy, or as a novel therapeutic to ameliorate conditions affecting myelin sheath development in neurons, or other disorders involving neural tissue which occur secondary to aberrant fatty-acid metabolism. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 824 of SEQ ID NO:38, b is an integer of 15 to 838, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11. One embodiment of this gene comprises polypeptides of the following amino acid sequence:

FCKHNGSKNVFSTFRTPAVLFTGIVALYIASGLTGFIGLEVVAQLFNC (SEQ ID NO:360). An additional embodiment is the polynucleotides encoding the polypeptides.

This gene is expressed primarily in suppressor T cells, endothelial cells, dendritic cells, and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, immune system disorders related to abnormal activation of T cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. hematopoietic, developmental, neural, immune, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:188 as residues: Tyr-14 to Leu-24, Pro-59 to Gln-66.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the immune system related to altered activation of T cells. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of immune disorders. Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 593 of SEQ ID NO:39, b is an integer of 15 to

607, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

This gene is expressed primarily in the fetus and in tumor cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of rapidly growing tissues such as cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of rapidly growing tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. fetal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene primarily in the developing fetus indicates a role in the treatment and/or detection of developmental disorders and growth defects. In addition, expression in tumor cell types indicates a role in the detection and/or treatment of tumors. Furthermore, expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 868 of SEQ ID NO:40, b is an integer of 15 to 882, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 31

This gene is expressed primarily in salivary gland, and to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, digestive and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the salivary gland and other glands of the exocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. exocrine, digestive, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:190 as residues: Glu-25 to Gly-31, Tyr-62 to Thr-68.

The tissue distribution in salivary gland tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of digestive and immune system disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

51

a-b, where a is any integer between 1 to 945 of SEQ ID NO:41, b is an integer of 15 to 959, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The gene encoding the disclosed cDNA is thought to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in brain tissue of adults, as well as infants. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative and behavioural disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central and peripheral nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:191 as residues: Ser-16 to Val-33.

The tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Furthermore, expression of this gene product within the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

52

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO:42, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

This gene is expressed primarily in the synovium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases affecting the synovial lining including arthritis and autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculo-skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endothelial, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for use as a factor that may protect against articular damage or promote growth of the cells in articulating joints. Furthermore, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and

dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 616 of SEQ ID NO:43, b is an integer of 15 to 630, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in B-cell lymphoma cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, such as diseases of B-cell lineage including lymphomas lymphoblastic leukemias, myelomas and hairy cell leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:193 as residues: Lys-82 to Pro-90.

The tissue distribution and biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of B-cell lineage including cancer. This factor may be useful in the terminal differentiation of malignant cells or may act as a growth factor for B-cell proliferation or differentiation, which is supported by the biological assay data. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 557 of SEQ ID NO:44, b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS

element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in osteoclastoma derived stromal cells,

placenta, pancreas and several tumor derived cells and to a lesser extent in brain, melanocytes, dendritic cells, and several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors of the pancreas, uterus, ovary, bone, or adrenal gland. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. placenta, pancreas, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing tumors of the reproductive organs, pancreas, or bone marrow. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g. hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:45, b is an integer of 15 to

930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 36

When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in kidney and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal and nervous system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal and nervous systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. renal, urogenital, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:195 as residues: Lys-117 to Lys-126.

The tissue distribution of this gene in kidney tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of renal disorders including kidney failure and Wilms' Tumor in addition to the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease,

schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 423 of SEQ ID NO:46, b is an integer of 15 to 437, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 37

One embodiment of this gene comprises polypeptides of the following amino acid sequence:

20 MPKGAATQRTLLCLPRLHPASGPPLPXAGPLRGLRQLPALPVPAAACRRRPAP
RLCAAGPCTVGPAAAPHGPPASLAHV AHRQSVSGTVCLGLRDGHV
RGGCAAVRGXALPWDAAAAGPDHMGVGGSPALL (SEQ ID NO:361). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in pituitary and to a lesser extent in thymus and breast.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types or cell types (e.g. thymus, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of endocrine, metabolic, and immune disorders including growth and developmental defects, in addition to the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1010 of SEQ ID NO:47, b is an integer of 15 to 1024, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene is expressed primarily in hemangiopericytoma.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular disorders such as stroke, aneurysm, cardiac arrest, hemorrhage. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. circulatory system, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:197 as residues: Cys-14 to Gly-23, Met-45 to Gly-51.

The tissue distribution of this gene solely in hemangiopericytoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of vascular disorders including hemorrhaging, aneurysm, stroke and cardiac arrest. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 449 of SEQ ID NO:48, b is an integer of 15 to 463, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

The translation product of this gene shares sequence homology with a serine protease which is thought to be important in regulating the availability and action of proteins *in vivo*.

This gene is expressed primarily in cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system related to abnormal growth factor regulation, including neurodegenerative conditions such as Alzheimer's disease and psychiatric illness such as Schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central Nervous System, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. CNS, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:198 as residues: Ser-17 to Gln-22.

The tissue distribution in neural tissue, combined with the homology to serine proteases indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the central nervous system including neurodegenerative diseases and psychiatric disorders. Furthermore, expression of this gene product within cerebral tissue indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia; ALS; or Alzheimer's Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 871 of SEQ ID NO:49, b is an integer of 15 to 885, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed primarily in CD34 depleted buffy coat.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.

immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in CD34 depleted buffy coat tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders of the immune system including autoimmune diseases. Furthermore, expression of this gene product in CD34 depleted buffy coat indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 833 of SEQ ID NO:50, b is an integer of 15 to 847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

This gene is expressed primarily in B-cell lymphoma cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of B-cell lineage including lymphomas lymphoblastic leukemias, myelomas and hairy cell leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of B-cell lineage including cancer. This factor may be useful in the terminal differentiation of malignant cells or may act as a growth factor for B-cell proliferation or differentiation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 566 of SEQ ID NO:51, b is an integer of 15 to 580, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

This gene is expressed primarily in brain and CD34 depleted buffy coat. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, autoimmune disorders particularly those of the central nervous system such as multiple sclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:201 as residues: Pro-35 to Ala-40.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating autoimmune disorders such as multiple sclerosis. Furthermore, expression of this gene product in CD34 depleted buffy coat indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 584 of SEQ ID NO:52, b is an integer of 15 to 598, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed primarily in tissues of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. CNS, brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful as a neuronal protective agent and as a growth factor for cells of the central or peripheral nervous system. Furthermore, expression of this gene product within the brain indicates that it may be involved in neuronal survival, synapse formation, conduction, neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 557 of SEQ ID NO:53, b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The gene encoding the disclosed cDNA is thought to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in embryo and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryo and fetal tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. fetal tissues, developmental, cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in embryonic and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that

this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the abovelisted tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1233 of SEQ ID NO:54, b is an integer of 15 to 1247, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

The gene encoding the disclosed cDNA is thought to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed primarily in infant brain, placenta, some immune tissues, and, to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the early developmental stage tissues and immune tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to

the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO:204 as residues: Val-32 to Met-39, Leu-44 to Val-49.

The tissue distribution in fetal and immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental and immune disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The protein product of this gene is useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 834 of SEQ ID NO:55, b is an integer of 15 to 848, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

When tested against Jurkat T-cells, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in brain tissues, and to a lesser extent, in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neuronal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:205 as residues: Ser-33 to Ser-44.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal and immune system disorders. Furthermore, expression of this gene product in T-cells, as well as the observed biological activity of this gene product, indicates that this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the expression within brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 655 of SEQ ID NO:56, b is an integer of 15 to 669, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Contact of cells with supernatant expressing the product of this gene increases the permeability of bovine chondrocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the chondrocyte cells. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating bone cells.

This gene is expressed primarily in breast and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pregnancy disorders including miscarriage. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast and placenta, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. placental tissues, breast, bone, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another

71

tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in both placenta and breast indicates a role for this protein in the treatment and/or detection of miscarriages in suspect individuals, of birth defects, of breast cancer, and female infertility. Furthermore, the biological assay data strongly indicates that the translation product of this gene is actively involved in the initiation of several signal transduction pathways and the activation of several cell types.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of $a-b$, where a is any integer between 1 to 666 of SEQ ID NO:57, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to $a + 14$.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 48

The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11. One embodiment of this gene comprises the polypeptides of the following amino acid sequence:

25 MWGQRPVDSVWSSSIPKKSVESNDNKSHLHKEH (SEQ ID NO:362),
MTTKAIFTKGNDLSFKSNMWSVYI (SEQ ID NO:363). An additional
embodiment is the polynucleotides encoding these polypeptides.

30 This gene is expressed primarily in the pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pancreatic related disorders such as diabetes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this

72

gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. pancreas, endocrine, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution of this gene in pancreatic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/detection of endocrine disorders and metabolic disorders associated with the pancreas including diabetes, pancreatitis, and pancreatic cancer. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g. hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

20 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of $a-b$, where a is any integer between 1 to 510 of SEQ ID NO:58, b is an integer of 15 to 524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to $a + 14$.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 49

30 This gene is expressed primarily in chondrosarcoma tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, including diseases of the skeletal system, particularly with respect to the

cartilagenous structures and also cancer of these tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. bone, connective, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in chondrosarcoma tumors indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/diagnosis of cartilage disorders including arthritis and cancer. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 413 of SEQ ID NO:59, b is an integer of 15 to 427, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

The translation product of this gene shares sequence homology with sorbin which is thought to be important in the manufacture of vitamin C. Additionally, sorbin is thought to be important in the process of stimulating water and electrolyte absorption in various cells in the body. Porcine Sorbin has activity in stimulating water and electrolyte absorption across mucosa. It has been pursued as a regulator of electrolyte absorption in the nasal and enteric mucosa. This gene was identified in hypothalamus suggesting that it could play a role in the CNS regulation of water or electrolyte absorption.

This gene is expressed primarily in human hypothalamus tissue from a patient suffering from Alzheimer's disease.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurologic disorders (e.g. Alzheimer's disease). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:209 as residues: Leu-29 to Leu-37, Gln-65 to Asp-70, Gln-85 to Gly-95.

The tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Alzheimer's disease. Additionally, the translation product of this gene, based upon its homology to the porcine sorbin, could be useful for the detection and/or amelioration of disorders involving the CNS regulation of water or electrolyte absorption. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1249 of SEQ ID NO:60, b is an integer of 15 to 1263, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

75

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in synovium, and to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, synovial diseases such as synovial sarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the synovium, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., connective tissues, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovium indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of synovial diseases such as arthritis. Furthermore, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders affecting connective tissues (e.g., trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e., spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Alcolostegensis type II, metaphyseal chondrodysplasia type Schmidt). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

76

a-b, where a is any integer between 1 to 706 of SEQ ID NO:61, b is an integer of 15 to 720, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in immune tissues and fast-growing tissues, such as tumor and early-stage developmental tissues, and, to a lesser extent, in some other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and growth related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune tissues and fast-growing tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., developmental, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:211 as residues: Ala-28 to Ala-47.

The tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of immune and growth related disorders. Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

77

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 575 of SEQ ID NO:62, b is an integer of 15 to 589, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

One embodiment of this gene comprises polypeptides of the following amino acid sequence: DSXLDRRPSGPDVKFLSNKHFSMVC (SEQ ID NO:364). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in spleen, and to a lesser extent, in a range of hematopoietic cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. spleen, immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:212 as residues: Cys-25 to Trp-30.

The tissue distribution of this gene in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency

78

diseases and leukemia. Expression of this gene product in spleen indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 672 of SEQ ID NO:63, b is an integer of 15 to 686, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

This gene is expressed primarily in human normal breast, and to a lesser extent, in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, glandular problems involving cells of epithelial origin including breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the female endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. breast, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:213 as residues: Ser-32 to Asn-44.

The tissue distribution in breast tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of both malignant and non-malignant problems of the breast tissues, including cancer. Alternatively, the expression in dendritic tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphoproliferation, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 438 of SEQ ID NO:64, b is an integer of 15 to 452, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in early stage human tissues, immune tissues, and to a lesser extent, in other tissues such as prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, development and immune related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and early stage human tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in embryonic and immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental and immune related diseases. The biological activity data supports the assertion that the translation product of this gene is useful in the treatment and/or diagnosis of diseases related to the immune system. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 356 of SEQ ID NO:65, b is an integer of 15 to 370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with medicago sativa salt-inducible protein.

This gene is expressed primarily in human chronic synovitis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal or rheumatoid disorders, particularly, chronic synovitis.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. connective tissues, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:215 as residues: Lys-30 to Ser-44, Pro-77 to His-82.

The tissue distribution in synovium indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of and as a therapeutic agent for chronic synovitis. In addition, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as

dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 973 of SEQ ID NO:66, b is an integer of 15 to 987, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

The translation product of this gene shares high sequence homology with the rat and mouse peroxisomal membrane proteins [gi297437], which appears to play a crucial role in transporting proteins into the organelle. Some human genetic disorders involving peroxisome biogenesis, such as Zellweger syndrome, may be caused by genetic defects of the import machinery located in the peroxisomal membrane. When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in normal human liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the hepatic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic disorders and liver metabolic

diseases, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. liver, cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:216 as residues: Lys-57 to Ser-66.

The tissue distribution in liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases relating to the liver. Furthermore, the homology indicates that the translational product of this gene may be useful in the detection and treatment of a number of disorders resulting from the improper transport of proteins into the organelle due to defects in peroxisomal membrane proteins, such as Zellweger syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1004 of SEQ ID NO:67, b is an integer of 15 to 1018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed primarily in human fetal dura mater.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, developmental or neurologic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:217 as residues: Ala-19 to Lys-34.

The tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological diseases. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, and/or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 748 of SEQ ID NO:68, b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

The gene encoding the disclosed cDNA is thought to reside on chromosome 16.

5 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in T helper cell and human uterine cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, relating to hemopoietic and uterus disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and female reproductive

15 system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-helper cells and uterine tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders relating to both the immune and female reproductive systems. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell

types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 616 of SEQ ID NO:69, b is an integer of 15 to 630, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 60

This gene is expressed primarily in human fetal epithelium, and to a lesser extent, in testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental or reproductive disorders, in addition to diseases of the integumentary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases relating to the epithelium; expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. epithelium, testes, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal epithelium and testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of epithelium related diseases. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles,

freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Furthermore, the tissue distribution also indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 926 of SEQ ID NO:70, b is an integer of 15 to 940, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

35
FEATURES OF PROTEIN ENCODED BY GENE NO: 61

When tested against both U937 Myeloid cell and Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the G_{AS} assay. Thus, it is likely that this gene activates both T-cells and myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (G_{AS}) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the G_{AS} element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in human adult lymph node and in early stage human lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, lymphatitis and pulmonary disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and respiratory system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in adult lymph indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases relating to the immune system and respiratory system. Furthermore, expression of this gene product in lymph nodes indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency

diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The biological activity data supports the notion that the translation product of this gene is an activator of various cells of the immune system, and thus could play an important role in the activities of the immune system.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1089 of SEQ ID NO:71, b is an integer of 15 to 1103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This gene is expressed primarily in glioblastoma and anergic T-cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural and immune disorders, such as glioblastosis cerebri. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders relating to the CNS and the immune system. Furthermore, expression of this gene product in T-cells indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 885 of SEQ ID NO:72, b is an integer of 15 to 899, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

One embodiment of this gene comprises polypeptides of the following amino acid sequence:

CLAEA VSVIQSIPIFNETGRFSFTLPYPVKIKVRFSEFFLQIYLMIFLGLYNFRHLY
KQRRRYGQKKKSTKKKDLDFLPV (SEQ ID NO:365). An additional
embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in keratinocytes and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, or neurological and behavioural disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Alternatively, expression within keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia

congenita, familial osteoarthritis, Aiclostogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 535 of SEQ ID NO:73, b is an integer of 15 to 549, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

LCSTPPTLFCPRIVLELVVLRSISEQCRRVSSQVTVASELRHQWVERTLRSR
QRONYLR (SEQ ID NO:366). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal disorders, and diseases of the haemopoietic and immune system, particularly cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bones, immune and haemopoietic system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. skeletal, haematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO:223 as residues: Ser-59 to Glu-67.

5 The tissue distribution in osteoclastoma tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the bones, immune and haemopoietic systems and cancer. Moreover, the protein may play a role as a therapeutic in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders. For example, in rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 576 of SEQ ID NO:74, b is an integer of 15 to 590, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

When tested against dermal fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblast cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell

types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 ARGETAYDGAAVEFQEPLSCLFSSLNPHHWPTLGVGRPVMLTLEDKD (SEQ ID NO:367), ELQCMLEASTLIHLHPRPGFPALCSFLGFRHHLHHDALCIRV LPDELEAKLVSLHQLLHRGLCLPGFGAACPGDQSGSEDEARPPA VLRAVALLR AGLRHLSVHSGWYHLPH SRNGLPLLALVVHFPEYGGGPREPVPGQSG EFGRRTSLTKGDTGDSRNSHLAQDMASLPFFKPCETHV AVCSPPHPLCQ YLCL (SEQ ID NO:368), LQCMLEASTLIHLHPRPGFPALCSFL (SEQ ID NO:369), HQLHRGLCLPGFGAACPGDQSGSEDEARPPA (SEQ ID NO:370), and/or LALVVHFPEYGGGPREPVPGQSGEFG (SEQ ID NO:371).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in testes.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, male reproductive and endocrine disorders, cancer, particularly testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive and endocrine systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, testes, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO:224 as residues: Lys-53 to Leu-60, Pro-94 to Gln-99, Ser-176 to Gly-184, Ser-199 to Val-207.

30 The tissue distribution in testes, combined with the detected EGR1 biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of male reproductive and endocrine disorders, including aberrant testicular function (e.g. endocrine function, sperm maturation). Moreover, in light of the EGR1 activity, it may also be useful in the diagnosis and treatment of a variety of proliferative disorders, especially testicular cancer. Protein, as

well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1042 of SEQ ID NO:75, b is an integer of 15 to 1056, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QSVTAPARLPMALPQMCDSGLASTLYC (SEQ ID NO:372), QSAAQWFVWPGRSASLGGAKGMQPPSLASWPXPRIKCLRAPAPC SXPSASSAAVQVACCCSLACCGPSRPASQGHRLWDPYHLRDLVYLTVESSEK ESCRTPKVVVDIPTYEBAVSFPVAEGPTTPPAYTEALEPSGRDALSTQPA WPPSYESISLALDAVSAETTPSATRSC SGLVQTARGGS (SEQ ID NO:373), GSTGLWRGDRGPIEGPGLAL TDHSRVSPVAEGPTTPPAYTEAL EPSSGRDALSSVXGASWPGWAVASPSLHQAKQSVPAITRTTVPLTMQ (SEQ ID NO:374), QWFWWPGRSASLGGAKGMQPPSLASWP (SEQ ID NO:375), SSAA VQVACCCSLACCGPSRPASQGHRLW (SEQ ID NO:376), VSFPVAEGPTTPPAYP TEEALEPSGRDALLS (SEQ ID NO:377), and/or RVSPVAEGPTTPPAYTEE ALEPSG (SEQ ID NO:378). Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 This gene is expressed primarily in pituitary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine disorders, such as dwarfism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this

gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pituitary indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the pituitary gland and endocrine system. Moreover, considering the vital importance of the pituitary in serving as a master regulator for various endocrine glands, the protein product of this gene would also be useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:76, b is an integer of 15 to 930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 67

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

35 SNEELSPQNYTYIQWLNGSLIHGLWNLASLFSNLCLFVLMPPAFFLESEGFA
GLKKGIARILETLVM LLLALLLGIYVVASALINDAAS (SEQ ID NO:379).

Polynucleotides encoding these polypeptides are also encompassed by the

invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in the developing brain, liver and heart, and to a lesser extent, in cancerous tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, neural, hepatic, or cardiopulmonary and haemopoietic disorders, in addition to cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal tissues and the haemopoietic and neural systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, neural, haematopoietic, hepatic, cardiovascular, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, bile, serum, pulmonary surfactant or sputum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:226 as residues: Glu-67 to Asn-74, Glu-88 to Asn-93, Lys-95 to Ser-105, Arg-152 to Ala-164, Ala-204 to Arg-210, Phe-254 to Thr-262, Pro-295 to His-311.

The tissue distribution in developing brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of haemopoietic and developmental diseases and cancers. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or

neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the relatively specific expression of this gene product during embryogenesis indicates that it may be a key player in the proliferation, maintenance, and/or differentiation of various cell types during development. It may also act as a morphogen to control cell and tissue type specification. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers, which include, but are not limited to the following tissues or cells: pulmonary, immune, neural, hematopoietic, or hepatic tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4449 of SEQ ID NO:77, b is an integer of 15 to 4463, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 68

The translation product of this gene shares sequence homology with a putative yeast transmembrane protein which may play an important role in intercellular signalling, intracellular transport, or regulation of cellular homeostasis. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PTRPVLLLAINGVTECFTF AAMSKEEVD RYNFV (SEQ ID NO:380), and/or NDKLLFLKGFWSLLKNETPPPHRLRMVTGVSCGTLWCLISGV AVTPLQSPQWG SYTECVPTTELPIAGPGASGVQASLKRHFVSASGHT (SEQ ID NO:381). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in pulmonary, immune cells, epididymus, and testis tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive organs, immune, and pulmonary systems, in addition to endothelial and epithelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, respiratory and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. pulmonary, immune, reproductive, testes, epididymus, endothelial, epithelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, pulmonary surfactant or sputum, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:227 as residues: Arg-45 to Thr-52, Tyr-60 to Gly-66, Ala-87 to Trp-92, Leu-105 to Ser-115.

The tissue distribution and homology to putative transmembrane protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the reproductive, pulmonary and immune system. Moreover, the protein product of this gene may be useful in the diagnosis, treatment, and/or prevention of a variety of male reproductive disorders, which include, but are not limited to, aberrant testicular function, male sterility, impotence, or related endocrine disorders. Protein may also serve a role as a contraceptive. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 777 of SEQ ID NO:78, b is an integer of 15 to

791, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 69

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

10 SENRIYRNGLEKMRREVTIGRSSICLDQQVKAGNAVHHQWLKYYCWMVVVV
GGSGVGDDGG NLGM (SEQ ID NO:382). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in PMA induced T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as inflammatory or immunodeficiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:228 as residues: Ser-62 to Thr-73, Phe-80 to Gln-88.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and diagnosis of immune system disorders. More specifically, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease,

sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1278 of SEQ ID NO:79, b is an integer of 15 to 1292, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

25 This gene is expressed primarily in monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, which include, but are not limited to, leukemias, lymphomas, AIDS, arthritis and asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in monocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Moreover, this gene may also be useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

25 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1269 of SEQ ID NO:80, b is an integer of 15 to 1283, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 71

When tested against dermal fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblast cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-

103

STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 NVSGRRRLRMWPSAALSPA VSSPALATSPPKPLKGEVWLRWKLGSRAVGLF
AFIALGTQSPPLHRACL PVRQSGCSEHKAYPILRLQPDLETQVGPBGHGVN
WDLRTQIRITIGELGDDGCSE MRPLF (SEQ ID NO:383), and/or NLFTSPCKRQ
KLKLEWTEAPNVALRCSLSCLLPGLSPDLSEAPEGRSVAKMEIARQSCWL
VCI YCFRNPESLAPGLPACAEALGILRAQGLPHFASPARLGNITGGAWPR
10 SKLGSQNTN (SEQ ID NO:384), SSPALATSPPKPLKGEVWLRWKLIG (SEQ
ID NO:385), EHKAYPILRLQPDLETQVGPBGHGVNWDL (SEQ ID NO:386), and/or
ALRCSLSCLLPGLSPDLSEAPEGRSV (SEQ ID NO:387). Polynucleotides
encoding these polypeptides are also encompassed by the invention. The gene encoding
the disclosed cDNA is believed to reside on chromosome 11. Accordingly,
15 polynucleotides related to this invention are useful as a marker in linkage analysis for
chromosome 11.

This gene is expressed primarily in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders and
cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful
in providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
25 reproductive system, expression of this gene at significantly higher or lower levels may
be detected in certain tissues or cell types (e.g. reproductive, placental, and cancerous
and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma,
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
30 the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID
NO:230 as residues: Gly-22 to Gly-29, Gln-37 to Ala-44.

35 The tissue distribution in placental tissue, combined with the detected EGR1
biological activity indicates that polynucleotides and polypeptides corresponding to this
gene are useful for the treatment and diagnosis of developmental anomalies, fetal
deficiencies and pre-natal disorders. In addition it may be useful in the detection and

104

treatment of ovarian and endometrial cancers. Protein, as well as, antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy targets
for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
5 and accessible through sequence databases. Some of these sequences are related to SEQ
ID NO:81 and may have been publicly available prior to conception of the present
invention. Preferably, such related polynucleotides are specifically excluded from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
10 polynucleotides comprising a nucleotide sequence described by the general formula of
a-b, where a is any integer between 1 to 694 of SEQ ID NO:81, b is an integer of 15 to
708, where both a and b correspond to the positions of nucleotide residues shown in
SEQ ID NO:81, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 72

In specific embodiments, polypeptides of the invention comprise the following
amino acid sequence:

20 LAPECCGSVTYPRAL VPRPCPEPRAPLQLTLGLFSANPVNASPWGRCSR
GRGNLPLGHPVSTAFSSGDS (SEQ ID NO:388), and/or NTLHSKL VPSVYHSTE
KSCLV CFGMCPSTYKKMKSVLLIGTRMLL WLSHISQGRPEAVLPRASP
SAAHPWL VFRKPGKRKPLQGMQOK REGKPA SGSPC (SEQ ID NO:389), YPR
25 ALVPRPCPEPRAPLQLTLGLF (SEQ ID NO:390), and/or VLLIGTRMLL
WLSHISQGRPEAVLPR (SEQ ID NO:391). Polynucleotides encoding these
polypeptides are also encompassed by the invention. The gene encoding the disclosed
cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to
this invention are useful as a marker in linkage analysis for chromosome 7.
30 This gene is expressed primarily in infant brain, and to a lesser extent, in
placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental and neurological disorders. Similarly, polypeptides and
35 antibodies directed to these polypeptides are useful in providing immunological probes
for differential identification of the tissue(s) or cell type(s). For a number of disorders
of the above tissues or cells, particularly of the developmental and neurological

systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, developmental, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:231 as residues: Thr-45 to Arg-50.

The tissue distribution in fetal brain and placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of various developmental and neurological disorders and diseases. The protein product of this gene is useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1450 of SEQ ID NO:82, b is an integer of 15 to 1464, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 73

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 WIVMFGKVLKIKDFMSTYSHTYTHTHMHAHTHTLTLSSLQNVLTLVAISDS
15 DK ALLIF (SEQ ID NO:392), MTLIAEKTWRPWPQCWGYLGAEGDRHLEG
RSLRLHLQGAETPVLPDLQPSHIGKQAWSH ALGSL (SEQ ID NO:393),
MSTYSHTYTHTHMHAHTHTLTLSSL (SEQ ID NO:394), and/or GAEGDRHLE
GRSLRLHLQGAET (SEQ ID NO:395). Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in the spleen of patients with lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, lymphocytic leukemia and other cancers, as well as immune disorders such as AIDS, arthritis and asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of

lymphocytic leukemia and other cancers, as well as other immune disorders and conditions including, AIDS, arthritis, asthma and microbial infection. Furthermore, the protein product of this gene may be useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoeisis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 602 of SEQ ID NO:83, b is an integer of 15 to 616, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

When tested against Jurket and fibroblast cell lines, supernatants removed from cells containing this gene activated both the GAS (gamma activating sequence) and the EGR1 (early growth response gene 1) promoter elements. Thus, it is likely that this gene activates immune or fibroblast cells through the JAK-STAT and/or EGR1 signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation

of cells. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VVEPGILKASLGA

MSTLSPSLFPRVTETLWFNLDRPCVEETELQQEQEQHQAWLQSLAEKDNNLVPI
GKPASEHYDDEEEEDD EDEDESEDEDEDDMQDMDEANDYNESPDDGEVN
EVDMEGNEQDDQDWM (SEQ ID NO:396), LFRVTETLWFNLDRPCVEETEL
(SEQ ID NO:397), and/or YNESPDGGEVNEVDMEGNEQDD (SEQ ID NO:398).

Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 11.

Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

This gene is expressed primarily in cells of the immune and haemopoietic systems, and to a lesser extent, in several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and haemopoietic disorders, such as multiple myeloma, immunodeficiencies, and inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and haemopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:233 as residues: Pro-21 to Gly-30.

The tissue distribution in immune tissues and cells, combined with the detected GAS and EGR1 biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, haemopoietic, and integumentary systems. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia,

thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell *ex vivo* culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 914 of SEQ ID NO:84, b is an integer of 15 to 928, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MGFDIHGVLGEA VAEPREKKQE RAKWAPHDYDDPSLS LQDLLISWMISTWLIPMWKCQATTWFSLIQRLNAYCMPGNFRHWEIAANTTN KT PGLMDPKFL (SEQ ID NO:399), EPREKKQERAKWAPHDYDDPSLSLQDL (SEQ ID NO:400), and/or MPGNFRHWEIAANTTNKT PGLMDF (SEQ ID NO:401). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

This gene is expressed primarily in fetal liver and spleen, and to a lesser extent, in prostate cancer and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, immune, and haemopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and developing systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, hepatic, reproductive, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in developing and immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the hematopoietic and developing immune systems. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell *ex vivo* culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The protein may also show utility in the treatment or diagnosis of various hepatic or reproductive disorders, which include, but are not limited to hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells, and prostate cancer, and/or congenital defects such as X-linked conditions. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 709 of SEQ ID NO:85, b is an integer of 15 to 723, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 76

This gene is expressed primarily in fetal spleen and Wilm's tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic, immune, developmental, or renal disorders, such as congenital defects, multiple myeloma, or Wilm's tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic and developing systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, immune, hematopoietic, renal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the haemopoietic and developing systems and cancer. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the

production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 556 of SEQ ID NO:86, b is an integer of 15 to 570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 77

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS

element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in induced T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune and inflammatory diseases. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility);

chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding

nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 625 of SEQ ID NO:87, b is an integer of 15 to 639, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QSVSPPLAPPLPSPFLFTETRSHYVARLVNSWAQM ILLPWPLKVLGLDVSHCAWPKSVFLQAMEEIADECLFSVKYQVSSMTCF DRT SYMKNTYL (SEQ ID NO:402), and/or LFTETRSHYVARLVNSWAQMILLPW (SEQ ID NO:403). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, anemias (leukemias), immune deficiencies and other hematopoietic-related disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of

115

hematopoietic and immune disorders, which include, but are not limited to the following: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and other hematopoietic disorders, such as multiple myeloma. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 694 of SEQ ID NO:88, b is an integer of 15 to 708, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 79

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

25 SQKSEKHHGKAYTCTQTQSTGMQSTLTIVAKKKSRRNHTESYTRKKQENQIV
LIPWHQKKHPEGTHCSSLRRDNTAADTQKRAHRYTYRRDKYSDTLVTH
DHYKGDKHPNSNTHTPR XEFLQPGGSTNSRAAPRXSSFCFPS EGYs
SWGYH (SEQ ID NO:404), GMQSTLTIVAKKKSRRNHTESYTRKKQ (SEQ ID
NO:405), KKHPGTHCSSLRRDNTAADT (SEQ ID NO:406), and/or RRDKY
SDTLVTHDHYKGDKHPNSNT (SEQ ID NO:407). Polynucleotides encoding these
30 polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as leukemias, lymphomas, AIDS, arthritis and asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification

116

of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:238 as residues: Asp-38 to Leu-43.

10 The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including leukemias, lymphomas, AIDS, arthritis and asthma, as well as other conditions which potentially implicate the immune system, such as atherosclerosis, cancer and infection. In addition, This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO:89, b is an integer of 15 to 949, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KHLPLKAPIDLDNKNSCMFCSRDFCRFH HSTAWLFL GRITRILGLHHYLIRYQFEIENLCMLKIVIPVVSMTKNCQDFLGLKQNLVH (SEQ ID NO:408), APIDLDNKNSCMFCSRDFCR (SEQ ID NO:410), and/or IENLCMLKIVIPVVSMTKNCQDFLGLQL (SEQ ID NO:409). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in prostate carcinoma cell line stimulated with 30 nM synthetic androgen, R1881 cells and, to a lesser extent, in activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or immune disorders, particularly prostate cancer and prostate ailments. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of prostate cancer and prostate ailments, or related proliferative conditions in either said tissue or other tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1157 of SEQ ID NO:90, b is an integer of 15 to 1171, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

The translation product of this gene shares strong sequence homology with human protocadherin 42 (GenBank accession no. gi387675), PCDH7 (BH-Pcdh)a, and its associated isoforms PCDH7 (BH-Pcdh)b, and PCDH7 (BH-Pcdh)c which are thought to be important in tissue and cell-cell adhesion, repair and development (See Genbank Accession Nos.gnllPIDid1026122 (AB006755), gnllPIDid1026123

(AB006756), and gnllPIDid1026124 (AB006757)). The polynucleotides encoding this gene have been gened by another group subsequent to our filing (See Yoshida K, et al, Genomics 1998 May 1;49(3):458-61, which is hereby incorporated by reference). The cytoplasmic domain of cadherin interacts with the cytoskeleton through catenins and other cytoskeleton associated proteins. The cytoplasmic domain is not present in all cadherins, but in those which possess it, it is essential for the cadherins adhesive

function. The cadherins which do not possess a cytoplasmic domain appear to function via a different method from those with a cytoplasmic domain. This protein sequence is involved in cell-cell adhesion. This sequence may have regulatory functions in the cell, as well as the cell-cell adhesive properties. Antibodies produced against this sequence are useful for modulating the binding activity of protocadherins, and can be used

therapeutically. BH-Pcdh has an extracellular domain consisting of seven repeats of the cadherin motif (EC 1 to 7). EC2 of BH-Pcdh is unique in having a 55-amino-acid insertion in the middle of the motif. There are three isoforms of BH-Pcdh, denoted -a, -b, and -c, which have different cytoplasmic tails and a 47-amino-acid deletion in the

EC2-3 region of BH-Pcdh-c. While only a 9.0-kb message was detected in normal tissues, 4.5- and 9.0-kb mRNA species were seen in the human lung carcinoma cell line A549. Furthermore, only the 4.5-kb mRNA was detected in HeLa cell S3 and

119

human gastric cancer cell lines MKN28 and KATO-III. Southern blot analysis indicated that the BH-Pcdh gene is likely to be conserved among various vertebrates. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 GTSVNESVSNATIDSQIARSLHIPLTQDIAGDPSYEISKQRLSIVIGVVAGI (SEQ
ID NO:411), PKIKMAMKPAKKITKTLHPNSMTNLKSLKTRKTKNLSSLSTA
ALSLWLLSQMDRGMVMSRCQTAQAWGDTGPLMVGPVLTWQGITNL
VPHCLTFSPSHQLOEKNTRPYKYHQPHLWEQETTFQLDQTALSTAYKP
10 ITSTANRCVYIHITLLCLAEFHSNMMLHYAPYCDDLSTPKPAGACFPWPGVSQS
LLVPLVVFHEFESFSFYTEK (SEQ ID NO:412), CSIMHHTVMFTLLRNLEPA
LGRGVSANHCLEHLLYLFLSLFLSHQKNSMKIK (SEQ ID NO:413), TAIDS
QIARSLHIPLTQDIAGDPSYEISK (SEQ ID NO:414), YCRSKNKNNGYEAKKDH
EDFF (SEQ ID NO:415), GPGSPDLARHYKSSSPLPTVQ (SEQ ID NO:416), and/or
15 LPANTFVGAGDNISIGSDHCSEYS (SEQ ID NO:417). Polynucleotides encoding
these polypeptides are also encompassed by the invention. The gene encoding the
disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides
related to this invention are useful as a marker in linkage analysis for chromosome 4.
This gene is expressed primarily in ovarian tumors, and to a lesser extent in,
striatum and HL-60 cells.

20 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, cancer and reproductive dysfunction, in addition to cardiovascular and
neural disorders, such as atherosclerosis, and neurodegenerative disorders, such as
25 Alzheimer's and Parkinson's, or other disorders resulting from aberrant cell-adhesion.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
reproductive, nervous and immune systems, expression of this gene at significantly
30 higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive,
neural, cardiovascular, and cancerous and wounded tissues) or bodily fluids
(e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or
cell sample taken from an individual having such a disorder, relative to the standard
gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
35 individual not having the disorder.

120

Preferred epitopes include those comprising a sequence shown in SEQ ID
NO:240 as residues: Tyr-15 to Leu-59, Ala-68 to Asp-85, Pro-87 to Asn-96, His-120
to Lys-129, Ser-153 to Gln-170.

The tissue distribution in ovarian and muscle tissue, combined with the strong
5 homology to various cadherins indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis, study and treatment of various
neoplastic disorders such as squamous cell carcinomas and related tumors, and nervous
system and reproductive disorders. Considering the vital importance of cell-adhesion
amongst various cellular functions, in particular chemotaxis by the immune and
10 hematopoietic cells indicates that this gene product may play a direct, or in-direct role in
the regulation of cytokine production, antigen presentation, or other processes that may
also suggest a usefulness in the treatment of cancer (e.g. by boosting immune
responses). Since the gene is expressed in cells of lymphoid origin, the natural gene
product may be involved in immune functions. Therefore it may be also used as an
15 agent for immunological disorders including arthritis, asthma, immunodeficiency
diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,
inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis,
hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to
transplanted organs and tissues, such as host-versus-graft and graft-versus-host
20 diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue
injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia,
rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene
product may have commercial utility in the expansion of stem cells and committed
progenitors of various blood lineages, and in the differentiation and/or proliferation of
25 various cell types. Furthermore, the secreted protein can also be used to determine
biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions and as nutritional
supplements. It may also play an in-direct role in the regulation of a very wide range of
biological activities. Typical of these are cytokine, cell proliferation/differentiation
30 modulating activity or induction of other cytokines;
immunostimulating/immunosuppressant activities (e.g. for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation
of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation
or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating
35 wounds, stimulation of follicle stimulating hormone (for control of fertility);
chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic
or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-

inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1137 of SEQ ID NO:91, b is an integer of 15 to 1151, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

The translation product of this gene shares sequence homology with the G-protein coupled receptor TM3 consensus polypeptide which may implicate an important function for this protein in various signal transduction pathways. G-protein coupled receptors are known to have a variety of functions including modulating immune system tissue through interaction with cytokines and lymphokines. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

GTSNASVSPTICIMCGYVHIWFFICLVYLKVLQGSACPWIAAAVVMRRMRK
VQEKGEVFRNMAATWAL RSGIQSLNSLVSSAFFITFMTLGSSWNLVLSLVL
NWTGLSFYFSRN (SEQ ID NO:418), CLCVYLKVLQGSACPWIAAAVV
MRRMRK (SEQ ID NO:419), and/or TIFMTLGSSWNLVLSLVLNWTGLF (SEQ
ID NO:420). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast lymph node.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, breast cancer, or other immune or reproductive disorders and diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, breast, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, breast milk, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:241 as residues: Cys-34 to Gly-48.

The tissue distribution in breast lymph nodes and homology to a conserved G-protein coupled receptor TM3 consensus sequence indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for breast cancer or immune diseases. Considering the vast roles which G-protein coupled receptors play in the maintenance of important cellular functions, the secreted protein may have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

123

ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 700 of SEQ ID NO:92, b is an integer of 15 to 714, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 83

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

15 QPDIPVLVGFSGQCSFKVSGCWKGGIAEKVGTLTGTPKGRRAWPETEF
FRLLEGLP (SEQ ID NO:421), and/or RGFMAQPLVNTFQVAVPEVDL
APQNPSPRPADPALLSLTGSLAPGKVTVVNVSTAIIVPTWDSMAI
20 GELTIASHASMTLHIGRPGSRKRKNSVSGHARLPFGVPSVPT FSAISPP
FOQPETLKEQF (SEQ ID NO:422), EDLAPQNPSPRPADPALLSLTG (SEQ ID
NO:423), and/or TWDSMAIGELTIASHASMTLHIGRPGSRK (SEQ ID NO:424).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated T-cells, hepatocellular tumor, pancreas islet cell tumors, and hemangiopericytoma.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hepatic, and endocrine disorders, such as cancers, particularly of T-cells, hepatocellular tumors and pancreas islet cell tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hepatic, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

124

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:242 as residues: Glu-43 to Lys-50, Ser-53 to Phe-60.

The tissue distribution in T-cells, hepatocellular tumors, and pancreas islet cell tumors indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of immune, hepatic, and endocrine disorders, and other cancer types. Expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders in various tissues, aside from those disclosed above. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

20 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 796 of SEQ ID NO:93, b is an integer of 15 to 810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 84

25 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

30 VSPQLMGIKRREPSAAQLSVGEEHTLDREGRELVDLPQPSQKIKIKNKSSLPFG
LIIPP AHYKTAATTNLF (SEQ ID NO:425), and/or PSAAQLSVGEEHTLDREGREL
(SEQ ID NO:426). Polynucleotides encoding these polypeptides are also encompassed by the invention.

35 This gene is expressed primarily in hepatocellular tumors. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic disorders, such as liver diseases and hepatocellular tumor, including proliferative disorders in other tissues and cell types. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. hepatic, proliferating, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hepatocellular tumor tissues indicates that

polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of hepatocellular tumor or other liver disorders. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1162 of SEQ ID NO:94, b is an integer of 15 to 1176, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

When tested against reh cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is

likely that this gene activates B-cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NCDHDFIQLHTPMSAL FQSEFS (SEQ ID NO:427), SILNM GLFTEQRPWPAARCARQSTVAGAIRRAGTVMVQVAGAAW ASPDRRAKV (SEQ ID NO:428), QKSKGSLQTCCLPTLPMQERPADEWSTPGDQGKSYIK KPPGGLQKGHRLHRKLTLKQGRHRGVE GLNEIMVTVLKEEFPVSKPGLNV LPTFRRHECYQHGMNLTARISVVS (SEQ ID NO:429), ARQSTVAGAIRR ARGVTVMVQVAGA (SEQ ID NO:430), PCRRGLQMSGPLQATRGRTVLRSHQ (SEQ ID NO:431), LPMQERPADEWSTPGDQGKSYIKKPP (SEQ ID NO:432), and/or NVLPTFRRHECYQHGMNLTARI (SEQ ID NO:433). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human fetal kidney, adult testis, T-cell lymphoma, and a fetal liver/spleen cDNA library.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal, developmental, reproductive, immune, or hematopoietic disorders, particularly kidney disease, lymphoma, congenital defects, multiple myeloma, SCID, male sterility, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the kidney and immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, reproductive, renal, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:244 as residues: Gly-35 to Gly-40.

The tissue distribution in fetal kidney and T-cells, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of kidney diseases or immune disorders, especially cancers. Specifically, this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falcon's syndrome. Expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1014 of SEQ ID NO:95, b is an integer of 15 to 1028, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 86

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in breast, human embryo, and chronic spleen lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, developmental, hematopoietic or immune disorders, such as breast cancer, congenital birth defects, or leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast or hematopoietic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, immune, hematopoietic, developmental, breast, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, breast milk, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:245 as residues: His-2 to Asn-8, Gln-35 to Phe-44.

The tissue distribution in breast and lymphocytic leukemia cells, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or intervention of breast cancer, leukemia or other hematopoietic related disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopneisis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 733 of SEQ ID NO:96, b is an integer of 15 to 747, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 87

This gene is expressed primarily in brain containing medulla blastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly specific brain tumors such as medulla blastoma, as well as other diseases and conditions of the brain, such as schizophrenia, Alzheimer's disease, Tourette's syndrome, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, depressive and addictive predispositions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of specific brain tumors such as medulla blastoma. In addition it may also be useful for the diagnosis and treatment of developmental, degenerative and behavioral conditions of the

brain and nervous system, such as schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, mania, dementia, paranoia, addictive behavior, obsessive-compulsive and sleep disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 614 of SEQ ID NO:97, b is an integer of 15 to 628, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 88

When tested against Jurket cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates T-cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: INVLYCSRDSLGRTIMESSDYIKKGANVSPVLGVRQQ AV (SEQ ID NO:434). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adrenal gland tumor and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the endocrine and immune or haemopoietic systems, particularly inflammatory or immunodeficiency conditions, such as AIDS. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and endocrine systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells and adrenal gland tissues, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune and endocrine systems and cancer. Moreover, the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 890 of SEQ ID NO:98, b is an integer of 15 to 904, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SLMYFVFKIFFQSLCYLGYCILLPTVA (SEQ ID NO:435). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:248 as residues: Thr-43 to Thr-48.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune system disorders. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product

may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 562 of SEQ ID NO:99, b is an integer of 15 to 576, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

RLWMTKAHPALRHLLLTLLALTLAQGCCAVAPSGCADLAGFCSLGHSC
(SEQ ID NO:436). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human stomach.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, digestive and gastrointestinal conditions, particularly ulcers and cancers.

30 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. gastrointestinal, metabolic, mucosal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, chyme, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

35

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:249 as residues: Pro-32 to Gly-38.

5 The tissue distribution in stomach tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of gastrointestinal disorders, or other disorders afflicting mucosal or endothelial tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 699 of SEQ ID NO:100, b is an integer of 15 to 713, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

25 The translation product of this gene was found to have homology to the conserved K07F5.14 protein from *Caenorhabditis elegans* (See Genbank Accession No. gnIPIDc233697) which may be important in regulation of important cellular functions, including homeostasis and cell division. When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) pathway. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element

30 found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

35 RTCTPVMGFVCLVCSLFAPVPTSRKYL VSKPGCYQRRRV FGVCFKPL (SEQ

ID NO:437), WLSSEKKG (SEQ ID NO:438), and/or GVFYKAAVIG (SEQ ID NO:439). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly multiple myeloma, immunodeficiencies, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and endocrine systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in bone marrow and T-cells, combined with the detected GAS biological activity in U937 cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of immune and hormonal disorders and neoplasias. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also

be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the protein may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated

cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune

infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 635 of SEQ ID NO:101, b is an integer of 15 to 649, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 92

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185

This gene is expressed primarily in ovary, spinal cord, and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, and neurological conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, reproductive, ovarian, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:251 as residues: Pro-34 to Pro-53.

The tissue distribution in spinal cord and fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of neural, hematopoietic, and developmental disorders. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia,

leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include, but are not limited to bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 683 of SEQ ID NO:102, b is an integer of 15 to 697, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DEGVQGERLFRILRINGEKPFYFVDFHCEY (SEQ ID NO:447), KVVRIIDNGILCSHKKTEIMSLQQHGWWRPYLKQTNTGTENQIPHTL TYKWELNFEYITQXRGXXDSEAYLKVEGGRREGIQKLPIRYVYVYLGDKIICIT SSSCSMHLLM (SEQ ID NO:448), HKDTCMSMFT AALFTIAKTWN (SEQ ID NO:449), MPTNDRDLDFKRWYV (SEQ ID NO:450), TMESYVAIKRQRSCPCSNM VSGGHLISKL TQEQT KYHLS LISGS (SEQ ID NO:451), EIMSLQQHGWWR PYLKQTNTGTEN (SEQ ID NO:452), and/or RREGIQKLPIRYVYVYLGDKIICIT (SEQ ID NO:453). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bladder tissue from a human male.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, urogenital, and nephrotic conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the gastrointestinal and excretory systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. renal, bladder, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:252 as residues: Arg-52 to Ala-57, Pro-66 to Thr-72.

The tissue distribution in bladder tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of gastrointestinal and urinary tract disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:103, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

This gene is expressed primarily in bladder tissue from a human male.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal, renal, and urinary tract conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the intestinal and urinary tract, expression of this gene at significantly higher or lower levels may be

detected in certain tissues or cell types (e.g. renal, urogenital, bladder, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in bladder tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of urinary tract and gastrointestinal disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1013 of SEQ ID NO:104, b is an integer of 15 to 1027, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 95

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LHGEQVPI YIFLLMQPLNECISFLNCIEQYSVGVI HNSV TTYACDRENCMDIRYL (SEQ ID NO:454), and/or GTSWASRFTCH (SEQ ID NO:455). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory disorders, particularly immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of

the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:254 as residues: Lys-28 to Thr-34.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune system. Moreover, This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 696 of SEQ ID NO:105, b is an integer of 15 to 710, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

GPPRXFXPKKAILGXPPXGRVPPFRYRSRNSRGRPHXSAPRVRECLNSWLR
(SEQ ID NO:456), and/or PLNTMMCMCKMKVSPKFSKLKRKYLNSTLTKL
EMQTVHLESSLASCSPNKGXVGRTR GVDPGNSGTGT (SEQ ID NO:457).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in lymphoma and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and haemopoietic diseases, particularly neurodegenerative conditions such as Alzheimers and Parkinsons. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in frontal cortex and lymphoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the neural and haemopoietic systems. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this

gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Moreover, the expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Since, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:106 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 516 of SEQ ID NO:106, b is an integer of 15 to 530, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

This gene is expressed primarily in the spleen of a patient with metastatic melanoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly metastatic melanoma and other cancers, as well as immune disorders and conditions such as anemias, AIDS,

arthritis and asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:256 as residues: Pro-26 to Asn-34.

The tissue distribution in spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of metastatic melanomas and other cancers, as well as other immune disorders and conditions including leukemias, lymphomas, AIDS, arthritis, asthma and microbial infection. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, or thrombocytopenia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 378 of SEQ ID NO:107, b is an integer of 15

to 392, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 107, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 98

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GTVTQKRK CVFGKYLLSTCSLMFSSMHGACSWKA

KQTSSSAGFLCLHVLCPALQLTREKYKTWPWPSFI (SEQ ID NO:458), and/or

10 MKEGQGHVLYF SRVNCAGHXTCRQKPADELVCFAFQEQAPELLNI

RLQVLNLYLPNTHFLFCVTVP (SEQ ID NO:459). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

15 This gene is expressed primarily in pineal gland and synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine or skeletal disorders, including cancers. Similarly,

20 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endocrine, pineal, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in pineal gland indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the endocrine system. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, the expression of this gene product in synovium would suggest a

role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 977 of SEQ ID NO: 108, b is an integer of 15 to 991, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 108, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 99

25 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

TMTGIDSSPEELRQVGCKQQQKQGVHEVGSSAEAGEAARGGGAK GGGG

AAGKGTSKVGTLLRTRGST (SEQ ID NO:460). Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 This gene is expressed primarily in breast and fetal spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the reproductive system and developing organs, particularly congenital defects afflicting the immune or hematopoietic system, such as immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification

147

of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing and reproductive systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, developing, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

10 NO.258 as residues: Gly-23 to Asn-30, Ser-37 to Asn-43.

The tissue distribution in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases involving developmental tissues and reproductive organs. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hemopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors), hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:109 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

148

a-b, where a is any integer between 1 to 898 of SEQ ID NO:109, b is an integer of 15 to 912, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:109, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 100

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

10 A QREAGSRPRRRKSLKAVAMLXVEMGGCGRSMGPGVSA GSRVCRGSSL
PQVAFNPRAHLPPVVG GGLNSVWLSGVQLSTPPYADWEGVGQSPQ
PRGPWMGSSSLGTVPQCVLSGCTPVKANGGSPCSEMLGER RLLEPSVG
PVSGCPERREGGHGARGAAGVVKGHASVQLNFLSLI (SEQ ID NO:461),
15 KAFTFAKEKNAKAQLGKKGTRWVKHDKRKEQLYGCYTLNDPSCP CPYP
TLPPFWTA TYGSHGRFQPPFSQHLRAGGAPVGLDCGAPTOYAA RPHGPK
(SEQ ID NO:462), GCRSMGPGPGVSA GSRVCRGSSLPQ (SEQ ID NO:463),
QPRGPWMGSSSLGTVPQCVLS (SEQ ID NO:464), and/or GAAGVVKGH
ASVQLNFLSLI (SEQ ID NO:465). Polynucleotides encoding these polypeptides are
20 also encompassed by the invention.

This gene is expressed primarily in endothelial, immune, and cancer cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases involving immune, endothelial, and hematopoietic tissues or cells, particularly cancers, inflammatory or immunodeficiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoietic and endothelial systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. endothelial, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune and hematopoietic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis

and treatment of disorders of the immune and haemopoietic systems, including cancer. More specifically, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:110 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO:110, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:110, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 101

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GKPLSAIFPICH MMFLPKENLGISHRCCRM T SPWVDK RQQLRQECKSDPHVQNPRIHFPESKNSFSPA YIFVSEGNVSPSK WHCIY SGTSLSH (SEQ ID NO:466), and/or GERGRYQSKYSATWMVTPHYLTQRC

35

KLREMSWIQNEFLDSEHEGQIYTPVSTVDAYPKD (SEQ ID NO:467).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human kidney, and to a lesser extent, in liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, kidney, urogenital, hepatic, and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal or endocrine systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. urogenital, kidney, endocrine, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, bile, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:260 as residues: Glu-38 to Lys-43.

The tissue distribution in kidney indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of renal disorders, including noninflammatory and inflammatory lesions, and tumors of the kidney.

Moreover, this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Alternatively, expression within liver

indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

151

15 ID NO:111 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 445 of SEQ ID NO:111, b is an integer of 15 to 459, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:111, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 102

15 This gene is expressed primarily in kidney cortex and fetal tissue-utility. The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:112 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 595 of SEQ ID NO:112, b is an integer of 15 to 609, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:112, and where b is greater than or equal to a + 14.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 103

This gene is expressed primarily in ovary and brain.

152

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and neurological conditions, particularly proliferative disorders, such as ovarian cysts or cancer, in addition to neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, reproductive, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 The tissue distribution in ovarian tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of reproductive disorders, such as infertility. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:113 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

5 a-b, where a is any integer between 1 to 1390 of SEQ ID NO:113, b is an integer of 15 to 1404, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:113, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 104

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ISIRGRIL

15 YKMA YFKVCVIW FQFCVEETSI IKNVRMLTSEFQNSYATPVSGLLPGA VAWR
NO:468), KPFAFSARNPTTMLSEAYFQDPRMRQHHLGVERMTV AWVPSAIP
AWRASPTRTQHHPSKPQHEGAQKQGWHMNSGILMSA YEHFL (SEQ ID
NO:469), and/or HSKQNICKEVNILKMFLHEIKKTTVDNISTQRFTYNNHQPGS
VSIFSVDILDVEVPFGL (SEQ ID NO:470). Polynucleotides encoding these

20 polypeptides are also encompassed by the invention.

This gene is expressed primarily in melanocytes, and PHA stimulated T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or integumentary system disorders, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.integumentary, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of cancers and immune system disorders. Alternatively, the expression in melanocytes

indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:114 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 839 of SEQ ID NO:114, b is an integer of 15 to 853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:114, and where b is greater than or equal to a + 14.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 105

This gene is expressed primarily in B cell lymphoma, and to a lesser extent, in dermal fibrosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or integumentary disorders, particularly lymphatic and soft tissue cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in B-cell lymphoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the protein product of this gene may also be useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to

viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, linea, athletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:115 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 831 of SEQ ID NO:115, b is an integer of 15 to 845, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:115, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 106

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

KVIDVIFSLPPGRKATFSCPLAPLSGAXGLPGGGANRPQPLPCIQPWGPIRLP
EGC (SEQ ID NO:471), MSSSLCPQGGKPPSLAPWPLCCQGXVCRVGVPT

GLALSSPASSHGLCDCRKAWLVPQAQARG RAAWFFYFLTLFSVL (SEQ ID NO:472), and/or LALSSPASSHGLCDCRKAWLVPQP (SEQ ID NO:473).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in T cells, fetal liver, and to a lesser extent, in various normal and transformed tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or developmental disorders, including immunodeficiencies and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:265 as residues: Arg-5 to Pro-12.

The tissue distribution in B-cells and fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of immune and developmental disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow

transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. In addition, expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues

rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:116 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 746 of SEQ ID NO:116, b is an integer of 15 to 760, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:116, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 107

One embodiment of this gene comprises the following amino acid sequence:
 MQRERWAPWMASTVESRMPEGKVRFRSTDLATWGATPARSWTKASRGSTT
 AWTRLPMRSTMVLDDKQERKQSRSLAMGSTLLDRPGRKQTKRSKGSTLGSTRL
 GRKQRNLAKGSTMLLTLLERXWRSLAQVPTMLLARPKRSCRMILMGSTKPAR
 RPTSC (SEQ ID NO:474). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in keratinocytes and tissues undergoing wound healing, and to a lesser extent, in osteoblasts and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders; fibrosis; scarring; osteoporosis; osteopetrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, bone, or connective tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. skin, bone, connective tissues, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine,

synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:266 as residues: Gly-76 to Leu-83, Ala-108 to Glu-113, Ala-126 to Lys-132, Gly-145 to Leu-151.

10 The tissue distribution in keratinocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of skin disorders. Elevated expression of this protein in skin and keratinocytes suggest that it may be involved in keratinocyte proliferation, survival, and/or differentiation. Thus, it may play a role in such processes as fibrosis and wound healing. Similarly, expression of this protein in osteoblasts indicates that it may also play a role in osteoblast survival, proliferation, and/or differentiation, and that it may be useful in the treatment of such disorders as osteoporosis or osteopetrosis.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:117 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

20 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 974 of SEQ ID NO:117, b is an integer of 15 to 988, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:117, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 108

30 The translation sequence of this gene shares homology with a mouse calmodulin binding protein. The calcium-binding regulatory protein calmodulin is an essential subunit of the erythrocyte and other plasma membrane calcium ATPases. A rise in cytosolic calcium induces the binding of calcium ions to calmodulin, which triggers an allosteric activation of the calcium ATPase, and subsequently an export of calcium ions from the cell is accelerated.

35 This gene is expressed primarily in teratocarcinoma cells, and to a lesser extent, in myeloid progenitor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental defects, calcium-transport defects, in addition to immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of embryonic and fetal tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developing tissues, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:267 as residues: Tyr-124 to Gly-129.

20 The tissue distribution in teratocarcinoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental defects as well as for organ regeneration. Moreover, expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Alternatively, the homology of the translation product of this gene to a mouse calmodulin binding protein indicates that the translation product of this gene may be useful for disorders involving calcium transport across the plasma membrane, for example. It has further been suggested this type of disorder may be responsible for disorders such as hypertension.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:118 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

35 Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:118, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:118, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 109

One embodiment of this gene comprises polypeptides of the following amino acid sequence:

MRPLLGLLVFAGCTFALYLLSTRLPGRRLGSTEEAGGRSLWFPD LAELREL
SEVLREYRKEHQAYVLLFCGAYLYKQGFAPGSSFLNVLGALFGPWLGLLL
CCVLTSVGATCCYLLSSIFGKQLVVSYPDKVALLQRKVEENRNSLFFFLFLR
LFPMTPNWFLNLSAPILNIPVQFFFSVLGLI PYNFICVQTGSILSTLTS LDA
LFSWDTVFKLLAIAMVALPGLTKFKSQKHLQLNETSTANHHRSKDT (SEQ ID
NO:475). An additional embodiment is the polynucleotides encoding these
polypeptides.

This gene is expressed primarily in ovarian tumor, and to a lesser extent, in smooth muscle and breast cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, particularly of the ovary, musculature, and breast, such as rhabdomyosarcomas or fibroids. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. ovaries, breast, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, breast milk, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:268 as residues: Arg-24 to Arg-29.

The tissue distribution in ovarian tumor tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of

cancer, particularly ovarian and breast cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:119 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1434 of SEQ ID NO:119, b is an integer of 15 to 1448, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:119, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 110

The translation product of this gene shares sequence homology with bovine acrosin inhibitors IIa and IIb which is thought to be important as protease inhibitors. This gene is expressed primarily in keratinocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary disorders, such as psoriasis, and wound healing aberrations. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumental system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:269 as residues: Tyr-39 to Lys-58.

The tissue distribution in keratinocytes, combined with the homology to the bovine acrosin inhibitors IIa and IIb indicates that polynucleotides and polypeptides

corresponding to this gene are useful for the acceleration of wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:120 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:120, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:120, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 111

This gene is expressed primarily in fetal liver/spleen, T cells, and to a lesser extent, in bone marrow and primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:270 as residues: Glu-28 to His-34.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells

and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. This is particularly supported by the expression of this gene product in fetal liver and bone marrow, the two primary sites of definitive hematopoiesis. Expression of this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Furthermore, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:121 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1160 of SEQ ID NO:121, b is an integer of 15 to 1174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:121, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 112

The gene encoding the disclosed cDNA is thought to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

This gene is expressed primarily in fetal liver, spleen, and to a lesser extent in melanocyte.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, integumentary, or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of fetal and embryonic tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine,

synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:271 as residues: Met-1 to Met-7, Gln-43 to Glu-50, Thr-89 to Thr-95.

The tissue distribution in fetal liver and spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of developmental hematopoietic disorders. Additionally, the tissue distribution indicates 10 that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. This is particularly supported by the expression of this gene product in fetal liver, which is a primary sites of definitive hematopoiesis, and strongly suggesting a role for this protein 15 in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:122 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1032 of SEQ ID NO:122, b is an integer of 15 to 1046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:122, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 113

30

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS

element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in B cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, B cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above 10 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:272 as residues: Gln-23 to Asn-31, Tyr-42 to Ser-58.

The tissue distribution in B-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of lymphomas, particularly B cell lymphomas. Furthermore, expression of this gene product in B-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders 25 including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the biological activity data supports the notion that the

35

translational product of this gene activates specific immune cells, and therefore may play a role in the initiation of immune system activity.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:123 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1146 of SEQ ID NO:123, b is an integer of 15 to 1160, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:123, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 114

This gene is expressed primarily in neutrophils: IL-1 and LPS induced.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of certain immune disorders, especially those involving neutrophils. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a

usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:124 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 879 of SEQ ID NO:124, b is an integer of 15 to 893, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:124, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 115

One embodiment of this gene comprises polypeptides of the following amino acid sequence: DIMPASVIFLICEGVL YGVQG (SEQ ID NO:476). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, placental insufficiency, developmental abnormalities, aberrant angiogenesis, abnormal development and/or maintenance of the placenta. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the placenta and, more

generally, the vasculature and/or endothelium, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developing, placental, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 125 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1035 of SEQ ID NO: 125, b is an integer of 15 to 1049, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 125, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 116

This gene is expressed primarily in keratinocytes, as well as in synovial hypoxia and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, immune, or skeletal disorders, particularly wound healing and rheumatoid conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumentary system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. skin, connective tissues, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 275 as residues: Thr-42 to Pro-53, Val-78 to Glu-86, Glu-103 to Met-112, Ala-124 to Gly-131.

The tissue distribution in keratinocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of integumentary disorders, particularly with regard to wound healing. Furthermore, the tissue distribution also indicates that the translation product of this gene is useful for the treatment and/or detection of disorders of the connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Ateleostegenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 126 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

171

a-b, where a is any integer between 1 to 1612 of SEQ ID NO:126, b is an integer of 15 to 1626, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:126, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 117

This gene is expressed primarily in hepatoma and testes tumor, and to a lesser extent, in brain.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic, neural, or reproductive disorders, particularly metastatic liver cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer and metabolic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. liver, brain, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, seminal fluid, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in hepatic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some types of cancer including hepatoma, testes tumor and related metastases. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:127 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

172

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1163 of SEQ ID NO:127, b is an integer of 15 to 1177, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:127, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 118

10 This gene is expressed primarily in CD34 positive cells, and to a lesser extent, in pancreatic tumor and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, endocrine, or immune disorders, particularly pancreatic cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumor, immune and metabolic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, liver, spleen, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in pancreatic and CD34 positive cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some types of cancer, especially those involving CD34 cells and pancreatic cancer. Furthermore, expression of this gene product in both CD34 positive cells and spleen indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for

immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, z. rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:128 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO:128, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:128, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 119

This gene is expressed primarily in osteoclastoma, fetal liver/spleen, and to a lesser extent, in primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, osteoclastoma; hematopoietic disorders; lymphomas; impaired immunity; immune disorders; inflammation, in addition to integumentary disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and bone, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, bone, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:278 as residues: Thr-23 to Pro-29, Thr-68 to Pro-76.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of bone and hematopoietic disorders. Elevated levels of expression of this gene product in osteoclastoma indicates that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. More generally, as evidenced by expression in fetal liver/spleen, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors. Expression of this gene product in primary dendritic cells also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:129 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1320 of SEQ ID NO:129, b is an integer of 15 to 1334, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:129, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 120

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in hemangiopericytoma.

175

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, soft tissue cancers, such as hemangiopericytoma, in addition to other proliferative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. circulatory system, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:279 as residues: Pro-49 to Thr-64.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hemangiopericytoma. Furthermore, the biological activity data demonstrates that the translation product of this gene activates fibroblast cells. Fibroblast cells have the ability to undergo vascularization, and thus the translation product of this gene may be involved in disorders of the vascular tissue, such as hemangiopericytoma.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:130 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 518 of SEQ ID NO:130, b is an integer of 15 to 532, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:130, and where b is greater than or equal to a + 14.

35 **FEATURES OF PROTEIN ENCODED BY GENE NO: 121**

176

This gene is expressed primarily in kidney cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal or urogenital disorders, particularly nephritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. kidney, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:280 as residues: Pro-33 to Ser-38.

The tissue distribution in kidney cortex indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the kidney, including nephritis. Furthermore, the tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:131 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:131, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:131, and where b is greater than or equal to a + 14.

35

FEATURES OF PROTEIN ENCODED BY GENE NO: 122

5 This gene is expressed primarily in spleen from chronic lymphocytic leukemia. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as chronic lymphocytic leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. spleen, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of chronic lymphocytic leukemia. Furthermore, the expression observed predominantly in spleen cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immunodeficiency diseases, leukemia, and septicemia.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:132 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 715 of SEQ ID NO:132, b is an integer of 15 to 729, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:132, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 123

10 This gene is expressed primarily in neutrophils, dendritic cells, and CD34 positive cells (Cord Blood).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of some types of immune disorders, especially those involving neutrophils. More generally, as evidenced by expression in CD34 positive cells, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors. Expression of this gene product in primary dendritic cells also indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:133 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1065 of SEQ ID NO:133, b is an integer of 15 to 1079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:133, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 124

10

This gene is expressed primarily in adult lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, respiratory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the respiratory system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. respiratory, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in lung tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of respiratory disorders, such as asthma, emphysema, and ARDS. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:134 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1283 of SEQ ID NO:134, b is an integer of 15

to 1297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:134, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 125

5

The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

10

This gene is expressed primarily in T-cell lymphoma and fetal liver/spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, developmental, or hematopoietic disorders, particularly lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:284 as residues: Gln-25 to Phe-43.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of T-cell lymphoma. Furthermore, expression of this gene product in fetal liver/spleen indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma,

immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:135 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 603 of SEQ ID NO:135, b is an integer of 15 to 617, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:135, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 126

The translation product of this gene shares sequence homology with C9, a gene of unknown function. The gene encoding the disclosed cDNA is thought to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3. One embodiment of this gene comprises the polypeptides of the following amino acid sequence:

GTAFQHAFTNDCSRNVYIKKNGFTLHRNPFAQSTDGARTKGFSEGRHAWEV
WVWEGPLGTVA VIGIATKRAPMQCGYVALLGSDDDQSWGWNLVNNLLHNGE
VNGSFPQCNNAPKYQIGERIRVILD MEDKTLAFERGVEFLGVAFRGLPKVCLYP
AVSAVYGNTEVTLYLGKPLDG (SEQ ID NO:477). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in placenta, and to a lesser extent, in apoptotic T-cells, as well as in smooth muscle, testes, and microvascular endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, muscular, vascular, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells combined with the homology to the C9 protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving T-cells. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses), or male infertility. Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:136 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1297 of SEQ ID NO:136, b is an integer of 15 to 1311, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:136, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 127

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and

polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:137 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1081 of SEQ ID NO:137, b is an integer of 15 to 1095, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:137, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 128

This gene is expressed primarily in neutrophils; IL-1 and LPS induced.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:287 as residues: Lys-36 to Asp-42.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some immune disorders, especially those involving neutrophils. Furthermore, as evidenced by the expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:138 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 678 of SEQ ID NO:138, b is an integer of 15 to 692, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:138, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 129

This gene is expressed primarily in neutrophils, IL-1 and LPS induced.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:288 as residues: Pro-32 to Gln-38, Gly-51 to Asp-57.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of certain immune disorders, especially those involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:139 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 734 of SEQ ID NO:139, b is an integer of 15

to 748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:139, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 130

This gene is expressed primarily in neutrophils, IL-1 and LPS induced.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:289 as residues: Gly-22 to Ser-28.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of certain immune disorders involving neutrophils. Furthermore, as evidenced by expression in neutrophils, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the number of stem cells and committed progenitors. Expression of this gene product in neutrophils further indicates that it may play a role in mediating responses to infection and controlling immunological responses, such as those that occur during immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:140 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

187

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1118 of SEQ ID NO:140, b is an integer of 15 to 1132, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:140, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 131

10 This gene is expressed primarily in corpus callosum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly diseases of the brain, such as neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. brain, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in neural tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of brain disorders and diseases, including paranoia, schizophrenia, depression, mania, and Alzheimer's disease. Furthermore, elevated expression of this gene product within the corpus callosum of the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. Again, it may also be useful in the treatment of such neurodegenerative disorders as schizophrenia, A.L.S; or Alzheimer's. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:141 and may have been publicly available prior to conception of the present

188

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:141, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:141, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 132

The translation product of this gene shares sequence homology with the putative transposase of the Tigger-1 transposon.

15 This gene is expressed primarily in atrophic endometrium. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular disorders, particularly muscular atrophy. Similarly,

20 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, muscular, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in endometrial tissue combine with the homology to a transposase indicates that polynucleotides and polypeptides corresponding to this gene are useful for DNA repair in atrophying tissue, particularly of the endometrium. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:142 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

35

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1070 of SEQ ID NO:142, b is an integer of 15 to 1084, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:142, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 133

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARAFQHLMVADHSHFRTLKQSPMPNATFYHIF (SEQ ID NO:478). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in hemangiopericytoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, soft tissue tumors, particularly hemangiopericytoma, or other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:292 as residues: Ser-39 to Ser-44.

The tissue distribution in hemangiopericytoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of various soft-tissue tumors, in addition to other proliferative disorders which may afflict other tissues or cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:143 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1036 of SEQ ID NO:143, b is an integer of 15 to 1050, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:143, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 134

This gene is expressed primarily in hypothalamus of a schizophrenic patient, and to a lesser extent in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or immune disorders, particularly Schizophrenia or neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, immune, hematopoietic, spleen, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hypothalamus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Schizophrenia, as well as other central nervous system and immune system disorders. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating

diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction. aneurysms, hemorrhages, schizophrenia, mania,

191

dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, disorders of the endocrine system, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:144 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1099 of SEQ ID NO:144, b is an integer of 15 to 1113, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:144, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO. 135

The translation product of this gene shares sequence homology with a chicken ring-finger-zinc finger protein, C-RZF, in addition to, the human multiple membrane spanning receptor TRC8 which is thought to serve as a signaling receptor in renal and thyroid carcinomas. (See Genbank Accession No.gi3395787 (AF04801)) The TRC8 locus has been described in a family with classical features of hereditary renal cell carcinoma. The 8q24.1 (locus of TRC8) breakpoint region encodes the 664-aa multiple membrane spanning protein, TRC8, with similarity to the hereditary basal cell carcinoma/segment polarity gene, patched. This similarity involves two regions of patched, the putative sterol-sensing domain and the second extracellular loop that participates in the binding of sonic hedgehog. In the 3-8 translocation, TRC8 is fused to FHIT (fragile histidine triad gene) and is disrupted within the sterol-sensing domain. In

192

contrast, the FHIT coding region is maintained and expressed. In a series of sporadic renal carcinomas, an acquired TRC8 mutation was identified. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

ARALPEIKGSRLEINDVCAICYHEFTTSARITPCNHFFHALCLRWLYIQDTCP
MCHQKVTYEDDKDN

SNVSNNGFFIPNETPEEA VREAAAESDREL NEDSTDCCDDVQRENGVIQHT
GAAAGRI (SEQ ID NO:479), FSTQAQOLEFNDDTD (SEQ ID NO:480), RLQLE
INDVCAICYHEFTTSARI (SEQ ID NO:481), LYIQDTCPMCHQKVTYEDDI (SEQ
ID NO:482), VSNNGFFIPNETPEEA VREA (SEQ ID NO:483), and/or DDSTDCCD
DDVQRENGVIQHTGAAAG (SEQ ID NO:484). Polynucleotides encoding these
polypeptides are also encompassed by the invention. The gene encoding the disclosed
cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to
this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in human embryonic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities, particularly congenital defects or proliferative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryonic tissues, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g developmental, renal, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in embryonic tissue, combined with the homology to ring finger-zinc finger protein and the human TRC8 receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of abnormalities of the embryonic tissues, in particular proliferative disorders. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, detection, and/or treatment of developmental disorders. The relatively specific expression of this gene product during embryogenesis indicates that it may be a key player in the proliferation, maintenance, and/or differentiation of various cell types during development. It may also act as a morphogen to control cell and tissue type

specification. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. Moreover this protein may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:145 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:145, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:145, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 136

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VAGITGAHHHAQLIFVLLVEMGFHHV GQAGLKLLTSDN PRTSASQAGITGMSXGRRITCGQEFKTA VSYNCTTALQPDRAKLCFLFKKKK KISIQ RTLPGIKRVINYERYVDSSKGHNSQVQWAHA CNPSTLGGRRGGQIV (SEQ ID NO:485), AGITGAHHHAQLIFVLLVEMGF (SEQ ID NO:486), RVYIN YERYVDSSKGHNSQVQWAHCNP (SEQ ID NO:487). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in microvascular endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular or endothelial disorders, such as the following: arteriosclerosis, tumorigenesis, stroke, embolism, aneurysm, microvascular disease, and various cardiovascular disorders. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. vascular, endothelial, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in microvascular endothelial tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of vascular disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:146 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

20 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1024 of SEQ ID NO:146, b is an integer of 15 to 1038, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:146, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 137

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed primarily in fetal tissues, most notably fetal cochlea and fetal lung, and to a lesser extent, in rhabdomyosarcoma and healing groin wound tissue.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

195

not limited to, embryological/developmental abnormalities; hearing defects; respiratory diseases; rhabdomyosarcoma; general cancers and other proliferative conditions; fibrosis; wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryo/fetus or of striated muscle cells, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. developmental, pulmonary, auditory, muscle, fibroid, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases involving abnormal cellular proliferation, such as cancer. Expression of this gene product in rapidly proliferating cells, such as those found in the embryo; in rhabdomyosarcomas; and in wound healing tissue, indicates that this gene may play a role in controlling or promoting cell proliferation. Alternately, expression of this gene in fetal tissues indicates that it may play a role in cellular development and differentiation, particularly of the auditory system as well as the lungs. Thus, this gene product may be useful in the treatment and/or diagnosis of hearing defects, as well as respiratory disorders. Expression of this gene product in rhabdomyosarcoma indicates that it may play a role in the progression of such cancers, and may also be involved in metastasis and/or angiogenesis. Additionally, expression in wound healing tissues again indicates a role in the proliferation of connective tissue types involved in wound healing, as well as in the fibrosis and scarring that accompanies the wound healing process. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:147 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 837 of SEQ ID NO:147, b is an integer of 15

196

to 851, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:147, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 138

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in adult brain, and to a lesser extent, in cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and diseases of the brain, particularly neurodegenerative and behavior conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:297 as residues: Pro-25 to Ser-30, Thr-36 to Ser-47.

The tissue distribution in neural tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders and diseases of the brain, particularly paranoia, Alzheimer's, depression, schizophrenia, and mania. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, A.L.S., psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance,

and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:148 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

15 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 600 of SEQ ID NO:148, b is an integer of 15 to 614, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:148, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 139

This gene is expressed primarily in cerebellum.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly neurodegenerative disorders, such as Alzheimers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g.neural, cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30

35 This gene is expressed primarily in brain tissue of a patient with Alzheimer's disease, and to a lesser extent, in human adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

The tissue distribution in cerebellum indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of brain diseases and disorders. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:149 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

25 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1186 of SEQ ID NO:149, b is an integer of 15 to 1200, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:149, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 140

This gene is expressed primarily in brain tissue of a patient with Alzheimer's disease, and to a lesser extent, in human adipose tissue.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or adipose-related disorders, particularly neurodegenerative disorders, such as Alzheimer's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, metabolic, adipose, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neural and adipose tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Alzheimer's disease and other nervous system disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. More specifically, the protein product of this gene may show utility in the treatment, diagnosis, and/or prevention of neural disorders which occur secondary to aberrations in fatty-acid metabolism, such as improper development of the myelin sheath of nerve cells, for example. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:150 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 669 of SEQ ID NO:150, b is an integer of 15 to 683, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:150, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 141

This gene is expressed primarily in T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly T cell leukemia, immunodeficiencies, and inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:300 as residues: Asn-62 to Leu-68.

The tissue distribution T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of T cell leukemia and other disorders of the immune system. Moreover, this gene product may play a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene

product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:151 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 813 of SEQ ID NO:151, b is an integer of 15 to 827, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:151, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 142

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in the frontal lobe of the brain, and to a lesser extent, in synovial fluid and embryos.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental or neural disorders, particularly neurodegenerative, behavioral, and congenital abnormalities of the brain. Similarly, polypeptides and

antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:301 as residues: Gln-24 to Lys-31.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of abnormalities of the brain. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the skeletal or cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:152 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

203

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 821 of SEQ ID NO:152, b is an integer of 15 to 835, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:152, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 143

The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal disorders, such as osteoporosis, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in osteoblasts indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of osteoporosis and other bone degenerative diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:153 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

204

a-b, where a is any integer between 1 to 544 of SEQ ID NO:153, b is an integer of 15 to 558, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:153, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 144

This gene is expressed primarily in CD34 positive cells (cord blood) and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and immune disorders, particularly proliferative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, reproductive, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in cord blood and placental tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of certain immune disorders, especially those involving CD34 cells. Expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:154 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1187 of SEQ ID NO:154, b is an integer of 15 to 1201, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:154, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 145

This gene is expressed primarily in frontal cortex of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or spinal cord disorders, such as neurodegenerative conditions and other abnormalities of the brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:304 as residues: Pro-21 to Ser-27.

The tissue distribution in frontal cortex tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of the abnormalities of the brain. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive

disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:155 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1012 of SEQ ID NO:155, b is an integer of 15 to 1026, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:155, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 146

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed primarily in adrenal gland tumor, breast tissue, and to a lesser extent in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine or reproductive disorders, such as adrenal gland tumor, breast cancer, metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adrenal glands and breast, expression of this gene at significantly

higher or lower levels may be detected in certain tissues or cell types (e.g. reproductive, metabolic, endocrine, breast, adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, breast milk, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:305 as residues: Arg-44 to Lys-49, Asp-60 to Phe-66.

The tissue distribution in adrenal gland and breast tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders involving the adrenal gland. Expression of this gene product in adrenal gland tumor indicates that it may play a role in the proliferation of cells of the adrenal gland, or potentially in the proliferation of cells in general. In such an event, it may play a role in determining the course and severity of cancer.

Alternatively, it may play a role in the normal function of adrenal glands, such as in the production of corticosteroids, androgens, or epinephrines. Thus it may play a role in general homeostasis, as well as in disorders involving the androgen hormones.

Expression of this gene product in breast and adipose tissues also indicates that it may play a role in breast cancer, or in supplying vital nutrients to the infant during lactation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:156 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 890 of SEQ ID NO:156, b is an integer of 15 to 904, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:156, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 147

This gene is expressed primarily in LNCAP, and untreated spleen; metastatic melanoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, integumentary disorders, such as metastatic melanoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and cancer metabolic systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. immune, hematopoietic, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:306 as residues: His-47 to Thr-53.

The tissue distribution in spleen and integumentary tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of some types of cancer, especially metastatic melanoma. The protein product of this gene is useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, vitrearia, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Ateleostogenesis type

II, metaphyseal chondrodysplasia type Schmid). Alternatively, this gene is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

15 ID NO:157 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 902 of SEQ ID NO:157, b is an integer of 15 to 916, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:157, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 148

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: AGAEVVMFLFLTPSS HHQHECYRRAFECGDCCHILLDNNV LGVDCGAGAGERA VHLEDHFVHDTISLLEDALEYSALIAGHPKSD LPPGLSRC

30 RPWEHHWPISYTG (SEQ ID NO:488), TI SYLCNNVSYMQLQKLVGKSMIFLP YSLPHLPNGNHRLLLPVGMRLRGCCFSPYITDFKWC (SEQ ID NO:489), EMGQWCQSQGLHLDSFGGKSDFGCPAINAEYSRASSKSRLMVMWTKWSSRC TALSPAP (SEQ ID NO:490), RAFECGDCCHILLDNNVLGVDCGAG (SEQ ID NO:491), and/or LVGKSMIFLPYSLPHLPNGNHR (SEQ ID NO:492).

35 Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1.

Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in ovary, and to a lesser extent in meninges, the adrenal gland, and the cerebellum.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, neural, and endocrine disorders, such as ovarian and brain cancers, neurodeficiency disorders, and infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive and endocrine systems, expression of this gene at significantly higher or lower levels may be detected in certain tissues or cell types (e.g. neural, reproductive, ovarian, and cancerous and

10 wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in ovarian and endocrine tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovarian cancer and other endocrine disorders. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases,

25 peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo,

35 sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well

as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:158 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 907 of SEQ ID NO:158, b is an integer of 15 to 921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:158, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HNGEU17	209299 09/25/97	Uni-ZAP XR	11	826	1	826	277	277	160	1	17	18	23
2	HNGDJ72	209299 09/25/97	Uni-ZAP XR	12	524	1	524	185	185	161	1	19	20	113
3	HNGEO29	209299 09/25/97	Uni-ZAP XR	13	491	1	491	98	98	162	1	32	33	44
4	HNHDL95	209299 09/25/97	Uni-ZAP XR	14	403	1	403	121	121	163	1	23	24	58
5	HAGDS35	209299 09/25/97	Uni-ZAP XR	15	813	1	813	52	52	164	1	23	24	118
6	HNGEQ48	209299 09/25/97	Uni-ZAP XR	16	264	1	264	10	10	165	1	20	21	54
7	HNGDG40	209299 09/25/97	Uni-ZAP XR	17	520	1	520	13	13	166	1	36	37	127

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HSLFD55	209346 10/09/97	Uni-ZAP XR	34	1564	1	1564	105	105	183	1	21	22	43
25	HSAXJ29	209299 09/25/97	Uni-ZAP XR	35	1035	1	1035	129	129	184	1	19	20	57
26	HSFAM39	209299 09/25/97	Uni-ZAP XR	36	620	1	620	117	117	185	1	23	24	68
27	HTODO72	209299 09/25/97	Uni-ZAP XR	37	973	1	973	183	183	186	1	16	17	24
28	HADDZ85	209299 09/25/97	pSport1	38	838	1	838	270	270	187	1	36	37	57
29	HDPCM26	209300 09/25/97	pCMVSPORT 3.0	39	607	1	607	174	174	188	1	19	20	66
30	HSZAA13	209300 09/25/97	Uni-ZAP XR	40	882	1	855	147	147	189	1	19	20	88
31	HDTBP04	209300 09/25/97	pCMVSPORT 2.0	41	959	1	959	65	65	190	1	15	16	220

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HHGCQ54	209300 09/25/97	Lambda ZAP II	42	875	1	875	62	62	191	1	15	16	51
33	HSNAB12	209300 09/25/97	Uni-ZAP XR	43	630	1	630	151	151	192	1	27	28	71
34	HBJID05	209300 09/25/97	Uni-ZAP XR	44	571	1	571	137	137	193	1	20	21	111
35	HSNBM49	209300 09/25/97	Uni-ZAP XR	45	930	1	930	27	27	194	1	21	22	60
36	HJMBF77	209300 09/25/97	pCMVSPORT 3.0	46	437	1	432	60	60	195	1	24	25	126
37	HJMBM38	209300 09/25/97	pCMVSPORT 3.0	47	1024	316	1023	387	387	196	1	15	16	112
38	HHGCL33	209300 09/25/97	Lambda ZAP II	48	463	1	463	74	74	197	1	20	21	65
39	HCEWE20	209300 09/25/97	Uni-ZAP XR	49	885	13	885	166	166	198	1	18	19	51

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
56	HSVAA10	209300 09/25/97	Uni-ZAP XR	66	987	1	987	38	38	215	1	16	17	209
57	HFPBA88	209300 09/25/97	Uni-ZAP XR	67	1018	284	1018	33	33	216	1	38	39	195
57	HFPBA88	209300 09/25/97	Uni-ZAP XR	159	804	70	804	98	98	308	1	41	42	102
58	HFTBM50	209300 09/25/97	Uni-ZAP XR	68	762	1	740	158	158	217	1	20	21	34
59	HHEBW54	209300 09/25/97	pCMVSPORT 3.0	69	630	1	630	97	97	218	1	37	38	71
60	HFEBH21	209300 09/25/97	Uni-ZAP XR	70	940	1	940	21	21	219	1	30	31	52
61	HFTDZ36	209300 09/25/97	Uni-ZAP XR	71	1103	231	1103	547	547	220	1	22	23	68
62	HGLAW96	209300 09/25/97	Uni-ZAP XR	72	899	246	899	308	308	221	1	24	25	68

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HKAFK41	209300 09/25/97	pCMVSPORT 2.0	73	549	1	549	243	243	222	1	30	31	43
64	HOSEG51	209324 10/02/97	Uni-ZAP XR	74	590	48	590	232	232	223	1	31	32	102
65	HTEJT39	209324 10/02/97	Uni-ZAP XR	75	1056	1	1056	146	146	224	1	32	33	213
66	HPTRH45	209324 10/02/97	pBluescript	76	930	1	930	92	92	225	1	26	27	108
67	HDHMA72	209324 10/02/97	pCMVSPORT 2.0	77	4463	216	2158	287	287	226	1	36	37	315
68	HNTBL27	209324 10/02/97	pCMVSPORT 3.0	78	791	71	791	100	100	227	1	23	24	115
69	HCFMX35	209324 10/02/97	pSport1	79	1292	1	1292	160	160	228	1	21	22	106
70	HMSFS21	209324 10/02/97	Uni-ZAP XR	80	1283	1	1283	28	28	229	1	17	18	37

Gene No.	cDNA Clone ID	ATCC Deposit	Nr and Date	Vector	X Seq.	NT	ID Total	Seq. Clone	Seq. Clone	5' NT	3' NT	of	of	5' NT	Start	Signal	NO: Y	Sig	Sig	Secreted	of	AA	Last
71	HMUAO21	209324	10/02/97	PCMVSPORT 3.0	81	708	245	708	289	289	289	230	1	25	26	67							
72	HCHAR28	209324	10/02/97	pSport1	82	1464	325	1463	482	482	482	231	1	46	47	50							
73	HLVDU25	209324	10/02/97	pSport1	83	616	1	616	250	250	250	232	1	22	23	40							
74	HOEJH89	209324	10/02/97	Uni-ZAP XR	84	928	18	903	25	25	25	233	1	19	20	41							
75	HPFDG48	209324	10/02/97	Uni-ZAP XR	85	723	165	700	283	283	283	234	1	18	19	47							
76	HWTBM18	209324	10/02/97	Uni-ZAP XR	86	570	1	570	45	45	45	235	1	21	22	39							
77	HCFOM18	209324	10/02/97	pSport1	87	639	1	639	28	28	28	236	1	20	21	63							
78	HMWFO02	209324	10/02/97	Uni-ZAP XR	88	708	1	708	20	20	20	237	1	38	39	60							

Gene No.	cDNA Clone ID	ATCC Deposit	Nr and Date	Vector	X Seq.	NT	ID Total	Seq. Clone	Seq. Clone	5' NT	3' NT	of	of	5' NT	Start	Signal	NO: Y	Sig	Sig	Secreted	of	AA	Last
79	HNGAV42	209324	10/02/97	Uni-ZAP XR	89	949	1	949	278	278	278	238	1	28	29	62							
80	HL3AB91	209324	10/02/97	Uni-ZAP XR	90	1171	1	1171	158	158	158	239	1	21	22	56							
81	HSDSE75	209324	10/02/97	pBluescript	91	1151	1	1151	160	160	160	240	1	18	19	181							
82	HLMFD85	209324	10/02/97	Lambda ZAP II	92	714	1	714	33	33	33	241	1	27	28	70							
83	HLQCI74	209324	10/02/97	Lambda ZAP II	93	810	1	810	261	261	261	242	1	17	18	61							
84	HLQCK07	209324	10/02/97	Lambda ZAP II	94	1176	1	1176	410	410	410	243	1	18	19	34							
85	HTEFU65	209324	10/02/97	Uni-ZAP XR	95	1028	1	1028	231	231	231	244	1	24	25	46							
86	HLYBF22	209324	10/02/97	pSport1	96	747	1	747	39	39	39	245	1	32	33	50							

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
87	HMDAP35	209324 10/02/97	Uni-ZAP XR	97	628	1	628	70	70	246	1	21	22	50
88	HTOJK60	209324 10/02/97	Uni-ZAP XR	98	904	1	904	217	217	247	1	19	20	32
89	HWBCN75	209324 10/02/97	pCMVSPORT 3.0	99	576	1	576	184	184	248	1	34	35	48
90	HROAH06	209324 10/02/97	Uni-ZAP XR	100	713	1	713	29	29	249	1	43	44	115
91	HSAXA83	209324 10/02/97	Uni-ZAP XR	101	649	1	649	92	92	250	1	22	23	74
92	HSDJE10	209324 10/02/97	Uni-ZAP XR	102	697	1	697	157	157	251	1	21	22	62
93	HBAMA40	209324 10/02/97	pSport1	103	1288	1	1288	95	95	252	1	31	32	72
94	HBAMB34	209324 10/02/97	pSport1	104	1027	1	1027	87	87	253	1	35	36	48

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
95	HCWKC15	209324 10/02/97	ZAP Express	105	710	1	710	37	37	254	1	18	19	40
96	HDTDM65	209324 10/02/97	pCMVSPORT 2.0	106	530	1	530	159	159	255	1	40	41	53
97	HMMBF71	209324 10/02/97	pSport1	107	392	1	392	153	153	256	1	24	25	40
98	HPBDH41	209324 10/02/97	pBluescript SK-	108	991	288	991	373	373	257	1	15	16	41
99	HPBEN24	209324 10/02/97	pBluescript SK-	109	912	363	912	541	541	258	1	20	21	52
100	HCUIM65	209324 10/02/97	ZAP Express	110	875	331	736	557	557	259	1	27	28	47
101	HKNA95	209324 10/02/97	pBluescript SK-	111	459	1	459	114	114	260	1	28	29	52
102	HKIYH57	209324 10/02/97	pBluescript	112	609	156	609	336	336	261	1	23	24	54

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	Start of AA of Signal Pep	First of AA of ID NO:	Seq of AA of ID NO:	Sig of AA of ID NO:	First of AA of ID NO:	Last of AA of ID NO:	First AA of ID NO:	Secreted of AA of ID NO:	Last of AA of ID NO:
103	HBIBW67	209324	Uni-ZAP XR	113	1404	1	1404	685	685	262	1	33	34	38	ORF	
104	HCFUCU88	209324	pSport1	114	853	1	853	326	326	263	1	14	15	23		
105	HBJMGA49	209324	Uni-ZAP XR	115	845	1	804	53	53	264	1	17	18	46		
106	H6EDC19	209324	Uni-ZAP XR	116	760	324	760	389	389	265	1	25	26	114		
107	HSKHZH81	209346	pBluescript	117	988	1	967	57	57	266	1	27	28	247		
108	HBJFX78	209346	Uni-ZAP XR	118	1947	1	1947	34	34	267	1	18	19	177		
109	HEMFSS60	209346	Uni-ZAP XR	119	1448	63	1448	111	111	268	1	17	18	78		
110	HKACRB56	209346	pcMVSPORT 2.0	120	496	1	496	27	27	269	1	23	24	80		

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
119	HSKNB56	209346 10/09/97	pBluescript	129	1334	449	1334	484	484	278	1	25	26	85
120	HHGCW91	209346 10/09/97	Lambda ZAP II	130	532	1	532	107	107	279	1	18	19	95
121	HKIYE96	209346 10/09/97	pBluescript	131	685	145	685	284	284	280	1	19	20	97
122	HLVAN59	209346 10/09/97	pSport1	132	729	1	729	254	254	281	1	40	41	54
123	HNEEE24	209346 10/09/97	Uni-ZAP XR	133	1079	1	1079	213	213	282	1	21	22	71
124	HAPRK85	209346 10/09/97	Uni-ZAP XR	134	1297	1	1297	175	175	283	1	29	30	43
125	HLTEJ06	209346 10/09/97	Uni-ZAP XR	135	617	69	617	197	197	284	1	22	23	55
126	HMEKT48	209346 10/09/97	Lambda ZAP II	136	1311	1	1115	47	47	285	1	19	20	48

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
127	HNGHR74	209346 10/09/97	Uni-ZAP XR	137	1095	1	1095	53	53	286	1	18	19	41
128	HNHED17	209346 10/09/97	Uni-ZAP XR	138	692	1	692	282	282	287	1	19	20	48
129	HNHEP59	209346 10/09/97	Uni-ZAP XR	139	748	1	748	247	247	288	1	27	28	109
130	HNHFJ25	209346 10/09/97	Uni-ZAP XR	140	1132	1	1132	145	145	289	1	22	23	63
131	HCPAA69	209346 10/09/97	Uni-ZAP XR	141	1112	1	1112	8	8	290	1	20	21	41
132	HEAAR07	209346 10/09/97	Uni-ZAP XR	142	1084	1	1084	48	48	291	1	31	32	42
133	HHGDW43	209346 10/09/97	Lambda ZAP II	143	1050	1	1050	107	107	292	1	41	42	44
134	HHSDX28	209346 10/09/97	Uni-ZAP XR	144	1113	1	1113	90	90	293	1	21	22	56

Gene No.	cDNA	Clone ID	HE8ER60	209346	Uni-ZAP XR	145	685	1	685	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
ATCC	Deposit	Nr and Date	10/09/97	209346	Uni-ZAP XR	145	685	1	685	X	Seq.	NT	Total	NT	ID	NO:	NT	Seq.	Clone	5' NT	48	294	1	32	33	74	ORF
135	HE8ER60	209346	10/09/97	209346	Uni-ZAP XR	145	685	1	685	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
136	HMEJQ66	209346	10/09/97	209346	Lambda ZAP II	146	1038	1	1038	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
137	HRDAD66	209346	10/09/97	209346	Uni-ZAP XR	147	851	99	851	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
138	HCMST14	209346	10/09/97	209346	Uni-ZAP XR	148	614	1	614	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
139	HCEBA03	209346	10/09/97	209346	Uni-ZAP XR	149	1200	1	1200	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
140	HFAAH18	209346	10/09/97	209346	Uni-ZAP XR	150	683	79	683	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
141	HJAA110	209346	10/09/97	209346	pbiscript SK-	151	827	135	827	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	
142	HFIBV09	209346	10/09/97	209346	psport	152	835	129	835	Seq.	Clone	5' NT	3' NT	5' NT	Start	Signal	AA of	First	5' NT	48	294	1	32	33	74	ORF	

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No.Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

- 5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988).
- Polypeptides of the invention also can be purified from natural or recombinant sources
- 10 using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

- Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

- In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

- As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

- Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

- "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

- By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

- As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:
- Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3'

truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brulag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

5 The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

10 As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln; replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

15 Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

20 For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

5 In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO.X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO.X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

10 Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO.X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

15 In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

20 Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-

60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred.

5 Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

20

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

30 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

20

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the

35

polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life *in vivo*. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Trautnacker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Elton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Genitz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).) Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and lac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and puc99a, pKK223-3, pDK233-3, pDR340, pRT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium

phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

35 The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat

polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

5 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

10 Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

15 Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

20 For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

25 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinherence between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease 30 could be one of 50-500 potential causative genes.

35 Thus, once coinherence is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988), and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991)). Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying

personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

251

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

252

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1).

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

10 Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

15 Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

25 A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

30 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

5 Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

10 Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillus, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Hemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis,

25 and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

35 A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g., osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

259

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

- 5 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

- 10 Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

- 15 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

- 20 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

- A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

- 25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

- 30 Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

- 35 Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type

260

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

- 5 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

- 10 Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

- Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

- 15 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

- A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

- 20 A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

- 30 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

5 Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

Vector Used to Construct Library	Corresponding Deposited Plasmid
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lalfmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR ^{2.1}	pCR ^{2.1}

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res.

25 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

35 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

- DH10B, also available from Life Technologies. (See, for instance, Grubet, C. E., et al., *Focus* 15:59 (1993).) Vector *lambda* BA (Benito Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector PCR[®] 2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *BioTechnology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

- The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone, but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

- Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.

- The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

- Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

- Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

- This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.₆₀₀) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

271

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressonist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors.

The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHIE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinophosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (L.TI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHIEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

35 Example 6: Purification of a Polypeptide from an Inclusion Body

272

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at

15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min, the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem

columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{260} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commae blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

15 Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase; using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987). One μ g of BaculoGold™ virus DNA and 5 μ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture

275

and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ³⁵S-methionine and 5 µCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

20 **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

30 Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QCI-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

276

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

5 The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., BioTechnology 10:169-175 (1992).) Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

15 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 4:38-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

25 Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

30 A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

35 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., *Nature* 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```

GGGATCGGGAGCCCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGCC
CAGCACTGAATTGAGGGTGCAACCGTCAGTCTTCTCTTCCCCCCAAACC
CAAGGACACCCTCATGATCTCCGGACTCTCTGAGGTCAATGCGTGGTGGT
GGACGTAAAGCCACGAAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACG
CGGTGGAGGTGCATATGCCAAGACAAAGCCGGGGAGGAGCAGTACAAC
AGCAGTACCGTGTGTGTCAGGTCCTCTCACCGTCTCTGACACGAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAAACAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACACACAGGT
GTACACCTTGCCCCCATCCCGGATGAGCTGACCAAGAACACGAGGTGAGCCT
GACCTGCTGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGCGACGGGAGAACAACTACAAGACACGCTCCCGTGTCTGG
ACTCGACGGCTCTTCTTCTCTACAGCAAGTCTACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTATGCTCCGTCGATGATGAGGCTCTGC
ACAACCACTACCGCAGAAAGACCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGGACTCTAGAGGAT (SEQ ID NO:1)

```

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera

279

containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N. Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

280

It will be appreciated that Fab and F(ab)₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab)₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulikane et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhitaker) for a working solution of 50ug/ml. Add 200 µl of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10⁵ cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhitaker))/10% heat inactivated FBS(14-505F Biowhitaker)/1x Penstrep(17-602E Biowhitaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 µl Lipofectamine (18324-012 Gibco/BRL) and 5ml OptiMem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine;

0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

283

284

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schindler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

Ligand	TyK2	JAKs Jak1	Jak2	Jak3	STATs	GAS(element)s or ISRE
IFN family						
IFN- α /B	+	+	-	-	1,2,3	ISRE
IFN- γ	+	+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11 (Pleiotrohic)	?	+	?	?	1,3	
OnM (Pleiotrohic)	?	+	+	?	1,3	
LIF (Pleiotrohic)	?	+	+	?	1,3	
CNTF (Pleiotrohic)	-/+	+	+	?	1,3	
G-CSF (Pleiotrohic)	?	+	?	?	1,3	
IL-12 (Pleiotrohic)	+	-	+	+	1,3	
gC family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >> Lys6) (IGH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>Lys6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS (B-CAS>IRF1=IFP>Lys6)
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994)), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5' : GCGCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCG
 10 AAATGATTTCCTCCGAAATATCTGCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5' : GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5' : CTGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATG
 20 ATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCGCCCC
 CTAATCTCGCCCATCCCGCCCTAACTCCGCCAGTTCGCCCATCTTCGCG
 CCCATGGCTGACTAATTTTATTATGACAGAGGCCGAGGCCGCTCGGC
 CTCTGAGCTATCCAGAGTAGTGAGGAGGCTTTTGGAGGCCTAGGCTTT
 TGC AAAAGCTT:3' (SEQ ID NO:5)

25 With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMR1E-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at 20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 40°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14: High-Throughput Screening Assay Identifying Myeloid

Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in

Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jak-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^6 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^6 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal

Activity

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGFR1 (early growth response gene 1), is induced in various tissues and cell types upon

activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)
5' GCGAAGCTTCGGACTCCCGGATCGGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

291

To construct a vector containing the NF- κ B promoter element, a PCR based

strategy is employed. The upstream primer contains four tandem copies of the NF- κ B

binding site (GGGGACTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary

to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5'-GGGGCCCTCGAGGGGAGCTTCCCGGACTTCCGGGACTTCCGGGAGC
TTCCATCCTGCCATCTCAATTAG-3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter

and is flanked with a Hind III site:

5'-GGGGCAAGCTTTTGGCAAGCCTAGGC-3' (SEQ ID NO:4)

10 PCR amplification is performed using the SV40 promoter template present in
the pB-gal-promoter plasmid obtained from Clontech. The resulting PCR fragment is
digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following
sequence:

15 5'-CTCGAGGGGACTTCCCGGGAGCTTCCGGGACTTCCGGGACTTCC
ATGCGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAAGTCCGCCCA
TCCCGCCCTAAGTCCGCCAGTTCGCCCATTTCTCCGCCCATGGCTGACT
AATTTTATTATTATGAGAGGCGGAGGCCCTCGGCTCTGAGCTATTC
20 CAGAGTACTGAGGAGGCTTTTGGAGGCGCTAGGCTTTGCAAAAAGCTT-
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-

promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII.

25 However, this vector does not contain a neomycin resistance gene, and therefore, is not
preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP

cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI
and NcoI, and inserted into a vector containing neomycin resistance. Particularly, the
30 NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP
gene, after restricting pGFP-1 with SalI and NcoI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are
created and maintained according to the protocol described in Example 13. Similarly,
the method for assaying supernatants with these stable Jurkat T-cells is also described

292

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to
wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

5 As a reporter molecule for the assays described in Examples 13-16, SEAP
activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the
following general procedure. The Tropix Phospho-light Kit supplies the Dilution,
Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x
dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a
plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven
heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and
prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room

15 temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the
table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20
minutes. Since the intensity of the chemiluminescent signal is time dependent, and it
takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each
time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the
results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25

28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is

incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.

The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mV; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating

tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

- Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyn Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyn Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

- To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyn plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 μ l of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 40°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 40°C at 16,000 x g.

- Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here. Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg²⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

- The tyrosine kinase assay reaction is then terminated by adding 10 μ l of 120mM EDTA and place the reactions on ice.

- Tyrosine kinase activity is determined by transferring 50 μ l aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 μ l of anti-phosphotyrosine antibody conjugated to horse radish peroxidase/anti-P-Tyr-POD(0.5u/ml) to each well and incubate at 37°C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

- As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp. (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene

Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR

products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin-deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Invision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

Next, 50 μ l of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

Add 75 μ l of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23. Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 μ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 μ g/kg/hour to about 50 μ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bolus solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, fecally, parenterally, intracisternally, intravaginally,

intrapertoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.

Sustained-release matrices include poly(lactides) (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Siddman, U. et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days.

After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

PMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

5 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

10 The amphotropic PA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dubecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

20 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

30 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

35 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

305

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 212, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 25 SEPTEMBER 1997	Accession Number 208289
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division	
For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer	

306

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 215, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 25 SEPTEMBER 1997	Accession Number 208300
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division	
For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer	

307
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>220</u> , line <u> </u> . N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit: 02 OCTOBER 1997	Accession Number: 208324
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: Sonya Barnes PCT International Division <i>SDG</i>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer: _____

308
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>225</u> , line <u> </u> . N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit: 09 OCTOBER 1997	Accession Number: 208346
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: Sonya Barnes PCT International Division <i>SDG</i>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer: _____

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z.

311

- (g) a variant of SEQ ID NO: X;
 - (h) an allelic variant of SEQ ID NO: X; or
 - (i) a species homologue of the SEQ ID NO: X.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
- (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

312

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO: Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO: X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.
 <120> 148 Human Secreted Proteins
 <130> P2019.PCT
 <150> 60/063,099
 <151> 1997-10-24
 <150> 60/063,088
 <151> 1997-10-24
 <150> 60/063,387
 <151> 1997-10-24
 <150> 60/063,148
 <151> 1997-10-24
 <150> 60/063,386
 <151> 1997-10-24
 <150> 60/062,784
 <151> 1997-10-24
 <150> 60/063,091
 <151> 1997-10-24
 <150> 60/063,090
 <151> 1997-10-24
 <150> 60/063,089
 <151> 1997-10-24
 <150> 60/063,092
 <151> 1997-10-24
 <150> 60/063,111
 <151> 1997-10-24
 <150> 60/063,101
 <151> 1997-10-24
 <150> 60/063,109
 <151> 1997-10-24
 <150> 60/063,110
 <151> 1997-10-24
 <150> 60/063,097
 <151> 1997-10-24
 <150> 60/063,100
 <151> 1997-10-24
 <150> 60/063,098
 <151> 1997-10-24

<160> 492
 <170> PatentIn Ver. 2.0
 <210> 1
 <211> 733
 <212> DNA
 <213> Homo sapiens
 <400> 1
 ggagacgcgga gcccaatct tctgacaaa ctacacatg cccaccgtgc ccagaccctg 60
 aattcggagg tgaaccgtca gtcttctct tcccccaaa acccaaggac accctcatga 120
 tctcccgagc tcttgaggtc acatgcgttg tggtagagt aagccagaa gacctcagg 180
 tcaattcaa ctgttacctg gacggcgttg agtgacataa tgcacagaa aagccgagg 240
 aggaagacta caacagcagc taccgtgttg tcaagctct caacgtctcg caccaggact 300
 ggcctgaatgg caagaggtac aatgcagaag tctccaaaa agccctccca accccatcg 360
 agaaaacct ctccaaagcc aaaggagac ccgaggaac acagtgttac acctgtccc 420
 calcccgga tgaactgacc aagaaccagg tcaagctgac ctgcctgttc aaaggctct 480
 altcaagcga calcgccgtg gagtggagaa gcaatgggca gccggagaac aactacaaga 540
 ccacgcctcc cgtctctgac tccgacggtc cctcttctc ctacagcaag ctacacgttg 600
 acaagagcag gtggcagcag gggaagctct tctcatgttc cgtgatgcat gaggctctgc 660
 acaaccacta caccagaaag agcctctccc tgttccggg taatgatgct cgaagcgccg 720
 gaactaagag gat 733
 <210> 2
 <211> 5
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> Site
 <222> (3)
 <223> Xaa equals any of the twenty naturally occurring L-amino acids
 <400> 2
 Trp Ser Xaa Trp Ser
 1 5
 <210> 3
 <211> 86
 <212> DNA
 <213> Homo sapiens
 <400> 3
 gcgcctcggg atttcccca aattcagatt tccccgaat gatttcccg aaatgatttc 60
 ccggaatat ctgcacatcc aattag 86
 <210> 4
 <211> 27
 <212> DNA
 <213> Homo sapiens
 <400> 4
 gcgcaagct ttctcaag cctaggc 27
 <210> 5
 <211> 271

<212> DNA
<213> Homo sapiens

<400> 5

ccccgagattt ccccgaaatc tagatttccc cgaatgatt tcccgaat gatttccccg 60
aaatattcgc catctcaatt agtcagcaac catagtcccg cccctaactc cggccatccc 120
gcccctaact cggccagatt cggccatc tccgcccact ggctgactaa ttttttttat 180
ttatgcagag gccgagcccg cctcgccctc tgaactatc cagaagtatg gaggaggctt 240
ttttggagcg ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgcctcagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgctt c 31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggacttct cc 12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcggctcga ggggacttcc ccgggactt tccggggact tccgggact ttccatctg 60
ccatcctaat tag 73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgaaggga ctttcccggg gacttcccg ggaacttccg ggaacttcca tctgcctct 60
caattagca gcaaccatag tcccgcctt aactcgcctt atccgcctt taactccgccc 120
cagttccgc cattccgc cctatggctg actaattttt ttatttatg cagagggcga 180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggtttttttg gaggcctagg 240

cttttgcaaa aagctt

<210> 11

<211> 826

<212> DNA

<213> Homo sapiens

<400> 11

ggccagaaa tatatggtt tttgtattc tattatagg aaatgtccag aataggcaaa 60
tccacagaaa cagaaaacta gattggtat cgctagagc ttggggcagg gggctggggag 120
tgggtaatga cttctaata gttcttttt aeggtgatga aaatgttgta aaattgatcg 180
tgattattgt actaaaacc atttaacgta tattaagtg ggttaattgt atggcatcg 240
atttatctat caacaagct gtgagtgct gcgccatgt atggaatgtgt atgtgtgtgt 300
atatatctct atacatgtat acatggtgc ccatgtgat ctatgtagaa tatgtaaaaa 360
aaacatgggg tagtttgata tttagtctcg gactacaga gagatctaag ccacgagacc 420
aagattcaga aatcagcagt cactgaggtt gtagtagta atggattgt ctaaaagaaa 480
tgagagggga ggaatgggg ttccacaga caacctctt tggaaactga aaagaatcca 540
ctagacagaa ggaatgaac tagaagagc tggctaactt ggaagtcaag tctgagcttc 600
atttctgccc tgcgagtg gaaacttatt tctaactgat tctctgggtt tcaaacacac 660
ctctgggttc tccaggcat agggagtg tctgtgtca ctgtggcagt ggggagtgga 720
agactgaata aatatgcaa atggagggac cagccagagg gtcaaaaggc ctcgaggaga 780
tgagggaatg cagtcacca gcagagtttc aagcagtcca ctatgg 826

<210> 12

<211> 524

<212> DNA

<213> Homo sapiens

<400> 12

gcacagaggg cttgggtgca ggtggtttat ttgggaagtc atcctggaaa atccaaaag 60
aaggatgga gaagatag aagacaagaa agaattgcat gctcgtgggt catgggata 120
gaaagtctt aggaagcttc tgcagaaccc tatgcaatgt gccctgaatt gtccaaaggaa 180
ttgaatgggg agctgtgcca ttgtacact actctgtctg ctactgatg ggcacacagg 240
ctttatccc cagccttccc aggetgcccc gggagacacag cagctatggg gaggcaccaa 300
ccccggggt gactcattc cagaacctt cctcccctac acgctgacag tcaattatcc 360
accaagtgt aactcgaat tctactacc taaaatgcgt ttggcataca tctgcatgct 420
acactcacac tgtccctatc ttggtcaga cattacaac actccctga actactgcag 480
cagcttccca ctgaactcc tggctcattt ggtctatatt gctg 524

<210> 13

<211> 491

<212> DNA

<213> Homo sapiens

<400> 13

ggccagggc aaaagcttgt gctgttagct ttaagtgta ttaaaataa atctgaatc 60
atttaacag catgaacctt ggiggccaaa tagatcaatg acaagagga gaaaacctag 120
atacaggctc attttgctt tatatgctt gagattagt tttctatta gagctgtgac 180
taatacagat gcatacggc tgagagcaaa gcaggtgaa tgtccctatt aattgcacc 240
atggtgcgag gctggaatga gggctggccc agctaagagg ggaattgctc ttctgcct 300
agaagtctct catgttctc tgtctctct tgtccagg tgcttagcac acttctcttt 360
ggatattaat gcttttata gctggaacc tgaagttctt cagaaactcg cacatgctta 420
ctagatgggtg ctctggattt tctttaaga taggaagaaa aaggcaaaag caggctctg 480
acgttcttca c 491

<210> 14
<211> 403
<212> DNA
<213> Homo sapiens

<400> 14
ggcgcgagcg gggccctaga gāgacatcgg aggtccaaac cccatcct aaagaagg
agcgcgggc catgaatc catgcctcc aagctccag agctataaa tggtagagc
atgcctagg ggcctcgtc tctctctca tggtaactg attataac ctggtaact
atgcttcca aaagcttla tgtcaaatg atcttgcg ataaccaca cttaagcag
atgatatcat gcaatggaa cagtcagaa atccaaatg cttaagatg cacttgatg
gcaatctcgg gaattggagc ctctccca aagccaatg tctctctga aacctctgt
tcttaagc tgaagctcg gatgcctcg aggaagagc cga

<210> 15
<211> 813
<212> DNA
<213> Homo sapiens

<400> 15
ggcagagat cacttctcg cccctccat cttagctga cggctccct gatgtgtac
ctgctctcg tactgata aactcgaga ctctcattc atcccaagg cctccaggca
gtaccaatg gggaaatcag tctaaaga accagaacca cgtttccag cccctcatt
ctggtagctg aagggggaa agaattggag gggtaact tgcctagtg atgaaagga
aaccaactg caaatracta cactctctg gttctcatt acagtagaat tctccagca
cacttctat gctcaaggg gaattgag atgttgagc tgaatagaa tgcctggag
gggataaatg gaggggata gatctcagc ggtttgaa aagttaag tcttaata
atgcgccca tctgaagaat ttttctaaa accagaatc ataaatat cactgata
gcttgcctc tcatctctc gccacagag atgtcttga ctaggagac tggtaata
atagcttgc tctgaatc ccagtagct cctctgtgt gaggaaagga tagaatgtc
caggacaca tcaatagag tccatctla caaagtcca gtatgagtg cgtctacag
gaagcttgg aactgaaac aggtctggg cactcagc acatctagc cgtccaac
agaagctcga ttttgtctc ggggttggag gaggaaacg actgaccaa aggactaaa
taattgtct atactaaaa aaaaaaaaa aaa

<210> 16
<211> 264
<212> DNA
<213> Homo sapiens

<400> 16
gttaataata tgcctagtg attataatg atgacatct ctctctctc agatttct
taagtggcc aaaggtcag attagagat gctagaacat ctatcgaga tatcttaaa
tggtaagtg actataact gagggcagat atagaatg aaagaatc atagggaaag
gattctctg aagattctg cagatgggc aaatgaaga agctctcat agctatcaa
aacactggc atgttcttc tcga

<210> 17
<211> 520
<212> DNA
<213> Homo sapiens

<400> 17
ggaaagagc ctatcgagg aagtgcagca ggacagag gaaactatat ctacggagc

ctgtgagat ggcctctgc ctgggtatc tattaagc atgcataaac ccatcgagg
gaagattaa ggttctctc ccgagggaa aacttgagg taaagaggc tatgagcat
gagacagcc aggtcacaca gctgttagc gccaagctg actccaact gtcctagg
gacttgaac cctgtctcg gccccaac tgggagagc gtctctctc acaagcat
gctcgagat taagatctc tagcaagc ctgggagac cgaagagct cccctgctg
ggagtgtg gaggacct ggttctctc cttagacct caagatcac aggaatca
cccgaagta acttaacta tagtgtctt atgaacagga aagggttaa
gtcacatg ttcacaaac aacagctgt aaactcgtc

<210> 18
<211> 993
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (478)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (474)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (551)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (581)
<223> n equals a, t, g, or c

<400> 18
ggcagagga acaactag gtagaagcc tggggccgc agactgaca tggtagct
agctataca ctatctctc taatctctc agtagtag ctggcagctg tccatttag
ctgatgtac tgggtcag gtagtagct tttgtgct tctagcact agccctga
ggaagagct gttgtactg gtgagctcg ttaaaaca tgcattctc atggctatc
agtttctg gtttagctc gccatgagc ggtctaac tggtttcaa ctgtagctc
tgcataact gttctctaa gtagactca ctattgcta ctctccact ggggcatc
atccacag ccaagctla tgggtgtga acaataagc taattatct tgaatgtg
cttatgtg gtgtactc agtggagct caccagac tgggtagag acanacng
taagagaaa ggaatcacg gtagaagct tcaagagat aatgcact tcaacttg
gtgtcataa ngcatctcc cctatgata tgaattga nagaagac tgaagaatg
gagacagga caccagatc atarggtc ctactgat aattctacc ttaagatgg
tgggcagag acccaatc catctctt gctgtcct gctgttgg atgtctcc
aggaatcca acgtatag tgtgtccag tgtgagta ttaataca tctgtcaat
cagttcagc atccgttcc ctctcaata tttacaaa gtaattagc cccactcg
tatctcagc attgtaagc acagctctg tttatcagc attctgag tggaaagc
tgaacatg gttgtgtgc ataatctt aggaattgt acttagtgc acacataa
atgtagct gatgtgtct tagattgct cga

<210> 19
<211> 459
<212> DNA

<213> Homo sapiens

<400> 19

ggcagcagga agcgtgaacc ccagggaaca gcgggtccct tcctctctca gacacaagcc 60
 acctcagctt ggggtcttgg gcccccagcc ccaccaaccc acctgttcat ttattcaaca 120
 gacaatgaca gctgatattt attggacatt tgcaccatgc caagcattcg gcttggatta 180
 tccatttgt ttctcacagc cggattattat tgtctgtctc tctgtgceag gtcgtgctt 240
 ctgggcaggg gcactgcacg ggtctgctgc cctgtgtggg cttgtgtgtt gatgggtgag 300
 gctgacccaa gccacccca ttgcccaacg ggcacgggca agagtacaca caggggcctc 360
 ataccatg tctaatatt taaaagttt tcaatcaagc taacaaactgt taataaaat 420
 atgttctatt ctcctacttt gaaaaaaaaa aaaaaaaa 459

<210> 20

<211> 555

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (50)

<223> n equals a,t,g, or c

<400> 20

agctccacag cgttgggccc cgtctcagaa cttagtggat cccccgncn tgcaggaaat 60
 tccgcacga gcaaggtcac agagctagaa aaaggcagaa ttgggacctt tacccagaaat 120
 tcttaactct agctctgtaa agctgggaca ctggagaagc agaggttttg gtgtagtact 180
 cctctagctt cgggtgtctta gaagtcacaa tggggtctgt ggagtgggtga ggggagatgg 240
 aggtgggaag aaggagagaag accctattc cctattctc tttaacacag agagattccc 300
 tgcattatt taccgtctg tgaatctatc tgaagagaat tctatgaccc cccaaaatct 360
 ggaattcact ctgttccagt tctgttacc tttatacttg gagctagaac tgggtctcag 420
 atcaactgca caagagtga ccagagaatg gtccttgagt tactctttt taacaaaagt 480
 ttcgtggcaa gttctctgta gtgagtctct gctgttaaaa gagaacccat tcttactctt 540
 ggagaaaaaa ctga 555

<210> 21

<211> 665

<212> DNA

<213> Homo sapiens

<400> 21

ggcagcagaa actccagta atgccatta ttttctctct tgttctctta acctccctgc 60
 cttctagggg ttataatgag aagaactcaa cagacaatat tcaagttag attttcaag 120
 ttctttatga agaagccaca gatccctaca aggaagaat cgtgcacag ctgccagta 180
 ataaaccaga aggcctagaa aataatgtag atcagatctt gaaatgatt gagcagtgga 240
 tcaagatca taactcttga ctataaagg tagtactta atactactc ttgttgatat 300
 ctctccgcac atcatagaa ttgttcaagt gtccaaaca cttactaaa atcatgttc 360
 agaacccaga ggtggatagt atatagggtt atgcctgtgt tctttctc catgagaaag 420
 ctaaaatga aataaatga atatagtaat tatlaaggga ttgacacaa aactgtgatt 480
 ttaactcta aattgtctaa gaataataca atctgacaaa atgggtgag atcttttaag 540
 ttattacag aaaaatgc agatgatctc ttaaaataaa actaaagata agcaaaaaa 600
 aaaaaaaa aaaaactcga gggggggcyc cggtaaccaa tgcacctatg agtgatcgt 660

attac

<210> 22
 <211> 777
 <212> DNA
 <213> Homo sapiens

<220>

<221> SITE

<222> (274)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (278)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (295)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (676)

<223> n equals a,t,g, or c

<400> 22

ggcagagctc aggtgaagarg caaaattact agaataattca ctctcactga aaatgagtaa 60
 aaactaact tagatgaaaa tcttatctt gtctattttt attcctggcc ttctgggtga 120
 gaagaatggg ccagaccatg tctgtgtgtg tatgtgtgtg cgtgtgtgtg tgtgtgtgca 180
 cttgggttta ttatatagag ccggtaaaaa ttggttcacc attcaattat gttaatttac 240
 caactttta aatgagaaca gtgagaattt tctncatngt taataataca ctgncatgt 300
 catatatga tcacgaagag aggatatttc catigataat agat:ttcaa atacatcttc 360
 ctgtttaag attttaaat atggaattat atakaaaaa tagttaagc attggaagaag 420
 caaactgca wctttctctt atttgagawc tcaactttag aaagtctatg ttctcaacta 480
 cagaaaaataa tttttagacc agtcaacttt cagattcttg cagtgcttat ttctccag 540
 ttgagggctg gtttttgtt ttgttttgt ttgttttgt ttctcgatta aaagtgaaga 600
 atacggccag gcgcgatagc tcatgcttt aatccagca ttctgggagg ccgaggaggg 660
 cagatcacct gaggtnacag agtccagac cagcttggt aacatgggtga aacctagttt 720
 ctactaaaa aaaaaaaaaa aaacttcgag ggggggtccc ggtactaat cgtccctt 777

<210> 23

<211> 540

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (341)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (378)

<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (425)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (450)
<223> n equals a,t,g, or c

<400> 23
gaagatccccc acaaggccccc tccctagacc tggggagtcg gcaatgctcg tctaggcccc
ttagggagaggg ggagcaggggg gcaagcagtag aaatcgtggc ggggtccgact tgggtcttcc
ggccgtctctt ggtcctctgtt tgggtatctg gagtgtcaat cgtctcttat gtcctccacg
gtctcagacct ctccatctgtc gttctcggccc caggctcttc cctggctgtcc ctgtgtat
ccatctctctt agcccggtgct tccatgtcag amcggtcttc tctcctggam agcctgtctg
caatcggggc atctgtcttg ttggcttgct tctgggtgca ngcagaaccca ggaatgggtg
tccctgtccc ccgagcancct gttctctgtgc tctgggtgtg tgtgagttcca tctgctctgc
tcgantgtgc cccaaccag cccccccan cccctctct ctctctctca atctccctt
tctctccaa cccctccaaa tgaagtgtct gagtgcggtg ggttggaggg aagcaatggt
50
60
120
180
240
300
360
420
480
540

<210> 24
<211> 484
<212> DNA
<213> Homo sapiens

<400> 24
ggcaccgaggt ccggggagccg agggatctga gccctgtcta caatccacgg acaaggagggg
gagatctgcaa cctagccctgt cctctctgtc attctgtga tgcacaaag ctgtctgcac
acaatgcagct accaaacaaag ccagactggtt ggggtctcta aaggltctga ggcccgctca
cagcccccct tgcctctagtg ttgcttctcc tcccagttgc cggctcttg taattgtgc
taattacaga atctcttaaga ccaaaagggtc gaggctgggg ccaagaacct gttgagcaac
aagtaactgt ctctgcccc tccacttttg acaagggtga cccgggtgtg ggaagcgtg
atcctagacc cgtctgcacc tgttgggtctg ttcagtgcga tgaagttaaa gaacgaatgt
gtcccactgc tcaatgttta tccctgtcac ttggcagagg gcatagacata aagcaagccc
tcga
60
120
180
240
300
360
420
480
484

<210> 25
<211> 707
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (562)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (570)
<223> n equals a,t,g, or c

<400> 25
gggtcagacc acgcgtccgc dcaagcttcc gtttctaca acccttagga acatcaaat
cagtgctgtg tgggtgtcta ttaataaam agttctctg agtccactcc cagtgcctgc
60
120

cagttctgag attagggct cagctagagc cttagtttc gaaagctccc agctgtctc
atgcagccag cctggctcty gctctggkc tggagctgg gttggagac agtctctgtc
gtcatcttc tgaacttca aagttggctc ttgactccc cctgtatctg tcaakactgc
tattcaggtc tgtcttccc ctgtatctga aactcttga tgcctgttc atctcagtc
atgagctcag ctuacagtg gttccagtg gaacagatgc tgaatggct caggtcgtg
ggagggcagc gttgtgtgt aagtgaaga caaaaatcat ttlaaaaga atctcttgc
ccttcagctc tgtttgcct gatttactt gatttactt agtggaaacc agtgcagct
aagttgaggt ctggccctga antggagcct gttatgtat cagcagagct gccaaaagct
ttttggggga aatgttctc tgcacccc agtctgata acctaaagt tcaatccctg
tcaaccagac ttgggggca tctgtacttc tgcggagctg gtatgat
180
240
300
360
420
480
540
600
660
707

<210> 26
<211> 793
<212> DNA
<213> Homo sapiens

<400> 26
ggcaccagta ccaatttatc agctctagac atatactagg cagtgtcta agacttgatc
tggagatagg ctacaccaaa agtctgtgtc tactatcagc tgaatctgt agggagagca
cataacttcc tcaagctatc twtcttaac tcaagagacg gaaccttaa gattcactc
tgcgtctct cctttgacc actaaagag actcaaggtt attagatcat ataaacaaag
ggttatcaac agactctgtt ttwtgtctga tccctgtcaa caccctcgag ctcaaaaat
cttaagttca aatgtctcta gcttacttta tttgtgtaca caactcagaa accgaagaa
ctgtcaaaaa cctgtgaagg caaaagctag cctgtgtctg ctctacagcg cctctgagc
agctaaagat acttagctct cagttagacc caactcaaga gcaatgtct taagtcttc
ttaaaccac gacacacat accgaacacc acacacacac agactctgaa gtttctctg
cctctccatc taactaacac cactcttacc cctgtctgaa aaaaacttca accgtgttc
ccacttaat actttctcaa ctcaaaaagc caagtgtctc tttaaacct taactagaa
caacgcacac tctgtcttca gattcccaaa ggaattctac gtaattcata tctaaactac
ttaagatgac ccaagggcct actaatcttg gccgtcttac ttccagcgg caggaagagg
aactagcttc gta
60
120
180
240
300
360
420
480
540
600
660
720
780
793

<210> 27
<211> 638
<212> DNA
<213> Homo sapiens

<400> 27
gataagaat taattaaat tctttaaga taatttccc caatttagcg tctcttcca
tttgccat tctcttcta ttatccata tgggtcgtt tgttccagc aaacatttg
tagatgtct gtttccaag taaacttcaa acatattcaa agttctaaat gttgtctta
tgtatttta aaggagatg gtaaaataga atgtatttc ctctcccty atgaattcc
cgtatatat ttcaattaat attttgact ggttaagca gtaagaccaa accaatgtg
accagagata cagatttcaa aatgtcatga gagaatcata aatagaatga tatggagag
cttgacagta tagtgaat gtcttcaagt aatttgacac attagaaat tcaagcatc
accgtccagt aaccttact agaaataga ttggaatat ggggtcacca gttcaagac
attcttctgt gaggctgaa caatcaacaa aagttcagc tataggaata aaaaatgacc
tattccagtc attgaactgt ttctctgaa taagtctct ctctctctcc ttctataaaa
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aactcgaa
60
120
180
240
300
360
420
480
540
600
638

<210> 28
<211> 528
<212> DNA
<213> Homo sapiens

<220>	gcctctatagt ggaagcgtg	919
<221> SITE		
<222> (421)		
<223> n equals a,t,g, or c		
<220>		
<221> SITE		
<222> (436)		
<223> n equals a,t,g, or c		
<220>		
<221> SITE		
<222> (459)		
<223> n equals a,t,g, or c		
<400> 28	ctcaaaaaat aaataactatc ttctctctcg gctctctcat cctccagaca atcaactgaat	60
	tacaataatt gcttaacagt agattatgt caattttctg gaattttata tgactgatat	120
	aacatgtttc cctctttcat acctgagtag cctctgagc cctattttat tagatgttct	180
	tccttttct ttattattat ttattttca catagcaggg atgcataatt tgacattctat	240
	caatcatgat atatgagtag ttcatctttt ttactttaga atatgacatg ctatggaaat	300
	cactgtatcc gaattcatct gcttatgag atgttatgc ttctctatgt ttgtctgttag	360
	gaataaaact gcttgtaag caaaaaaaa raaraaaaa tactcgaggg ggggcccga	420
	nceaatctcg ccttanctg gctcgtat acaaatcant ggcctcgtct ttacaacgct	480
	gtggactggg gaaaaacctg ggcggttaac cccaacttta aatcgggc	528
<210> 29		
<211> 919		
<212> DNA		
<213> Homo sapiens		
<220>		
<221> SITE		
<222> (432)		
<223> n equals a,t,g, or c		
<400> 29	gacgtgtttt gccattgag tgaccaacag gactgtggac ctacgtaaag gctttcccta	60
	catcagatc tgcgactct tcccctcca ragctgcatc ttacagccagg tgcataatat	120
	ggagatgct ctgcccgcgt ggaatcgat tgcctgttac caccagctcc gggactgggg	180
	cgccagaag tggcctaacc agctgactct atggacgggt ctctctgttg ccttgggac	240
	ytccgtggta ggcaatttac caggtgagac ccagtcggcg cccagggtct gtmcgggce	300
	ggcstygga aytacaactc cagcatgac ccgtggccat aggtcttawg tctcgggggc	360
	tggttcccg ccgccttcn tgggacttgt attttctct ggccattggc ctggaccggc	420
	tgatctcttt gntctctgag tggggcatca cyagcgaggc tgtttgtatg taggatctgt	480
	tgattccagg acgttgggat aattttctgc cagccctct ccccagctta tttaagtatg	540
	aaattactgg tccaggcgca gtggccctat cctgtaattc cagcactttg ggggcccggg	600
	ggaggggat cgcctgaggt gaggagtgtg agaccagctt gggcaaccac catggtgaaa	660
	ccccgtctct cctaaatat gcaaaaatta gccgggcagt gggcgaggcg acttaatccc	720
	agctactgtg gaggcgaggg cggggaatc atttgaacct gggaggttggg ggttgcagt	780
	agccgagatc gaggcattgc actcaaacct gggggataag agtgagactt cctcaaaaa	840
	aaaaaaaaa aaaaaaaa aaaaaaaa actcgtagg ggggkyccgg taccacaacg	900

atctgtcaac tctgcaagag acaaggtctg gacagaaa tatcatctta tcaagaagaa 180
 acccttctct ctacagtagg tactaccctc ttgagcttga tctgataaat aaagcttctt 240
 tctgcaataat ccaaggtctt ccaaacacata tatctgact cctttacaga ctgatatgca 240
 aagtttgttt taactatag gaaattcttg aacctcttc tccaagttc acacactaca 300
 ctgtgcttcc cctctacc ttgaattcatg tgcattcccc cagttttctg cctttgaat 360
 ggggtgttca gttctctgc agccacagtt gcaaggaaac caattgtat cagcaactgc 420
 cctgcctaca aaagctatca gtgcamaigt tgrtaatgac ggaaccagtt gaattgtgcg 480
 cctgcctaca aaagctatca gtgcamaigt tgrtaatgac ggaaccagtt gaattgtgcg 540
 attcaatggg tagactttat tctgttccact cccataggcc ttgtcttcaa atgagatttc 600
 taactgtctt agtttttacc tcccttaaga caagagagat taaccactaa ccaaccactt 660
 gtaataatgc caggttttgaat tgaataatgc ggaaggttaa gacataatcc taacttttgg 720
 gtgtgaagac agcgccctct aaaaacttg gctctccacc ctaattttg cctaaagaaag 780
 ttgtaacaca ctgcaatttg ctctgaagtt ataatgttta ttgtcttcaa tgaactatag 840
 gtagaagaag gtacagttat gttctcttc agaatcaaac acattagacc taaccgtgcaa 900
 aatcaatcac caattacttg caagcaaggg cttaaaaaa aaaaaaaaaa acttca 960

<210> 33
 <211> 566
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (400)
 <223> n equals a,t,g, or c

<400> 33
 gggctcctga gctgactcag taagtaatga gctgtgtgtt gctgagaca ggcacgttg 60
 ggccctgagc gctcgtcgcg tctgtgattt tgaataatgt gtgtatctta attctgacct 120
 cagttcttca agctctgtgt tctcctgttg tgaaggagag caatatgtgt ggaaggaggtg 180
 aggaactctg ggaaggagag tctgtgatac agttcagtt ttgctatgtg ttggtctgaa 240
 ggaaggagag ggaagagttt ggaaccgaca ccgtcagttg tccaccaggg atgaggtctg 300
 accgagactt ctgacagccc gctgtgtgtg ttggtgtgtg caatgtcag gggcctgtga 360
 ggaagcttca ggaagctgtt gcccttgtaac tcccctggan gttccccaat cctctccctt 420
 cctgtgtcac ttgcccggcc tccgtgtgga aaggtctat ttgaacctc gctttttt 480
 gtcaatgggc ttctgcggcg ttctctcttc gaagggtgta wtccaagagc agacatcat 540
 gctcgcattt ggaactcctg gctcga 566

<210> 34
 <211> 1564
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (796)
 <223> n equals a,t,g, or c

<400> 34
 gaattcggca cgnatattc cttaaccatt aaagctttg cccaagtga cctcgtgtg 60
 aggatgatga taatttatla aggaattctc gctgcccaga catcatgcca agtgccttgc 120
 ctgcatttca tttaatacac acaatatctc taagggttag ttgctgtagt tgcatacat 180
 gcttacaaca ttggaacctg ttggttgaag agttcatag ttgttcccaa cccatgtctc 240
 ccaattatag agtcaacttg gaacttcaa aacttctga ttggtgaacca caccatggcc 300
 cagtttaaat acagttcttg agttgtgttc caggtacgg ctttttttc agtcccat 360
 gtgcggccaa gtttgaagac cgaagttcac acaggtcga agttgagagc ttgacttcca 420
 accaggaag gctggtgcca aagtacagc ttgcaaaagt caccatcagg ttatctactg 480

ggaatttcaa attatgctgt caagctatcc taagaatgta cccctttgtt ttctcaagt 540
 ctttccacgg aacttgcac agactattt tccctatcca ggaattaaag aatggggctc 600
 cgtctcccca ttaccttga ggaattctcc cccactacag ttatattctc tttaagtctc 660
 tcaattttag agtttccact taatctact ggaacatggc atcatctgac ttgggttttc 720
 ttattttt cacaagagcat aacatctac ttgtattca gaaacagctg ttggtcttca 780
 ttaacaaagt gataanaac ttgggtctwg aagatattga ggalatcag ttactgaact 840
 gtgtcttag attgttccc ttctctctg gaaacatit tcaagtagag cttgtgtga 900
 gactgttga ctgaatctgg gctatagag ccttcagact cctttccccc ttgcaagagc 960
 tgaattgta gatcccatag ttgcaaacac catgtaccca ccaatattgt ttatgtgcca 1020
 gttgtggcca ttgaaaggtt ccaagatttc ttacttcta accgttccatg ttgaaggag 1080
 aagacctct cctcccttca caccagaggt tcaatagagc accatggagc ttgtatcta 1140
 aatgaagaat gcaatttctt gtgcctggg atgtgtccc ttactacccc gttttaat 1200
 ttactcttg ttgaagaat actcagttt aaatgtccc aatatgaagc aaggggtctg 1260
 gaaagttgt caagcttga atccacagac ttgtgaaaga ttgaagtcgg gtatcaactg 1320
 agttctggag ttcaagaaca gcttgacca catgtcgaaa cccatctct actaaatla 1380
 caaaaaatct ctatgaatgg ttgacatagc ctgtatctc aaatactaga gtagctgaag 1440
 caggaagaat gcttgaacct ggaaggtgaa ggttgcagtt agccgaagat atgtactgc 1500
 acccagacct gggcaacaga gtgagacttc gttccaaaa aaaaaaaaaa 1560
 tcga 1564

<210> 35
 <211> 1035
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (522)
 <223> n equals a,t,g, or c

<400> 35
 gcaatttccc agcacatcc gttgaagaga ctgtctctc cctgtcgaac gatcttgca 60
 gaccttcca aaaaagata accataaatg cgaaggcca cctctgaac ctcaagtctg 120
 ttccattatg gttatgact gctttatctg ttctctatca ttctttatg agattgtat 180
 tcaagttcag ccaaatatag agaacatgga gaggctcagg aaaaacaca gttatcacaa 240
 caggtcttag agacgaagca tgccttgcca ttggtatag ggcacatttg ggaagagctc 300
 aggtgtgta ggaagagga atgattagag tactgcttc atcgagttt ccttaggtta 360
 gggcagggcg aacagttttag ttgataatc ttggtatc tttagacttg cgtgtgtgtc 420
 tctgtgcttg gaccttgct ctggatgat aggtatagga gtaagtcttc ttgtgtata 480
 agggccagat agagagata ttgcttga ttltgatal cttgtatag cttgtgtata 540
 cctctagctg ggtccyrtg tatctttag aattgttag accctggag gacagttct 600
 caattatga gaaagtct tttaactgt aaacatcat atacaagaa agctaagat 660
 ccaattctg cagtgcata ctgtctkgct tactgtaga gttgtgtag ttctgaatt 720
 aggaagtgt agcggggcg ggtgtctac gctgtatc cgaagactt ggaagctga 780
 gtgtgttga tcaagagtc aagagatcaa gaccatctg gccacatg ttgaaccaca 840
 ttcttactaa aaatacaaaa attagctgag gtgtgtcag gcatctaac tcccagtgc 900
 tggagagct gagggtcaga gaatcactg aaccagagag gctgtgttg cagtgtctc 960
 ggaattgagc cactacatc caggtgtgag acagagtag atctgttca aaaaaaaaa 1020
 aaaaaaaaaa tctga 1035

<210> 36
 <211> 620
 <212> DNA
 <213> Homo sapiens
 <400> 36

acgcaggagg ccaaggggcc tcttcaggc tctgggacc tccagctgag gggatcgagg 60
 ctgagaggag atgagtggct ccaagtggag gaagaacatt acctactica gattttatgc 120
 ctctgtctct gaaacagagg cagcttttcc ttatcccttg gcttttccc caggaggttt 180
 gccggttga aggtgaacaa cttggctctg gaaaggagg atttttccag ttggccattg 240
 cctcttggcc cagagtattat cggaaacatt cgcctcttg gaaggagacc caatctgcaa 300
 caggttcacag aaaaactgat taagaagta ggcactcat tcttacttcc tgcacacctt 360
 ggaggtgaagc aacatcacaa tcccaageta attggttggc agaccattgg aaataacggt 420
 agagctcgtg taggttagct ccaacgtgt tatcttcytc cgggcttttt attgcttgag 480
 agtctcttct ggtgcatttg aaaaagctgc agtctcttca catctcaatt taccacaga 540
 catctctatt taattattcc ctgagagagg gaagtgggt atggcggttg gaggtggaca 600
 ggtctctaaa aaaaactcga 620

<210> 37

<211> 973

<212> DNA

<213> Homo sapiens

<400> 37

ggggactcag tcacacagaa aatagaagaa tgcgtgaca gtggagggt ctacagaaa 60
 agagctctgt tggacagaat gaccagctcg gactactgc catttttcat gaccatcat 120
 caaccacat tacagatgta acttagtgg agaaacatc tccctgtttt ccttcataat 180
 ttatgaata ttactttttt ctagtatttt gctatctta cgtcaaatg ttaaatatct 240
 ttgacctct gactaataa caagccaca tcagttttag ttgcctttct ttttccctta 300
 ggtcagtttt ttggtatacc atttcaaac caatggtagg aacattttaa ggcactcttt 360
 gctcgaata wgttttagca tgmccagct gaaagtctta tatgtttatt aatttttgtt 420
 tataattgtt aatgaatatt aattttgta atgaatat attaaccaa ttaataaaca 480
 gtcacaaagc tgcacacgk ttaataaatt ataaagttt taatttttta atggattttg 540
 gtcacttaag ttcggaatg aaatacaca aactgttct tactttgcca aattgtccta 600
 cgtgttctca gaatcaaat ttttagacat tatgtagaaa cactctttaa cctagtgtts 660
 tcaggcttag tagagaagg aaaaagaaga agctggagc tggagaggga aagtgtgtaa 720
 atgtgttcag tagtgcattt ttgttgacca ggcaagtctt gcagaacctc tictgaacac 780
 ctccacctgt tgaataccc aggcatttagt taatctccaa ccaataggc aggatattga 840
 tctgagagca aagaggcaaa tggcaagcag agatcaaaa ggtgcaagag cttagatagt 900
 gatagaaca gtgcaggagc gatctaaatt cctttgcatt gtcatacgc aaaaaaaa 960
 aaaaaaact cga 973

<210> 38

<211> 838

<212> DNA

<213> Homo sapiens

<400> 38

cccacgctc cgcctctccc tcactctctg tctgtcttcc atttctgga gtttcaatag 60
 atatctcata taggtggaat cataaggcat ttgtcttttt gtgattggct tatttcat 120
 agcataagt cctcaagggt cattcatgtt gtgcagtga atagaattc cttttttt 180
 aagggtgaat aatatttcat ttgtgtgtt gaggttagg accttataa tgattatgtc 240
 atgagggttc tgcctctcgt aatgaattaa tgcattacc atgggagctg gtctcrgata 300
 aagaatttg gctcctttct ctcactcttc tgcattctt ctggccctta ttgtttttgc 360
 catgggatgt tggagaaga agtcccttca tcagtgtga gccataaac cttagatttc 420
 ccaactcca gaactgtaaa taaattttct tttaattac ccagcttttg gtattctgtt 480
 atagcaaac aaaaagtact aaaaacagag attagagaga cttctctt ttgacagttt 540
 tctcaaatgc caaggtggca taaattgaa tagtgttcc tgaactctat tagagattcc 600
 tcatgtttgc tctatgctat gccatgtagg gagagaggg cacaacagg ttgtggacat 660
 gccacaagt ttctctctcc tctacagga atactgtct ggttacaatg gcttagtgc 720
 tattcttcca cagctagctc ctatagtttt ttgttttaag agatgaggtt tcaatccagc 780
 ctggggggaca agagtcgaga ttctgtctca aaaaaaaaaa aaaaaaaa 838

<210> 39

<211> 607

<212> DNA

<213> Homo sapiens

<400> 39

tgcaccacg cgtccgcca cgcctccgt tctcaagca caatggtagc aagaactgtct 60
 tcagacactt cgaacacct cagtcctgt tccgggcac ttgacttttg tacaagctt 120
 caggctctac tggcttcta ggtcttgagg ttgtagccca gtgttcaac tgtatggtg 180
 gactactgt aatagcact ctcacctggg gctacacag gtattctggc caatctctg 240
 agctggcgg agctattgat ttgtgtccg catatgtgtt ggagcaggtt tcttctcta 300
 tcggtaatc cactcagcc acttgaggc atctgagg atgcagtgtt tgaagacca tccatggata 360
 aaaaagctca atagcatct aacgtgaag tcaacaaga acacaacag cccctactga 420
 ttcttgggtt tctgcacgg ccacagttc atatccagag gaatggcaga tctgagaga 480
 tccaggaaga gctaaaaat ggccttgtaa taatgagca gacctctctt ggtgttcaa 540
 attataaac acacttccat ttctcttga aaaaaaaaaa aaaaaaagg 600
 cggccgc 607

<210> 40

<211> 882

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (198)

<223> n equals a, t, g, or c

<400> 40

ggggcatarg gtctgtctct tggggctctg tctatatggg atgacgacgc ttaacgcat 60
 tatctatgcc ttccacccc gaaatctgcc cctgataaag acgtgttgc attatcagcc 120
 tgcgacacat gccccgggc gtcccctagt ccaactacct gaaatgttc gcagccagtc 180
 tctctggcat gtgcgchg gcagaagtgg tgcacaggta ctaccgaccg gccctgatga 240
 gaaacaggtt gagaagatg agtgtattt cctcaagcca catcattta gtgagatgat 300
 ttgaggatct gaagcccaag cttctgtttt gcmaactgg catcaagt cttctggctg 360
 gagaactgga agcttgggca gactcgagca gaggagacct gatgctgac tagacttctg 420
 ctacgtctg ttgtggggag aactgtacg acatacctga aatccacca aagcgtggag 480
 aactcaaac ggagcttttg ggactgaaag aaagaaaaa caaacctcaa gttctcaac 540
 aggggaact taataacta tgcgaagaat tctgtgata atataagttc taatatgta 600
 ttcttaatt tattgcatca aactacttct ccttaagcac ttagtctaatt gctaactgca 660
 agaggagct gtttagccga tacyttgaaa tttaattacg gtttgattga 720
 tatctctga aaacgcgcaa agcacatc atcaaacat tcaatgaata tgggtttgaa 780
 gatgtttagt ctggaata atgcgaata gaattttgt aagctacta tatgggttgt 840
 ctttatttca tataaattaa gaaattattt aaaaaaaaaa aa 882

<210> 41

<211> 959

<212> DNA

<213> Homo sapiens

<400> 41

ccacgcctcc ggtattttct aaaaataaa atttatagtg ttaattattca tagggccaat 60
 caaaaagaag cttctctttt gggcctcgat ttgatgtgtt gcttttcaa ggaagagacg 120
 gtctcccttc attggtgagg atgacaatga cgtatggcac ccaattcacc catctctgaa 180

tatlccctat ggcatacgcga attaccacc tccctttat tatgcacag tgaatacagt 240
 ccccaagttac gcctgggaata cttaacatga ccaagggtta ccttcgtac ccttgatcc 300
 aacttccct gatttccct atgtatcca catccgtgt ttcccttag ctaccagtt 360
 gaattgtcc ccttccccc ctagggttt cccgtttgc ccccttcaa ggttttttc 420
 agaatgtcca gaccgcgtt ccccaattc tgaagttag cctgtgcag ctgaacctt 480
 taaggtcaca ccttgaaagc ctgacatcc tgaaggttg cctgtgcag ctgacacct 540
 tggaaagagc cactctgtg agcttagcc tgttgaaag gcaacctgt cagctgagcc 600
 tgcgtcagag gaacctgtg ccccaagac tcaaccttc ccttctctg aacgtgcaga 660
 tgcataagc aagcctgtt ccccaagag gtacatttc atactgtg agaattagt 720
 tcaatgaat tcttgaagc agtaccatg gtacatttc atactgtg agaattagt 780
 gaattcaca aaagtcttc tcttcca aagaattt catctgtg tatcaagt 840
 atctatcca ccaattgat ttgttctg tatgttcc ttgactta ttatattga 900
 aaaaacatg ataatat ataatat gataattag accaaaaa aaaaaaaa 959

<210> 42
 <211> 875
 <212> DNA
 <213> Homo sapiens
 <400> 42
 ggcaggagtg ccaggtccc gtgcctcca gtgtcaaga ttctgggagc tgcctgtcga 60
 aatggaaagtg ttgtgtcca gccctggag cctacatgc agggcgtccc cagcaaacac 120
 ccaccacgc accacatcca ggaagaaac ccttgatgc aaaccaaag gcccaatgga 180
 ggcgtgaaag ccttcggaaa tgcgtcaccc tgttgagag cgggtctgaa ctcaaggag 240
 tggagttcca gctgtgtgt taaagagaa ctgaaggagc cgggtctgag ccttcagct 300
 gcatctcgt ggcgaatcga ttccgcaat acagacctt acctcttcc gtgcagagct 360
 cacccttgc tgttgatgt tgtgaagga aatgagcca gacaaagact tggctcagg 420
 ctcctgtgaa caagccaaga gctggggag ccccaacct gggcagagc 480
 agcaggccgc tgaacaaaca ccccaagc cagcctgt gcaagggtgc gggagatgc 540
 ccccttgagc ctctctccc cctcagact gaatgacct cacaatttgg gctgtccct 600
 gcccttccc ctgttaatgc ataaaggag agggaaagct tccctggggc ttgagctccc 660
 tctgtgagc tgaaggagtg agattcctt cactccag gaggggcaca atgactgat 720
 tatcttatg tatctacaa gagaatgat tttctcca gaaatgtgt cgtgttaaca 780
 aagaaatcac ttaagaaat gattgatat cttaataac tgtgcataac caattttaa 840
 aaaaaaaa aaaaaaaa aaaaaaac cgtag 875

<210> 43
 <211> 630
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (26)
 <223> n equals a, t, g, or c
 <220>
 <221> SITE
 <222> (29)
 <223> n equals a, t, g, or c
 <220>
 <221> SITE
 <222> (56)
 <223> n equals a, t, g, or c

<400> 43
 ccttccctta agggagacca agctgaagt ccaacgcgtt ggcggccgc tagaantgt 60
 ggaaccccg gtctggat cygacagaa aacatgagt tcaagtacc tgtctagata 120
 ttctgattta ctacagcagc ctctagact atgttggaa cccatctat accttccca 180
 ttctgtcta gaacatgtt gatatcttc tgtttaa at cctctgtg ctcttttt 240
 cccatataa aaattcaaac tccatttacc cttaattca taacaaaac cttcaagat 300
 tgcctctac ttaattcttc tttttccct ttatcttca tatcttacc ttttttct 360
 accaaacct gtaagcttat cctctcttc ttatcttca ttatcttca ttatcttca 420
 tcttgaaag ctagtgttg tttaactagt cctccattc ctcttctgg aattcagc 480
 tcttcttcc cccctaatc agtataccc tactgttcc tgaagatca gtttaagtt 540
 taattccca aaaaattca atcagttct cctctgtat cccatcttc aaaaaaaa 600
 aaaaataac cgaaggggg gccgttaac 630

<210> 44
 <211> 571
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (460)
 <223> n equals a, t, g, or c
 <220>
 <221> SITE
 <222> (494)
 <223> n equals a, t, g, or c
 <220>
 <221> SITE
 <222> (562)
 <223> n equals a, t, g, or c
 <220>
 <221> SITE
 <222> (566)
 <223> n equals a, t, g, or c

<400> 44
 gaaacatcgt ccttactcct gcaattttt gacgggcatg ctccacaga gcttggcaa 60
 cacaagcgg gctgtcaaac tctgtgtca atgttataa gatcacataa caaaatttc 120
 atcctggagc tctctatgc gctgtgtt gctgtttg cgtttggcc tgcgtcacct 180
 ggtgtcgtc catgtccagc aagacataa ccaagagac ggcagctcg gcgcataga 240
 aatgtgcctc gggggtctga atgcgtgtc ggaagggcag gccctggagc tggaaatga 300
 cagccggcct atgaaccttg tgggttctga gcatgtagc accagagcgc cgaataaagc 360
 caaggtcgc gccgtgcga aacagctgaa aatccatcg ggcctgttc aactgccca 420
 aagcgcagct tgtgtgtca gaaacaaag aatcaacagm cgttgtgtt gacaaacgg 480
 aagccagga tgaagagat gaacagctt ccgaaggaa aaggcggcgg cggcccaaa 540
 agatgatca agacaaat gnaatnacg c 571

<210> 45
 <211> 930
 <212> DNA
 <213> Homo sapiens
 <400> 45

ggacaaatt gaccatttt caataatgt ttataaccag ggctgtttac tgtttttttt 60
tttttycct agtcacaat tgaagacag cgagacaaac cagaaatggt ttccgacag 120
ttctgttag aagacaaagg acttacgga gctcttttt atgtgattt ctttgttgt 180
gttacaagg agatctgtca gctgttcaat taattgaaac ttctctgtca ttgatttgc 240
atttccaagg agataatctt ctttttgtt cctaattttc tagatgataa tagcttagt 300
ttgattttt gctattttt agaaactt tccgggaaga gatggcattt agaacttcag 360
ctttgggct caggatataa gccaattcaag gtacaattgt accataaagg gaacaatctg 420
ttttgtatg cacagtttct aatttttaa acttctaat ttctttatgc tagacataa aattatttt 480
aagttcacag aaccataaac atttcaatt ttctttatgc tagacataa aattattttt 540
caaaactgat agatttgggg taanaagttg ttccagtctc tctcccaatt gcaatgaaa 600
aaaaagctt aatttttaca ttacttttaa ttitttaaaa ccatgcaact ccatgaaaca 660
catttttcaa cttgaagttt gcatagcaga cttttaataa cettgggatt tatctgttag 720
aacaatagt gtttcacatt ttittcataa ttatatattg tgtatgttaa aactattttc 780
cagttgtttt gctgtataaa ctgtctttat caatatgctt aatgggtctt tgtacaattt 840
tgaagtttc taccgtgata taatgtagt taaccagttat caataaatca ttctataat 900
cttaaaaaaa aaaaaaaa aaactgttag 930

<210> 46
<211> 437
<212> DNA
<213> Homo sapiens

<400> 46
gtctcgag gccaatcc ggcccgctg ggaagggga gactgggggt agagtgaaca 60
tgacgaatt agcagatgg ctttggggac tagcgatcct gggtccacc tgggtggccc 120
tgaccacgg agccttggg ctggagctgc cttgtctct ccagaaagt ctgtggccac 180
tgcccgcta cttgtgtgtg tcccgcgct gctatgcct gggaactgt ggctatcgtg 240
tgccactt ttatgactgc gaggacgcy cagcgagct gcagagccag atacaggagg 300
ccagcgca cttagccgc agggggtgct cttctgacag cctaaccaca ttctgtgcy 360
gcagacctt cctccattt cccattaaag agccagtta ttttcaaaa aaaaaaaa 420
aaaaaaa aaaaaa 437

<210> 47
<211> 1024
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (713)
<223> n equals a,t,g, or c

<400> 47
gtgntcccg cgntggcca ggaattggca cingggcgctg gccgcttcc agctgtcaa 60
cttgaactgg caacgtgggg ctctctctgc gtcggatcc cagcatcgt ggcgtgtagc 120
tgcccgccg cggtctgggc cagggtcggg cttaactgta ccaatgcaa agcctgtagc 180
cgccacgag cggacactgc tctcctgccc gcgtctgcat cctgctcgg gaccactact 240
ggcmtactt gggccgctgc gtgggcttcg gcaactaccg gcccttctg tgctgttagc 300
ttatgcgcg cggcgtcctg ctccactct ctgtgtgct ggcctctgca ctgtggccc 360
tctcgagc ccaacgccc ctccactgg ctgcctctct cctgttccc tggctatgt 420
tctcacagc cagagtgtct ctggcacagt ttgcttggc cttcgtgac gacactgcy 480
tgccgggtgc gctgtgtc tgggctkagg tgcctttcca tgggatctg ctgtgcggg 540
gcagacac atggagtag gctcggggcc agcactctta tgactgggt ccttgccaca 600
acctcagc agccttgggg cccgcctggg cctgtgtg gctcggccc ttcttgctt 660
ccccattgcc tgggtagtgg atcaccttc agaccacagc agatgtgga canacagctt 720
cctgactca ggaagacca gactgtgca gggagaaagg ggtgagagg ggcctccac 780
acctagatc agtaagaaag tgggttggc ccttaacatc tgcattggac aactccacc 840
cttccctggc ctggccctg ccgcttaca ctctactg tccagggctt gggcgtgac 900
ttaggcagc ggtgcagag gagggtctg caggggctgc tccggccgc tagtgcgcc 960
tttgccaggt taataagca ctgacttgtt aaaaaaaaa aaaaaaaa aaagggtcggc 1020
cgct 1024

<210> 48
<211> 463
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (463)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (463)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (463)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (463)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (463)
<223> n equals a,t,g, or c

<400> 48
gaattcgca cgaattacag gcatgagcca ccgtcccgct ccttgactgg tgattttcta 60
ctgaaccca gacatgttag gtattcag agcttgggtc ttactgaac ctgtctccc 120
acgtgttac tccagcacag gaggaggtg gctgccgct tgcgtgagg tggggcgga 180
agtcagggt cccactcag caccatgga ccttagaga gggggcactg tgccttactt 240
tggagggtgt gggagtcta gatttacta gaccagcact gctgtgcgg ggtgggggtg 300
tcacttact gctcttcat ggcctcact ttcacatat tctcaggatg gcagtgcctt 360
tggagtggag agaggggatg tgattgggca ggaagcagc gaggtctcaa aaaaaaaa 420
aaaaaaaa aaaaaact gggggggccc cggaaccaat tnn 463

<210> 49
<211> 885
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (713)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (233)
<223> n equals a,t,g, or c

<400> 49
aattcggcac gaggggcgc catccttgcg ttccttgagc tctgcgcgtc gggagcatcc
atgctgcatc gcaaggggcgc tgcagacatc catctctctt gctctctctg tctctgttag
tcaaacacac ccagcagatc tccagttccct tgcagatcag tctgcatggc ccagccacat
ctctctccca tctctgtgcg tatctctctt tgttctccac aaacctccca ggttctgcgc
tcaggggccc tgcctgttga agtgcctcca gcagttctcc tccatgtctt accgaataac
tctgcgtccc tgtgtgtcgc agcccaacag acaactcagc cagagatctt gctctccagc
tctctcccaac tctgcgtgac tgaagcctgc cgttctgtgc camcgccasg gaggccacag
tgcacacgc tccaaacctt acgtaatcgc catcccaaga gggagagaca gattgaaatg
ggcagggaaa gatcatatga gaattcgttc ctgacataaa aaagatctag tctatctct
tctgtaggagc gctgtagatga agcttgaaac catcatctcg agcaaacatc cgcagaggaca
gaaacccaaa cacatctgtc tctcactcat aggttggaat tgaacatga gatcaattg
accaaaggtc gggaaatcca cacaccggcg ccgtctcgtc ggtcaggggg atggggcagc
gatagcatra ggaatatatc ctatgttcaa tgaagatcta atgggtgtca gcaaccacac
atggcccatc tatacatcgc taacaaacct gcatgttgcg cacatgtacc ccagaactta
aagtatataa aactaaatc aaaaaaaaaa aaaaaaact cgtag
60
120
180
240
300
360
420
480
540
600
660
720
780
840
885

<210> 50
<211> 847
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (407)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (415)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (415)
<223> n equals a,t,g, or c

<400> 50
ggcagggatc gaaacataaa gaaacacaa ggggtgataa atataaatc caactgtgtc
atcacctgtc tacgggcagc acctatgat ggaagtcac ggttatgttc tgttcccaa
gctggggggc aggggtacac ggggtgtgac ttatataaa tgcctccac cgtatagta
tatcttatat attctgtctt acatattga gattgacga atgtgtaacg ctccgttaac
taaggtataa tgaactgtga agaattagag atggatctt gaggatctt tgttctgt
tgaattctg gagaacagat ccgtgtcttg cgttcangct gggaaatgcag tgaattatc
catggcccca ctccagcctt taccctctc gggctcagct gatccctcca acttngggc
tctgaatcgc tggggatccc aggttgacac caccacacc agttgacct taaattctc
gtggagatagc gttctccctg tgtatgtccc cagctgtgtc tcaattctt ggtctatga
atctctccctg agccaagtcg ctggccagct tttgtgttgt ttgtttctc ttatttgaga
tggcaatttc gcttatctgc ctcaagctcg agtgcagtcg cgcattccg gtcacatga
accctcaact cccaagtata agcgttcttc ctgcctcagc tactcgggaa gctagggcag
ggaattcact tgaaccacag aggcggaggt tgaagttagc caagatacag ccactgtact
ccagttccga gcaacagagc caagctcgc tctcaaaaaa gaaagagaaa aaaaaaaaaa
60
120
180
240
300
360
420
480
540
600
660
720
780
840

aaaaaa

<210> 51
<211> 580
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (557)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (569)
<223> n equals a,t,g, or c

<400> 51
caagaagctc tgcatttata acacaatga cacatgttaa gtccctcttc acaatcttcg
tgaattgacac tcaagtctc tttctctcc ccaaaccttc taagcatttc taaaacctg
acctcagatc gttattttag gttctccca acctttctc tgcctcccaa ggaatgtgag
tatctctgac tttccacagc ctcaacttga ttcataaac caagctcttc tccctctgga
gtcggagaca caataaggat gggatctgc gcagaaagag aggtatctat gaattccat
agttatctt caaccacccc aaatgtatc atattaaag acccaatgaa gtagctgtgc
gaatgtgag acctctgtct gaagctcta tgtacacca atataatctt ctcttaagc
ctctctccac taagtgaag ggaataagct tgcggacac taagaaggag catlaattc
cccaatccca tgaagctcat ttgaagatca cagtataga aagtcggggc ttatcacag
tctcttggga agaaagaaa tttttctcng gacagcttc
60
120
180
240
300
360
420
480
540
580

<210> 52
<211> 598
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (515)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (523)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (558)
<223> n equals a,t,g, or c

<400> 52
ggcagggggc tgcggcgaca gggcggggct gcatgcgatg acgtcagatc gtccggcgcc
gggcctggcc tggcgagacct cggcgatctc ctgatatct agcctcgggc ccagctgggc
cgcggcggc gacaacttgg ccgctgtccc ataacacag cagctcgcc cagctctgcg
cgacgctctg aagaaatctt cggggccgat gcccggcgca tccccatgag tgaatgccac
gggcagggag ggtttcacgg tgcctgggat gggattcgtc tgcggataat gctaacccg
tctcggcgcc aggcggggc ttactgtctc cgtttctcg gcggttcgat gacggccgat
60
120
180
240
300
360

tcgaagatga cagtggcgcg cttgggagcc caagccgggtg gcgttggtttg gagtgatctc 420
 cgttgtaag cagcttgggt tcccatggat ttgcgaatgc tggttcgcgc gcttgcacg 480
 cctgggtctc tcaagtcca acccaagttc agcancttgg ctncceggaa gcttttaagt 540
 ttaacctggg aaagtgncc cttgttcgaa ctttggcttg aaccttcggc ttcaatgc 598

<210> 53

<211> 571

<212> DNA

<213> Homo sapiens

<400> 53

gaatctggca cagtcctcac cagccccca aaaaacctct cagtgtttc tticagtga 60
 caaatgatg agcatctttc tatgatggg tttaaacat tttcagggt ggtctttgt 120
 tttaaatct ttttttaact aataagattt acgggtgtga tttatacag aaatgcatta 180
 taaatgttt taatgttgtt ctgtttttg cagtctttaa gtgccaatgc aattgtctt 240
 atattctata gaagtctgct caaaatactc aacaggggaa taggcagcgg acagtcgaa 300
 tgggtggaat ttggcttctc taagaaaaac ttatttttgc ataaagcatg ggtcagatca 360
 ttgtgcat atgcagcctg gatggatgt taagttaagt ctgtttcagt gccggtacat 420
 ttactaaat ctgtttttat ttgtgtcatg tagaatacta ctgtggtcat cataatgtaa 480
 tcattcttg tacccttttt tttttttt acittgaagt cttaaataaa atgtataata 540
 cccaaaaaaa aaaaaaaaaa aaaaaaaaaa a 571

<210> 54

<211> 1247

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1131)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1202)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1209)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1226)

<223> n equals a,t,g, or c

<400> 54

cncccaanc cacaaattgg tttgttgggt tgtaagtcat gcttccccacc aaagtccaat 60
 atttcaaca ctctagtcca ataaaaatta ttattaata gctaagaggc gtgcagtgg 120
 gaaagtcag tgcatacccc tttaggaggg gagaatgttg taatatatca gctatcgagt 180
 tgttaaaaa aagtgtatyc aaycgtatat tgcctatagt atgtgcatg aaatttgcatt 240
 ttatgatag taacaggggc aaagccaaat tcatgttact ctgttcagtc agaaacattt 300
 tgggcatac agcatctctg ggaagtcgtg tactttgttt cgttttggtt ttagttttgc 360
 atttagatg ccttataatt gatgcctatt ttaatagcat ttctttttag cttttgttgc 420
 gtatttccat tcactgttcg tatctgttcc ttctatttaa agcattatct gttacacaa 480
 tgtacaaaa ctcttgaat aatatgtatt ctagttttc agccaagtcg gggatgttag 540
 tgattgtacc agccmaagc acctggataa tcaggsgcct tcttctttt ataatacacc 600
 atcaacatca gaaaaagcta ctgtttttat ttatatccc ttcaaatccc gctctggaa 660
 atgcagtaac tgcaccaaac ttattttagt acaaatatc attggcaact ttggaatata 720
 ttgtgatttc cattaggatt ttcttaaaag gggaaataaa ctatatatat atatgtatct 780
 taccaccaat tcttcaaca gaattctcat aggaagccat ggaatgagtc ataatgttgc 840
 cacatattac atgatttttaa ataactctca aaatacccaa ggaactctta aagatgtttg 900
 gtatgagtat actactttgg tttaacttta gcttcattga tgttctgcat ggaagatatt 960
 ttgtttcca ctttttccca ttgctagcag agtgaaatcc aagagaccaa acatttgcac 1020
 gcaattgatt tgaacacttt tgaataaac aaagaaaaaa aaaaaaaggga aaacatatat 1080
 aaactctaaa aaaaaggtat ctaggaaaggg ctacctcag gattggggac ntctctaac 1140
 ctacctcag ggaacccggg ggagggaatgt tgccctatg tgggggtctg ttatttccat 1200
 tntttttt tttaggttg gtatcatttt tgggggggttt ttttccc 1247

<210> 55

<211> 848

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (98)

<223> n equals a,t,g, or c

<400> 55

cccccaaga acagnttttg gtaaatccaa aaattatgcc acttttaaaa aaaaaaaca 60
 aaccttaaaa caggatcttt aataccctcc cctgtntc ccttctttt acctctccac 120
 ttagaatat ttctctaaa aataccctca aggaactgtg aggaagagct gtggtacctg 180
 acctgttga aatcaagggc cggcactgtg ctacagggct gttaacagat tatatcgggt 240
 aactgaatgg gtaccagggc ttacccaag aggtacttttt ttgtgttgtg tgttgtttta 300
 ggaataatg taccaatttt aagagcattc cccccactg tcccacaca cccadqcaaa 360
 atgtgtgtg gtgtccttca aaaaagagaa gtittgttc attaacatga cagaagaact 420
 tttaaaaa aataactgt caactattct atttcatct agggagactgt tmatctatgc 480
 tagattgtca ttttccctcc ttctccaca gaagtattct ggtagtccat gtcatgtctc 540
 gtgcctacc ctctaacat acctatgaaa tgcaggcaac caagtgaata agagatcttc 600
 gtgggcatc actgacacg ctcatgtttt acacatagt gagttaacag cataataga 660
 attatcttgc attgctaaa tcatatgcat atagtgaatg ttataataa tactctggag 720

gtcgtgttca attcaattga ataaagatac aatatcttgg ttgtgtcggc atatattaaa
ttatattatg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaggg
cggcggcct 780
840
848

<210> 56
<211> 669
<212> DNA

<213> Homo sapiens

<400> 56

cagccctcaat tcttcagatg cccagaggtc taagataaga ttcttaact ggaattcttc
ttaatcact tgaagatcgt ttaagagga ttgaactgt gctgcggctt ggtgcccaa
tctatcact cctgtgacgt cctgtgaca catgacagag taatcaccaa actaaact
agcaatctgt cctggacatg ctctccaac agtaagccac agggaaagt ttgttttta
gggttaactgg gcttgaaatg ttgtgtgcat atctaaagt gctttacct ttctttttt
ttgtctgttg gaatttggtt ttgtgtgcat cttgtttcaa catgaaaac aagtcacgaa
ttctttctc ttctgtcttg ttctgtaga cttgtttcaa catgaaaac aagtcacgaa
gaacctcttc tgaactgtac ctctgccca agcacacca aactttatg ctcaatgttt
actaaagcag gtgtctcttg gaatctcttg gaatcttg aggcatttga agcagaatat
aagatgggtc catctcttc cttaacttc cgtgtcgttg ggaatgtcca ctgtatcaac
agattttctt atcacagata tgcctcacgt ttcttaactg tgaacctgtg cgcgaatctg
cagattcaat gtctctgtta cagattgaat aatctttac ttggaatwtt aaaaaaaaaa
aaactcgag 60
120
180
240
300
360
420
480
540
600
660
669

<210> 57
<211> 680
<212> DNA
<213> Homo sapiens

<400> 57

gtcccaatgt gcaatgacta ctccagagtc cctggagaca ttatgtctt ttgtcacact
gtctcccaat tccaagctta taagctctct atatgcaagg taactcttag atttgacaa
ttgtccacc gtctctggct cctgtatcac accgtgtgtc tctttactaa atgaatgat
tcttcagatg tggagatcga gagaagagag aggaagagag agaatgttggg
tgcctattct aactctgtgt ccaatcacgc tgcaggtcag ctgcacaga aactcttag
gtctgtctc ctgcagttag gcaagttaac c:ctgtatga gaacacaga gtatcccat
gcaaatgtga gcaagaaat gtaataaca catgccaata gccagctcgt atacttaaaa
gccaaatgc aaaccggctc ctgtgcccc gaaggtgtg cagaatacag ttgtctctgc
aggctttaac ataatgtgc actatagaca cccagctgaa gcaaggtcgt tggctgtgtt
tgaatctct ctgtcttcta ctgaatgcga aatgtttaac ttgtgtcttg gtacatttta
atgcagacca agatgtctat ttctatgtac aatatcttat atttaaaa caaaagatc
ctaaaaaaa aaaaaaaaaa 60
120
180
240
300
360
420
480
540
600
660
680

<210> 58
<211> 524
<212> DNA
<213> Homo sapiens

<400> 58

gggtccatat tctccggatg agtgcattc ttgtctgtt tacacaagt ctgaaggga
tcgtgtgtgt accaatatg atgttccag tgggggcaac caagaccagt ggaattcagt
tggaggagact ctatccctaa aaatatagta gaattatg acaacaagg cactcttcc
aaaaagggaac atgtattct taagtctta atcaacaatg tggcagatc acacttga
tgcattagtc aaatataac ataatatg gtgtgtatg tcaatgaaat tttaagtgt
aaaaagcaga ctgtgcatt tttaagttaa taaattatg gatttattgt taaacaagag
tatctcttgc acaaatatga atattctgt gagaagatc acctttccag tggctcaaaa
60
120
180
240
300
360
420

attctctta ggtccagaga ttctaatggt tatattaac aatataaat attttgtctg
tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaggcgg cggc 480
524

<210> 59
<211> 427
<212> DNA
<213> Homo sapiens

<400> 59

ggcacgaggt catttcaacc ttatgaattg cccagataaa gctatgcaac cttaaggcc
aggtgttagt ggaacttgg gcaagaaat tacaatttca actgtgtgat aagaaggctt
taagttaaag atcaaatatg agaaagctt agctgttcca gctggccatg tttaaaaga
tgtgtctct ttcccaagta ttctgtcgc ttgcatgtcac tgaagctctt tgaagaagg
cccacatgag gcatcttcc cagacagga cggattctgt cgttaactag aggtgttgc
attcttgcct tttaagatat tcaattgca tcttttaata gtgatattac ggtgtcttaa
aagttatgtc atttgaanaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa
aaaaaa 60
120
180
240
300
360
420
427

<210> 60
<211> 1263
<212> DNA
<213> Homo sapiens

<400> 60

ggcacgagcc ccttcgggca aaagcgagc agtaagcagag gcaacttctg agagctggg
caggcagcag ctgtctgacc aagttcacgt gaagagaag ctgtgtccag ccggagagag
gaagccgggg acaggaattga agcaacaaca ccttgcagga cagtgcagcg gccaaaggac
tgaataaaga cgaattttaa gcaattcac atgtgtcaca agctcgatga tgacacagac
atgtataata ctcttatac atacattgca gttctgttaca acccaacctc cagtctcag
tccacacctg ctgcaaaagc ccaacctac agacctctt ccaaaagca ctctgcacac
agcccaaatg ctttaagga ttgtctctcc ccaagtgcac ccccaactgt tccacctcca
gtcccgccgc ttgacaagag agatgtgtct tcaacagaaa agcagatgt gaaacctcca
gaacgaagaa tggacaagaa aaaaattcgg tctgagcaga ggaattatt tgaatatga
ccgtgaagat caltaattct tcaagatgaa agaccatga ccaagcttca agtctctgga
ttgatgttca ttccaagga tcaaatatc atttcaact gaaatatttt tccaattatc
taattatag caaacaaaa tatctatca cttaagabaa accacttgcg tccctgaagc
gcaagtctac acaatagttc tcccttggcc ttcttgggt ttgtgattcc ccaataccc
ctgtcatgtc ctgtgtctcc cctcagaat cagtgtctcc aggtatttct ttgaaaccc
acagtctctc ttgactctct tccaagctta ctctatgaa aacatttga atcaattgca
attactctc aatttttgt ttaaaagaa tttaagtgtg agtgaacag aaaaaggagag
ttctcttgtt ggaatctctt caaggtctc caagaaatca cactcatat aatccaaagg
cagacctgtg gtttaatttg aaactctagc ctgtcccaac ccaacatag ttctctgat
tgaacttga aaacctgtg ttgtgtgtg ttgtctgag aagcatgtc aaaccttat
cacagataa ttcatagag atatttgtct aagctctctt acctttctt taataaactc
atatctttaa gattacaggt actacaanaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa
aaa 60
120
180
240
300
360
420
1263

<210> 61
<211> 720
<212> DNA
<213> Homo sapiens

<400> 61

ggacagagat ttccacaat gacaaattct caaatatgc taatagtaact gtcgaatttc
ctacatttgt aatttgaag aattgttaa tgcataatc agcaaccagt ttgaattctg
60
120

tgaaataaa gatgtttct tttcaatgc aagttcacag atcactggag ttctagctac 180
 agttttgttc agaccagag ttgcagatat ttgttctta taaagagaca catggttaat 240
 atttttggct ttgtgagctg taagttttc ttgtagctg ttacagctctg ctacagaag 300
 caaccataga ccaacactta caagtggtc acttttgat accaataaaa cttattttag 360
 aaataacaga gggctggatt tggctctagt ttgtgaacc cttttctaga tgaagctcc 420
 ttctgcaag actggctccc ttacttggct gacaaattc cactttggga cttagcatt 480
 gttgtgtc ttgttatt ttcatgtct ttccatgt ttggtgtctg gttttaaac 540
 ttttttctta catttaattt aaacatcatt actgagcgt ggtatgtcta gttttttc 600
 ttcttttccc tcttttctt ttctttttt ctttttttt atttgaaggc tctactctg 660
 tcaactccag ctgggtggca gaccaggacc ctgtctctaa aaaaaaaaaa 720

<210> 62

<211> 589

<212> DNA

<213> Homo sapiens

<400> 62

ggcacgacc ccgcgcattg ggaagttaggc tcggaccggc ccgcggagct gctgcagctcc 60
 ttccggcctt cctgccttc ccacgcaga tcatgtcca gttctgctt ggaattacac 120
 tgggcaactg gtttggatg tatctggctc agaactatga tataccaaac ctggtaaaaa 180
 aacttgaaga aattaaaaag gacttggatg ccaagaagaa accccttagt gcatgagact 240
 gctccagca ctgccttcag gatactatga ttctactgt cttgagggcc tegtttacta 300
 ttgaaaccaa aagcttttgt ttctgtctcc agcctcagca cttctctct ttgtagacc 360
 tctgtttttt tgccttaaa caagcaaat gggcccccaa ttggaact acccgacatt 420
 tcaacatac tcaactcttc ccaatactcc ttccaactg catggagggt tctaaagactg 480
 gaattatggt gctagatag taacatgac tttaaaaaa aaaaaaaaaa 540
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ggcggccgc 589

<210> 63

<211> 686

<212> DNA

<213> Homo sapiens

<400> 63

tgcacccag cgtccgaact gccaaaact ggtgattctg ggcagagctt tcactttgga 60
 gccagggat ggggtggggg agccccatgg gcttggaaag gagggtgctg tggagggggc 120
 tgcagggctg accagcaggc agcttcact ggtcgggggc gggggcgga gagacagaag 180
 cgggtctccc gttcttggga ctgtcttgggt tggccacggg ccttgagggat gcaagggtgcc 240
 tggggctctt gtccgggtg ggggggggca tgttggcttc tgagcgatca ggcgaggcca 300
 gcgaggggtg gcttgcnaat tcaagcaata agaggggggt tccctgggggc ttccagccca 360
 ggttagaagc ccccatggct tctggcagct ggcacatcgc cccaggtatt ggggtgattt 420
 tggctcatgca agtgtgctg tcccactgtt acacgcata aggggggta tgggtggggg 480
 tggggactca aggttggacc gactctagt ggcactgatg tgaatttct gtaacacaaa 540
 caccactttt caatgggtt ctaggagat tctgtatg aagtttcta attatgcttt 600
 tcaaaaaat actaaaaa aaggttcaag ctgcccaaaa aaaaaaaaaa 660
 aaaaaaaaaa aaaaaaaaaa aaaaaa

<210> 64

<211> 452

<212> DNA

<213> Homo sapiens

<400> 64

attgtgtagc attcaaac ttgtgaacac tcaacctcaa tgtatattct ctgtttctggc 60
 ctgtctcaag gtcaattaca ctactctctg ggtatgggct ttctctggt taagcttggc 120

tgctctggc tttcccaag atcacagcc aaagggcaca gfggggaaaa ttatggcct 180
 attcagaag agtgagcagc ctaaccaagc aagccttga ttgggggttc tcacttcac 240
 ggtattttcc ctctgtccc aattgggttt tctatagtta ctgattttcc aggcctccaa 300
 gggagattct gagccttgat tgttctctgac tgtgttttgg ctttgtgatg ctgagtgcca 360
 gaaatactct gtaataaaa aactaccatc gttctttgaa acaacaaga ggaataaaga 420
 acttaattct ggtgaaaaa aaaaaaaaaa aa 452

<210> 65

<211> 370

<212> DNA

<213> Homo sapiens

<400> 65

ggcacgatt gggggaacc agaattataa cagtgcgtc atctgactgt tttagatgt 60
 acagcctagt gtaaacattc ttgttatctt ttgtgcctt atcaaaaaa ttctctgac 120
 actggtttca gatgttcatt tattatattc ttccaaga tccagagatt ggttttgctc 180
 atccactatt gtatgttttg ttctattgac cctcagtagt acctgatct ttccactttt 240
 ctgttttcgg attggagaag atgtaccttt ttgtcaact cttactttta tcaagatgac 300
 aactcacgta ttggatctt tatttgtttt ccaataaaa tatttaaggt taaaaaaaa 360
 aaaaaaaaaa

<210> 66

<211> 987

<212> DNA

<213> Homo sapiens

<400> 66

gtttgtctc gggacccaa aggtagcaat ttgaacatg agggatcaga ttctactgtt 60
 ttgtcttcta ggaacaactc ggtcattacc acagctcaaa cctgttttg gactccctcc 120
 cacaacatg gctcggatc agggaaact accaaacca cagcagtcac atcaggctct 180
 tctcttcta agtcgatc cattaacaca gatgtccaca ctggggccag atctgcatct 240
 gttaaact gctgcaggaa tgacactgg taccagacc caccatga cctggggagg 300
 gttgaatgta caacagcaac tgcaccaca tgtgttacca atttttgca cacaacttgg 360
 agccagggc actactctaa gctcagagga atggccaca atcttcaga gctctatcat 420
 cacttctctg ttcccggar gcatcctgcc caccagtcag gcatggcta atccagatgt 480
 ccargatgr agcttctcag caggaggagc aggtgcaaat cctgccccc agggactccc 540
 agcaggccgc ctcccaactc ccagtgccac mgmtgcagc ttwgcagtga ccaactctgc 600
 aggcactcaa agggacacac atgcccacga ggaagccacc acagaaacga caaatggaat 660
 tcagtaaggt gttcaaat ttttcaacta agtgcctcg aatttggta tacatgtgaa 720
 tctttatcat tgattatatt atggaataga ttgagacaca ttgatatgic ttagaagaaa 780
 ttaattctta atttactga aaatatctt gaaatttcag aaaaatggt ctatgtagaa 840
 aaacccaact ttbaaaaaa ataattcaat ggaataatct gctttgaaa tataactta 900
 tgtctgctcg atgatatga tattaaaaa tatttggaaa actgaaaaa aaaaaaaa 960
 aaaaaaaa aaaaaaaa aactcga

<210> 67

<211> 1018

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1014)

<223> n equals a.t.g. or c

<220>
<221> SITE
<222> (1015)
<223> n equals a,t,g, or c

<400> 67

gtgtcccccg ggggacagcg gtcgggggag cgaatggccc ggcgcggccc aggcctgggg
ccgaagccgg gctcggggcg ctgcgcggcg ggggcctcgc ccagttactg cctctctcgc
ggcttaccgc ggtgtccagc aaggcgccca ccagtggcat ttgtctcagca ctgggaacct
tcccgcccca gatgtctgag aaaaagcgga cctcagaagt ctggatctgc
gtgggcctct gagaatgcg gttacgggt tctcttcac aaggcgccgc agtcacttcc
ttcactctat ctggaaacat tggacccttc ctggagttcc cctggagggg ctccacagcg
ttctcttgga ccgctcgc ttgtccacgg cctctcccat gttgtctctc ctacatcaga
acctctgga ggggaaagac gctccagcct tcgcgcgcaa gatgaggggg ggtctctggc
cgagcgctgag gatgaacctg cgggtgtgga cgccactca gttcactcaac atccactacg
tccctctgaa gttccgggtg cctctcgcga acctggcagc tctgtctgg tatgcctacg
ttggcctcct ggggaagtga cgaacgctgg agaaactca gttgcactcg ggaagtgggt
ctgggggttc caccggccca gcgagagcag aaccatcca gtccaggaat cctcggaatc
aaatcaggtg atccagatg cccaaaatg atgagtagag aaacagaaat cctcggaatc
cagaaccctc tctcttaaaa aggtggtctc tgccttcagg tgggtcggcc ccagaaacct
aaatgaagt cgaagcagtc tcaatgtta ctggggacg aattagatcc acaataacg
ataatggag ttcttcabaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaa
aaaaaaat actcgaggg gggcccgta ccaatcgccc tgatgtatc ctgmncac

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1018

<210> 68
<211> 762
<212> DNA
<213> Homo sapiens

<400> 68

ggcagcgatg cctctcagtc atgtctctc caatgtcag atccagctcg tgcagatcg
ctctggatc gctatctatg tctgtgttg cctaaatctg ctgagccaaq tgcacatgga
tggcaggaat gctacatba cagggaaaaa tctatctatg caagcagctg gttcccat
tctgggatg atagttcca tctgtctac tgcctcagc talaaagtgc catgtctc
ggcgcaatc caggaaatc aaagcagag tggatctca ctgtaaccac agatcccat
ctggagatcg gttcgatat gttctctcc ctcaacttc agcagagctg agatctcag
ttctcagtcg cgtcacctt ggtgtccaca acctaacctg gtgctcagag gtgcaaatg
tctcttcaa tcaaggcccg tctgtcttc tcaagctcca atctcctaaa agccaattg
tctcttacc gaagctatg aaagctctc accatcttc gttctaatg aacctcagtc
atgaaagatg caaaccaagt gatgtctca atgctcagag acagtgagat ctgagaccca
aaagcaagtc tcaagcaagc tgtctgaaac tctccatcac atctctaac ccccaagtc
ttcactgaat gaacatgcca gtgcactca agaaatgaa tctccaaagt atcttcaaag
ataataact aatgcagaaa aaaaaaaaa aaaaaaa aa

60
120
180
240
300
360
420
480
540
600
660
720
762

<210> 69
<211> 630
<212> DNA
<213> Homo sapiens

<400> 69

tgcagcagcg cgtcggctg gttctcacc ctgttgagat cagcttcaa gatgcctg
ggccctgctc tgcaccatcc tggctggcag ggtctgagt ttccatctg ttgcctctc
ttatctaat ccaagtctt agccaagaac acctctcac ttctgtctg ttccagacct
ctgtctcga ctgtggctg gctctctg ccacctcg gacgtggcc ctggtctggc
catctcaagg ctcaaacct ctgggggctc aaggaagctt gggctgctca gtcctctat
gggtctgct aatggaaagt agcatatag tgccttaaaa atattaacct ttctgaag

60
120
180
240
300
360

aactggagaa aaaaatgat aattatcc catcttaac attctgctc agcaacctgc 420
gataactaga tgaactctt gtggtcttc caaatctgag taccagatct tctaaatcag 480
acctcttctg aattaaacta tgaacagct cactcgatc agttcaatga tgaatgcga 540
ggggagacct ctcaagctcc catatgtca aaaaaaaaa aaaaaaa aaaaaaa 600
aaaaaaagg cggcgctct agagatccc

<210> 70

<211> 940
<212> DNA
<213> Homo sapiens

<400> 70

ggcagcgagg gactctggcg atgctgtgt cctctgggac tgaagggtct gggcctctc
gtgcctctc ctgcctcag tgcctctcg ttctggccc tgccttacc tctggatccc
tctggagcct ggaagagact cctgccttc aagggtcttg tgaattggc cagctctaaq
tgtagatct agttttaga ccaattctc ttgtatctt gtatttcaa ttttttggg
tacctgtac atacgtttg aggtatgggg taagtgaat atttgaat aggtatcgag
tgtgtataa tgcattcag gtaagggtc atccaaacct caaacattg tcccttggt
tccaataac caattaatc tcatgtgat ttagaatgt atgataat atgtgtgctt
gtatctctc tgtctggca aacacagat ctacatgct ctctccat atgatttga
cgtgtcacc cctccacct cctgtatct agttttat ctgtcttc cccaagatc
acggaacctg gtggggagag gtgagatcca ctccagatc ttggggccag cccctggc
ttctcttag gaccatgtt ttctgattg ttcttacc tctgtgcca gtttaagcag
atgcagatc atgagctct tgcgaaac ttagggtaga taccagatc aaaaatgctc
caagcggagt gaggcagga ggcacagaaa gggagggaaa ggaagctag ctgaacctc
ccaacccca gggctggccc tccctaacct cctgtttgag taagagtggc agccactgc
ctgtccccc ggggtgcaa ccttgatct ggaaggcgag cccctcagtc cctcttcta
gacctgttc acctgagat gttctctag ccagctcaa

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
940

<210> 71
<211> 1103
<212> DNA
<213> Homo sapiens

<400> 71

gcttaatga gcaacgcaa cagcgtctc cagtttagaa agagagaa: aaatcacga
gagatctct gtctgaagtc tcaagtgtt ccatctgag aaaaaaaca gactctcgc
ctgtctacc catgtactg caaaacag aaaaacac aaagtctag tagcatctca
agaacagatc aatttaagt tgcacatctg caaatgagt ggaatagca acataactc
taatggatcg tgaatctca atctatctt aattctgat gttggctat tgaactctc
aaaaatgga aagaactatc ttanaatcaa aagaatttc taacagatc cagcttga
ggagtcttc tgcataatc ggggaagtaac actggaaagt aggaattgg tcatgagat
tgaatgagc tatatttca atttgaatc taactgaaat ctttgtctc tcatcactg
taaatgga atggaatgt aagctttaa gaccttcaa tatataaat tctcagagt
gtatatag tacaatag ctgtgtctc ttaagtctc tctgtgt ctgtctcca
ctgattcat accagctat gaattgata ttacagctc tccagagctc tagaatpat
cagaatgtc aatgatatg tcccaatcaa caggagcg aaatcttaac gggatctc
ttcagatat atgattgttc tctagttct tgaataaat atgtcttca atctaat
actagcag atgtaatc tggaaacat gttgtgtaat gaaactgag ttgaaaaag
gctgaact atgtaccaa tcaagaccaa tgaatagcag aagtgtgca atctcaagt
aaactgata ttttatttc caaagaaat tagacattg aaataactg acatactta
agtttaatc cgaatttc ttatatag atgaacaa ttgtgttca agctttaat
tctcgaatc ttataact aaatctccg caattgtca ccttgatgt tactgttca
aaaaaaaaa aaaaactcg tag

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1080
1103

<210> 72

<211> 899

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (85)

<223> n equals a.t.g, or c

<400> 72

ggcagagctgg ggcggcgctn ggtggatgag tcacatcct cctcaaggga cgtcttgggc 60
 aagttatctg gcccattag ccagaaacca gggaaatgta gctgcaggaa aatcaactcg 120
 ttccctcggg atgttttttc ttaggctggc ttcttttaca agctgcaatt atgttccatc 180
 ccacgeaatt cagttcaagtg gcacttttca gagaactgtg ctggcgatc attggggctg 240
 ctgtgggac ggggttgagg agagaaggga gtgagagctt ctactgagtt tagtttggttt 300
 ttgtgtccat agccatttac aaactttgca cctgattggg ccagtttgca gttctttgta 360
 ttccctacc agccaagctg ttgaagctgc tgagcccgga atgattgittat caatgaggca 420
 gatgaaacac cctctagttg ctgaaacaca aactgtccc cagctcggtg ttccgtttt 480
 ttgtactag tgcctatttg ggtctgtat ataatggtga aaacagggaac gttttatttt 540
 aggtgtcaag aaaccaacat taagacaaga agatgtcatc ttagttracc ttgtaccagt 600
 acctatggcc agatactatc tagatgctta taacatctt acctaatct ttgaataata 660
 agcccaagc taggttttat atcccattt tatggatggg ggaactgagg ccaataactt 720
 caataactt atccaaagcc acaaaactag taataaacag agtgaatctt aacccaaaaa 780
 caataactaa atccaaattt cttactctt atgtgtctg tacttgcgt tactagcaaa 840
 gtctcttgg tgggagttac ccaatccctt ccccaaaaa aaaaaaaa aactctag 899

<210> 73

<211> 549

<212> DNA

<213> Homo sapiens

<400> 73

tcgaccacg cgtccgggt gacatgatgt attctgcca gatgtggca gttgtggaaa 60
 ctatcaatgc agcaatttga gtaactacgt caccggtgct gcttctctg atcagcttc 120
 ttggaagaaa tttttatttg ttatcatct ttggcaccat ggaagaaatg cagaataaag 180
 ctgtgtttt ctgtgtgtt tattttggga ggcgaattga aatttccagg tactctttct 240
 acatgtgac gteagttgac atgatttga agtgtctac atggcttctg tactactctg 300
 gatttccctt ataccactg gggatgttg gggaaactg ttctagttgat tcagtccatt 360
 ccaatattca atgagaccgg acgattcagt ttccattgc catatccagt gaaatcaaaa 420
 gttagatttt cctttttct tcaatttat ctataatga tatttttagg gttatcata 480
 aatttctgc acctttataa acagcgcaga cggcgctatg gacaaaaa aaaaaaaa 540
 aaaaaaaa

<210> 74

<211> 590

<212> DNA

<213> Homo sapiens

<400> 74

attggatcgt ttctactatg ggaactggcc caagttctc cgtgactctg cagcaactt 60

gttccacc ttgtctgcc caggatttgg ctggaagtgc tggtttgtc cgaagcacc 120
 agcgaacagt gcgcgctgt gtcacccag gtcaccgttg cctcagagct gagacacagg 180
 cagtggtgg aaagagcgt gcgtctcgc cagcggcaga actacctcg tatgtgagt 240
 agtatcac tactgtccc tgtgtcagc ctgatactgt tactcattgc gctggagt 300
 gtaacattc atgtgtttg tgggaagaat gcgcatgagt atcagcagta cctaaagt 360
 gtaagtcca tcttgcagta caggagaac cgtgtggctt acaccagttt gaaaagaac 420
 aagtggatg aaactatcaa tcttaorcat acagctttgt tgaataatg gactttagt 480
 gagaagaac aaatgttaat acatttagcc aagaaatcca caagttaagt actttatga 540
 aaacttgtaa aaaaaaaa ararrraaa aaaaamctcg aggggggggc 590

<210> 75

<211> 1056

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1051)

<223> n equals a.t.g, or c

<400> 75

ggcagagc gaaacgcct acgacgctgc cgcagtgag ttccaaagc ccttgagttc 60
 ctgcttttt ttactctga atcccacca ttggcttaca ttgggagctgg ggcgacctgt 120
 gatgttagc tttagagaca aggcacatgaa gggattctcc ttggccatag tcccagctt 180
 aactctcta ggtacctga ttactcgtt ggtctccatc ttctcttct ggttcagct 240
 gacaaaag gagtccacg aagcttttt cagtggccta ttgagaact ggttcaatgc 300
 caatgctgg aagctcgac cctatccat ttcatcatc ctggccggg tttctcgtt 360
 ctctcagtt ttcttggtt tctgaccac ctctcatgt atgctctttg cactcagtt 420
 ctctcagg acctggaac aaaaatttgt gtagcctgc atcagttct tcaaggggc 480
 cgtgctct ctgcttggg tctgcatgc cctggagatc aaggctctga ggtagaagct 540
 cggcccttg cagtctcca ttgctggtc ttactacgt ctgggtctcg gcatcttct 600
 gtteatagt gctgtacca ttgctctat tcaagaatg gtttgcctt gctggcactt 660
 gtgtccact tcccagata tggaggaggga ccacgggagc ctgtactgg acaactctga 720
 gagtgtgga ggagaaccca gctcagtaca aaaggagaca caggtgacag cagaacacgt 780
 catctagccc aggaatagc ttcttacc ttcttcaagc catgtagtg tacacatgta 840
 gctgttgta gctctcca cctctctgc cagtatctgt gctttgagg agctctctgc 900
 gtgtcagac aactctcac ctcccatac tcaacagtat tctatctgc ttgtatgta 960
 aatttgtaa agtctcttc aacttaaaa aaaaaaaa aaaaactcgt aggggggggc 1020
 cgttaccaca tctctctga tgaagttaa ntatta 1056

<210> 76

<211> 930

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (919)

<223> n equals a.t.g, or c

<400> 76

gcagagctgg acagccttg ctgcgcctt cccgatggcc ctgcccaga tgtgtgacgg 60
 gaggcaattg gctccacc tccgtattg catgacgtc agcgacacag tggttcttgg 120
 gggcggaag ctctgtctg ctgtgtggag cgaagggat gcaaccgcc agcctggcca 180
 gctggccca mcacggagt atccgtgccc tgagggcccc agccccctgc tcaatctcgt 240
 cagctctgc tgtcgggtg cagttggcct gtgtgtctc attggcctgc tgtgtctcgt 300

<210> 77	<211> 4463	<212> DNA	<213> Homo sapiens	caagggcagc atcccagggc caccctcgat gggagcccta tcactctcc agagaccgtt aactaccac tggtagatcc tcaaggagag agagctcgag gaccccacaa gtggtttgaa tcccaccta cgaaggagcc gtgagctcc cagtggccga gggggcccaa aaccacccg caaacaccac ggaaggagcc cggagaccac gtgagtcgag gtagtccctg ctgagacc agccggcccg gcccccac agctatagaa gcatcagcc tgcctttag ggcgtttccg cggagagagac accgagggcc acacggctcc gctcagagc ggttcagac gcccgggag ggaagttaag gtccttgaca gttcccgat ccaagacaa aatggcccg cctcccacg agctatagc agtgcctggg acacagttag cactcagcaa accgtcgctg ttgaagctg ttcatatc ctatctcggt ataacacac accccagaa ttatggggctt aaatatatc ccatttatc atgtcaaaaa aaaaaaaaaa aaacttcga gggggggctc cgttacccaa tcggccctgat gagtgaatmg tatgtctcg	360 420 480 540 600 660 720 780 840 900 960
<220>	<221> SITE	<222> (1308)	<223> n equals a, t, g, or c		
<220>	<221> SITE	<222> (13469)	<223> n equals a, t, g, or c		
<220>	<221> SITE	<222> (4119)	<223> n equals a, t, g, or c		
<400> 77				60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440	

<210> 78	<211> 791	<212> DNA	<213> Homo sapiens	cagttatg cagatctctt acagacatat agaacagggc atctctctgt agacatcgc tcagtctgt aatatatac accatatga aaaaattgt tccacctgac atgaataatg tagaagaagg aaactccggg actctaaag attactaa atccatatc gtactttat cgaagtatag aagctgact gaagggatc ctgtgtacta agtgaagctt atccagaaa tgcattcttc aatggaaagc gaaatctgt gtgatatca ttcttcagc gtatctgga gtctgaatgg ttgcaattat gttccctat tccctaaag caaaaggggt agttctgag tcaattata gaaatgact gatagagc ttgagccagg ggaataact aaatctctt aaacttgag ccttagagag ccaagagat atctctgt gtacacata attcagat gtagaaata tcaatgaac acagtttaac gacgttat gtatatat aattcagat tcccctgac aacatgctg ccaggttca atcacctgt aacttgatc ttacactat aggctatag tatctcaggt tttaaagc atttttca gatatcact aattcccat gctctcgaca tgcataaaa aacttaac atcgatat gccattgaa gccccagct cagtataa agtctcagc ctgtgttac atcgatat atgttgaa agcagtttg cagtataa taaacacca agttcacag atccaatcgc atgttgaa agcagtttg cagtataa cgaatcgaa atctcagc tatataatc taatatata ctggagatg tcttcggct taagttccat gaataaaaac tatgaatag cactctgtg caaccatca ctgagataga atccgaaat ctgtgcacg aaaaataga gatggccca ttggacaca atcgatggt atcgagctcg ctatataat atgtcacat gcaatgttg atgaagatc atcgatggt gttcagaca aagtaaaaa ttttttcaa atgtttac attcagaa gatgtctgt atcagaatc ttatctcgta tatttacac ctgtgtgag tcaactccc ctatattat ataagaatc ttatctcgta tatttacac ctgtgtgag tcaactccc ctatattat acgtctgcat ttcctccga gttccacac ttcttaaac gccagctgtg tttaataaa aagacatcc attctgag tcttaaac cttcagaa tccaccagc atagatctg tgaattcttc agcatataat cgaatcact aaaaagttaa taaattcag ctctttca attcatatg tatgctcat gaagtatcaa ttgccaggt tgaattttag tgaagcttg agttcatatc ttgagcagac caagttaag ggaacacaa agaaaccca ggaatgagt aatatcact ctgcacttac aaccattcca ggcacacca aagaattcct agtatctg aaaatgctg aaaaatttta agtaaaatc taaactttc aggttttag ttgaagctt gtcatcttg aagttctct ccatccagag acttaagca gttttgagt ttgaagctt gagtaacata cacttccctg aggcacccc atctgctg aagcaaaaga tatgcaggg gtggaagagc ggtctcgac ctgggaccca tatgcttga ttgagcagag atgttcag ccttgagntg ctgtgtaac acgttccccc gaggcttc ctgagcaaat gcccaagat ctgcctctg agagactgac tccaatatc ttgagctcca ttggagctag gtcgagagc gtttatag acgaactccc agaatgagt gccagata cctgagtc ctgcagccc gcttcgtga agagagctcg ctctgggggt cctcatita cctgagtc ctgcagccc agtgaagaag aggaataga ccttggaag cagagctga gatgtccat atcagtgca tctcgagct acagattctgt ttctgactg atagagatg accagtgat gtccatcaa gcaagcttc tatctctc cctttgagt cgaatttaa gggcatlag cactatgtt cgaagcttc ttgggaaaaa ctggagatc ctatcaat gttctgca taattata aatatctta caattatag ttctcagat ataacatag tatcaatc gttaaaatg ccaagatct tcttagatc actatlag tagcttag tacatctc gttaaaatg accataat atgagctct acatgaatc ttgacacaa taacaccta tgtatctc ttaaattgt gacataaggt gctgttagt agagatgac gggggcttc gcttttgt ctgaatag ttgaagcgc acgtgaccc gcttcagag cctgttcggc ctcccacat gctgtgtgc catgycggc ccttcagcc cagtatgna gccgtctg cmrgggac aggttttat cattaacag stctatag ctgatttgt ttgtaagc ttattatg cataaagca gaattctac agtttttt tttaatg aatatatg cagacccag tttttaact tgaaaaaact gttataagc taactttaa aaataaact tgcataat agtaattct atgttgtag agatctctt gttcaaat ttgtatct tgttccatg ttcaaaaaa aaaaaaaaaa aaa	1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3420 3480 3540 3600 3660 3720 3780 3840 3900 3960 4020 4080 4140 4200 4260 4320 4380 4440 4463
----------	-----------	-----------	--------------------	---	--

<400> 78
 ccaacgcgtc cgggtctctc gcttgccatc aatggagatg cagagtgttt cacatttgc
 gcatgagca aagaggagt cgaaggtac aattttgtga tgcctgccc gtcctctca
 ttcttggtgt tatectatct, ctgacccgt tgggtgtgga ggtggtgtt catcttgccc
 aactgtttta acatgggcat tggatcacg cagagccttt gcttcatcca cgcctactac
 cgaagagccc ccacagccc ctggctggcc tgcacctatc gcaactcctg ctggggacat
 ttgcctcag tgggtgggtt actgctgttt cggaggtatt cctctgctgt gagcagggt
 ggcaccccag actggcacac atgctgttgg gggcctcttg ttggtggaca actctggga
 cagcattct cagagagacc aagctgctac attctctcag gactcagtta ggtgtgccc
 gagcactga caaaatgagc tgaattcagg gaacctgga caccgagggc actggagcca
 gcatctggga gttctgtgtg tgaacacat tctgttaag agcccactg agggctctgc
 agcggagtga cagcaacccc agagatgag caccagagag tgcctactga tggagacat
 gtgaccattc aagactgaa atgcgggggg ggaatttcat tttaagtga agaccaaaag
 ccttttaaa ataatagttt ttatcatitt tatagtataa aaaaaaaaaa
 agggcgccgcg c

<210> 79

<211> 1292

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (488)

<223> n equals a.t.g, or c

<400> 79

tcgacccatg cgtcgacta cttttataat cagaaatag gatatataga aatggctctgg
 aaaaaatgag gagagagt acaatagga ggtcatcttc aatctgtttg gaccagcaag
 taagaacagg aaatctgtc caccacaaat ggcttaata tgtgtgttgg atggtgttgg
 tgggtgttgg ttctgggtt gggatgggg ggaaccttgg gatgtgatgg ttctcttagt
 cagagatggt gctttacagc tgggaagtat cttgaatttg gttgaggtct atccagacat
 caggcagatt tcataatttc acagacaag gctacgttta cgtctaaagg gaaacacaa
 aatactaaga tagaaactc catgcccct cacttttca gacaacaga acccccaggg
 cagagggtct tctcactct cagatttact ttgactcttc atctggttcc gtgtgggtta
 tgcatttnca cctctgagt ttctttcttt ttaaggtaat ttcattatga cgtttgtct
 ttgcacaaga gctaattctg cagaattcta cccaggagg gtcgagggaa gttagtgaag
 gtaacgatac cagttagaaa gttgagtttg ggtcatctca ggggcctctc ttggcctctc
 ttggcctatg ttctagagt ggcctctact tcccaggaa agatagttgat gttctactga
 gtgcaggta ggtctgtat tgaagcgcaa gatitcttc cctgacttct cttggaaacc
 ttaccaggga cgtgtgcttt cctcttccat atccctccac caggargcag gctctagcc
 tctgtgctgt catccttttg ccacttccat gaacatgctc tcaatactt gaaaaagta
 ctatagctga aagtaacta tctcttttg gtgagtctt ttgcatcttt cttataacc
 agagacttgg aataaacta cagcttggga cttggcggc ggtgcttctt cttataacc
 agcacttgg aaggtctgag aggttggatc acctgaggtc gggagtttga gacacgctg
 accaacaatg agaaacccc tctctacta aagtacaaa ttagtgtgga tgggtgcaca
 ttgctgtagt ctgagttact cggagagctg agcaggaga atcgcttgaa ccttgggggt
 gggagttga gtgagttgat acttgccat tgcactccag cctggggcaac aagagtga
 cgcactctca aaaaaaaa aaaaaggcgg cc

<210> 80

<211> 1283

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (341)

<223> n equals a.t.g, or c

<400> 80

gaatcaaaag tttaaccaat gtgcaaaatg agcagtttta ccttaggatt attatttita
 ttatattta ctactgcaga aaattattg attcttttc agaaaaata ctgttgtgtt
 aatttttgg gggagttttg aatttcacat acgaaagaaa taacacagcc ctttcaact
 cactgtgttt caactgcaa agttttttt gtgctaaaga ttgagctttt gtagaggtat
 cctttttgt tctttctctt ccagaaatct cagctacatg ggcgtccctg ccaatgattt
 ctggggcttc gtcccagggt tggcaggac aagtgttca nttgaagctt catttggttt
 ggaactctt cctctctga gcwacaaaag ctcgggtcca cgggtactct gcaaaatc
 acaactctag ttaggcattt ggcagaatag gtgagcagg gatgaactt taacaaatg
 taatgttct tttgtggaa tgtgcagagg ggcctcaag atgagcacac attaaagt
 aaacacaga ataatggca gtagaattta ttgtcaact ctgagtcta cagtgtctac
 tgaattcagt gattccacg tctttattac aactaaagc tgggtagaac ggaactctct
 taactatga agggaaaat ccaagacaag attccgcagg ctgctgtga aaaggggtgt
 tatcatgag actcactct aacagattag cagagggaag tggaaatgct cagagattgt
 caatgcmmg ttgtgtttw trgcamaac actggaaca mcacaggagt ctaaaatag
 aggcctgga gggaaaatg tacagctacg cataatgtt agttaaata aaaaagaaag
 atgagcttct gacagccca gaggttatt gataatgtt gtaaaagaaa tgtgtatga
 tgcgagctca gactacaa gggcataata cgcattttg gtaaaagaaa tgtgtatga
 gatatgtaa tagatttga tacgaattat tglatatagc aagaaagagt gccaagctt
 acataccag ctttataag ttttaactc tctgtattac aagaagagt gggagatgg
 gattctgtt ttattttat acaactcgc atgtttgaa tttttttt tttaagaca
 agctgtatt tctctggga gttcaaaaa aatacaaaa aaagggaatt cgaattcaag
 cttatcgata cgtcgact cga

<210> 81

<211> 708

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> n equals a.t.g, or c

<400> 81

agccagggc tccacagacc cccatggccc ccaggagcgn agggaggagc agagccttc
 agaacaggc cctcatctca ctgcatccc catcacccc tagttcccca atggctctaa
 ttgtgttct gagatccag tttactcgt ggcagggccc cactctgtt tcaagtctg
 gctggagacg cagatgggg taggcctgt gctctgagca acccagctc tgcctacag
 ggcagggc cgggtgcaag agtggactt ggttctcaa agcaataat gcaaacagc
 caacagctct gctgcctag aattccatc tttagccacac tctctcttc aggggtctg
 gaggagagt cagggttag cgcgggagt agactgcagg agagagagca ggcgggggccc
 acatctggag cctcgtcca cctcagttt atcagctttt gcttttga cggagtgtga
 acaaatctc agctctgtt tttttccca tcccagatt tactacagt tctctttaa
 agtatctaa gcgtttacag tagcttccc ttcacttgat tcatgtgtt gtttcttatg
 ttggaataa ttacccca atactagat atttctctt caccgattt tgaataaaa
 gagatgtga tgcacaaa aaaaaaaa gggggaggc gggcgccg

<210> 82

<211> 1464

<212> DNA

<213> Homo sapiens

```

<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (63)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (132)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (887)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (889)
<223> n equals a,t,g, or c

```

gagctcgtcga	gacgnaaagag	taaacacatc	cggatgcgcg	tgctcccgag	gagcccgagg	60
gagctcgtcga	atgttgatatac	gagctcggca	gtccctggcgca	caactcacaat	gtccagctcac	120
cgcgcacagctg	gttttaccatg	gttttaatac	acattgcgac	tcacagctgtg	ccctctcttg	180
ttatcctactca	cctggaatac	cgtctcaatg	tgctttctggga	tggtctcttg	cattttaaatg	240
aaataatgaaa	ggtgtccctc	aattggcac	cgaatgtctc	tggtgtctag	tcaaatccc	300
gaagggccctc	gtccgcagggg	cgtgtctcgc	cgaagcccgga	gtcccctctga	agctcacctc	360
tggtctctctt	tccgcaaacg	cggtaaacgc	aagccctcttg	ggcagatctga	gaacacaaag	420
agggagggggga	aaactcctgc	tgggtcaccc	tgttatagaca	ggctctctac	cgggagagag	480
catggaataac	tccctctcag	tgcctccggag	tgtgtgtctag	tgttctgttg	gtctctggag	540
ccctctctctg	cgtgataatc	aagctgcctg	tgttgcagct	ctctctctgc	tctccacaac	600
cccacccggat	gtgcaccgag	atgagatgtgc	atpcaacagt	cttaagaggg	aaagagagct	660
cctgtgtgggg	ccctcggggg	ggtctccagc	caaatcttga	gtccgcgaaca	gtgcagcgca	720
cccggtcttacc	agatctgttga	gctttctctt	cctctcgggt	cggactctgc	tgtgtccctc	780
gggtgtgtgta	gaatccagag	cccagagaga	gtccaaagcg	gtccctcgcg	aacgggggaga	840
ggctctctgc	ggcgcgtctg	ggcgaaamgc	gctgtgtaat	cggatnangg	gggggtctgt	900
tggaaacacct	tccctgagatg	tccgcggctg	tcaattgagc	ctgtctcttc	cttaacaagt	960
ctgacataat	taactcgtcac	cttcaaccca	gaagactctga	agggaaagag	catgtgtggg	1020
tccgtgttaac	tcgatataaaa	ggcgacggggg	atggcaccctg	ggcgagagtc	tggaccgcgt	1080
cagcgtctgac	cccaacggcc	tggccggagc	actctggcct	gctagatctg	actctccctc	1140
ccacccctcac	atgacccggg	tgaattataga	cgtttctttaa	gacacccctc	tccaatactc	1200
gttaacacat	tgaatctggg	aaagattgaaa	cctctcgaaac	cttaacatgtc	cttaacacat	1260
tgtgctgcaca	tgaagctctag	ccagctctgt	cctccagaac	cttagctctt	gtaattctta	1320
atttttaatt	cagcttcaat	ccctatgtgc	tcttttatta	agatgttggg	aaagggagag	1380
gtatgtctgac	ctcaattatc	ggcaaaaatg	aaacataaag	tctctcaaaa	tataaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	aaat				1461

<400> 83
cgagccacccg cgtccgcgtca aattatgtgaa aataacacaba ttatattcc 60
aatatgacct cgaataatccc aatatgacct ctctatgata cgtttctcag tatcttggac 120
tggaaacggcc aattctcaagc tatgtcttga agcaacatc tggagattaa atacctatg 180
agccatcgtc ctgtaagcgc gacataaagg agcaatgct tcccatcctc aaaaaaacg 240
ttatattgaa tgaacctcgt gctctgtata agatattata tcttctgagc tgtatgcgtc 300
aagaagaacta ggcagatccc agtatattata gaattcccca gttctatgty gttctgcgat 360
aacagcacct aaaaagatc cactaaatca gttattatg gacaggtcaa ccaaacccag 420
aggtgttgaa tgaagactty taattaccag cgaaaaaa tcatggaac tacacttcaa 480
aattatcttg agacttata ttactctcag gaagagtgct gggataatgag gaagaggcaa 540
aaggttaatg gttcccgctt gttctgtctc ataatccag gaataatata aaccacgggc 600
aaaaaaaa aaaaaa

```
<210> 84
<211> 928
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (916)
<223> n equals a,c,g, or c

<230>
<231> SITE
<232> (917)
<233> n equals a,c,g, or c
```

<400>	84	aaacacaaag gaaacgaag acgaatcgct tggatgac ccgattctg gtgggtctc	600
ccgcctcaagc tgggtgaag gttcccggt cgcgcgcgc agcaactcc cggcgcatg		1200	
aagacactga ggtccgaga gtttaatgta ctcaagcaag gtcaaacgc taataaatg		1800	
tggatgcacgc acccaagac agtctagag cgaatgtcac ttgtctcc tcaactcc		2400	
ctcggtgacg tgaactctg tggtttaac tggatgcac ctgttcga gaagcaaac		3000	
tgcagacaga gcgaacgac catcagcct ggcctccaa catcgcggg aaacacaca		3600	
acctgtctc tatgtgcac ccaacccaa agcaactga tgaagatga gaagatgatg		4200	
atgaagatga tgggttaat gaagagact cagagatga tgaatatga caggaactg		4800	
acgaatgaa tgaatcaat gattcacag atgaatgaa gtcaactga gtgaaactg		5400	
aaggaacaga acagatcac gaccatggt tgaatctgt acaacaagca ggtgtgcac		6000	
aggagatcat caggccacgc caactctcc tgaactcaa ccccaccc ctgcctcac		6600	
aaacacatga tggccatg gctcgaagt ggcctatgc acctccac ctgtctcga		7200	
gatactgctt ctttggccc tccacagca tcaatctga ctgaaatc ccagggctc		7800	
aaactcaatc caactctgc agtcaatcc caaccttga tttccatgct tggcttaat		8400	
tctcttaata aagacaacg agtaatttc caaaaaaa aaaaaaaac		9000	
gtgggtgggc cggaaatat ttcccca		9200	

<210> 83
<211> 616
<212> DNA

```
<220>
<221> SITE
<222> (722)
<223> n equals a,t,g, or c
```

<400> 85
 tattgtagtt agaaccatct gacacatagc tttttatcca ttgggtttttt gttatgtctt
 tttttacag aatttgaagt ccatcagcc gggagttttt ttgtttgtt ttgtgttat
 ctcccagtc ctataattgc ctggcataca gtaggcattt aataatcttt gaatcagtag
 aaaccagatg ttgggttggc atttcacat aggaatgagc caggtggaaa tcatccagga
 240 tacaataga ttttgaagt ataaaggaag gtcatacaa tcatgtgggg cccattttgc
 300 ctttttgtt ttttttttc taggtccagc aacagctcca caagggactc catgaatate
 360 aaagcccata tccacatgtt gctagaggtg agagcagtc accccactac cagactttgt
 420 gtttaggtg gtagccctgaa gaagggaag aycgaagaa gggcgtaacc cagaccagt
 480 ctaaacctga gtaacggag gagggtcaga gcaagcctgg gggcgtaacc cagaccagt
 540 ctttgttcaa tcttttttgt ccttttttc aggggtttag agaactacaa ggcctcaga
 600 atttccaga gaagcctcac catgtactc tttccctcat cctcagacat taagagcct
 660 gaatgccttt gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
 720 ang
 723

<210> 86
 <211> 570
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (6)
 <223> n equals a.t.g, or c

<400> 86
 gaattncga cagatctgt cgtttcatt ctgtttagaa gttcatgttc atcttagcca
 120 ttgggaact ctctatttc tatctttct ccacgttggc tgggtttgic tgcaaatcat
 180 tgggtcaaaa tcaaatatt tcaaaacag cccatttgtt ctgagccctt ccccttagtc
 240 ctctgtgggg gtcctatgt ctgcagaggt agggacaga attcttcagt ttaccctct
 300 gactctctc ctgactcat cctgttccc tcatctaat attgacaaag gatgactcat
 360 taagtcaac tggttatga actttcaat acccttcatt tgtatgtcag gatctgagga
 420 acaaatgat gcatctaat cggaaactaa atgtgacaca acaaacgtgc cagcaatacc
 480 tgttttgtaa ataatgttct gagccacag tgttctctgg tatgtgagtt tatatcaagt
 540 gaaaggtct ctaattgac atcaagttt tggaaatgaa agcttcacaaa aaaaaaaaaa
 570 aaaaaaaaaa aaaaaaaaaa aactctgtag

<210> 87
 <211> 639
 <212> DNA
 <213> Homo sapiens

<400> 87
 gaaaaaatgc tagggagaca aatcaaatg ttaaggggct gggctctcag cacattttg
 60 gtttgcatt tccagtgggt cagaagcctg acaatccgcc tagctctbgc tttagagctc
 120 aggggacca gttctattcc tgcactctta gccatcatct acacatttt tatctttct
 180 tttaaattt taaaaattgt gaaattctata tacataaag ccatatgttc aactaaaga
 240 atagttaaca actgtgtccc taggatccaa gtaagaana agatcagagt cagtttctta
 300 gaagcttca tatgtgttct tcccagtica tgtctctcc tgtctctacc tgaaggaat
 360 tacaagtttc atgcttttct ttatagtttt cctttacaca cataccctta agctctcaag
 420 tactatatgg ttctgttttt caagcccgag aagcctattt taatctgtca tataaata
 480 tgcagccgg gtabgtgtac tcatactgt aatccacga ctttcagagg ctgtggcagg
 540 aggtttgtct agctctagga attcaagacc agctctggga atatatggag acccttccac
 600 tacaataaa aaaaataaaa aaaaaaaaaa agggcgcc

<210> 88
 <211> 708
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (14)
 <223> n equals a.t.g, or c

<400> 88
 tgggtcacg agnncgaaaa tgaagaaggt acaaatcttc aaaaagcatg cctcttctct
 60 cagtttccag ttgtttagat gctctcttc catgtatata tggatcacat tegtgttaga
 120 tggaaagttt ggaatccact gttctccaa acggtctct tcccttgta cctatcatag
 180 tgtacatagc tcaactctt gattttgatt ctagtgttca aagataggtt ttttcatat
 240 aagatgtctt gtcagaagaa gtcattgaac ttacctgga ttaactgaa acaaaacaaa
 300 aatcagcaat ctcttccatt gcttttagaa atactgactt aggccaggca cagtggctca
 360 cgtctaacc cagcaetttg agaggccaag gaggagrat catctgagcc caggagtctg
 420 agaccagcct ggcaacatag tgagaccttg tctctgaaa aggaaggaag gaaagggag
 480 gaggagaggg tggagccaga ggaagggagg ggaactctg ttatactat cgaagagtg
 540 tatccaggtg tggtagtgca gccgatagtc tcaagtactc agggagctga ggtggagga
 600 tcaattgggc tcaggagttt gaggctgcag tgagctatga tggtaacctg tactcagcc
 660 tgggcaacag agacagacca gactctctaaa aaaaaaaa aaaaaaaa
 708

<210> 89
 <211> 949
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (508)
 <223> n equals a.t.g, or c

<400> 89
 catgataacc ccaactcgaa taaccttcac taaagggaca aaagtggag ctcctcggc
 60 gtgcccgcg tctagaatta ttggatcccc cgggtctgcag gaattcgaca cgaaggtctg
 120 ttgtgttgtt gcttgggtgt ttgtctctct ttgtaaggtc gttggttgaca agtgtgtcag
 180 agtactgtc cctctatat tgtatctat gcgcagctat cttctttgt gtgtctgctg
 240 cgtatattgt gctcttctt agcgagtggc tgcaggtatg ttgtccctcg ggtgtgtctt
 300 tctgggtcca tggatagat actatcttgt tctcttgttt ttctctgtg tagctttcag
 360 ttgtgtttct ggaatttttc ttgcaacga tagtaagcgt actctgactt cctgtgtctt
 420 gtgttttgtt gcaagtatat gctttcccta tatgtttct tctgaaattg atttgactc
 480 gtgtgtgtgt gtacacggct ggtgtcancc atttctgaa atgcagttgt gtgtgtgtgt
 540 gtgtgtgaga gagagagaga gaggagagag agagaagaag agactatggc taggtgtgt
 600 gkmaaaart catgtaaagc tatgagtcgc tctctgtg actggagctg tatgtgttca
 660 catgtgttca caagtgcaca ttcaagtcca catacaga gatacatatt tagggtctga
 720 acctggaagt ttgctccag ggtcatctga acctgattc aggttcagat ccaagggcct
 780 ctgaacctgg atcgtgtgtg tgggaaagac ccaggacca cacacaatgt cakaagctgt
 840 ggttaattgt gtgctgtgtg ttggtgtgt aatctgtgt tgtgtattgc ctgtgtgattg
 900 tctttggcat ggtctgttgtt ccacggggcg tgagggttcag gagtctcga
 949

<210> 90
 <211> 1171
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (291)
 <223> n equals a, t, g, or c

<400> 90
 gaattcgga cgaagccctc caggtctat gtaagaat gaagaatc aggaagat
 ggccttcgt ggaagacgc gctcgtgat tggccacct gtcactgaa gtcgtgtgag
 ggtgtctca cgaagatgtg gccgagatgc ttctatgat atgtctgaa gmaacgtgt
 gctctcttg gaagcttctg ggtactcag tgggggggct ttcccttgcg gtcgggctc
 tgcacctat gactgttat ttggggggct ggaacaaaga agactgtca ntgataatg
 cactgtagaag agcagagagc tcccttaag ctcaaggtgc tctgggttca gttctctga
 gcaaggaaac cagaagcttg cgtcgtct tcttktgta aaatggaaa ataccctgca
 tgcacacta accaagtcc tgaagagat agtctgtga agcagacag tccccacaa
 tcttatagaa taaggtgtga ttaactctg agtctgtga agcagacag tccccacaa
 tctgtctcaa aagcccggtg tgcctgtcga gtcgcatit agttatctac cttaagaaag
 cagaatttgg ggtcgtatg tgaatagat gctctgtgag aaatgahkt tatatycgt
 aataatgat gtcctgtgaa aactcaatag ttgcaatga atccgtctt aatcgtctg
 ggcacatctt ccaatgcgaat accctcaata actgaaaca ttgcctctg aaagcccaa
 tgcacttga caataaaa agtctcagtt ttgtcttag agatatttc tgcgtctc
 atcatctcac tgcctgtgta ttccctagga gaataacaga taagatact gggctctc
 actatctat caggtatcag ttgtgaaga agatctctt ccttatagaa atagaaatc
 ctgtatgtag catgaataa aatctcagtt ttgaatcag taattctct attgaaagt gatatctta
 tgcacacta ggcgtgtagt tttaagatc taattctct attgaaagt gatatctta
 aaatctgaa aaagtcttg ttatagatc caaagagat tactaatat acaatacgt
 aaattacaaa aaaaaaaaaa aaaaactcga g

<210> 91
 <211> 1151
 <212> DNA
 <213> Homo sapiens

<400> 91
 ggcacagatg tcaatgaag tgttctaat gcaactgga ttgactcca gatagctaga
 agttgcaca tcccactcac ccagatata gctgtgtac caagctatga atatagcaaa
 cagagacta gatatgtcat tggcgtggtt gctgtgcat tgaagctat tcaaatcaca
 ttaattgtag tgaatgtcag gtaactgcat tccaaata aaatgtgta tgaagcggc
 aaaaagatc acgaagatc ttctaacac cactcaga gcaatctga caatgtgga
 aaggaacaga aaacaaaaa atctaatag agtctatg agaatgtc agaatgtc
 gcttctaac caatgtgga gaaatgtat ggtccggga gttcgtact ggaagatc
 agaatgtggt gatacagat cgttaattgt tggcggga gttcgtact ggaagatc
 taataatca gttcccatc gcttaattgt cagttcat ccaagtcac aactgtgga
 aaaaaaac aggcctgca agatctaca cgaacaca catctgtgg agcagagac
 aaatctcaa ttgtgtcaga tcaactgct gtagacag gtaaaccaa taacagtac
 agcaaacaga tgggtctca tccatcat actgtgtg gctgaatcc accctaat
 gatgtccat tatgacat actgtatga ccttctact ccgaacctg ctgagacctg
 cctctgttg tgggtgtca gcaatcact gctgttca ctgtgtgac atttattc
 tgaatcttt tcttctcat atacagaaa atagatgaa aataaatca atgtatgaa
 cagtataat gcaaatgtt gtaactaag gatgtctgag tcaacagaaa ttccatctt
 aagagcggt ttagactca ttagactga cagtatgct tttaaaaa tccaaagca

WO 99/22243
 42
 PCT/US98/22376

tactgcaca ataatgtga gactctgtt gaacaaagg aaatcagcc tcttatgtc 1080
 tgcctctaa tactataat actgtatttg aataaaatc taatgtgac aataaaaaa 1140
 aaaaaaaaa a 1151

<210> 92
 <211> 714
 <212> DNA
 <213> Homo sapiens

<400> 92
 ggcacagatg atgtcttgt ttcctccact atatgcataa gtaatgtg gtaagtcac
 atctgtttt ttaattgtt gctgtcat cgaagatc tgaaggtcag gctctccct
 tgaatcttg ctgcaggtgt gataagaaag atgaagaaag tgaagaaag aggtgtgtg
 tgaagaaag tggcggccac ctgggacctt cgtctgtgca taacaaagct gaattctct
 tgaagcttg cctttctac taattctag acctgtgtgt cttctgtgaa cctcatctgc
 tcaattctc catgtgttaa ttgacaggtt cctttctt tctactctc aagaactga
 tgaagatcaa tgaatgtgaa tctggagccc gtttgtgt aaaaagagat aaggtgtgt
 agaaagctga gtaatgtca taagaaagg gaaacatat tgttaacct gtagatgat
 agagctcag ggaagacatc tcttcaact gtaactgtt aactgtgtg gcaaggtgca
 gcccacatc tatctgtgc tgaagtgtat gacatgttag tgcagatgaa taagaaagca
 aacaaatgc aggtactgtt gaaatgaga tcaagatct atgggtgaa atctagctt
 ctgactgtc accgtgaaga aactgtgta tttaaaaa aaaaaaaaaa aaaa 714

<210> 93
 <211> 810
 <212> DNA
 <213> Homo sapiens

<400> 93
 ggcacagatc ctgcctcat tttctgtgg cctcatcttg tatgcaagaa aataagcaaa
 aacacctgaa atctcagag aagtgtacgc cagacatccc agtctctcc gtaaggttt
 acagaaact ttcctttag gttcagagct gctgtgaagg aggtgtatga gcaaaaaag
 tgggaacct ggaatctca aagggaagac ggcctatgc tgaacagag tcttctgct
 ttctgtgac tggctctct atgtgtgaag tcatgtgtc atgtctgtca atgtatct
 caccgatgac catgtgtgac caagtgtgac atattatgt gtaaaagat acatcaacc
 agatgacctt gctgggggac agaatagagc cgtgtgaaga ggaagagcag gcaagatg
 ccgggaagcg agaggtgtt tgttgaagag accctctta aaggaaagc atgtatgac
 aagatctac caaggtctgt gccaatgaa accctctta aaggaaagc atgtatgac
 taaggtgcat tcttttcta atgtatgtt tcaagatct tgtctcac gctcgtgtg
 cacaagca caacagcaag ttcctcagat cagcagaa tctctgcat tctttgat
 aacaaagct cttaagctct atgtctgtg taagatgtt ctctcaatga caggtatca
 gttgaaaca atgtatgtt cactgtctt atgtatgga gatattcga ttatgtctt
 ctgcctctg gggaaaaaaa aaaaaaaaaa 810

<210> 94
 <211> 1176
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (569)
 <223> n equals a, t, g, or c

<400> 94

ggacagagtg agcttgaggga tgatatctat aagccagacc aatattaatt acatcttcaa 60
 gtaaaagac attaccgac tccctcgagt tttaacccta tacagtggaa ggtgagcctt 120
 tccctctcc aggaattgtt agcataacta ctgacagttc cagacagtat ggaagatcc 180
 cagtagatag ggaagagtc cccactgaa ggtccagcc tagtgggata cctctctgg 240
 gcacatggtg ccaagagatg acttaatat ctacaaccac ttgacagctc agttttttg 300
 gggactactc cagagtggt ccttcacaga ggcagtggtg gaaaagtaa ggtagaaaa 360
 agcagtaaga caggatgtt tggacaaggc attcattctc aagaagaggaa tgatagcaga 420
 ttgtagtgct ttgtttatg cttctgtat tgacgttact gccaatgaat ttgctctac 480
 atgacacctt ttaacgtcaa aagtgctcaa atagatttgt ttgtgttgcg gttttgtaat 540
 gggcgggtgg tattataat cctggatgna ggttgattt attttttt ttaatttttt 600
 ggtctgggtg acctggaaga tctactagct cctgcccct acggtccaa ggtgtctctt 660
 ccccccactga cagttgggtt gttgatggct cctttttaa tccatcagc tggaggtcga 720
 ctacgtcaac attctctcc catctggag cccaagaata caggaaaaag gctcagagac 780
 ttgacacatt atttttgtt taagtatga gcaactgatg tatattttta gtcgtgtgtt 840
 aaatattctg aaactgtgt tctcttttc ctttaattta aatttgctt cataaagtgt 900
 gtttacaaaga acattctctt atcaagttta ttggaatttt ctgggtcaaaa agtacaagtgt 960
 atttctggac ttctcttgac aaaaagtacc aagaaaagct gcaattaaaac aacaaattcta 1020
 attttaaaaa cacttagtga gctaaaagct agactcaaac caactcaatg aaagctattt 1080
 aagagaagtc agttgaagta gttccagaa ttattttcat tgttttttca actcttgttt 1140
 aacaccataa acgtgaatta aaaaaaaaaa aaaaaa 1176

<210> 95

<211> 1028

<212> DNA

<213> Homo sapiens

<400> 95

gcatgacct gtggaacaca gtttgggac atagatgtga attaagacac caccgagata 60
 cgggctgtga ggttcatacc gtcctgatag cactcgttgt gctgtgaaa tgtgggtaag 120
 acattcaaac ctggttttga tactgaaac tcttcttta aaactgtgac catgatttca 180
 tteagccctt ccacacctt atgtctgctt tgtttcagag tgaattttct atggagcctg 240
 tggccacctt ggaagccacc tgggtgctt ttaagttaac tcttccccg gtcgctggga 300
 gtggacacct catctgcagg cctctctgc atggggaggg taggcaggga gcagcatgtc 360
 tgcagggggtg aacttttgt cttctgtcag gcgaggccca ggtgcacca cccacctgcc 420
 acatggtagc agtgcacagg gccctggta tggccctgc aacctgtct tggggggcac 480
 acctggctgc tgcaggccaa ggcgctgctt cagtgaagag tccatgtttt agtatgact 540
 aaagtcccat gtttagccay tggcccagtc tccctgacc ccagaaacca ggtcactgga 600
 ccacagtccc agatctctat cagcgcgggtg agcactctaga agtgaagaca ctgtattcct 660
 acaatgtaca ctgggatat tctctctatt tagtttctag tgaacaaaat caagttagga 720
 actatcttta gtttagatgg aattcatttgt tttaatttgt tgcgcatctt acctatag 780
 ctaatatctc aagataagta atgacaaaa cctgtctaaa ccttttgttt ccaatgaatg 840
 aaagctatgc acttattta taggtctcat gttttggctt ctgcagtaact ttattatct 900
 atacataatt tggccaaaaa taagaatttg gaagaatga aatgtttagt ttatagtga 960
 aagaagatga tgacactaag ttgtgaaat atgttgtgat ttattgaaa caaactcacg 1020
 gcacgtag 1028

<210> 96

<211> 747

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (605)

<223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (642)
 <223> n equals a.t.g, or c
 <220>
 <221> SITE
 <222> (645)
 <223> n equals a.t.g, or c

<400> 96

tgcaccacg cctccgccc aaggaatctt gagtatgtat gcactttaa agaaccaga 60
 atcatcaaa tattgtaca tggctcttgc aagtgtgat aatagtgatg cttataataa 120
 tgaagattag ctgcactcat cagctcgtta aagtaaaaaa gttctctttt cgaatttccc 180
 ttcttttga agataaaatc ataatgttga gaaataatag ttctttttaa agactaaactt 240
 cctcaagcc ttctctgtc ttgtctaata actctctgtt aagccctatc ctatgttgct 300
 gttagatata agggataaag tatattctat gtctgtact ttagccaaga tatttggct 360
 ggacatgtct acaggacagc tccagctggc agcctatgcc ccttctctat ttggaatat 420
 tattactttt ctgaagtctt ttgcaagcaa cttctcttt tctcttgctc tctgttgct 480
 ttccctatat aggaagattt taagtattta gccagtcggg tttaatttaa atttggaggt 540
 ccagctccag ccaatggaga caggacacaa gctgcataag ggataaaaaa tgcctccctc 600
 cttnttcgg gtgtgctgtc accattgttt catctgtgag gngncctct tctgcagaa 660
 agtaaaatg ccttctgaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 720
 aaaaaaaaaa aaaaaaaaaa aaaaaa 747

<210> 97

<211> 628

<212> DNA

<213> Homo sapiens

<400> 97

cggcacaggt atatatat ttttaatat atataaaa agactttcag atagaattct 60
 catattctga tgaactatca cgtgttgtt gatttttaa tctgttgtct aaagaacag 120
 ttatactag cctcgcagac tattcaaca tcactcagga gcaaaaaaat tctatggtt 180
 ttaagesgta ctattattgc agattcaacc ttattattt aatactttaa aacagtgaaa 240
 aggtataag atgtggagct catctggagc taaattaaa ccaacaaaaa ggcatagaca 300
 aagtacaarg gaaacaaaa ccaaaaaact tcatgtatcc caaaaaata atttgcgga 360
 taatgtctt aaagtgggc aaaaaaggag gttctcagt agaattatc gcaactgaag 420
 gcaaatggaa aactctaca tagcatctaa taaggtttta catgcaatat atccccctat 480
 cccaagaat atctgcagtt caaagctgct ttbaaatta atgtctccta gtgttgctg 540
 ttataaatc ctaaatatta aaggggtgagt tcttaataa tactatttta atagtaacta 600
 agactttctt aaaaaaaaaa aaaaaa 628

<210> 98

<211> 904

<212> DNA

<213> Homo sapiens

<400> 98

ggcacagat cgtcttgtga caagacttgc tgagaagcac cttaaaattc actgtgagcc 60
 gactttgtc tttaactgtc tcactggata gggtagatca atgtcttcta ctgacgaga 120
 acattctca tgggcaggag catcatgga agttctgact acatcaagaa aggcacaa 180
 gtctacctg tgcctggggt caggcagcag gctgtgatgc cgggtccctt ctggttgga 240
 ctgtgtttt gcttctgtt atatgtagcc tcacgaagga cctttggatt agcaattac 300
 atgcccctac cctgagctt tccccagct cttgacttc ctggacatg gtaaatccc 360
 tgaataagca aaaggagtaa aattcataga aatattgttg caaaataata caatttcagc 420

ccagctcttc ggggtccatgct tggtaaggag tccagctggc aagacaagct gcccaaggaa 480
 gggccctcaga agctcgggic aaagaaggag gccagatctg ttcctgtaga ccccatgtga 540
 tggtaactat ttttaataat atataatcaa gaggacaaa ttaatactc caiggtcttg 600
 ggggaacttg tggcttaag tccctgaatg gggctgggca cggctggcca tggctatcaa 660
 tcccgagatc ttgggaagcc aaagtgggct gaccactga ggtcaggagt tcaagaccag 720
 ccctggcaac atggcaaac ccctgcacat gctggctcgg aggtcggag aagaactcg 780
 ctgaaccgg aggggaagag gttcagatga cctgagatg ggcacatgca ctcaactcg 840
 ggtgacagaa tggagctcgg tctcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900
 aaaa 904

 <210> 99
 <211> 576
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (521)
 <223> n equals a, t, g, or c

 <220>
 <221> SITE
 <222> (535)
 <223> n equals a, t, g, or c

 <220>
 <221> SITE
 <222> (572)
 <223> n equals a, t, g, or c

 <220>
 <221> SITE
 <222> (576)
 <223> n equals a, t, g, or c

 <400> 99
 aaatccccc gttcgaacca cggctccggg caacatcccg ttacatagag aaatctatgt 60
 aataagcttc gtctataaac ccatcagctg taattatgat cttactaat gtaatttctt 120
 ttttaagatc ttttcagag cctcctggctg cgggtatctt gtaacttcc ctgtaacata 180
 gcaagctga ctgcgggct ggtactcttg gctgaccag gacctgtaaa cttaatggct 240
 cggctcttgg tggtagatgt gatgttggc tggctatag ttggtaaatg tgaatttact 300
 tccacataaa cagaaacagac aaaaacatga ttaatgatg aagaccagat gaggagcagt 360
 ataaagccaa agtcaatgt gaggatagat attcttgata gtaatacca tagaaccttc 420
 ttcccgagat aggaacatgt ggggtctaac tgaattggat atctggagat ataaagtgtg 480
 gaggatcaca tcttcttct tctcttaaaa aaaaaaaaaa ngcgcgccgc tctaaagat 540
 cccctcgggg cccaagtcta cggctggcat gngacn 576

<400> 100
 ggaagaggtg caagcaaaag tttacgtat gatcaatgt taatttagc ggcctggggc 60
 gtaagagctc ttgatagac aaggtccac ctggccctcg gcaactlttg ctgctctcaa 120
 gccaagctc caccctcg gctcagggt gctgtgcgt tggccctcaa ggcctggccg 180
 accttcagg attttgta ctggcccat cctggagac cttaacatc tgccttgta 240
 aaccttcag agtgtatag gacttgaaa catagtccct ggggccaagc ctltgggtgt 300
 aatccagac ttccctatt ctacgttga ccttgggaaa gtgtctagc caatttggc 360
 gacctttcc tccctgaat gaaataatg atagtgcctt cttaacagyl aaatggaggt 420
 atgaatgaa ttcacataa taagcttct agagcatctc ctccctctt ctccagatc caaacctc 480
 gatctaat ttgcggggg tggcaccttc tccctcttc ttcctgctt tgaaggtgct 540
 gccaccacta acaataaac ataggagaa gaaacccagt caatcccg aaagtctc 600
 agtgcacca gaagtacaa taatttgt ccatgtatc aaagtcatc tagggagctt 660
 tagaagatta gatgcatgt ggttcttaca gaggaaaaaa aaaaaaaaaa aaa 713

 <210> 101
 <211> 649
 <212> DNA
 <213> Homo sapiens

 <400> 101
 ggcacaggga agtctcaag gggcgctccc ccaatcccg cgtatatac actgaaccg 60
 gaccctcac ccaagctcag ggcagccgc catgaagaa gtgtactctc tggatggat 120
 tctgtgttt ggtttgctc ttgtttgac ctgtgtcac ttcaagaaq taactgtct 180
 caaaccttg cgtctacag agaaagagg tgtttgggt gttgtttca aagcgtgt 240
 gattgaaac agtctcagc cgtcttggc aatgtctgt gttgaaatg cctttacgt 300
 cctgtcata aaatgaatc caaagacc aatgatacaa ctgcacaaa agggagcggg 360
 gatgaagaa cgtttggaga cctgaaccca gtgtagagaa gtccagctga atctatggt 420
 cccagagatg aacacacag atctgtccct gctatagtg gggaaactc atgtacga 480
 acaattatg ttgttcagg gactacagaa agccagctc ctltgacta tgttcaatc 540
 agtcttggc agatgacaa taattggcg ataatatac cccctcggtg ataaagtatc 600
 atacctcct catataaac tgtataaaaa aaaaaaaaaa aaaaaaaaaa 649

 <210> 102
 <211> 697
 <212> DNA
 <213> Homo sapiens

 <400> 102
 gattcaggga gggggctgt atgtaaaag tctccctcg caaaggagg gcaagtgtc 60
 gtgtcagtc ctgttcttc caatttctc gaaacatcg cccctctgic cggggagaa 120
 gggacgtgt ttgcagagaa ttggggccac ggtgttagtg caagctccg gttgtctgic 180
 ttgtctgtgt ggtcttcag aggttgagag gtgtctggag ctggcagggt ccttcagag 240
 agtccagac tcccccggc gcccccacaa ggtcttcaaa caaaacccgga gagggtgtg 300
 gggagcagc ctccagctg gctgtkccg caggcaacc ttgaaactcg gcaagctcag 360
 ctccgtggcc tgggtgtgtg ttgtgtgca caagtgtgt agagtctcg aagccacac 420
 cctcgaactt gaattctag caaaacaaa aactgggttc ttccctccc cgaaacttc 480
 cccagctag tcttccctc gtcttcctg cctccagcg cccggcgag attttgaat 540
 cctggagaaa aaactgtatc tgtatgaaa atttttgt actgtatla ttgtatlaa 600
 cgaattttc aaaggagat tctgtacat tagaacctc gtaattttaa aaccgactc 660
 tttttttaa ctgtataaaa aaaaaaaaaa actcgag 697

<210> 100
 <211> 713
 <212> DNA
 <213> Homo sapiens

<210> 103
 <211> 1288
 <212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (462)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (813)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (825)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (834)

<223> n equals a.t.g, or c

<400> 103

cgatgaagggt gtacaggag aaagattatt taggatctctg aggatcaatg gagaaaaacc 60
 atcaaatctt gttgattact ttactgtga atacatgggc taactactca accgggacct 120
 cagagctact ttacagatc tgtttccgc agtttgcttg ctctctctgg gttccatagt 180
 gaactgtttt ttaaatgatg tctcaagcc actgaccttt aacttttcca cggactctc 240
 agcatggaga aagagctcat cagcttgaa ttcccttggt ctctaccac caacagatga 300
 ataccacca tgaacatcca ccttcggccc ctctctagc tcaagtgggt tctctctat 360
 tagtctcgg tttctatc cattcaatc ctaccctcc tgcctgctca gactctcac 420
 acctatga actgattac cctttwctg ttttggctt tngtttttt gagacaagt 480
 ctaccctcgt cccaggtta gagtgtgggt gcataatcat tgcctactgc agccttgaa 540
 tctcgggttc aagcatatt cctaccctag tctcttgagt agctggaaact acagggtat 600
 gccaccttgc cagcttatt ttcattttt tacagctctt ctittagttt cagggtatca 660
 tgtgcaggtt tgttactca gtaaatgcat gctgcaggag ctgtatgtac agattatttt 720
 gtcaccaagg taataaatc agtaccctat aggtatgttt tgaataacct cctctctccc 780
 acctctcacc ttaacagtag cctcactgc tgnrtgtccc ctctctctgt tctctatgta 840
 ctcaaaagtt agctccact tataagttag agtatgtgtt atttggtttt ctgtctctgt 900
 gttagtttgc ttaagatag gcttccagat caaacatagt tgcgtcaagg acatgatctc 960
 tgtcttttta tggctacata ggaattccatt gctctatagt accacctttt aaatccagtt 1020
 ctatcattga tgggcattha ggttaattcc atgtcttgc tatagtgaat agtctgcag 1080
 tgaacatact catgcacgtg tctttatgct agaaacatat ttaactaaa gagctcttgc 1140
 acagcaaaat aagctatac agagtaaca gacaacctac agaattgggaa aaatatctg 1200
 caaactatgt atccacaaa gatctaata cagacgcta taaggaaact aaacaaattt 1260
 aaagcaaaa aaaaaaaaaa gggcgccc 1288

<210> 104

<211> 1027

<212> DNA

<213> Homo sapiens

<400> 104

gtccgcccac gctccgtac aatgatgggt gtgtgtttgt gtgtataggt ttgtataaat 60
 ttttaacttt ttaaatagat ttaagtatgg tagtaaaaga tagactagta tctacatga 120
 ttttatgac tcttcacata cctttattt ttgtatatt ttgtcttat gaggtctac 180
 tggtttttca aattgttga aatctccaaa aaattttcca atacatttat tgaaaaaa 240
 tccatgtata agtggagccca cacagttcaa accaaagttg ttaaggattt gactatttgt 300

ctatctaac atacctaac atagraaagg tacagtataa atcagattt ataattctat 360
 gggatccca ttgtctatgc aggtctgacat tgaatgtca ttatgtacag catgcttga 420
 tagtcttcc gagtctctg aggtctctca gcaactaat ggaactcaag aagggtttat 480
 gggaaaccta actatagct agttggttag gacctttggt caccatctgg ggtctctgat 540
 tgcacttga agtggagcc atcttgggc actgagcytt caacctatgg tatctgatgc 600
 tatctccgt agtgaagaa gtgaattgaa ttagaggaca cccacttga gttcttga 660
 aaattgctta ttgttaaat gcgtgggaa cccctctca cacacatctg ggtcagaaa 720
 ggggtgttg agtaaatg gggagaact gaattgttt attctatat tcagatagg 780
 gtcttgara acatcatgt ggttaagcata gatgtctaa agtcagactg cctgggttca 840
 tctctctgct ccaccacttc gaggttact ttagtctact gtgcttcatg tttctatca 900
 attgggataa taataccatc tcatagtagt acttaagaat taaatcagtt aatacatca 960
 aagcactcgg aagtgttga agcatttaata aacattcaat agctaaaaaa aaaaaaaag 1020
 ggcggcc 1027

<210> 105

<211> 710

<212> DNA

<213> Homo sapiens

<400> 105

ggcagagct gggctccag gttcttacc tgtcacatga tcatctaca tatttggatc 60
 tgtttattta ccatcagcat catagaagag caaaaagaag aaatactgtg ctccactaaa 120
 accagagctg agaaaacagt tactacatt gagcagtgag tgaccactag gggggcattt 180
 gttctatagt gcatggagaa caagtccca tatcatctt tctgctgatg cagctctcaa 240
 atttgaatg catcagtttt ttaacttga ttgagcaata ttccgtgggt gtagtccata 300
 atagcgtac tatttagcc tgtgacagag aggaactg taggtatc agatctctt 360
 aagagctttt taactttaa tcaagttagt actttttaa gatgtatag gccaggtcagt 420
 aggtcacacc tgaatccca gcattttggg aggtcaagat ggggtggtc ctaagggtca 480
 agatttcaa gccatctcgt ccaacatgg gaaacctcat ctctactaaa aatacaaaa 540
 ttagtgggg tgtgtggga ggcgctgta accccagcta ctcaagggc tgaagcaga 600
 gaatcagttg aagccaggag ttggagattg cagttagcca agatcatgcc acttctacc 660
 agcctggaca gcagatggg acttctctt aaaaaaaaaa aaaaaaaag 710

<210> 106

<211> 530

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (16)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (22)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (45)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (47)

<223> n equals a, t, g, or c

<220>

<221> SITE

<222> (54)

<223> n equals a, t, g, or c

<400> 106

ttggccccc taaggcttt tngccaaaaa aggtctattt agggngnce cctttaggaa
gggtaccccc ctctaggtac cgtgcccgga attccgggg tcgaccccaa ggtccggcc
cagcggcccg ccttcttgg gagaacagct gggtcaggat gactccaagt gtactgttg
cattccaat ttggttaag cattgaat taatatctt ctttttagct ttgaatat
tttgggtat accttatt ttgcattcat gacatcatg gtattcagg gctagatga
ttctttccca gattactaa agttcgatgc ccaactatg aaagaatat ttgtttatc
tgccttaag atattgctaa ggttacttgg ctggctccta ttgttaact ctggacatg
gaattatct tgtttatct gtgcgtgcaa tgggaatata atgattgat gtattttgt
gcagcacact gaaaaaaaaa aaaaaaaa gggcgccgc

<210> 107
<211> 392
<212> DNA
<213> Homo sapiens

<400> 107

tcgaccacag cgtccggcca cgtctccga gggacttaa atgatatcc cctttcctt
ttccctaata accttctgc cagatttca agtaaggcat gataacgga gttggatat
tcggaaacgt gactcgaat atgtatgtg agatgtgcag aagatccag agacttcag
caatgttca catgtcttg gtaagcatgc tccctactgt ggttaacca aactatgac
aaacccccc gaattatgat attctacgc agtaaccag cttctcttc aactcatgat
agctaaaggga cgttatctc aaatcatcg aaaaacgga agttttcat gacaaatcg
tttgcatacg tacagttaaa aaaaaaaa aa

<210> 108
<211> 991
<212> DNA
<213> Homo sapiens

<400> 108

ggcagcagga attttgtcac gtgagctgtt ggtttactga gtgagtcag ttcatgtct
gcaattgagc ccttttgag attcttaaa ctacagctt ttctagctt tccattctat
tccctctaaa gnaaacatt tggactttgt ctggctctc ggttaacct gtgacctga
ttactaaggc acagtcagac agaaaagaa gtgtgtgtt ggttaatat tatgagcac
ctgcagctt agttttaga gttatgcatg acctgtgcca gctctgagc tgaacagaa
tcaactcaga ggtttctct gctgtcatgt acctgtgcca gctctgagc tgaacagaa
gaaataaaaa aatgtgacct ggtctctct catlttaaa ttcttcttc ccaagacct
acctgttga agggacttga gaagccaaag ctggagaataa acaaaaggag gctccgctc
gagaaattag tggcttaag ttgtgttct caaactcag cgtgcgttg aatcgcttg
gggtcttgc agccacaga acccaatccc tgaattctg aatcaattgg ctggttggc
ggtcgttga gaatttcat ctatataat tccagatat gttctggcg ctggttggc
acctgttgc agcagacag ggtctggcg gggcggtgg ctacagctcg taatccgct
acctcggag gccgagacg gctgattcag aggtcaggag atcgagaca tccgtttaa
caggttgaaa cccgtctct actaaaaa caaaattag ccggcggttg tggcgcgcg
ctgtatccc agtatacag gaggcttag caggagatg gcatgaacc gggagcgga
gcttcagatg agtcagatc ggcgcactcg acctcagct gggcgacaga ggaattcg
tctcaaaaa aaaaaaaa aaaaactcga g

<210> 109

<211> 912

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (896)

<223> n equals a, t, g, or c

<400> 109

gggtcagacc acgcgtccgc ctcaagttgc ctactttgc gtttccctt ccagcagctc
ccccccccc cttagccccc cctctctgg cagctctccc tgcctctgt agtctccct
ccacgtgttc caccctcta cctgtctgt gttaatacc aacttcccg agaatttcc
ctggggagga atctattct gtcatgttc agtgcctgg agggaaagaa ctctctgg
gtagggtgc ctccatctga aacggccag gtagacaca tgcayaaagc ctccatctg
tccgtcaga tcttggttg ggcacagcg aatctctg acttattggg agtggcttg
tggttccctc ctggatagc ctccatgaa ccaatagg ctctccaac agtccctct
gaaatagctc ctgctcaga atccctctt tttaagcac ttctaaagc ctccagatg
ggggagctra acagacatg catattctag ggttaagtc aggaattcag cagtgaagc
atgtctggga ccaactggag tgcattcat ttaactcaa atctcttgg gatactgac
ctccctggga accagatct tggcttcaac attgacagc tatgcactag ttccagaaa
gccactaaca ggtctcatg ttatagttga ggtcttaag agatcaagg ctgggtcac
tgatcacctg atgataact cagctctgg catttagtct ttccctggt gataatccc
caagcagct ggaattggag ctgttggcaa gtgaaacta ttaaaattg atttctgg
gactgtcaaa aaaaaaaaaa aaaaaaaa aaataactcg agggggggcg cgtanccaa
ttccctcat ag

<210> 110
<211> 875
<212> DNA
<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> n equals a, t, g, or c

<220>

<221> SITE

<222> (872)

<223> n equals a, t, g, or c

<400> 110

ggcacagcg gaggctggc cccggccag gagaagaag tccgtcaag cagtggcat
gctgmgctg gnaagggag gctgttcag tgggttcag gggccggct ctggatctc
ggcaggagag cgtgtctga gaggctccc ctgtctcag gtggcccg tcaaccag
ccgggccat cctctgcac cgcctctcg tgggttla aattcgtgt gttcttctg
gggtcact agcacccc ctatgcaga ctggaggg gtcggcag cccctagcc
acgggaccc tggatggct ctatgtcact tggggctta aattcgtgt gctatcag
tgggttccc aacgtcaag tgggacctt agtggctgt ccagaaagc gggagggctg
ggcgttcac gaacttcag tgggacctt agtggctgt ccagaaagc gggagggctg
gagcgggca cggggggcag ctgggtctg cgtcaaggt caagcatccg tacagtga
ttctctct ctatcatgt tttaaccac ttgtccctt ttcccccat ttgtcttg
cattttct ctggcaaat gtaactcag ccttcatc atgacgttg aatttcag
ttctctgag ttgtcagc gggctggaa ccaagctga aactcagta atagagga

attttttgtc ttatacttt ggcattgata ttatttttac aaataatttt aaaggccagg 780
gtcgggtgct cagcctgtga atcttcagcac ttggggaggc ggaatccgag 840
gtcaggagat cgagaccatc ctggccaaca cagtgaacc ctgtctccac taanaaacac 900
aaaaaatlas ccagggtgtt ggtggcgggc acctcagtc ccagctastc aggagcttga 960
ggcaggagaa tggcatgaac ccgggaggcg gagcttgcaq tgagccaaga tggcgcact 1020
gagctccagc ctgggaaca gagcgagact atgtctcaaa atagtaataa taataatttt 1080
aaaataaggg ggaanaaac actgataaac caaaaactc aaccttaaga aacgttcaac 1140
tctgtatagc taatactctg acgatgggga tacaaaaaca cttcactca ggggtcttgc 1200
agatatcatt tttttccag tattttttg aaagaaccaaa tctttgtctt ttttctctc 1260
ttctcaggga actttatgaa tccagaaaga gccaacgttt gaatgattac tgcattctca 1320
catcatcaaa atctctgatac ctgcaacca gagatgagta gggatgtgg atcccaagag 1380
gtgacctgta acatactgcc cccct 1404

<210> 114
<211> 853
<212> DNA
<213> Homo sapiens

<400> 114
gggtgcacc acggtccgg gtgaattaac acgtaccaca tggccaagag tagatttggg 60
tgtcagtgt aaaaatttca tttcaaaaa cctggtgttc tcagttacag ctttatataa 120
gtatagtaat aactttagca gagctgtaga gagatagatt tgcaaaacttg aagtatattg 180
ggataaatct ccatacgttg tagaatttta tataaaatgg cataattcaa ggtatgtgtg 240
attatttggc ttacgaatt ctgtgttga gaaactagta tcaaaaaaa ttgttgtatg 300
ctgacatcag aattccagaa ttcatatgcc accctgttt ctgggtctct tctgtgtgct 360
gtggcttga ggggtgtgct tgtgtacggg tgggtgaggc acgcatgca ggtattgtcag 420
aaggaaacca cgaaccgtc atcttttcta ccccaagtg atcgtgctc attctgggtt 480
ctgtgaagta ggtttcaact aacatgttag ggaagtctct ggtgaaaaa gcaaaaggct 540
ttatacaatg ggtttatcc tggagccctc tggcaaaagg cagtggaac tcagggggaca 600
gaaatcactga agcttttga aaagacaac atctgctcat cacagtcca agggacttcc 660
aaaatacaga atgtctgtga cggagaagat ggaacacag cctggctgat gattttaggt 720
gaattctctc ttgtctgaga tgttatcagt gaccgttttc ttatttcat gaagaaacat 780
ttttaataa tgcactccc tgcataatt ctgtttactg tgttatgtt aaaaaaaaa 840
aaaaagggcg gcc 853

<210> 115
<211> 845
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (845)
<223> n equals a,t,g, or c

<400> 115
aaactagtga tccccgggc tgagggaatt cggcacaat ggaatctgtg ggaatgtgtg 60
tgcctctggg gtgtatgamt gttgtctgc accacttga cgaatccca agcctgccaa 120
gggcacactt tgcctgaaga tgccttcttg tgcacaactgt gctgccaag gacaggtgac 180
cagacacatc tgacagctt gtacactgaa caggcacggc cagagccaag ggggtgtgtg 240
cagctccctc tccagctgtc gcccttctct gcccttctct cccctctctc tggcacatcc 300
cccaaggctc tcaagctgac ccttgattt cagaacacc ctttcaata gaaagtatcc 360
agctcgggtt ccatgccat caacagcaag acacagctc cctgcataa acaggtgtgtg 420
aagtcaggag gactcaggga cagacactgt acacatcacc gaaagtcttc attcagctct 480
cccaactgct waaagttagg tgttaatatc cctgttttac agataaggta actgaggtac 540
aagaagttaa gtgatttgtt caaggtgtgc actgcagcag ttttgggtt tctctcttaa 600

aaaaaaaaa cttaaaaaa tttttaaaa acataaaact actctctacc tctgtcggcc 780
cagcctgtct cgcctgtgcc ggcgcagggt ggcctgtaac aatttcagtt ttgcagaaac 840
attcaggtat taaaaggaaa aaaaaaaaa anggg 875

<210> 111
<211> 459
<212> DNA
<213> Homo sapiens

<400> 111
gggtgagaga gggaggtacc agagttaata cagtgccact tggatgggtga caccacatta 60
ccttcagaca caaagatgta agctgaggga aatgaattct tggattccagg gaaatgaatt 120
cttggattct gaacatgagg ctgagattta catctctgtc tcaattgttg acgttatcc 180
caaggactag tcaattctga acatctgttg gaaattccca gattgaactt cccagggaga 240
aacatcatat gacatattgg gaaaatggct gacaatgggt ttccttagta agttcattga 300
gaagaaaagt gggcggtatga tttccacgt cttcactctt ttgaaagccc ctaaaacaat 360
ctgacacgtc ctagtgtgag cctgcttctt atcccatcag ttgtatttct gaatgcctta 420
tgatcattag cattcttcat taaaaaaaa aaaaaaaa 459

<210> 112
<211> 609
<212> DNA
<213> Homo sapiens

<400> 112
ttctgttcat ttttccctt tttccccc cattcattaa gaacctact gaaaccttag 60
gtcgaanaag gttgtgcttc ttgtgcaca ttgacccac cacaggactc actggactgg 120
acttcatttt atatggtatt aagtaactga tatatatata tatatatakt ttgtattgac 180
accaaaaaat tacccttgca caaatgccag acctgtgaag gtccagggcc cgtctgttyt 240
ccagaggggg agggaaactt ttggttggct tgggcaattc ctctgtacag attgtaactt 300
ttcaaaaaat tcccttacc cgtcactctg aataatgttc catagttaatt tgrtaagatac 360
ttttttctct tattttgtt gcaagacctc tccgaacaca ttcctgtata aagtattttg 420
cactatttaa agaaacccat atggatgaag tcaggatgtg caatagtatg gcgtcacagt 480
gctcacctgt gtaactgtaa tgrtaactaat cagtttaaat gtactatttt aaatatgtaa 540
aataatttt caccatgagc atgtttttaa gaaaaaaa aaaaaaaa aaaaacttca 600
ggggggggcc 609

<210> 113
<211> 1404
<212> DNA
<213> Homo sapiens

<400> 113
tacagagtttt ttttttttt tttttttta ggaagggtg caatgatgct ccttagctag 60
taagatgccc atcttggcct tctaaggga agataggtaa atgaaaagac tgcataatcc 120
aaggtcagac agcatataga agcttttata aagaacagg aaaaactcaga acataaata 180
agagatgtct tcttggact ctgagtttg cttcaatcat cggactctgga atattacttt 240
ttacagtttt gaaagccgat acacactgt aagtaataac tgggaaggt agagtatgat 300
tacttttttt accttccagt gtgtatcaat gttaaagtga caagagcmaa agaaaaacca 360
tatattttag attttgcaac atataaaaa taacaacact gggctggggc tggtytca 420
agcctgtawt cccagcaytt kggggagcca ggcaggggga tcaaaagtc aggagtttga 480
gaccagcccg scacaatag tgaaccccg tttcactca aaatacmaa aattagtgg 540
gtgtgtgtat gggcagctgt atccacagt actcggagg ctgaggcatg atgactgctt 600
gaacctggga ggcagaggtt gtctgtagcc gagattttgc cactgcacac cagcccgga 660
aacagtgcga gactccgctc taactgaaa aacatgaaca gccgtacta tctgaggga 720

gagcggagaga agtacaccca ggaactatgc cctgggaagc aagagggatga aattactcgg
 ccaggaatgc aacagctgaca gtagatgacg cgatggctgc gctttatgta gccgttaagtg
 aacaggaatc gggcttgagg ctagacacat acaattcac ggaatcccca cagcagatla
 aaaaaaaaaa aagatcacat attgtcccca tttaacagac caacctcac aagag-gggga
 tggctn

660
720
760
840
845

<210> 116

<211> 760

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> n equals a, t, g, or c

<220>

<221> SITE

<222> (300)

<223> n equals a, t, g, or c

<220>

<221> SITE

<222> (425)

<223> n equals a, t, g, or c

<400> 116

cgagcggcgtg gmgcggaagc gtggggaaaa aattaacaaa caaaaaacaa gaaaaaaaaa
 aacaaaacc ccglaaaalc acaagaanaa tacaacacca aaggcgagaa agccggcttg
 ccgtgtgtgg gggagcgtag gctaaalcc cctcccttc acttaacctg ttgaccttg
 ttatatcat gatatcaca aaagccgca tgtlaaaaa gttatagatg tcatctctc
 tctgcccca gggaggaaga ccaactctc ttgccccttg gccctcttg caggggcgaa
 gggtctgcgc gttgggggtg ccaacagggc ttgccccttc ctcctctga tccagcgaa
 gggtccctcg cgaatgcgg aaggttgcat ggtgtgcc aaggcgaca caggccggag
 gccmgctgc cttgtttat ttatattaa cttatttc tgtttatga ttgtgtgctc
 gcccaaccc accccttca gttttaagt ggagcccttg gggagatttc tccgtccctc
 cagccttcc caagacctcc cccctctga ccagcctac cctctgacca ggcagagggc
 ggaacgggtg ggcaggggac ttgaggtggc ttggtccagc ccaacagcca atggacctc
 cctcagggcg caggttgcgc cctgcccctt tttaaaaaa aatgcccctg ttgttaacc
 cttaagcgtc ttgaattaaa cccctctctc ttcttccaaa

60

120

180

240

300

360

420

480

540

600

660

720

760

<210> 117

<211> 988

<212> DNA

<213> Homo sapiens

<400> 117

gtagcagctgc ggtctccctg gctctctctc gcatctctcc cgaactccac agacaatagc
 aacttgcagc tctgtctggc tctgtctccc tctcttctgc actgtgtgac cgtgttgat
 gggcgagcag cgaatgaccc attgagaagc tcatltgaag gatcaacgga gggcgagga
 aggcagagag agagttgggc aaggtccctg atgtgaccaa cagtggatc accgacgcg
 gaaggggaag ggaagaagtc ttcaacggac ttgaacaat gggagggcac accggcaagg
 agctggacaa aggtgtccag ggtgtcaacc acggatagc caaggttgcg catgagatca
 aacatgtgat ttgacaagca ggaagaagg aggcagagtc ttgcatatgg gtcaacaagc
 ctgtctgaca ggcggggag/taagagaca aagcgttcca aggtttcac actgtgttcc
 accagcgctg gaaggaagca ggaagaactg gccaaagggt caacatagct gttgacagg

60

120

180

240

300

360

420

480

540

cgaggaagga atctggaagc cttggcccaa ttgccacca tgccttgcc caggccggga
 aggaatgca gaatgtcat aatgggtcca accaagccag caagggggc aaccagctgc
 tgaatggaaa ccatcaaaagc ggaatccca gcatcaca aggtggccca accagccgt
 taagctccgg ggtctgtgac aaccgcttc tcatcaact tccggccggc ttggggagcg
 tggcccaact catgcccata atgtgctacc ggtcttgctt ggaagaatc gtcgggttg
 tcaatcagc ttgacatgac ttgaggggtc ggggtgggg gaaagtttc tgaatccct
 gaaggggttc gtaattggat ttgtgataa acttgataa cttaaaaaa aaaaaaaaaa
 aaaaaaaaaa aaaaaaagg gggggggg

600
660
720
760
840
900
960
988

<210> 118

<211> 1947

<212> DNA

<213> Homo sapiens

<400> 118

gaattcgca cgaatctggt tcatatcat gcaatgcttc tctgtttct gtaactgttg
 ttgtgtgttc ttgcatttaa actaacccc aagcatatg ctgaagtgtc gttatgcat
 cacaagttca agaatatctc atgtaagt aaagtgtcc gcaagtcca agccgtgat
 agatgttga gaggacacaa agaatatca gctatataa aagctgttaa aattatcaa
 ggtgtcttc ataccaaact agagagaaca cgttcttga atgtggagc atcagaact
 atcatcaga gaaaatggag agctaatc cctgcaaga taagctcctga aactcttca
 atgataaaa gacatcagc ttgtgttg atccaaagc atataagag atataaaga
 agcagagctc tctctcgca gaatctgc gctttatga tacaataata tatcagaagc
 agggaggtcg gaaagcmga aagatataaa tatatgcat ttaaaatc acagtatcc
 taacaagcay gtgtgtgtgt tgg/taagac gaanaagatc ttggagccag aagagcaaa
 ttagaacttc ctccacttc actgagctg catatata cctgaagac gttagaatc
 aagagacctc taaactttac ctgtcttga agaatgtta caagcaggtc aattcagta
 tctgtatcca gagtgtgtc cgaagaaat tatagaana gagtatct cagaatatc
 atgacatcaa aagaattgag catgaaagtc aagaaatgtc gaggcagca aataggctc
 catcagtaat acagaagca gttgcctat tctctctcg taagaagcag gaaaaatca
 ctggttgat catlaaatc caggtatcat ggaagagctc tctgtgag aagaaatg
 atgtatcaa aatlaagct atagactaa gcttcaagt tgttaatag ggaatccag
 aagaataacaa actctaaaaa aagaatgac ttgcaacta ttactcttg acatatagc
 accctcttc catcttgag gctttaaac acctagaagc agttacatga ttgtccac
 ttgtgttga gaacatggc cagagtggag caattctaa aatctkgtc ttgaccgaa
 gttgtatcg cagatctcc ttatggagc tcatcctaa atactkgtc ttgaccgaa
 atgtatcaa gtaatggaa actatctcag caattatga ttatgaatc ttatagata
 tactatgga gcttttcag atatacag aagaagcttg taataagtc gtaagaag
 gcggaagcat tttaacaaa actgtgtc ttgtgtcat ttatcgag acacaaata
 gaggccctga tttacagatc aggtccaaag ttgttaccg tatctacag ctctacaa
 ttacagttca taacataaa atgaatctc aatgaatct ttacaagca aagaatac
 ctctataag caltctctc atccagaaa cactgttaa gaccagata gttcaagac
 ttaagccaga ttgtgttg agaaagata acatggaga aatcaaat cccctgaag
 ctatcaaat gttgtatgat acgtctgga tctctatca gtaaatgta acatcttc
 taagtatgt gtwaagaat actaaagca atcatgata cgtlaagta ttttcttc
 ctgttwcaa ctttaaat ctgacttgt tttaaaaaa cataaactgc tttcatat
 ctctacttc atcatatca gttttatga ttgaataac taatgttca taagtgaag
 aaaaaaaaaa aaaaaaaaaa aactcga

1947

<210> 119

<211> 1448

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

1680

1740

1800

1860

1920

<222> (1441)
<223> n equals a,t,g, or c
<400> 119

tcgaccacg cgtccgaac gtgctccgg ggtccagtc gcccgccgt gcgtccggg
agtcgaagt agcttctcgg ctgcccggg ggcgggggtg cggagccgac atgcgcgcg
ttctcggcct cctcttggtc ttgcggcgtt gcaacttcgc ctgtactctg ctgcgcgcg
gactgcccg cggggggaga ttgggttcca cggaggaggc ttgaggcagg tcgtctgggt
tcccctcga cctgcgcag ctgcccggag tctctgaggt ccttcgagag tacggaaagg
agcacccag ctacgtgttc ctgtctctct gcggcgcta cctctaaaca acaaggcttt
gccatcccc gttccagttt cctgaatgt ttgactgggt ccttgattgg gccatggctg
gggtctcgc tctgtctgt gtgacactc ggggtgcca catgtgcta cctgcctccc
agtatatttg gaaacagtt ggtgggttc taettctctg ataaagtgc cctgcgcag
agaaagttgg agggaaacag aacagcttg tttttttct tattgtttt ggaactttc
ccatgacac caaactggtt cctgaacctt cggcccca ttctgaact tcccacttg
cagtttctt tctcagttct taccgtttg atccatata attctatctg tggcagaca
gggtccatcc tptcaacct aacctcttg gatctctt tctctggga cactgtctt
agctcttgg ccattgcat ggtggcatca attcctggaa cctcatcaa aaaaatttag
cagaacatc tgaattgaa tgaacaagt actgtaact atatacag tagaaagac
acatgactg gatctctgt ttgccatc cctggactc agttgtctat ttgtgcaatg
gagtggctc tctaaagccc aaactgttt ttgattgctt tctatagtg atgtgacac
ttgcatcaa tgcacagt ctcttcagaa agacactct gctcttgaag gtatatac
tcaggtttc aaacagccc ttgtgtagca gacactgcaa cagatgctc ctgaaaatg
ctgtttgtgg cggggcggg ttgtcaagc ctgtaatcc agcactttgg gaggccagg
ccggtgatic acaagtccag agttcaagac cagctggcc agatgttgga aatcctgtt
ctaataaaa tacaanaatt agccaggct ggtggcagg accgttaact cagctactc
gggagggtga ggcaggagaa ttgcttgac caaggtgca gagggtgag taagccaaga
tcacacact gactccagc ctgggtgata ggtgagaca ctgtcttgac aaaaaaaaa
naaaaaa

<210> 120
<211> 496
<212> DNA
<213> Homo sapiens

<400> 120

tcgaccacg cgtccgaact gacacaatga aactgtcagg catgtttctg ctctctctc
tggtctttt ctgttttta acaggtgtct tcagtcaggg aggcaggtt gactgtgatg
agttccagga caccaggtc tactgcactc ggaatctaa cccacactgt ggtctgtatg
gcagacata tggcaataaa tgtccttct gtaaggccat agtgaaaagt ggtgaaaga
ttagcttaa gcatcctgga aaatctgag ttaaaagcca tgtttctgg tgaactgca
ggttttgag cctctcttc taactctgc ttacttttt gctggtggat tctcttaatt
cataagaca tactactct gctggggtct tggagggttc aatgtatgct tattctctt
gttactctg tcaataagt acattctgca aaagcaaaaa aaaaaaaaaa
aaaaaaaaa aaaaaa

<210> 121
<211> 1174
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1151)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1160)
<223> n equals a,t,g, or c

<400> 121
gagagggtca ggttggtctt gctggcatct tcacctaaaa taggtgtctgg cagacagcc
catgctgc atctcgcca cggcctgata gatggctgt gaatggcttt ttacatttt
aaaagtgtt taaaataa ttcatgaca tgaatacat gaaattcaca
ttcatatc tagaataaa ctttatgga tgcagccatg cctgtctgtc catgtctat
ctgtgtgc ttgtgtac ggtgcagag tggagtggct gggactgaga cggacagcc
tcttcaggg gcgcgtct tccacagga ccgcgggct actctgagg tctgtcttt
cccacggg gttggcttcc tgcattctc agtatctcg ctttggctct gagtgtgac
ctgcagaag agcgtttct tgtctcagt ggtgggca ctgsccttct tgttgggac
ttgactgata gackgttcc tgttackgc yccgaagta tcccagaaaa cctctyag
ttgcatgggt tgaacccagt cggcggtat tttagatttt gttcttggc ccttcacca
gaacagcgc accaccacc tctctccc ctgtgactgc ctgcacaatg ggtctgtct
gtgagatgtc gccacctgt ttgcactcg ggagatctc actccttcaa tttaattgc
tctctcctg tattttta gttctatgt atttacttt tagggactc cagccgggt
gacagatga cggctcaaa aaaaaaaaaa aaaaaaag cacaccagtg tcttcaatt
ctcttttaat cataatcatg ctttaaaaa tacctctgag cataggagc aaattcaga
taattgttc tttctgcta attcaatt actctcat ctggtctgt tctgtgcac
tbtggaccac tatgtgga tccgtggacc acttgcgtc gatctgtcgg ccagcagtg
gctgtctgg atgtagctcc atcgcaagc gaggagcact tgtgatttgt cctctgcta
tgggatagt tttctgcta ctgactgtg tagtaaat tttagactagg aaaaaaaa
aaaaaaaaa nggggggggg ccccgtaacc catt

<210> 122
<211> 1046
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c

<400> 122
ttgcaggaat tcnacacgag cactagtagc tggtytcca ggctggcggc gtcaccttt
ctctagccg ggtgacccag gggatttatt ttatgtggc ttctctgaa atgccaagc
cacccgatta ttacagctg agtactctt taactgttc cgtggagca ggaagattt
cgggacatt gcacagaca tggagaatga tgaacttcg tcaaggatg ggtgactg
ggtggatt gtactgtta ccagtgag cagcatttta ctatgtttt gaaactagtg
agactcaaa caggtggcc ttggaacaca ttaacagca cctgaggag cccctgag
gaaccatg gacacactc ttgaaagtc aattacttc cttgctttt tgggtgtga
cagttattt tctgtacct tacttacaga tgttttgtt cctatactct tgcacagag
ctgactccaa aacagtggc tactgtatca tccctatg ctttgcagtt atttgaact
gcacacagc attgtcaag gtttataat agatcagc actcaactg attgacact
aaatcagtc accgttttt cctcagat acaaaactg cagtcctata tggagtctg
tcacaagct cagtttctt cacagatctc aggaattgt cgtggggcag aggtcttta
aaaacatgt attaggagc tatcttctc tgaataaa cgaatttta ggttaaacct
gagatagat actcaaat catgtgatg acttcagat ttggaattta aatcagctt
gtatttga ttcttagaa acttgataa tcatcttct attactctt
gaacatag gatgattcag aaattttcc ttggggaaa aaatgata tgaacattc
cattgtta agtgaataa ggtccagca tgaataaa atttaattt tatacaaaa
aaaaaaaaa aaaaaaac tcttag

<210> 123
<211> 1160
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (325)
<223> n equals a, t, g, or c

<400> 123
gtccctatgt gctctaaact tatcagatcg ggaagctaga gaagaagata agtatctgc
tacttaattc ttagagataag acaatttaac ttccttggct tccctgtcca tggaccctac
tcaaccagta gtaatgtgggt gtttttcca cctttttct ccaatttat taaattctgc
tgggtatctt ccccttgcca aaccaagag aacaatcat ctactctat gttttattc
ttttgtatat gtaacataga gaggagagag aagaagaga tgaagagag tgaagaagaa
agatcccttc gcttgatcgg gcttngccag caatgacag cagtgacagc ctgtttccat
gagagagatc agatctaaat ttcataagaa aagagccag aggaattgaa aagaagaat
taaatctaac aagagagagc attgtatca tcatcaltc acgataaggtc atgattgaga
aagagctgggt gcttttggaa aacaattca ggtcttaac ttacccttc tgaatagtc
tctctcttc aacagaggtg ataatagag aatgctgaat gctcttccat tgaattgga
aactgcctgg ccagcatlag tgtgtatcg tctgcccaca cttttccaga tgcagttta
agatcatctc cagtggaac attgagagc ttgagatcg gaatccgaa tgcgccaag
ttaaatttaa tagatctgc cctcatcttg taactgtgac ttctaagt gacctttag
ttcaatctc ataaatttc catctaaaga gaatacaga wactgaagt tkaatttca
ataaagrat attctgtcg gtgcagctgc tcatgctcat aatccagaga ctttggagag
ccaagggcccg cagatcactt gaagtacag attgtatctt agcttgcca acatggcaca
acctgtccc tactaaagat acaaaaaa tagtgggga tgggtgtgca catccgtatc
cctactact tggaaagctg aggcacaga atcgctgaa cccggagagac agagtttca
gtgagctcg attgcacag tgcactcaca cctgggtgac acagtgagac tgattcaaaa
aaaaaaaa aaaaatcag

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1080
1140
1160

<210> 124
<211> 893
<212> DNA
<213> Homo sapiens

<400> 124
ggcacagata agagataag tgggctcgag cccagtacat cctctcgag aggtctgaagc
ttctgaaaaa agagtgtaga gagggttcag taggaagctc cacaaagtcag ctgagccaaa
ggatcccttc tgttcccca tgaatgccc agggagctcg ggtcgaaaggt ctgagagctcg
accagctctg gatcgatcg cctttctcgt gtttcttccc tctgtccct caggtctgga
gggctgggag cctgtctgct gctctgggac tttaactagt ctgttgagc caattcttc
gggaatctg gaccattct cttaaagac cagaattgct tcttccacc aagcatctaa
ctgttggag arggagagag cccctgtcag aaatctgggg atgcagactg aacaagag
gaacatagaa acaatgaag aacatggaga caatgacacc accttgatgc cagtggatg
aggtcgagct gcatlaaga atgaggaag ggacagagac aggtctaaaga gaagatgaga
caatcacaaga agaaagtcag ggggtgtgct ttaagccag gmtctcgaga ccaagctgaa
caatttggga ggtctgtcg tcaagatagc tcaagccag gmtctcgaga ccaagctgaa
caacatagaa aaaccccttc tcaacgaaa atcgaaaaat tagccagaga tggttgcatg
cccatctgac ctacgctact tgggagagct aggtggagag atgggtttag cctggagagc
agagttgga gtgagacag attttttaa aggcagaga tggttgctaa tgcctgtatc
ctcagcact tggagagcca aggttagcgg atcacctgag gtccagagct cga

60
120
180
240
300
360
420
480
540
600
660
720
780
840
893

<210> 125

<211> 1049
<212> DNA
<213> Homo sapiens

<400> 125
ggcacagaaa aagaccatc aaggtgtctaa gttaaaagaa aaaaaaagg ccttataagg
tactcagat ctacacagag tggtaatttc atgtttgtc ttaattgtt acctgttcc
ctatttcttc gtttccaat acctgtttgc agaaacatc agttttgtg gtaattcagc
ttgttcttaa agttaaagag actatacgca gatttaatt accttcatct gtttgcagc
attctggggt gacataatgc ctgcaagctc caatcttca atagtggag gggttctata
tggagctacag gttatgttgc taataacct ctgtaccct ttttctgtc ctcgatcat
gcatctcatc tccgttatag tgcattatg tatgtattcc tgaagaagc ctctgataag
agctgttag ggtatctccc tcttaagag aatgtttata cccctgcac tatcaattcc
atttctttaa attttccca tagatattc caacaatgtg taaatgaa tagattgaa
gaaattatct aagcmttaa gaggcaagctc aatgttcat agcaggaat ggaattcata
taatttctgc tggatgttca atgaaacat atgtattat atgaacatct tttagcaaa
taaaaaaag ctgaagtcca aaaaagttag ttaaaaaagc aaggtctaaa acagatgag
tagatattgc gtaactgtgc agatattgta cacacatgt agaggtcaat ttgataaag
tatcttgc tcaatttaca tatcttccc ttgtctctt ggtcttacty gttatctac
agtagcagct actcgaggt tactcagacta ctcaagagag tgaagcagaa gaatcgctg
aacccagag gtggaggttg cagtgacgg agatcgccc tgggtgacag aacaagatc
ggttcaaga aaaaaaag ctatgttctt gataaatc tcaawaaaa tgaactatcc
agtaaaaa aaaaaaaa accctcgta

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1049

<210> 126
<211> 1626
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (525)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (542)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (562)
<223> n equals a, t, g, or c

<220>
<221> SITE
<222> (607)
<223> n equals a, t, g, or c

<400> 126
ccacgggttc gagcgagcgc acggcgagc cctgtatggc cggataggt tactcgtgc
gcccctgtcg tgcctctctg tggggtggt gttcaagctc ggaatggag aggtcaacta
caggtcccaa ctgaaaggtg ggaattctc gatggagaa aattctccag acagagaga
tgttgaaggg cctgtcgagg aggcagacat gaacccttc gcatctgaca tatctcgtc
cacacaaa gatctcaggg atttgcag ggaagaaag tatcgacag aagctgagat
gttcagag agcttctct ttgagagct tgccttgcag gacttgagaa acaaggccac
ccagccaag aagctgttac tctgtgtct tccagtgaaa aagcatctt ggaagcagc

60
120
180
240
300
360
420

tgcaggctct ggctctggca tccgagagag actggagagc ccaagtgttac acgtgagctg 480
 gratcagcc cgtgcctaact gtgcytkgsg ggggraaacg actgnccac gggagggaag 540
 antggaggt ttctcgcgc gnagggggc ttgaargtc caagtcttacc ccatgggggg 600
 aactggnttc cagccaacc cagcaacct gtggcaggga aagtctccca agggagacaa 660
 agctggagat ggtcttcacg gactctccc agtgaatgct ttcccgcgc agaaacta 720
 cgggctctat gacctcctg ggaacgtgtg ggaagtggca gcatcaccgt. accaggtctg 780
 tgagcagac atgcgcgtcc tccggggggc atccctggatc gacacagctg atggctctgc 840
 caatcacgg gcccggtca cccacagat gggcaacct cagatccag cctcagacaa 900
 cctcgggttc cgtctgtctg cagacagcg ccggccgcga gggagagctgt aagcagccgg 960
 gtggtgacaa ggagaaaagc cttctagggt cactgtcatt cctcggccat gttcaaaa 1020
 ggcacattcc agctcagga gcttcagcct caggaagaa cttccccttc cgtctctccc 1080
 atccctctgt ggcaggcgcc tctcaccg gaggagaggg actcagcttc cgtgtttttg 1140
 gagaaggggc ccaatgtgtg ttgcagatgg ctggggggcca ggtgtttctg tttagagcca 1200
 agtattattg acacagattt gcaaacacac aaacaattgg aacagagcac tctgaaaggg 1260
 cattttttta gaattttaa atctatttc tccccttttc tccctggatg attcaggaag 1320
 ctgmactatg ttctctcaag cagaatttt cctgggtctg ttctctcagc cagttgtctg 1380
 ggaagggaaa tctttctttt gtggcccat cgtgtgttct gtctccctt gaagaaact 1440
 agtttccact gtgtacacag cagacatgta actattttaa gcaagtttca gtctaaaag 1500
 ggtctggag accagatga tgaactagggt gaagcatlgtc atgtgtggaa tcacaagga 1560
 aatagtactc cagaaagacc ctgtctcaa aaaaaaaaaa aaaaaaaaaa 1620
 aaaaaa 1626

<210> 127

<211> 1177

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (484)

<223> n equals a.t.g. or c

<400> 127

ccacgcctcc gctatcatca gagcatgca cagatctatg gactctatc tggtagctg 60
 tgttttattc caaacgtcta tgcgtcttg ttcaetgag cttctgttcc tttagctgc 120
 ctctgtgttg tgtctgtgt gtctatccat gctaccaggg tgaagccaca gtgaaagca 180
 tatgatgatg tcttcagagg aaggacaaat gctgcagaaa tccactgat ttatatctc 240
 ttgtctctga ttctcgtgac atgcttcttg gaggactcac acatggccta cagacacttc 300
 tggatgtctg ttctcttctg cattttcaac agtctgcagg gacttctatg ttctatggtt 360
 tatttctatt tacacaaca aatgtgttc cctatgaagg ccagtctcac tgtgaaatg 420
 aatgggcatc ctggaccacg cagagcttt ttccagcccg ggaagtggaaat gctctctgct 480
 ggaaggaata tcagcaagtc caccagaat ctcaatcgtt ggtatggagg aagtgccac 540
 ctgactctgga gagagatccc ttccaaacag ggaartcaag gccagccctgg rwttaagcc 600
 aagttccaca aatggggcca cgkctccctc ccttgaggga tatggccagg gttcactgat 660
 agcccatgag agtcccaagg agttctgat tttaataatt gcaattaaaa cttgtgtctg 720
 tctcagctgc atgtgataag aatctgtatg aggcagccag gaggcccgga cctctgactg 780
 actcccaga tctgtgagct ccaggagat accatcgcg gacatccac tgtagccact 840
 cactaaacat tgaactgagc acactttcat atttgtatca gctttgtgc taaactctc 900
 taagtacat cactctgtga ataggaacct gtgaattgta ctggatgatt aatacaag 960
 tgaattgtgt atttgatga taaattactg attgtatgt acctgaaat tcactgat 1020
 aagaagaagt ggtcagttgt gtacagtta atagatgtt catattccaa ggaattagt 1080
 tgttttttta atcactcat atggctaaca ttgtttaatg aagtaataa tcaataaagc 1140
 aatagaactc aaaaaaaaaa aaaaaaaaaa aaaaaa 1177

<210> 128

<211> 1276

<212> DNA

<213> Homo sapiens

<400> 128

tgcaccacg cgtccgcca cgcctccgt taatatctgt attccagtt attccagggg 60
 taaagcca aactccttag cagagaatat agggcccttag cttccacatt attcagcag 120
 taacaccca ctatgttctt caagactgca gccattaaact ttctagagtt ccttaaacat 180
 gcgtttact ttcatgctc tatcccggtg tctgtggaat gacttccctc ctgcctctt 240
 ctactgtac aaacctcat tctttaagac atagtacaaa tggcactctc tggttggcat 300
 ctctctgca ggcctcagg ctagtaagt attctctcc tctgtgtccc tgcatacctc 360
 catctcttg ttatgacat tataacttta ataagtacta aaactctgtag tctacaaa 420
 ctacggaca gaactcatt cttctatggy tctataatgg aactttacc aactctcag 480
 ttcccatac ccacagatgt ggaataattg aactctgaca gtccaaggt aactcagta 540
 ttctcagat tttctatg cttccaagat tgaacctcag tctcagaat gttgcctct 600
 ttctctctt ttgtctatg ctgggagagg cattgtgggg agggttgtct ggtttatggc 660
 tccattgct cctgcttga taaccacct gacttttggc cattagcagt cctctgtgac 720
 ttccacactc aggtagtgtc tgcacaggcc actctatgtc ttttccatgc tgaagaaatt 780
 ctttccagg ccaagtctgt gttctctctg ccacacagga aattttttag cagtctcatc 840
 ctccaagtc aatcagggtt ctgggttagt ggtctccacc tgtccagag acttctcag 900
 ccatttccac tctccacta gttgatgaag ctggatgagg gactgcaccc accagatca 960
 ggcacgggtc ctgtctctc ttgtagtccc tccaattgtt ctattccga gatttccat 1020
 gtctgtccc cttctgact ccagggtctc caaggagtg ggggtagtga agggagcct 1080
 ttccaaagt ccccacag ctctagtctc actactctg atactcttt tccacacgc 1140
 tggagaagag aactttcatt tgtcttgaaa tgaagaaat gtctctgaaa tattttgtat 1200
 tactctctgc tctgtcatt atggttaaca aataaaaaa ataaaaaaa aaaaaaaa 1260
 aaaaaaagg gcggcc 1276

<210> 129

<211> 1334

<212> DNA

<213> Homo sapiens

<400> 129

tccatgggt cagaggctgt gttgaccaca tagtaaat ttccagtcac agaccaagc 60
 ttccatgggt tttactctg ctgtaccact tgggtgkctt gattctgac ctgatgtgtg 120
 gctaatat attttaagca acacacacac acacacacgc ctcatgtaat ggaactttat 180
 acaaaaagaa aaaaatttga ttctcaattt acaaatggca aatttattat cctctcttg 240
 atgcacaaa gaccagcaaa gtttatagct ttccactca tattatataa gcaatctgt 300
 attataaaa tcaatattt tatcacatgc ttgaattttt tattttgttg tttaaaatg 360
 tgcacttaa acatcaca accttatttc tctctatgaa cttaagctgc ctgcgacaaa 420
 aaaaaaaa aatttaccaa atggagatgc agtagagtc ataggctcta aaactaaaa 480
 gaaatgggt gcagggggaa caagtattt gtctgagtt actgacttg ctgcacatgg 540
 ttgttgggta taaatcaca aaagaatcca ttccaggtat gcatgtctgg ggttgggt 600
 gtctcagat tagaaactg ttccaagct ttgcagtatg ggagagctc ctctctcta 660
 ctacgtctgt gtgtcttga taggcagta gcccgagat ggaacaccac ttcagtaaca 720
 ttggccccc ataccagta acagttagg caggaatctgt gggaaattat tgaatcagct 780
 ttgagtctt gagagaatg aaacaagat ggctcgaatt gtaaacgttt gtaacttga 840
 tgaattgt gtctttagg tcaacttaat accagtatc ttgttgagaa gtacacagat 900
 ctgatttctc tggaaatgt atcacatttt tgcattttaa aaattttaca gtacaaaa 960
 accaaaatc gctatgaaa caaaacatga agcaggacat attgggattc tatttttta 1020
 aaatttaatt ctttgcaaaa ttgaacttct caactaaaac gtgtccatgt cagaatttta 1080
 actgttagca ggtatgttgt ggaagaatg gctaaatat gaagcaaat agaatctgtg 1140
 tgaataact tgaatgtct ttttctgtt gagaactatc ttatttctc tattaccac 1200
 gaggcaata cctgaattg gatgtctgaa ttataactta tgcagggaata gtctctgaa 1260
 tacattttaa taaactgaa agatatttaa taaatagat atttactata aaaaaaaa 1320
 aaaaaaact cgag 1334

<210> 130
<211> 532
<212> DNA
<213> Homo sapiens

<400> 130
ggcagagagc ctgggacatc tccaaatg atcttaaca taatagctac agtaaaaga
aagaagagaa ggtataatg tgggtggaaa tccagagagt ttccaaatgc cgtggcttac
aactccgaga ttccccaag caccagagaa tggcgggca caggacttgg ctctctagg
agatactca gttgtatca gatgggctg tggagggtgc tcttaagca ttgcataca
tgaatgggac cctccagaa ggaaggactg caaaggatc gaaacttgg agaaacgag
cgtctcttc ttaccagcg cctgcagcg tcaaatgct gaaagcttca gtcgcctgac
agttcccaag ctgagctgac tcttcaatg ataggatct tggttcaga aacacacaa
aagttcaatc tgttataac tcaagatc tgtttttc gctggggta aatattctgt
tcaattcttc ctaggagaga aagaataaaa aaaaaaaaa aaaaaaaaa aa

<210> 131
<211> 685
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (491)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (661)
<223> n equals a,t,g, or c

<400> 131
tcgctcctct tcttctctc ctctctctg ttttbaagc aagattctgt caaaaaatg
caatctctc tttttgtc agcagacat caattcttc gtaagaccc ttctctctc
aacctgtcac tgcctgtg ggtacgtgt aaaaatggg aaaaagaata gttatggcgg
taaaagattt taattttat ttcaaatc catagaat atgtatatt taatgatcgg
tcaattctcc agttgttaac acatgtttag aaattgcttg tctatgatat tgcatttcc
cctctccct tctctcttc tctctccct ctctctgct tctctcccg tcaactgctc
cttctcttc tgggtcttc ctcccaatg ggtctctgg tgtcgacttg gcaatcaagg
agagagcatg tggcctgggt taagaaagag gacctgtcg ctggcaaaag cggagagatg
gattatagaa ncttatgca aagactatt ccagatcttc ctggcagctt cagaagtatc
tctcaacccc tgtaggggcg ttttaactgt acctaaact gctgttttat ctatatgtaa
aaacttctca aagcaaatac agtatcttc attttctat caaaaaaaa aaaaaaaaa
ncgagggggg gccgtacatc tcggc

<210> 132
<211> 729
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (725)
<223> n equals a,t,g, or c

<400> 132
tcgaaccacg cgtccggcca tttagaata atcaactct aatcacctgg ggtatgcag
taactaaagc acctcatga gctgtgaaa atttaagta ttatttaca taattgctt
taatttttag taatgttca gttgaagttt agttccaaa caaaggccg tgaattgtc
agtaactgtc tctgtacctc tgaattgaga cagttcagcc gggatagggg gggagctggg
tgaagagacc agaatgtac tggggcagc cagcaactt tgttttgc tctctctt
gaagcttggc ttgtctctg ataaactgg catataata cctatctgc tgttgggtg
gaagttaat gttgatatg tgtgtggag atgcttgc acgtcttga gttacttga
aatctgtc gctwtctt ttctaccta ccaattacc gttaccccg gttgtatc
gttagaatac acctgttaa gttggatgc ttctgaaa tctccctgc agcagtagt
ggcaatagcg gtcagaatc aagatgcaat gatttggct ctttctgt tggcatag
aagcttatct gcacatagcc tgattctct caatctgca aaaaaaaaa aaaaaaaa
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa

<210> 133
<211> 1079
<212> DNA
<213> Homo sapiens

<400> 133
ggcagcaggt gttagaagt ttccgaaga gttgtagct tgaactcttg tggctctgc
tcacagacac ctgtctatc cctgacctc ttaaatgta acctctgc tgaagaaat
cttcccttg tgtttagtc ttttctctc gttgaactta gataaacac ctatgttca
aaattttcaa taaggatcc atttttaat acatgagat tcaattcaaa attttggtt
tagttatcta tttaattca ctggacctc ttccagacag atgttctctc ctggattga
aagtcgaaat tcaaaagatt ttatattga attacttca cctctctctt gtaattgccc
atctgttag atacagctt gattgcctga caagagaaa atgtttccca tcatcttcc
ctggcctgaac tatacgcca ctgtgttcc agcatagttg ttcttaacc tcatagttg
tcagaatcac ttggcagagc tttaaaaac tctatagtc tgggagacc cccaagact
caattctgt gtcaggtgc aaagcagat ctctagatt gcagtagtg ttgaatacaa
ctagagtta accagattga atttaagtt aactctggct ggtcttgaag atgtcgtaa
tctctatca ttttttkga aaagtaccaa tgaattcaga aagttaatg taacacatc
agttgaatcc cctgtttta atagattggg aaacaaagc cdaagaaata taaccaaag
ctaccctgtca catagggcac aattctctt ccaatctc gttcttgcgt gttcttcaa
tttgcagaaac tccctttaa aaaaacttg gaagatgtat tggctcata ccccttccc
tcggcttga agaatgcac ctgtcaatta ttatgatat ttaattgcaa ccttgaagac
aagggtgtcc aattcttgg ctctccctgg ccacatttga agaaagaaatg tcttgggcca
cacataaat acattatga tagccgatga acttaaaaa aaaaaaaaa aactctgta

<210> 134
<211> 1297
<212> DNA
<213> Homo sapiens

<400> 134
gactcgtgcc gaattcggca cgaaggaaag gggcgtcttc tgcctcttg gtcgccttc
aggcttttg gagatcttc caggttcaat ccagagacc cccagacta ctgaatctga
atcgttttag tgttccaac ttccttctta gttgttaat agaggcaagg ttgattgtat
gggctggccc tcaatagac cctctccctt ttttctctc attgtgttt acttaaaa
ttaatcttt tctcccttc cctccacct ctccctccc tacttaag ttatgaacta
cactaaatcat tccgattgat cctccagaa gaaataagtg tctgtcttc tctgtcttg
taacatctgc ttcttggta agttcggaat atttctctc taacaccag tcatgaaag
tgaagctccc gaaccagcag cctcagacatc ctgagggaat ttgttaaaa cgtgaatct
caagcctac ccagamtac tgaatagtg tctgcatlga aacagatcc cctgttaatt
cmtatgaca tcaaatltg gaaggacag cctccaaag atgtcctgg tctctctcac

atccactcgt ggaaggtctt attctcatt cctgagctca tccactgaa gagctatggc 660
 acttcccaat cctgagcctt tctgaggttc tgcgtgtcag taagcttget tccgggcatc 720
 acctccgaaa acacttgggt tctgaggttc tctgaggttc tcttaagga gtggaggaaa 780
 gtgaggttt tcaagataac gcagtaaca tccaagagg ttaagtgaat tgcctaaagt 840
 cacacagaa gacacggaga ggaagtgtct caccatgttg cccggactgg cctcgactt 900
 atgggctcgg gcatccctcc cgtctggcc tccaagtcg tgagatcgca ggcgtgagcc 960
 acecgtccc accgggatac atagggttta cgttatcttc tgaacctcc ttaatacaag 1020
 agagtggaca aaactgtggg tccycmtyt tcaaaatggc cagtaaaaga ggaataaag 1080
 atageaagt ttagttattt tctgtgccc tctttaagt gatggggat cctttgtca 1140
 ctacttggg aagataaact acctctctat ccaactatgc taattggagc ttctctcatg 1200
 tcttaaggt tgcctgggaaa tttcaataa aaattcactg ggaatgtttt gaaattgcaa 1260
 aaaaaaaa aaaaaaaa aaaaatgac cctcgta 1297

<210> 135
 <211> 617
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (9)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (513)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (559)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (587)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (602)
 <223> n equals a.t.g, or c

<400> 135
 atggaaanc aggcatacc tgaatggc tggaaaaag ggaggagcc agcactycca 60
 ggggaaaaac ttggcattc ttgggaatc aaaggatgc agtgaaccca agccttttga 120
 agactcacc aatcagatgc cctctgcta tccatgagca gatgtttgat agtattgcgg 180
 aggcctccta gtgggtatgc tggcaagca cggagtgcc actgggtc taatccagtt 240
 gctatcctc ttacacctg catttcatc gccaaacaa aaccaactaa ctcagaaaaa 300
 aagaaagcc cctcaagggt cctttgccc cgtatctac atagatgcta tgggggtccc 360
 ctggagggta ccaaacraat tcaagctcg aaatcaata gctgctggat tcaagtctgt 420
 ccttttttgg tggctacta taataaaaa tgaagactgg ataaattaca tatactata 480
 aaaaaaaa aaaaaaaa ctcgaggggg gnnccggatc ccaattcggc ctatagttag 540
 tgcattaca atcatggnc gtcttttcc aagtcgtga ctggggnaaa acctggcgtt 600
 anccaattta atcggt 617

<210> 136
 <211> 1311
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (1284)
 <223> n equals a.t.g, or c
 <220>
 <221> SITE
 <222> (1296)
 <223> n equals a.t.g, or c

<220>
 <221> SITE
 <222> (1301)
 <223> n equals a.t.g, or c

<400> 136
 ggcacagctt ttaacatgc cttcagcact aatgactgct ccaggaaatgt ctacttaag 60
 aagaatggct ttaatttaca tggaaacccc attgctcaga gcactgatgg tgcaggagcc 120
 aagattgggt tcaatgagg cgcctatgca tgggaagtgt ggtggagggt cctctgggc 180
 actgtggcag tgattggaat tgcacaaaa cgggccccca tgcagtggca agtttatgtg 240
 gcatgtcgg cagtgatga ccagagctgg gctggaaatc tggtagacaa taactacta 300
 cataatggag aagtcaatgg cagttttcca cagtgaaca acgcacaaa atactagata 360
 ggagaaaaa ttcgagtcac cttggacatg gaagataaga ctttagcttt tgaactgtga 420
 tatgagttcc tgggggttg ttttagagg cttccaaagg tctgctata cccagcagt 480
 tctgtctat attgcaacac agaagtgaat ttggtttacc tggaaaaac ttggacgga 540
 tgacagtgcc tttytttga tgacagacac aatggaggag agatctgctt atgggaagca 600
 saacctgaa gtgactgta cacatgcatg tccaagaaac atctgaaaa cacaigaagt 660
 cgtaaactgg agaagcagct ctacagcaga gattatctg tgttctct tctactggg 720
 ccagaaaaat cctcaggggt cagttgggtt gagtgggcag ttgacatag catgttgac 780
 ccgattgtgt cctaaagta gcaatgtgt atttccagct ttaagggtga gatttgagag 840
 atgctgtcaa agggataaag aaatgcaag atttttaagt agtgtgtttg tgaagactga 900
 tcccatlita caactgctg tctttctcc agtcttttt ttccagcca gttgactat 960
 tgaanaagta tgaactgggt tgggttttat ttaatatatt taatatattg aagaactgg 1020
 tctgctgga ctgcacttct ctaaaagtga gataaaaat tggcagcta ttttaagt 1080
 tgtataaat atgtgtgtaa aaaaaaac tgaaaaaag raaggacaaa cagggtgttt 1140
 tgttctagt ctaattctt aaaaacact acatggttac aaatgtgaa taacttttg 1200
 gggggacac tgggggttaac taccagaaa gagggtattt aaagaggaga tgggtgtga 1260
 attgacccca ttggaataa tttaggctt acagtnccca nagctgttag a 1311

<210> 137
 <211> 1095
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (616)
 <223> n equals a.t.g, or c

<400> 137
 gatggatgt gtgtgtgtgt tataggtgga atgtgtgtgt tgtaggtgg gcactgtgtg 60
 tgtgaggtgt gctgggtatg tctggcatgt gtttgtgtgt tatgggaata tactatggat 120

taagaacatcgt gggatlatca aagaatcac cttttgtcct ttgaatatcgt aatatcaga
 aactgtgcct cacttgagag gacttttga atatcagaag gatatcga gaaactgcac
 ttgatcttgg gtaaccacac cagttccaga caagcatgcta aggcagaag ctaataaag
 ccccaagctc taactcttgg ctaattatc ccttgagcat cagttgagcg ctcttaagct
 gggagttcct gactgtccgc tggttttac agaatgttac agcttaagcc ttgggaacata
 gcccaagcac cttcaacargt tggttcgtt ctttaattc cagttccct ggaagcaga
 aggaacccg cctcaattcc ggcagagcac ccaattcgt tatgagcaaa tctccagagc
 tgcagagatg tcaagagagag accctaatg ctccakatt tgaattatt gtctctttc
 cctaggttct tcaatncag ataaccttgg taactttgt gtaattcac ttgaaacga
 caacttcaa ttttttaag gaaaagtcc taagaacac catgaccca ttcaattac
 attcagcaaa taactttcga ataaccttgg ttgtcagagc actgtgttgg ggcacacga
 tggctttct gttcccaaga tcttgcacat taattatca gttatctca cgcacttga
 ctacttggga caggagacat tggctttgt cgtatataa gaaacttggc ttgcacac
 agttgttct cgttgagcat gggcagaag ttgatgtcaa taactgtgg ccaaaaggg
 ttgtcttgg tcaagttgct aagtgttga gttgaaagca ttgtccaccc cctctgatac
 aggtatcctt gttgatgttg ttgtacacca gggccttccc atctgtcagc ttgtttgtc
 ctcaagtag ctctga

<210> 138
 <211> 692
 <212> DNA
 <213> Homo sapiens

<400> 138
 ggcagagagc gaatactgtt agctcagctg ttctgaatat gactgtttg taagaagcca
 caaaacaaac attaattct taattttat ctgaatttc accactaaa ccaacttcta
 ttgaagagat atataataaa agtgcattat cataatgtgt cacaatgag gattcaggtg
 cgaagagag acctatcctt gttgaataat agccctccc cagcagtttg tgaagagtt
 tgcagagct cctctctt gtgtgtccta taacaatc catgagagc ttggaataag
 tcaaatgat agttgttcta tctctccag tcttgagac ctcaatcag ccaactctt
 tcaatagac atactttatg ttctggaaag gttgtcttag ttggaaacac cctgtcctt
 ccaaatatc cctactgaca tccatggagc ctcaattcta ttgagcttg agatttggga
 attcagagtg gcaagagaga aagaaggggt ttggggagct gttcttga ttacttgcac
 aattcttccc ttgggtgtaaa gaaagatag ttgtgtcaat catcagagga ataaatgcm
 aaggtgttgg tatattgaaa atccaagga aattatccc agattgttcta
 ttttaattgct aggaactca actttcatg aa

<210> 139
 <211> 748
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (60)
 <223> n equals a,t,g, or c

<400> 139
 ggcagagat aagtcttg ttccacaga cggagacaag tcttagatgt ttctcaatan
 ataaagaaat aatcttgg ttggccaac cgaactcat tagttctga ctccaaacac
 aactcaagtt gacttggca taacaggtca ttctaggtt atgtcgaagt tatgttatac
 gggcacatct gccctacaga atccagcag aataaccaa tggagttgt ggtctggaa
 acggaaatct gggcagagct gaagctgcct tcttgggga ggtgtgtcat tggttgttg
 gtctgcctga gaaggtatgt taagggttga cactgtccac cagcaggtca agtttggcag
 ggtgttaag tccagttgga aggaagtcag gtaacagaa ttgtccagcc agaaacatg
 agttgggaga agtacaatgt gaagtattcg atcgagga tgcagtagc cccaagat

gaaatcagat ctgtccacag ctccacagca ttctcgtact gccctacatc accctcaga
 ccaaccgctc ctgggttttc ctttgatct ggtcagacag atgcctctgt gttgagctgg
 aggtctgag agattgagt gttgagacca ggcctcacg tctcccttg ccaagcaca
 ttgtccaggg ctatcaagtt cttaagccaa actgaagctc aagttgagct gttggcag
 ttggcgttag ctggaaca cactcag

<210> 140
 <211> 1132
 <212> DNA
 <213> Homo sapiens

<400> 140
 ggcagagga gtaacctta ttctgagaca tcttgagat gcaatargt gaaacttc
 tgttcccca atcccttg aggtgaata agatttttg ttgcgaacac tcttcaatc
 acaaaatat tttttctta taatatgct ttgttctct gttcaatgc tatataatc
 cttaagcctc tttcttccc atgtcagtg tctctac ctaactcta ctttgttt
 gctgttga ggaacctcgt gttctgtcca gaaaagctt gtaacttcc aatgaaatg
 ttgnaattc ctaatttct gaaatctat tactaaagt tatgcaagac atgaattt
 tgcacttc attccacat catltgttt atgaacaaa caaacaanaa aatctcaa
 cctaaacca ttgaagatg cttaactta aggaacact aggcacagc cagtacatg
 ggtgtcaca ggaatgaac aatggaag ttcttggaa ctggagaggg ttgcactgg
 aactgaagct gttcttcca tctctaggg cccaaccac atgttttcca gtttcttga
 tttctctat cttctctt atctcttc ttgtcttgc ttgtcttga atcaagagc
 cttgaaagc ctttctac catgtatg tttaagact tttcttcta taagaatga
 aggtatgac actgtatag taattgca ataacctgc actgttgc ctgtttatg taacttgc
 aagttagga aggaagagc acaactcga agcatagc catgtatgt gtaacgaata
 cggagagctc aaggtcctt ccaattccc atgtgaaat gattatlaa tatltcag
 taagaaaga aactgtgtc agcaactca ttgtgttg ttgtgttg ttgtatctg
 ttgtgtgtc tatattcaca aatattctga tatgtatga gaaacccac agagagatca
 aggtcttct atactctg aagttctga gtaattccc ataatgtgc cccaactac
 caatacccta tttccaatg tcaatctgc aatagagac caattccac tg

<210> 141
 <211> 1112
 <212> DNA
 <213> Homo sapiens

<400> 141
 gtcgcaatg ggtctacc ttgtttact tcttgttgc ttgaaccata taattttac
 aatcgaatg attattgtt atctttaaag ccaaccatc cttaatgga tctttctat
 tctgacttt taaggttat tgcagactt tatcagga cagacttgg gttatctg
 taagtgttag gaactgtga tctttgtt catatgtgt catgtacc cctatctg
 aaagtgaat ccttttcta agataactag ttgaatttc ttgtatgaa tgaatctc
 ctatgttcc ttgatatga atactgtca aggcacata gacagacag gaaatgat
 atagatgac ccccttatgc atgatttac ttctgtgt ttcaattac tatgttcaac
 ctgttccaa aatgttaa ttgaaatcc cagaataaa taattcata gttttgtt
 acgtatgct ccaactctgt gttttaaga ttcaagctc agctcccca atgaatatc
 agcatgtgc caactctgt ggtttaaga gttcaagct agctcccca atgaatatc
 ctgtcttgc taagtgtcc aggtgttct tgaattcgt gttcaata atctccac
 ctgtctccc aaggtcttg gattataag aaaaactc gcaactgtgc ctattcata
 gttttaat gttgacagt ttctgtagc acaatgaac ctgagctgt ccaattcat
 ctgtcttgg atgtgaatca tcttctgtt agtgttcca caetgtatc gtaaccgc
 caatgtcac ttaatgaca tcttcttat cagaacact gttgagttat tgtgttct
 atgttaagta acccttat tacttaatga ttatccaaag cagcagatga ttgtgttg
 caattcagat ttgcgaaga gaaactgtaa agttcctct taagtgaag agttaaagc

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (349)
<223> n equals a.t.g. or c.

<400> 144
gttggtgtg agcacagct taggcttaga ttcttcata actaggagaa gctgtgcttc 60
aatcacata ttctgttga tgggtctcaa tggcttcac tcaatttagc agaatctttt 120
ttttaacctc ttcttggag ctactgctt gtgcaaatca catcttggcc gctactctt 180
ctctacttgc tgacagatgt gtggtgaga aaagtctcat agctattgtt cctgaaagaa 240
gcttcagac caacttctag ggcagtgac atatgcagga aatcagctgc ttctgggcca 300
ggacagagct ggtcttttt ttatggggg atggcgggca gtggggcang ggaacttcaa 360
aatattttt ccaacagaca gatacatca gcaggtacaa ctacaagggg acttcatag 420
atcatcatt cacaaggcat tattattca acagtgaag agcactcgt ggtttttctg 480
taacaatlc ccaactcata gtgtaaacag gtactatttt gtccattac aattccggaa 540
ggaggggcac acttgcagg ggggaagaaa aggggaatcc taaagtaag tgaactcaat 600
aagagacaac acttgggcta acaactctgg atccacatt cagtcagggc ctccacata 660
gaggggaaag actttctct cagaagttag aatcttctt cctctttct tgttaactg 720
gagcagctgt ttgtttgct caatattca tgcacaaaag gagattagaa gaaatgcat 780
cacaaaccca tcttgaact tcaactcttc ctgccatac atcacactc ttgggttcta 840
gacgggggct gggaatacgt aagtgttttt tcttttttt ttttttaagt gaaagcaagt 900
ttattacga agcaagggga taaaagaat gtgcctccat aggcagagag cagcccgata 960
atcttaaaat aggaataatg acactatggc tacaataat aaaaaataa tgaggttaga 1020
aaaattttca caccaggagc ttgcctgttc caacttcata gtcttcata aatacttcat 1080
aagaagacaa aaaaaaaaa aaaaaaccc gta 1113

<210> 145
<211> 685
<212> DNA
<213> Homo sapiens

<400> 145
ggcagagca ctctctgaaa taaaagggag ccgtttacaa gaaataaatg atgtatgtgc 60
aatgtgtat catgagttta caactctgc tctgtattaca cctgttaac attatttcca 120
tgcactttgc ctctggaaaat ggtgttact tcaagatact tgcctaagt gccatcgaa 180
agtatactc gaagatgata tcaagataaa ttcaaatgta tctacaaca atggtattat 240
tccacccaat gaaatccag aggaactgt aggaagagct gctgctgaat ctgacagggg 300
attgaacgaa gatgcagta cagattgtga tgaatgtgt caaagagaaa gaaatggagt 360
gattcagcac acaggcgag cagctggag aatttaata tgaactgac tgaggaat 420
agctattat aatgattgag gtattgttt aaaaatcagt tcatccaaa tggagtaata 480
tcttccact taagtgtga accaagcaca aaaaactat caatgtgata tctgtgagt 540
gtttccgtt tactgtgat tgcactgta aataactc tttaattact tctgttctct 600
ttgtgacct gtttaattt gtgtacatta ttgtacatag aataaaatg ttccacttt 660
ttatgacaaa aaaaaaaaa aaaaa

<210> 146
<211> 1038
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (743)

tctcaacaaa aaaaaaaaa aaaaactcgt ag 1112

<210> 142
<211> 1084
<212> DNA
<213> Homo sapiens

<400> 142
ggtttgggg catcacagac tacaccgta tgaagagatg aacttaaatg ataaattgtg 60
tgggtgtgca tgcagtgtg cgtgcattg gactgttaca ccaattgtgc ctctgtctgt 120
ctctctccct ctcttcagcc ctcttctatc cctgggacac agaaattttt aaataaggcc 180
aataataat cctacatcgg tctcttactg gttagatgta aaagaagatt cacatatctc 240
taattttaaa tgaagagcta gaaatgatca agcttagtga ggaagccatg ttgaagctg 300
agatagtcca aaaaactagg cctttgcac agttagcaca gtgtggaag caaagaaaa 360
ggcctggag gatattttaa atgtgtctcc agtgaacaca caaagcatag gaaagcaaaa 420
tagccttatt gctgatagg agaaatttt aatggtctgg atagaagatc aaactcttat 480
caacatttc tgaagcaaaa tcttaattca gaaacagagc atagctgctt ccaattctat 540
gaagacagag cagagaggaa gctgtggaag taaagtttga aaataaggag ttgttcata 600
ggataaaga aagaagacat ctccataca taaagtgta agtgaacat caagtgcgaa 660
tcagaagct gcagcaagt atccagaaaa tctaagata ttgaagaagg tggctacat 720
aaacaataga ttttcaat atgcagaaga gcttctgtt gatttaggc attagccta 780
aaatggaaga agatgccatc taggaattta atggtagag aggaagatt gatactctc 840
ttcaaatgaa agactgactc ttgtgttag ggtgttgca gctgtgaca ttaagttaa 900
gcaatgtctc attaccatt ccaaaaatcc ttgtgccctt aagaattatg cttaactctac 960
tctgactgtc ttctacaagt agaacacaa agcctggagt acagcatatc tgtttatgt 1020
catggtttac taaatatttt aagcccatg ttgagacctg ctgctcagaa aaaaaactc 1080
gtag 1113

<210> 143
<211> 1050
<212> DNA
<213> Homo sapiens

<400> 143
ggcagagctc tttagcatt tgaatgttgc tgaccactc caatttcaca gaacctctat 60
caaacagctc tctatgacc caaagtcac ttctatacc acttttagc tcttctctg 120
ctactcatg aaaaatttg ggcataccag gcttcaatt tttagcctca ctgttctctg 180
gtttactat tatttcagt ttgtttatc gatctctgac tccagccag accattctgt 240
actccacatc cacatatcca ttgtgttgc tgaataact ctcttggatg tacaatgtg 300
ccttagactc attatgtgca gacatgaagt catcttttt ctctccagac ctgcttttcc 360
tctgtatc ttcttttgg tgaatgtgac aattattcag atggaacgtc caagtcacaa 420
gctgttctag aatctctcct cactctaat gccacatcca attagtgacc aaactctatc 480
gattggcctc tctaaatca tcaaaacat tcaattcaat tcaagtcac tgaatttct 540
ttaaigtgaa ccttcttat tataacatga tcaagcagag gccctgtatc tctatcttc 600
tgccttccag tctgtctatc ctactccgca gttcaatccc tgaatgtcat cttagtgatc 660
ctctcaacag tacaagattg gtcattggat ctccagcttg aaatactca tgtcttttgt 720
gggaacatgg atgagatgg aggtattatc acttagcaaa caaatgcatg aacgaaacc 780
aaataccaca tgttcttact taaagtggg agttaaagtc tgaacactca tgaacacaaa 840
caaatgaaca gcaaacctg ggttctactt ggggttggag ttgtgggaga gggagagag 900
cagaaaaggt aactattggg tactgaactt aatacctggg tgattaaata atctgttcaa 960
caggccacca tgatagagt ttaactagt acaaacctt cacatgtatc cccaaccta 1020
aataaaagt taaaaaaa aaaaaaaa

<210> 144
<211> 1113

<223> n equals a, t, g, or c

<400> 146

ggcagcagtg aagccatctat tgcacaatcg agggagatga tgaaaagtcg taagatgttc 60
aaatatttcg ctaatttca tgcattatcc taatatttat ctcttcaaac tgttccatc 120
tgcataaag atatacatat ttatctgttg caagaaactg aacattttaa atttttagtg 180
tgatccatat tctctgttc tgcacctca ttgtcatatc atattatcat aattcttcaac 240
aggaataaac accttttttc tctttacatc tgcatttttc ttgaaagtcg ttaattgttc 300
ctaaagatcg aataaaaaag ctgtagatgat atataacct aataataaaa ctcttgatgc 360
aacgttttcg aaaaataacc ttwaaataa atcaggagatg gtggtccataa ttctgtatc 420
cgtaccttgg gaaggcgagag tgggcgagac accttgagct gttcttgaac ttctgtctc 480
agacaactcg tcaactcctg cctcccaag tgcctggalt acagagcatga gccccatcga 540
ctggcctgtc atgtcccttc gatatacaca cctcttctta attataaag acctcttca 600
tccctgtgaa tgtctcttgc atagaatcac ttttttttct tttaataaag aaacggagtc 660
ttgtctgttc aggtctgagc gcaatgtgtgc agttabaat aactgcagtc ttgaacctc 720
ggccacaagt gatctcttcg cctn/gtctca taactgtat cccagccact tggggggcgg 780
aggtggcgcg attgtctgaa gtccggagtc tgaagcagc ctggccaca tgggtaaac 840
ccactctcac taataatca aaaaatagct gggcatggtg gtggcgacct gtaattccag 900
ctactcaaga gtatggagca ggaataatgc tggaaacggg gaaggcgaggg ttgcagttag 960
ccggatctac aacctgtcac tccagcttag gtgacagagt gagactctgt cttcaaaaaa 1020
aaaaaaaaa aaacctga 1038

<210> 147

<211> 851

<212> DNA

<213> Homo sapiens

<400> 147

ggcagagaga caaatctgata gtgagcatia aggttttcca agttgttttc gtaactcttc 60
atcatctctc gtaatgaaac ttcttgataa tatgtacata tgtatgtaaa ttaaacatctc 120
caaatctatc ttctctgtgt tagaatgttt cagcgtgact tccatgaaac tttaaatctc 180
acctgtctctc atgtgtgagc tcaaatgacac ttcaagtaag actgagatg taattccaat 240
agattacaaa gccaaaattt gatgttaaac gactcagaaa attttagtc gatttccaat 300
tcaagctact agtagcctaac gtttctgtcg cctctgtctc tttaagaaa ataggaccttg 360
tattgtgcatt gtggaagaaa ggaagatctgt acacattaat taactttctc taactgtaca 420
aataatttga ggaatagagag gaggagaagta gtgaagctca tgaactttaa catltggagac 480
aaattagagcg tcaagatatc ttgatatc ttatgtctc attataaat aaggaagaca 540
ttttgtgata tgttgaagagc gctatgtgaa gttttacca tctttccaaa gaactttctc 600
ttgttatctc ctctctgtgt ttcttaagc caaacaagaa aatgtctca aggaacagag 660
gtgggttttc ctgtgggctc ttgtgtgttc ttctgtkkgc catcgccctc taattgaaat 720
gaactctggc tgtttgattc ttttcatatc gtaatttcaa aattgtctgt acagtgccct 780
gtgagacaca agtaccacta gatgaataaa acgttatata tctaaaaaa aaaaaaaaaa 840
aaaaactcga g 851

<210> 148

<211> 614

<212> DNA

<213> Homo sapiens

<400> 148

ggacagagcc aatatccact ctacccagct gggcccccag tctacaacc tgcagtctc 60
ccccctataa tggcaccaaa gccctcttcc ccggagagct gaggaaacag ccattgtctc 120
gtcgccctct cagttatctc aactcttggga gatgcctca tctgtacctc gcatctgttc 180
ctgggggttg caggagacct ccagccacaa gggcccgagc caagcgagc cctgggtctc 240
acctgggaaa gaggcccaag gaagtggagc aggaactgaa ctagaacctc gaagggttgg 300
ggggagggtc tggattatg ggtcatcttc actgggggca agggggggag atgacagctc 360

gggtcacagt gccgttttc aaatattccc tctgtccca agatcccaag caggaaagac 420
tggggccctc atgtttgttc cctctggctt ggggtggggg gaggagagag gtccgttag 480
gcagctggca gtagcccttc tctctgttgc ccccatggc cacacttgc gccgttaga 540
ttaaagctgt aagacataaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 600
aaaaaaaaa aaaa 614

<210> 149

<211> 1200

<212> DNA

<213> Homo sapiens

<400> 149

ggcaccguga gaggagaagt gatgaagaaga ctgtctgaca ccgaactctg aaattctccc 60
ctttccactc ggaagatggc atgtgtcttc ctgtccgctc tctttctcgg ggtcttgtg 120
gtcacctca gacagacata caagtgtctg ctctgttcgc ccaggtctcc atggttagtc 180
gaagccaat tctgtcttga ctttatgagc aaaaattatc ttatgtctcc taagcattag 240
agttttctca ttacctatg taatttgagc aggaattgat aagttcagga aaagaagatc 300
gggaaacggg gatcccttct cagaagatcc tgggtgac tgtataaac cacaggggtc 360
aatgtatgt aggaactctt actataatc tcaaccatc gattttgtac gatgaaact 420
tgcacagagc ttgacgtgt tgttaagag tcaattttaa tgaagaata atctctatc 480
gttgtttct catctacac gataaacaca cagatcttaa taaagtctc aacatctatc 540
tgaattcaga tgtgagtga agaacataaa aaagaagtc acatatcact atgactgaag 600
gtacctagc ttaactgaa atataatca actgtgaac tctcttgata tgaattatc 660
tggataaac agaatttatc attgaaacca aagtagaaga tgaatgtcta catgtcttaa 720
aaatccctac aaggtctaaag tgaattcaata tcaagaatat tcaaaaaatc attcttaag 780
ttgatcgatc catgtctgac tgaatgaatc ttgaccgaaa gaattttgc tctcttata 840
tagttcag aatgtgttc ttaattttc attatgcac ttgaacaaac ttgaaagatc ttgaaagt 900
aaagcaacc cctaacaca aaatatccct ctaattatg tccctagctc tctcaatgaa 960
taccacata ttlttacaia gctatgacg ttgtgtacat tctctctgtc ttatctctc 1020
ggcccaaac atgtctctctc ttgtcaaac. agattctatc cctacaaatc taatgtctc 1080
tatatccatc ttgactgggtt aacctcactc aacctcata ttgatatatt gattatctc 1140
taattttca cctttttaa tagtgcgtc atgaatgttc gtaaaaaaa aaaaaaaaaa 1200

<210> 150

<211> 683

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> n equals a, t, g, or c

<400> 150

gggagaatag gttagaaga aatatctacc ctgagacag naaaaaaag aaaaatgacat 60
atacagaana gacataatga gacacagaa ctggtatgaa agtctatgaa aggcgtgtgt 120
ctctcacctc gtgttgggct taagtgtgct gaaagacaa accgctcgag ttaaaagaaa 180
aagttgagtg tcaagtggga aatactgaa agaaagtc ctgagagagc caatctctc 240
cctaaaaac aggaacttgc gaacaaatca aggtctcat ttcaagctaa gtgtgaaag 300
gcaatgcaga tgcagtgtgt atgttatgtg attactggaa ccaattgttg gaaatggagc 360
atgttggag cccctctcaa gaattgtctc taactctaaa atgtatcaca ctgtgatgaa 420
aaaacatcaa agtaacagtt agactaaagg atgtctccct aagttatgaa gactctttaa 480
caactctc tagttgagc ttgatatc catctgtctc tctctttctc tgaactctca 540
gtcttgcatc taactctgaa attccatc cctttctc taatgattct ttgtgtcttc 600
cttcatctaa ttcaactgaa taaatgaaa taataaatc tcaattgtca aaattctcaa 660
aaaaaaaaa aaaaactcg tag 683

<210> 151
<211> 827

<212> DNA

<213> Homo sapiens

<400> 151

gggacgagc ttgggctca agtgattctc ctgcccctag cctctcagga caaccacgt 60
ttgtctatc acgtgggaa tcagaccat gcccaaggcc agcaagagat tgytamtat 120
gtgtctctc aagcggcagc agctctccc agcccctgag ccaccttcag gggcctcat 180
ggaagaact caaggaatag ctgagagacc agagatccag atgggtttgaa agcgcagag 240
ccagaccact tctctccag gtccctgaat ttgaccagc caagtggcag tgcctctagt 300
gggacgacct tgcacatgga tgccttttag agtgggtccc agagcaggt ggtccactct 360
ggcctggggt tgcacatc tgcagactc aaagacttcc cttttctgct agactacatt 420
ttgtggggag cctgagact ctggattctt tggaggggac ctggatgtgt gtgtcttgt 480
taagaggct gttatcaggc ttaaccataa cctccaagat ctgcttgaca gtgattaaat 540
ccttagctca catcatctc catctctcgg gctccctagg cccaaggatg gcatgtgact 600
ggcctctgca aggtctctt ctttctcacc agccaaggca ttgataacca agtagccatt 660
tccctcttaa ggttctctc acaccccaca ggaacttcat gattctctc agggacagga 720
ttggaggcat tgagcgtgtt tattaacaaa ttgttttgg taataaaaaa aatgcttga 780
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 827

<210> 152

<211> 835

<212> DNA

<213> Homo sapiens

<400> 152

aaatatttt ggtagtaatt taataacaa gaacgaatat ttattgtcc acagttggag 60
atgttggaca aatgtctctt cccaagatc acaggacttt tgccttcat ttttgcttt 120
ttattacca ttataaag atctgtgtct gattatgaa ttaattgttt atcagctcta 180
tgtattctt tttagaggt ttgagaatga ttacacataa catgttttat aatcattaac 240
cattkatca aagatatatt tacattgggt ttgcccctt tcccttagat catgttaaat 300
ttttcttat gaggtaatta tgcactact atatttgaag gaagcttatg acattttaca 360
ggagctaaaa tgttgagatt aggtgactt ttactattt tccaaggc aactgatcag 420
ataattacc aaattatca agaaataga agaaataaa agaacaacat aatttctcaa 480
gaattcaty aaattatgy aatcagctct cgcactgcc atcttttcag ttttgaaaa 540
gaattgttt aatcacaat gtctcacagt ctttaaatgt agtagaatta gacagtga 600
tcacttgagt aattgattg gtgattccag agataagct aatattttaa attattatg 660
atactgatta gtataaaac gtactatca cagaatttga agcaaatatc atgtacact 720
caaagagtaa atgacaatg tataaatgt gtgctcagg attatagta cctttaaaa 780
tacactaata aagattattg ttcaaaatt aaaaaaaaaa aaaaaggcgc gccgc 835

<210> 153

<211> 558

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> n equals a.t.g. or c

<220>

<221> SITE

<222> (39)

<223> n equals a.t.g. or c

<400> 153

cgggaccgga taacaaatt caccncngga aacaggctnt gccccactag gcttttggca 60
aaaaagctat tttaggttgc cacttttaga ggtacgctgt gcaggtaccg ggtccggaaa 120
ttcggcgccg cgtcgcagtc atgactgtgt tggcacttta aaatatattga taccaccaaa 180
taaacaggggt tatcatgtat ataattccc acatatattta ctataaataa tccagtaaca 240
accgtctttg taccattctt tacagaaaag cttttctcaa tgcgtttagtc aggggtttctt 300
cccggggaga aaattatbaa tctttaaga ggcagttact cagaagtaga tttctgctta 360
ctctttcttc tttaatttgc ctcaacaaa taagcatga ctttttttac atgtgtctac 420
acatcgatgt catcctctaga gttttctga agcatgaatt caataacata taattagacc 480
tgattctgag aagattttct cttttctgc gacggggcgc cgaatcccg gtcgacgagc 540
tcactagtcg gggcgccg

<210> 154

<211> 1201

<212> DNA

<213> Homo sapiens

<400> 154

ggacatttgt aaccctataa acactagtaa attaaaaa gaaggacctt tatgtcttaa 60
catatctgtg ttgtgaaagg ctgcccctgt aaatacggga ttctttaaac atatttcaaa 120
aatcataggt gtcaatattt tttagaaatc catttaaat ttctcttgtt attttacaat 180
gactatttat ttatatagtg gctctgctga ttltgatga taccctaaag ttatatattt 240
ctttaaagga tgtttatac aacttatgt aaaaatttc agtatcttca catctctccc 300
ctgtcccttt gttttgctct tatatgttgg ttgtgctct ttctctggct tcaaacctta 360
gtaagactaa gacactaaag taactttgcc cyaggttttg gtaatgccck cyaaakcaca 420
tccaaagctc tctgtcatac agggggctcc tttagctct gtgtttttga gatcccatat 480
acctaaatcc cagtactcca aatcagtaet gctcagtttt agtgacaag tttaagatg 540
tattttaata tcaagtttag tttagtgcctt ctgtctctt tctcgactg ttgtatcat 600
gtkatctct tkaatgaat ctgggaattt attagaanaa attaaattat actaatgaaa 660
ctgatatttt ttgkgaatc atagatgaat ttggaaagaa ttgtttttaa tgaacclaaa 720
tcccttttat ttgaagacta tatgtgtctt tatatttatt ccagtttaca ttatatccac 780
tgagtaata taatgaatg ttgatacata cagctgtagt tacagatata aatatagata 840
taactgttta aatcatatc tatcccatat accatcata catgtaatat gtgtgtgttt 900
atacatatgt gtttatgca ttaagagct ccttcaaat ttltctttaa tttcccttat 960
aatbtggagt tgaagctgaa ttctcttgg ataaacagc aaatatattat actagtttta 1020
atactgagt tttagacattg tatcttatit tagcgtgaa tattttcaa attattata 1080
atatatcta atactaataa tgcactcgtt aanaatttt aaaaattttac ctttgattta 1140
ttttattgtt gaattaaaat tcccttataa tgataaaaa aaaaaaaaaa aaaaactcgt 1200
a 1201

<210> 155

<211> 1026

<212> DNA

<213> Homo sapiens

<400> 155

gtctaaatgt tcaagttttc ttctaatic caatgattct ctcattttct caatgtcctt 60
tgtccatctt tctgtctcca ttgcactgc ctcccaagg tcaactgtgc tccctctctg 120
actccacag tcaagttaca cttcataaa attctaaag cattttcaga agccacaat 180
ctatccctct ttaagctctt caaacttga ttgtgtaaat aaatactcag aaacaagatt 240
tctaaaaac aaacactatt ggcctcgtg ttgtcaagg agatacaaaa tgtttaacct 300
tatatgtgt aggccttcta aacttaatt caaaaaaga ctataacata agtgcata 360
tgtctataa ctacacaga aaattttag atcatcaat tgtgtattca ttggcgggaa 420

acaatcatgt aaaaaccaca gcccttgagc tgggtacgac agaaacaga agattcagca 480
 tttcatgtgt ggtgtactca atctctaaag ggtgtccagc ttaaaaaaa aaattgaaaa 540
 gaaaggaata gaattctgac ctgtctata aaattgaaag tgcgttgga aagtcttgcc 600
 tttccacttc tgaacaaagt gaggctcttc ataggtagac caagggacac gattgtagac 660
 tttctggcc ccnaattct tcaagaaat agtaatttga ggaagagac tgcgtatga 720
 taagggtgct gtttgactgc gatgaaat aagctcttc ctctccaa gattcttga 780
 ggccatgaag catgtatct caccaccac caatttgcg tccccctgc ctgttgccct 840
 taaccactca atcttggtc actgacttc ttgtcaagaa gccatgtccg cctaccact 900
 ggaacttcac ctctccaaaa tgtactctt cttaaggcct accgtgttca aaggctagct 1020
 cccaagcaca ccaatgtaaa ctgtgcgca atctgatalc aagctatccg ataccgtcga 1026
 cctcga

<210> 156

<211> 904

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> n equals a,t,g, or c

<400> 156

acccaagmgc ccggagata cttaatttta ttcatgtata gaataattgt atttatttt 60
 tggacataa ttatctact tgtcatcttc ttcaaccac ttgagaatgt ttagctctgc 120
 aaattaatgt ttggccgagc ctctcatct tctctcttc tgcctctcc ctgttgcaat 180
 gtaccgtctt caccatgctt tttaaaatgt ttccatccg talttagac cttaagaagg 240
 aagaacata gaattatcat gtccaaact tatttact tattgatat gacaagaatc 300
 attttttaa ccccatcaa atagatttca atcgactgt tccccatc ctlttgagcc 360
 aacgtcggcc atcgaaatag caaatttgt tttagaata aactgttmac cagtttgtta 420
 tgaacttcaa aagccttgc gctgggaac agaaagattc ctgaattcct aggtatgta 480
 ttaaatatta gtgtgtgagc cagagcttg acagagctgt tactatgct tgaaggcttc 540
 atctcaggc agtattcat tcatcttgc gtaagccct ccccaactc ctctaattra 600
 aaaaagtagt gaagaatat ttgtatgaa ggaatcaat ttctgtaac tgaatgtgtg 660
 atgagacaga gataaataat ttgtatgaa ggaatcaat ttctgtaac tgaatgtgtg 720
 aaaaattcat ttctgggaa atcatatagc catccaata ttcaagrat gtaactatga 780
 ttgtttcaa gagaatatgt ttacatgctt aattgtata ttgtctctc atcaattctc 840
 tcccttcag tcaatataa tgaatttcaa aaccataaa aaaaaaaagc 900
 ggc

<210> 157

<211> 916

<212> DNA

<213> Homo sapiens

<400> 157

gtttgtata ccaatgtctt cagaatcag gtaatgagc atcatgtctt ctgggtatc 60
 ctgtgtcttc tggcttttga aatggataa caacttgag ctatccac tggtagtat 120
 tccagcatgt gttgtgtctt caactcatgt calcatcca gaattccac acaaggcttc 180
 ccattaccca gatttttca acattgata ataaaggcta taacagatct taagtctga 240
 acaccagagg tctgggggca aggttggaat ttgacttacc atctctatga gataatctc 300
 cataagctct ttatatatat attgtgtta ttgataatc attcaaaaa tatatatga 360
 gcaagctgtg ttgtatagc tctgtctgc ccagtgaaga taactgata acaattgtgt 420
 gctgtctg ttccagctcc ttgtgttaca ttgttgatga aaatagtatc aataatttc 480
 tcaagctgtg gcaacagac acaacagagg agatataat caccagactt cagggggtg 540
 ggaagagaa ttggtttagc ctcccaagtg tccctgtctt agttttagct gtttcaggt 600

gtgtatnaa gctccaggag ctggcagagg gagagcagag gaagcttagag cttaacagc 660
 acaaggcca tgaccgcatg ccaagagggt gaagagagac aggggaaatg tagcgaatgt 720
 tctctctca gaggatgtta tatcatatc ttaaaatgt tgaatctgcg ggcacatgtg 780
 ttcaagcatg ttgtgtcagc actttgggt gccaaagtgt gaagattctt tgaatcag 840
 agtttgagac cagctgttgc aactatgtga gaccatctc cttaaaaaa aaaaaaaa 900
 aaaaaagc ggcgcg

<210> 158

<211> 921

<212> DNA

<213> Homo sapiens

<400> 158

ggaactgtct ctataggac tggctctct cctcttgca cttagctctg ttcaagaat 60
 ccagggaaga acttgaaagg caaatatcac tcttgatct gtctggctctt gggaaagtgt 120
 aacgtagaag aggggggtgt gtttaataa aacacagtgt cttagagcag ggcagaaggtc 180
 gtgatgcat tctgttgag tccagagc calcacagc atgaatgtgt tctgtggcc 240
 tttagtgtgt gcatgttca tattctgtg gataacaatg tatgggtgt cgaatgcat 300
 ggggcagggt agagggcagt acacttgag gaccatttg tccatcaga caccatcagt 360
 ctgctctag agaatgctt ggaattctg ggttgatgt cggggacacc gaatacagac 420
 ttgcacactg gactgtcag gtgcagacc ttggagcac actgtgccat ccttaacca 480
 ggtcgaacca ttctctctg tgtcagagc ttggatgtg cttagaccat ttgaatctgg 540
 ttatgtatga gggggaaaag cagagcttc gaagctcac gccactctgt ggcagagca 600
 gctgtgtgt tccgggaaga ttgatgggca gaaataagg aaggaagatc atgcttttc 660
 ctactaatc ctgttaactg atgtatgta caltatgca gaggtaagc atagttatc 720
 ggtattttaa aaacaaatra ctataatca tctgagtctc tctagtgtca ttgtctgaa 780
 atgtatgtct gtictaatc ctgttaattg atgtgtctgt aattatcttc ctgttgaga 840
 gatctatct atgcactctg accttaataa atactatgt cagttaaaaa aaaaaaaa 900
 aaaaaaaa aggtcggcgc c

<210> 159

<211> 804

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (801)

<223> n equals a,t,g, or c

<400> 159

aagaaacttc tagaagctg gatgtcgggt ggcctcttag atatgcgctt taacgtctt 60
 cttaacaggg ccgctggagc actctactca ctctcttcaa gaacatttga tccccctga 120
 gttccccctg gcaaggttca ggaagctctt cctggacagg ctgtgtctt caccggcttc 180
 cctaatgt ttctctctca tcaatgaact tctggagggt aagggcgtc cagcttgcg 240
 cggcaagatv aggggggtgt tctggcggg gctgagagat aactggcgg ttgtggagcc 300
 actcaagctc atcaacatca actaacgtcc tctgaaatc cgggtgtctt tggcaact 360
 ggcagctctg ttctgtatg cctaacctgg ctccctggg aggtgacgac cgtctggaga 420
 aacacaggtt cactgttgag gtgtgtctg ggtctaac cggccagcga gacagaaac 480
 aatccatca ggaattcat gactttaat cagttgatc aagtagccca aaatgatgtg 540
 atagagaaac agaatctctt gaattcaga accctgtctt ttaaaagc agctctgcg 600

tcaggtgggt gctgcccacg aaacttaaaa tttagtcgag gcagtttcaa ttgtactgt 660
ggaccgaatt aggatcacaa taacagataa tgcaggttct tcaaaaaaa aaaaaaaa 720
aaaaaaaaa aaaaaaaa aaaaaaaa aaaaaactc gagggggggc ccgtacccaa 780
tcgcctgat gatgatctgn ncaac 804

<210> 160
<211> 24
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (24)

<223> Xaa equals stop translation

<400> 160
Met Tyr Gly Cys Val Cys Ile Tyr Leu Tyr Thr Cys Ile His
1 5 10 15

Gly Cys Pro Cys Val Ser Met Xaa
20

<210> 161
<211> 113
<212> PRT
<213> Homo sapiens

<400> 161
Met Gly Ser Trp Cys Ile Cys Thr Leu Leu Leu Leu Thr Asp Gly
1 5 10 15

Gln Gln Gly Phe Tyr Pro Gln Pro Phe Gln Ala Ala Pro Gly Arg Gln
20 25 30

Gln Leu Trp Gly Gly Thr Asn Pro Trp Ala Val Leu Ile Pro Glu Ser
35 40 45

Phe Leu Pro Tyr Thr Leu Thr Val Asn Tyr Ser Pro Ser Cys Asn Phe
50 55 60

Glu Phe Tyr Leu Pro Lys Met Arg Leu Ala Tyr Ile Cys Met Ser His
65 70 75 80

Ser His Cys Pro Tyr Leu Gly Arg Asp Ile Ile Ile Thr Leu Leu Asn
85 90 95

Tyr Cys Ser Ser Phe Leu Ala Glu Leu Leu Ala His Leu Val Tyr Ile
100 105 110

Ala

<210> 162
<211> 45
<212> PRT

<213> Homo sapiens
<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 162
Met Thr Lys Arg Arg Lys Pro Arg Tyr Arg Phe Ile Phe Ala Leu Tyr
1 5 10 15

Ala Leu Arg Leu Val Phe Leu Phe Arg Ala Val Thr Asn Thr Asp Ala
20 25 30

Ser Arg Leu Arg Ala Lys Arg Gly Glu Cys Pro Tyr Xaa
35 40 45

<210> 163
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 163
Met Thr Glu Gly Leu Leu Ser Ser Leu Ser Leu Leu Tyr Leu Leu
1 5 10 15

Thr Trp Leu Leu Met Leu Ser Lys Lys Leu Tyr Val Gln Met Ile Phe
20 25 30

Cys Tyr Asn Pro His Phe Ser Gln Met Asp Ala Cys Asn Gly Thr Ser
35 40 45

Gln Lys Ile His Asn Ala Arg Gln Cys Thr Xaa
50 55

<210> 164
<211> 118
<212> PRT
<213> Homo sapiens

<400> 164
Met Cys Tyr Leu Leu Leu Leu Ile Gln Thr Ala Glu Leu Leu Ile
1 5 10 15

His Pro Gln Gly Leu Gln Ala Val Ser Asn Gly Glu Ser Ala Leu Lys
20 25 30

Gly Thr Arg Pro Thr Phe Ser Ser Pro Phe Ile Leu Val Thr Glu Gly
35 40 45

Arg Lys Glu Trp Glu Gly Val Phe Leu Ser Ser Gly Trp Lys Gly Asn

50 55 60
 Thr Leu Ser Asn Tyr Tyr Ile Ser Leu Val Phe Tyr Tyr Ser Arg Ile
 65 70 75 80
 Leu Gln Pro Tyr Phe Tyr Cys Leu Trp Gly Lys Leu Glu Met Val Thr
 85 90 95
 Leu Ile Arg Ser Val Trp Arg Gly Ile Asn Gly Gly Asp Lys Ile Ser
 100 105 110
 Val Gly Phe Gly Lys Cys
 115
 <210> 165
 <211> 55
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation
 <400> 165
 Met Cys Ser Gly Leu Leu Ser Met Thr Phe Ser Phe Leu Leu Glu Phe
 1 5 10 15
 Cys Ser Val Ala Gln Arg Leu Arg Leu Ala Asp Ala Arg Thr Ser Met
 20 25 30
 Gln Asp Ile Leu Lys Trp Phe Ser Asp Tyr Thr Leu Arg Ala Asp Ile
 35 40 45
 Ser Lys Ser Arg Asp Leu Xaa
 50 55
 <210> 166
 <211> 127
 <212> PRT
 <213> Homo sapiens
 <400> 166
 Met Gln Gly Ser Asp Ala Gly His Gly Thr His Ile Tyr Arg Ala
 1 5 10 15
 Leu Val Gln Trp Pro Leu Ala Trp Val Phe Tyr Leu Ser His Ala Lys
 20 25 30
 Thr His Trp Gly Glu Glu Leu Arg Phe Ser Phe Arg Arg Lys Asn Leu
 35 40 45
 Arg Leu Arg Glu Ala Met Arg His Glu Thr Cys Gln Val Thr Gln Leu
 50 55 60
 Val Ala Gly Lys Ala Asp Ser Asn Leu Cys Leu Arg Asp Ser Glu Thr

65 70 75 80
 Trp Phe Trp Pro Pro Leu Trp Ala Ala Cys Ser Ser Leu Gln Ala Thr
 85 90 95
 Ala Cys Arg Leu Ser Ser Pro Ser Lys Gly Leu Gly Ala Ser Arg Glu
 100 105 110
 Cys Pro Trp Leu Ala Ser Gly Arg Ala Ala Leu Val Ser Phe Leu
 115 120 125
 <210> 167
 <211> 56
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (32)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 167
 Met Gly Val Glu Gln Tyr Ser Tyr Leu Phe Leu Thr Cys Val Phe Met
 1 5 10 15
 Cys Val Ser Leu Gln Trp Lys Ser Thr Gln Pro Trp Val Gly Asp Xaa
 20 25 30
 Thr Cys Met Arg Lys Gly Ile Thr Gly Thr Glu Val His Arg Thr Asn
 35 40 45
 Ala Leu Phe Thr Phe Trp Cys Ser
 50 55
 <210> 168
 <211> 73
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (73)
 <223> Xaa equals stop translation
 <400> 168
 Met Pro Ser Ile Arg Leu Gly Leu Ser His Leu Phe Leu Thr Ala Gly
 1 5 10 15
 Ile Tyr Cys Leu Leu Leu Cys Ala Arg Cys Cys Ala Leu Gly Arg Gly
 20 25 30
 Thr Ala Trp Ala Ala Cys Pro Gly Gly Ala Cys Gly Leu Met Gly Glu
 35 40 45
 Ala Asp Pro Ser Pro Pro His Cys Gln Gln Gly Gln Gly Lys Ser Thr
 50 55 60

His Arg Gly Leu Ile Pro Tyr Val Xaa
65 70

<210> 169

<211> 70

<212> PRT

<213> Homo sapiens

<400> 169

Met Thr Pro Gln Asn Leu Arg Phe Thr Leu Phe Gln Phe Cys Tyr Ser
1 5 10 15

Leu Tyr Leu Glu Leu Glu Leu Gly Phe Arg Ser Leu Ser Gln Glu Val
20 25 30

Thr Arg Glu Trp Cys Leu Ser Tyr Phe Phe Leu Ile Lys Val Cys Trp
35 40 45

Gln Val Pro Val Ser Glu Phe Leu Leu Val Lys Glu Asn Pro Phe Leu
50 55 60

Leu Leu Glu Lys Lys Leu
65 70

<210> 170

<211> 80

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> Xaa equals stop translation

<400> 170

Met Pro Phe Ile Leu Leu Leu Val Cys Leu Thr Ser Leu Pro Ser Arg
1 5 10 15

Gly Tyr Asn Glu Lys Lys Leu Thr Asp Asn Ile Gln Cys Glu Ile Phe
20 25 30

Gln Val Leu Tyr Glu Glu Ala Thr Ala Ser Tyr Lys Glu Glu Ile Val
35 40 45

His Gln Leu Pro Ser Asn Lys Pro Glu Glu Leu Glu Asn Asn Val Asp
50 55 60

Gln Ile Leu Lys Trp Ile Glu Gln Trp Ile Lys Asp His Asn Ser Xaa
65 70 75 80

<210> 171

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 171

Met Lys Ile Leu Ile Leu Phe Ile Phe Ile Pro Gly Leu Leu Val Glu
1 5 10 15

Lys Asn Gly Pro Asp His Val Cys Val Cys Met Cys Val Arg Val Cys
20 25 30

Val Cys Ala His Leu Gly Leu Phe Ile Xaa
35 40

<210> 172

<211> 131

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (66)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (78)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 172

Met Trp Ser Val Ile Arg Ser Leu Cys Pro Ser Arg Leu Gln Ser Leu
1 5 10 15

His Val Cys Phe Cys Pro Arg Leu Cys Leu Ala Val Pro Cys Val Phe
20 25 30

His Leu Ser Ser Trp Trp Phe His Val Arg Xaa Xaa Phe Phe Ser Gly
35 40 45

Xaa Pro Gly Cys Ile Trp Gly Ile Cys Phe Val Gly Leu Leu Gly
50 55 60

Ala Xaa Arg Pro Arg Ser Gly Cys Leu Cys Ser Pro Ser Xaa Cys Leu
65 70 75 80

Trp Ser Leu Val Val Cys Glu Ser Ile Cys Leu Pro Arg Xaa Gly Pro
85 90 95

Asn Gln Ala Pro Pro Xaa Pro Leu Phe Leu Ser Leu Asn Leu Pro Phe
100 105 110

Leu Phe Gln Pro Leu Gln Met Arg Trp Leu Ser Ala Val Gly Trp Arg
115 120 125

Glu Ala Met
130

<210> 173

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 173

Met Gln Leu Ser Leu Ser Leu Cys Ala Phe Val Val Cys Thr Asn Ala
1 5 10 15

Val Cys Thr His Ala Ala Thr Asn Gln Ala Arg Leu Val Gly Phe Leu
20 25 30

Lys Val Leu Arg Pro Ala His Ser Pro Leu Cys Leu Xaa
35 40 45

<210> 174

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (63)

<223> Xaa equals stop translation

<400> 174

Met Gln Pro Ala Trp Leu Trp Leu Trp Xaa Trp Glu Leu Gly Trp Glu
1 5 10 15

Leu Val Phe Gly Ala Ile Leu Leu Xaa Leu Gln Asp Gly Leu Phe Asp
20 25 30

Ser Val Leu Tyr Cys Xaa His Leu Tyr Ser Gly Leu Phe Pro Trp
35 40 45

Ile Val Asn Ser Leu Met Ser Gly Ser Ser Gln Leu Met Ser Xaa
50 55 60

<210> 175

<211> 20

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals stop translation

<400> 175

Met Ser Ser Pro Lys Ser Leu Val Leu Leu Ala Val Ile Cys Arg
1 5 10 15

Glu Ala Thr Xaa
20

<210> 176

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (107)
<223> Xaa equals stop translation

<400> 178
Met Gly Ala Ala Leu Ala Ala Trp Ile Cys Ile Val Arg Tyr His Gln
1 5 10 15

Leu Arg Asp Trp Gly Val Arg Arg Trp Pro Asn Gln Leu Ile Leu Trp
20 25 30

Thr Gly Leu Leu Cys Ala Leu Gly Thr Ser Val Val Gly Asn Leu Pro
35 40 45

Gly Glu Thr Gln Ser Ala Pro Arg Val Cys Xaa Arg Pro Ala Xaa Gly
50 55 60

Xaa Thr Thr Pro Ser Met Pro Arg Gly His Arg Leu Xaa Val Ser Gly
65 70 75 80

Ala Gly Ser Arg Pro Pro Phe Xaa Gly Leu Val Phe Phe Ser Gly His
85 90 95

Trp Pro Gly Pro Ala Gly Ser Phe Xaa Leu Xaa
100 105

<210> 179
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 179
Met Gly Cys Trp Val Leu Phe Ile Leu Leu Tyr Leu Ala Leu His Ile
1 5 10 15

Cys Val Gln Asn Tyr Ile Tyr Ser Tyr Lys Ile Ile Cys Leu Gln Ser

<222> (41)
<223> Xaa equals stop translation

<400> 176
Met Asn Ile Val Pro Gln Phe Ser Val Leu Pro His Phe Ala Tyr Phe
1 5 10 15

Ser Phe Ile Ile Leu Tyr Trp Ala Val Leu Phe Ser Gln Thr Ile Cys
20 25 30

Ser Met Ser Val Phe Lys Val Lys Xaa
35 40

<210> 177
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 177
Met Thr Asp Ile Thr Cys Phe Leu Phe Ser Tyr Leu Ser Thr Leu Leu
1 5 10 15

Ser Pro Ile Tyr Leu Asp Val Leu Leu Phe Ser Leu Leu Phe Leu
20 25 30

Phe His Ile Ala Gly Met His Ile Leu Thr Phe Ile Asn His Asp Ile
35 40 45

Xaa

<210> 178
<211> 107
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids

20 25 30
 Phe His Tyr Ile Val Arg Lys Ile Gln Ile Phe Val Ser Xaa
 35 40 45

<210> 180
 <211> 67
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (67)
 <223> Xaa equals stop translation

<400> 180
 Met Leu Leu Ala Ala Phe Leu Ala Leu Phe Pro Leu His Asp Ser Arg
 1 5 10 15

Gly Leu Lys His Thr Gly Ala Gly His Val Asn Ser Val Ala Leu Leu
 20 25 30

Pro Ile Pro Leu Lys Ala Val Ser Leu Ser Pro Val Ser Ser Leu Gln
 35 40 45

Val Pro Cys Cys Ser Ser Phe Gln Leu Leu Thr Phe Leu Ser
 50 55 60

Val Ser Xaa
 65

<210> 181
 <211> 50
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (50)
 <223> Xaa equals stop translation

<400> 181
 Met Ile Cys Lys Phe Leu Ile Ile Cys Ile Thr Leu Leu Phe
 1 5 10 15

Ala Ile Cys Gln Leu Cys Lys Arg Gln Gly Leu Val Gln Lys Ile Ser
 20 25 30

Phe Tyr Gln Lys Gln Thr Leu Ser Ser Thr Val Gly Thr Thr Phe Leu
 35 40 45

Ser Xaa
 50

<210> 182

<211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (35)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (73)
 <223> Xaa equals stop translation

<400> 182
 Met Leu Thr Trp Val Trp Tyr Leu Ile Met Thr Ser Val Leu Gln Ala
 1 5 10 15

Ser Val Ser Ser Val Val Arg Gly Ser Ile Leu Val Gly Gly Ser Gln
 20 25 30

Asp Cys Xaa Glu Gly Gly Ser Leu Ile Gln Val Ser Leu Gly Tyr Val
 35 40 45

Leu Ala Ala Arg Glu Asp Arg Gln Glu Cys Gly Pro Asp Thr Val Ser
 50 55 60

Cys Pro Pro Gly Met Arg Leu Asp Xaa
 65 70

<210> 183
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 183
 Met Leu Ser Ala Leu Ser Ala Leu Tyr Leu Ile Ile Thr Ile Phe Leu
 1 5 10 15

Lys Gly Ser Cys Cys Ser Cys His His Cys Phe Thr Asn Gly Lys Leu
 20 25 30

Trp Leu Arg Lys Phe Ile Ser Gly Ser Gln Pro Xaa
 35 40

<210> 184
 <211> 58
 <212> PRT
 <213> Homo sapiens

<220>

WO 99/22243

Leu Asn Ile Phe Asp Leu Leu Tyr Xaa
20 25

<210> 187
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 187
Met Thr Leu Pro Trp Glu Trp Val Pro Asp Lys Arg Ile Trp Leu Leu
1 5 10 15

Ser Leu Thr Leu Val His Ala Leu Leu Pro Leu Cys Leu Leu Pro Trp
20 25 30

Asp Val Gly Ala Arg Ser Pro Phe Ile Ser Gly Glu Pro Ile Asn Leu
35 40 45

Gly Phe Pro Asn Leu Gln Asn Cys Lys Xaa
50 55

<210> 188
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 188
Met Val Gly Leu Leu Leu Ile Ala Leu Leu Thr Trp Gly Tyr Ile Arg
1 5 10 15

Tyr Ser Gly Gln Tyr Arg Glu Leu Gly Gly Ala Ile Asp Phe Gly Ala
20 25 30

Ala Tyr Val Leu Glu Gln Ala Ser Ser His Ile Gly Asn Ser Thr Gln
35 40 45

Ala Thr Val Arg Asp Ala Val Val Gly Arg Pro Ser Met Asp Lys Lys
50 55 60

Ala Gln Xaa
65

<210> 189
<211> 89

PCT/US98/22376

WO 99/22243

<221> SITE
<222> (58)
<223> Xaa equals stop translation

<400> 184
Met Cys Met Thr Val Phe Ile Val Phe Tyr Tyr Ser Phe Met Arg Leu
1 5 10 15

Leu Phe Arg Cys Ser His Asn Arg Arg His Trp Arg Gly Ser Gly Lys
20 25 30

Asn Thr Val Tyr His Thr Gly Pro Arg Asp Glu Ala Cys Cys Ala Met
35 40 45

Pro Cys Trp Ala Thr Trp Gly Arg Arg Xaa
50 55

<210> 185
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 185
Met Pro Leu Ala Leu Lys Arg Gly Gln Leu Phe Leu Ile Pro Trp Leu
1 5 10 15

Phe Pro Gln Gly Val Cys Pro Leu Glu Gly Gln Leu Gly Ser Gly
20 25 30

Lys Glu Gly Leu Leu Gln Phe Ala Ile Ala Ser Cys Pro Arg Val Tyr
35 40 45

Pro Glu His Ser Pro Pro Trp Lys Glu Thr Gln Ser Ala Thr Gly Tyr
50 55 60

Arg Lys Ser Asp Xaa
65

<210> 186
<211> 25
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (25)
<223> Xaa equals stop translation

<400> 186
Met Lys Tyr Leu Leu Phe Leu Val Phe Cys Leu Ser Tyr Val Lys Asp
1 5 10 15

<212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (18)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (63)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (89)
 <223> Xaa equals stop translation
 <400> 189
 Met Ser Thr Tyr Leu Lys Met Phe Ala Ala Ser Leu Leu Ala Met Cys
 1 5 10 15
 Ala Xaa Ala Glu Val Val His Arg Tyr Tyr Arg Pro Asp Leu Met Arg
 20 25 30
 Asn Arg Leu Arg Arg Val Lys Leu Ile Ser Gln Ser His Ile Ala Leu
 35 40 45
 Val Arg Arg Phe Glu Asp Leu Lys Pro Lys Leu Ser Val Cys Xaa Thr
 50 55 60
 Gly Ile Thr Ser Leu Ser Val Gly Glu Leu Glu Val Trp Ala Glu Ser
 65 70 75 80
 Ser Arg Gly Asp Leu Met Thr Ala Xaa
 85
 <210> 190
 <211> 221
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (159)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (221)
 <223> Xaa equals stop translation
 <400> 190
 Met Lys Leu Leu Leu Trp Ala Cys Ile Val Cys Val Ala Phe Ala Arg
 1 5 10 15
 Lys Arg Arg Phe Phe Ile Gly Glu Asp Asp Asn Asp Asp Gly His

20 25 30
 Pro Leu His Pro Ser Leu Asn Ile Pro Tyr Gly Ile Arg Asn Leu Pro
 35 40 45
 Pro Pro Leu Tyr Tyr Arg Pro Val Asn Thr Val Pro Ser Tyr Pro Gly
 50 55 60
 Asn Thr Tyr Thr Asp Thr Gly Leu Pro Ser Tyr Pro Trp Ile Leu Thr
 65 70 75 80
 Ser Pro Gly Phe Pro Tyr Val Tyr His Ile Arg Gly Phe Pro Leu Ala
 85 90 95
 Thr Gln Leu Asn Val Pro Pro Leu Pro Pro Arg Gly Phe Pro Phe Val
 100 105 110
 Pro Pro Ser Arg Phe Phe Ser Ala Ala Ala Pro Ala Ala Pro Pro
 115 120 125
 Ile Ala Ala Glu Pro Ala Ala Ala Pro Leu Thr Ala Thr Pro Val
 130 135 140
 Ala Ala Glu Pro Ala Ala Arg Gly Pro Val Ala Ala Glu Pro Xaa Gly
 145 150 155 160
 Arg Gly His Leu Leu Glu Leu Glu Pro Ala Ala Glu Ala Pro Val Ala
 165 170 175
 Ala Glu Pro Ala Ala Glu Ala Pro Val Gly Val Glu Pro Ala Ala Glu
 180 185 190
 Glu Pro Ser Pro Ala Glu Pro Ala Thr Ala Lys Pro Ala Ala Pro Glu
 195 200 205
 Pro His Pro Ser Pro Ser Leu Glu Gln Ala Asn Gln Xaa
 210 215 220
 <210> 191
 <211> 52
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (52)
 <223> Xaa equals stop translation
 <400> 191
 Met Glu Arg Leu Val Leu Ser Leu Trp Ser Leu Thr Cys Arg Ala Ser
 1 5 10 15
 Pro Ala Asn Thr His Pro Arg Thr Thr Ser Arg Thr Arg Thr Leu Asp
 20 25 30
 Val Lys Thr Lys Cys Pro Val Glu Ala Val Lys Leu Ser Glu Met Leu
 35 40 45

Pro Pro Val Xaa
50

<210> 192
<211> 72
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (72)
<223> Xaa equals stop translation

<400> 192
Met Val Gly Thr His Leu Ile Leu Phe Pro Phe Leu Leu Arg Thr Met
1 5 10 15

Val Ile Phe Leu Cys Leu Lys Ser Ser Cys Gly Ser Phe Leu Pro Ile
20 25 30

Asn Lys Ile Gln Thr Pro Phe Ile Leu Asn Leu Ile Tyr Lys Thr Phe
35 40 45

Lys Met Cys Ser Leu Pro Asn Ser Leu Phe Ser Pro Leu Ser Phe Ile
50 55 60

Phe Phe Ile Phe Phe Leu Thr Xaa
65 70

<210> 193
<211> 112
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (112)
<223> Xaa equals stop translation

<400> 193
Met Arg Arg Leu Leu Leu Ala Leu Pro Phe Ala Leu Leu Pro Leu Ala
1 5 10 15

Val Ala His Ala His Glu Asp His Asp His Glu His Gly Ser Leu Gly
20 25 30

Ala His Glu His Gly Val Gly Arg Leu Asn Ala Val Leu Asp Gly Gln
35 40 45

Ala Leu Glu Leu Glu Leu Asp Ser Pro Ala Met Asn Leu Val Gly Phe

50 55 60

Glu His Val Ala Thr Ser Ala Ala Asp Lys Ala Lys Val Ala Ala Val
65 70 75 80

Arg Lys Gln Leu Glu Asn Pro Ser Gly Pro Val Gln Pro Ala Gln Ser
85 90 95

Arg Ser Cys Val Val Ser Asn Gln Gly Ile Asn Xaa Arg Cys Ser Xaa
100 105 110

<210> 194
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (61)
<223> Xaa equals stop translation

<400> 194
Met Phe Ile Thr Arg Gly Cys Tyr Cys Phe Val Phe Phe Xaa Leu Ala
1 5 10 15

His Asn Cys Lys Ala Ala Arg Thr Thr Arg Asn Gly Phe Pro Thr Val
20 25 30

Pro Gly Arg Arg Gln Arg Thr Leu Arg Arg Leu Phe Leu Cys Gly Phe
35 40 45

Pro Leu Leu Cys Ser Gln Gly Asp Leu Ser Ala Ala Xaa
50 55 60

<210> 195
<211> 126
<212> PRT
<213> Homo sapiens

<400> 195
Met Thr Lys Leu Ala Gln Trp Leu Trp Gly Leu Ala Ile Leu Gly Ser
1 5 10 15

Thr Trp Val Ala Leu Thr Thr Gly Ala Leu Gly Leu Leu Pro Leu
20 25 30

Ser Cys Gln Glu Val Leu Trp Pro Leu Pro Ala Tyr Leu Leu Val Ser
35 40 45

Ala Gly Cys Tyr Ala Leu Gly Thr Val Gly Tyr Arg Val Ala Thr Phe
50 55 60

His Asp Cys Glu Asp Ala Ala Arg Glu Leu Gln Ser Gln Ile Gln Glu
65 70 75 80

Ala Arg Ala Asp Leu Ala Arg Arg Gly Cys Ala Ser Asp Ser Leu Thr
85 90 95

Pro Phe Leu Cys Gly Gln Pro Phe Leu Pro Phe Pro Ile Lys Glu Pro
100 105 110

Val Tyr Phe Leu Lys Lys Lys Lys Lys Lys Lys Lys
115 120 125

<210> 196
<211> 113
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (113)
<223> Xaa equals stop translation

<400> 196
Met Ala Ala Leu Leu Leu Leu Pro Trp Leu Met Leu Leu Thr Gly Arg
1 5 10 15

Val Ser Leu Ala Gln Phe Ala Leu Ala Phe Val Thr Asp Thr Cys Val
20 25 30

Ala Gly Ala Leu Leu Cys Gly Ala Xaa Leu Leu Phe His Gly Met Leu
35 40 45

Leu Leu Arg Gly Gln Thr Thr Trp Glu Trp Ala Arg Gly Gln His Ser
50 55 60

Tyr Asp Leu Gly Pro Cys His Asn Leu Gln Ala Ala Leu Gly Pro Arg
65 70 75 80

Trp Ala Leu Val Trp Leu Trp Pro Phe Leu Ala Ser Pro Leu Pro Gly
85 90 95

Asp Gly Ile Thr Phe Gln Thr Thr Ala Asp Val Gly Xaa Thr Ala Ser
100 105 110

Xaa

<210> 197
<211> 66
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (66)
<223> Xaa equals stop translation

<400> 197
Met Leu Gly Ile Thr Arg Leu Trp Val Leu Leu Lys Pro Cys Phe Pro
1 5 10 15

Arg Cys Tyr Ser Ser Thr Gly Gly Glu Val Leu Pro Arg Cys Cys Glu
20 25 30

Val Glu Ala Glu Val Gln Val Pro His Ser Ala Pro Met Asp Ser Arg
35 40 45

Glu Gly Gly Thr Val Pro Tyr Phe Gly Gly Cys Gly Ser Pro Arg Phe
50 55 60

Tyr Xaa
65

<210> 198
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 198
Met Ala Gln His His Leu Leu Ser Ile Leu Leu Ala Ile Leu Ser Cys
1 5 10 15

Ser Ser Gln Pro Arg Gln Xaa Arg Gly Ser Gly Ala Leu Pro Cys Glu
20 25 30

Val Cys Ser Ala Val Leu Leu Thr Cys Leu Arg Lys Ile Ser Gly Ser
35 40 45

Leu Cys Val Xaa

50

<210> 199
<211> 59
<212> PRT
<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals stop translation

<400> 199

Met Ile Gly Lys Ser Leu Val Met Phe Cys Phe Leu Ser Trp Gly Ala
1 5 10 15

Gly Val His Gly Cys Ala Leu Tyr Tyr Asn Ala Ser Asn Arg Ile Gly
20 25 30

Ile Phe Tyr Ile Phe Cys Phe Thr Tyr Leu Arg Leu His Glu Cys Val
35 40 45

Met Leu Ser Asn Leu Arg Val Asn Glu Leu Xaa
50 55

<210> 200

<211> 52

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals stop translation

<400> 200

Met Leu Ser Pro Leu Ser Gln Ser Leu Leu Val Ala Leu Asn Val Leu
1 5 10 15

Phe Leu Leu Pro Asn Phe Leu Ala Leu Ser Lys Asn Leu Thr Tyr Asp
20 25 30

Cys Tyr Phe Arg Phe Phe Pro Thr Phe Phe Leu Pro Pro Lys Glu Met
35 40 45

Trp Tyr Leu Xaa
50

<210> 201

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (81)

<223> Xaa equals stop translation

<400> 201

Met Cys Pro Ala Ala Leu Ala Trp Pro Thr Ser Ala Ile Ser Leu
1 5 10 15

Ile Val Ser Leu Ala Pro Ser Trp Ala Ala Ala Arg Asp Asn Trp Ala
20 25 30

Ala Ser Pro Tyr Thr Thr Gln Ala Arg Pro Ala Leu Arg Ala Ala Leu
35 40 45

Thr Thr Ile Ser Gly Pro Met Pro Ala Ala Ser Pro Met Val Met Pro
50 55 60

Thr Gly Arg Glu Gly Phe Thr Val Leu Gly Met Gly Leu Arg Cys Gly
65 70 75 80

Xaa

<210> 202

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (70)

<223> Xaa equals stop translation

<400> 202

Met Phe Leu Ile Val Phe Cys Phe Leu Gln Ser Leu Ser Ala Met Pro
1 5 10 15

Ile Val Leu Ile Phe Tyr Arg Ser Ser Leu Lys Ile Leu Asn Arg Gly
20 25 30

Ile Gly Ser Gly Gln Ser Glu Trp Leu Glu Phe Trp Leu Ser Lys Lys
35 40 45

Asn Phe Ile Leu His Lys His Val Val Arg Ser Phe Cys Ala Tyr Ala
50 55 60

Ala Trp Ile Gly Cys Xaa
65 70

<210> 203

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals stop translation

<400> 203

Met Leu Leu Cys Ser Val Arg Asn Ile Leu Trp His Thr Ala Phe Leu
1 5 10 15

Gly Ser Ala Val Leu Cys Phe Val Leu Val Leu Val Leu His Leu Glu
20 25 30

Cys Leu Ile Ile Asp Ala Tyr Phe Asn Ser Ile Ser Phe Xaa
35 40 45

<210> 204

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 204

Met Gly Thr Glu Ala Ser Pro Lys Arg Tyr Phe Phe Val Val Val
1 5 10 15

Val Leu Gly Ile Ile Val Pro Ile Leu Arg Ala Phe Pro Pro Val
20 25 30

Pro Thr His Pro Asn Lys Met Trp Trp Cys Cys Leu Gln Lys Arg Glu
35 40 45

Val Leu Cys His Xaa
50

<210> 205

<211> 62

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (62)

<223> Xaa equals stop translation

<400> 205

Met Phe Cys Trp Ile Leu Val Cys Leu Ala Tyr Leu Lys Val Pro Leu
1 5 10 15

Leu Phe Phe Phe Phe Phe Leu Ser Ala Leu Phe Cys Arg Thr Cys
20 25 30

Ser Asn Met Glu Asn Lys Ser Arg Arg Leu Ser Ser Asp Cys Tyr Leu
35 40 45

Cys Pro Lys Pro Pro Gln Thr Phe Met Leu Met Phe Tyr Xaa

50 55 60

<210> 206

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 206

Met Leu Phe Leu His Thr Arg Leu His Phe Pro Arg Tyr Thr Leu Leu
1 5 10 15

Ile Cys Lys Val Leu Leu Val Val Ala Ala Ser Val His Arg Pro Trp
20 25 30

Leu Arg Ser Ile Thr Gly Cys Phe Phe Thr Lys Xaa
35 40

<210> 207

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> Xaa equals stop translation

<400> 207

Met Ser Ala Ser Leu Cys Leu Phe Thr Gln Val Leu Lys Gly Ile Val
1 5 10 15

Trp Leu Pro Ile Leu Met Phe His Val Gly Ala Thr Lys Thr Ser Gly
20 25 30

Phe Ser Val Glu Gln Leu Tyr Ser Xaa
35 40

<210> 208

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 208

Met Phe Lys Arg Met Cys Phe Phe Phe Gln Val Phe Leu Pro Leu Ala
1 5 10 15

Met Val Asn Ile Phe Gly Phe Val Ser Cys Ile Val Phe Val Val Ala
1 5 10 15

Val Gln Leu Cys Tyr Met Lys Gln Pro Xaa
20 25

<210> 211
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 211
Met Leu Gln Phe Leu Leu Gly Phe Thr Leu Gly Asn Val Val Gly Met
1 5 10 15

Tyr Leu Ala Gln Asn Tyr Asp Ile Pro Asn Leu Ala Lys Lys Leu Gly
20 25 30

Glu Ile Lys Lys Asp Leu Asp Ala Lys Lys Lys Pro Pro Ser Ala Xaa
35 40 45

<210> 212
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 212
Met Ala Ser Gly Ser Trp Thr Ser Ala Pro Gly Ile Gly Val Ile Leu
1 5 10 15

Val Met Thr Val Cys Leu Ser His Cys Tyr Thr His Glu Trp Gly Leu
20 25 30

Trp Gly Gly Gly Thr Gln Gly Leu Thr Asp Ser Xaa
35 40 45

<210> 213
<211> 52
<212> PRT
<213> Homo sapiens

<220>

Cys Thr Glu Leu Leu Trp Lys Gly Ala Pro Cys Arg His Ile Phe Gln
20 25 30

Thr Gly Pro Asp Leu Leu Val Thr Gln Arg Cys Val His Ser Leu Leu
35 40 45

Leu Gly Tyr Leu Ile Ser Ile Phe Xaa
50 55

<210> 209
<211> 126
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (126)
<223> Xaa equals stop translation

<400> 209
Met Met Thr Gln Thr Cys Ile Ile Leu Leu Ile His Thr Met Gln Val
1 5 10 15

Cys Thr Thr His Pro Thr Val Leu Ser His Thr Leu Leu Gln Arg Pro
20 25 30

Lys Pro Thr Asp Leu Phe Pro Lys Ala Thr Pro Thr Thr Ala Pro Met
35 40 45

Pro Leu Arg Met Arg Pro Pro Gln Cys Leu Pro His Met Phe His Leu
50 55 60

Gln Ser Arg Arg Phe Asp Gln Glu Ile Gly Leu Gln Gln Lys Ser Met
65 70 75 80

Thr Gly Ile Leu Gln Thr Thr Glu Lys Trp Thr Gln Glu Asn Phe Gly Leu
85 90 95

Ser Gln Gly Val Phe Leu Asn Met Asn Leu Ala Ser His Gln Phe Phe
100 105 110

Ser Met Lys Asp Gln Leu Pro Ser Leu Lys Leu Pro Asp Xaa
115 120 125

<210> 210
<211> 26
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (26)
<223> Xaa equals stop translation

<400> 210

<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 213

Met Tyr Ile Leu Cys Ser Gly Leu Leu Gln Gly Gln Leu His Tyr Phe
1 5 10 15

Leu Gly Trp Ala Phe Leu Trp Leu Lys Leu Gly Cys Pro Tyr Leu Ser
20 25 30

Gln Gly Ser Gln Pro Lys Arg His Ser Gly Glu Asn Leu Tyr Pro Ile
35 40 45

Arg Glu Glu Xaa
50

<210> 214

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 214

Met Tyr Ser Leu Val Leu Thr Phe Leu Val Ser Phe Cys Ala Leu Ser
1 5 10 15

Lys Thr Phe Leu Asp His Tyr Phe Gln Met Phe Ile Tyr Tyr Ile Leu
20 25 30

Phe Lys Asp Ser Glu Ile Gly Phe Cys His Pro Leu Leu Tyr Val Leu
35 40 45

Phe His Xaa
50

<210> 215

<211> 210

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (143)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
<222> (179)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (182)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (210)

<223> Xaa equals stop translation

<400> 215

Met Arg Ser Thr Ile Leu Leu Phe Cys Leu Leu Gly Ser Thr Arg Ser
1 5 10 15

Leu Pro Gln Leu Lys Pro Ala Leu Gly Leu Pro Pro Thr Lys Leu Ala
20 25 30

Pro Asp Gln Gly Thr Leu Pro Asn Gln Gln Gln Ser Asn Gln Val Phe
35 40 45

Pro Ser Leu Ser Leu Ile Pro Leu Thr Gln Met Leu Thr Leu Gly Pro
50 55 60

Asp Leu His Leu Leu Asn Pro Ala Ala Gly Met Thr Pro Gly Thr Gln
65 70 75 80

Thr His Pro Leu Thr Leu Gly Gly Leu Asn Val Gln Gln Leu His
85 90 95

Pro His Val Leu Pro Ile Phe Val Thr Gln Leu Gly Ala Gln Gly Thr
100 105 110

Ile Leu Ser Ser Glu Glu Leu Leu Pro Gln Ile Phe Thr Ser Leu Ile Ile
115 120 125

His Ser Leu Phe Pro Gly Xaa Ile Leu Pro Thr Ser Gln Ala Xaa Ala
130 135 140

Asn Pro Asp Val Gln Asp Gly Ser Leu Pro Ala Gly Gly Ala Gly Val
145 150 155 160

Asn Pro Ala Thr Gln Gly Thr Pro Ala Gly Arg Leu Pro Thr Pro Ser
165 170 175

Gly Thr Xaa Asp Asp Xaa Ala Val Thr Thr Pro Ala Gly Ile Gln Arg
180 185 190

Ser Thr His Ala Ile Glu Glu Ala Thr Thr Glu Ser Ala Asn Gly Ile
195 200 205

Gln Xaa
210

<210> 216

<211> 195

<212> PRT

<213> Homo sapiens

<400> 216

Met Ala Pro Ala Ala Ser Arg Leu Arg Ala Glu Ala Gly Leu Gly Ala
1 5 10 15Leu Pro Arg Arg Ala Leu Ala Gln Tyr Leu Leu Phe Leu Arg Leu Tyr
20 25 30Pro Val Leu Thr Lys Ala Ala Thr Ser Gly Ile Leu Ser Ala Leu Gly
35 40 45Asn Phe Leu Ala Gln Met Ile Glu Lys Lys Arg Lys Lys Glu Asn Ser
50 55 60Arg Ser Leu Asp Val Gly Gly Pro Leu Arg Tyr Ala Val Tyr Gly Phe
65 70 75 80Phe Phe Thr Gly Pro Leu Ser His Phe Phe Tyr Phe Phe Met Glu His
85 90 95Trp Ile Pro Pro Glu Val Pro Leu Ala Gly Leu Arg Arg Leu Leu Leu
100 105 110Asp Arg Leu Val Phe Ala Pro Ala Phe Leu Met Leu Phe Phe Leu Ile
115 120 125Met Asn Phe Leu Glu Gly Lys Asp Ala Ser Ala Phe Ala Ala Lys Met
130 135 140Arg Gly Gly Phe Trp Pro Ala Leu Arg Met Asn Trp Arg Val Trp Thr
145 150 155 160Pro Leu Gln Phe Ile Asn Ile Asn Tyr Val Pro Leu Lys Phe Arg Val
165 170 175Leu Phe Ala Asn Leu Ala Ala Leu Phe Trp Tyr Ala Tyr Leu Ala Ser
180 185 190

Leu Gly Lys

195

<210> 217

<211> 35

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals stop translation

<400> 217

Met Gln Ala Arg Trp Phe His Ile Leu Gly Met Met Phe Ile Trp
1

15

5

10

Ser Ser Ala His Gln Tyr Lys Cys Pro Cys Tyr Ser Arg Gln Ser Gln
20 25 30Glu Lys Xaa
35

<210> 218

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (72)

<223> Xaa equals stop translation

<400> 218

Met Phe Pro Ser Cys Leu Pro Leu Leu Phe Asn Ala Lys Val Leu Ala
1 5 10 15Lys Asp Ile Phe Leu Leu Leu Cys Phe Ser Ile Leu Phe Cys Thr
20 25 30Val Gly Trp Leu Ser Ala Pro Thr Leu Gly Thr Gly Pro Trp Leu Gly
35 40 45His Phe Met Ala Gln Ser Leu Trp Gly Leu Lys Glu Gly Trp Ala Ala
50 55 60Gln Ser Leu His Gly Ser Cys Xaa
65 70

<210> 219

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 219

Met Ala Val Ser Leu Trp Pro Glu Gly Ser Gly Pro Leu Cys Ala Leu
1 5 10 15Ser Leu Leu Thr Cys Cys Leu Val Leu Arg Pro Ala Ser Ser Ser Gly
20 25 30Phe Leu Trp Ser Leu Glu Thr Pro Ala Leu Gln Gly Leu Cys Glu
35 40 45

Ile Ala Gln Pro Xaa

50

<210> 220
 <211> 69
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (69)
 <223> Xaa equals stop translation

<400> 220
 Met Val His Asn Cys Leu Leu Leu Lys Phe Leu Leu Phe Cys
 1 5 10 15

Phe Pro Leu Ile Ser Tyr Gln Leu Met Asn Gly Ser Leu Gln Ser Leu
 20 25 30

Gln Arg Leu Arg Met Ile Gln Asn Val Gln Cys Ile Val Leu Asn Lys
 35 40 45

Gln Gln Ala Gln Phe Leu Met Gly Ile Ser Phe Gln Ile Tyr Asp Trp
 50 55 60

Ser Leu Gly Phe Xaa
 65

<210> 221
 <211> 69
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (69)
 <223> Xaa equals stop translation

<400> 221
 Met Ser His Leu Gln Thr Leu His Leu Ile Gly Leu Ser Cys Ser Phe
 1 5 10 15

Leu Tyr Phe Pro Thr Ser Gln Ala Val Gln Ala Ala Gln Pro Gly Met
 20 25 30

Met Leu Ser Leu Arg Gln Met Thr Asn Pro Leu Val Ala Arg Asn Gln
 35 40 45

Thr Ala Pro Arg Ala Gly Val Ser Val Phe Cys Thr Asp Cys Leu Phe
 50 55 60

Gly Leu Asp Ile Xaa
 65

<210> 222
 <211> 44

<212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 222
 Met Leu Thr Cys Ile Asp Met Asp Trp Lys Val Leu Thr Trp Leu Arg
 1 5 10 15

Tyr Thr Leu Trp Ile Pro Leu Tyr Pro Leu Gly Met Phe Gly Gly Ser
 20 25 30

Cys Leu Ser Asp Ser Val His Ser Asn Ile Gln Xaa
 35 40

<210> 223
 <211> 103
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (103)
 <223> Xaa equals stop translation

<400> 223
 Met Trp Ser Ser Ile Arg Leu Leu Ser Pro Val Leu Ser Leu Ile Leu
 1 5 10 15

Leu Leu Ile Ala Leu Gln Leu Val Asn Ile His Ala Val Cys Gly Lys
 20 25 30

Asn Ala His Gln Tyr Gln Gln Tyr Leu Lys Phe Val Lys Ser Ile Leu
 35 40 45

Gln Tyr Thr Gln Asn Leu Val Ala Tyr Thr Ser Tyr Gln Lys Asn Lys
 50 55 60

Trp Asn Gln Thr Ile Asn Leu Thr His Thr Ala Leu Leu Lys Met Trp
 65 70 75 80

Thr Phe Ser Gln Lys Lys Gln Met Leu Ile His Leu Ala Lys Lys Ser
 85 90 95

Thr Ser Lys Val Leu Leu Xaa
 100

<210> 224
 <211> 214
 <212> PRT
 <213> Homo sapiens

<220>

WO 99/22243

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (109)
 <223> Xaa equals stop translation

<400> 225
 Met Thr Val Ser Gly Thr Val Val Leu Val Ala Gly Thr Leu Cys Phe
 1 5 10 15

Ala Trp Trp Ser Glu Gly Asp Ala Thr Ala Gln Pro Gly Gln Leu Ala
 20 25 30

Pro Xaa Thr Glu Tyr Pro Val Pro Glu Gly Pro Ser Pro Leu Leu Xaa
 35 40 45

Ser Val Ser Phe Val Cys Cys Gly Ala Gly Gly Leu Leu Leu Ile
 50 55 60

Gly Leu Leu Trp Ser Val Lys Ala Ser Ile Pro Gly Pro Pro Ser Met
 65 70 75 80

Gly Pro Leu Ser Pro Leu Gln Arg Pro Val Leu Pro His Cys Gly Val
 85 90 95

Leu Arg Glu Gly Glu Leu Gln Asp Pro Gln Ser Gly Xaa
 100 105

<210> 226

<211> 316

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (316)

<223> Xaa equals stop translation

<400> 226
 Met Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr
 1 5 10 15

Ser Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro
 20 25 30

Val Gly Leu Ser Arg Met Phe Thr Val Met Gly Gln Leu Leu Val Lys
 35 40 45

Pro Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu
 50 55 60

Glu Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Val
 65 70 75

WO 99/22243

<221> SITE
 <222> (214)
 <223> Xaa equals stop translation

<400> 224
 Met Lys Gly Phe Ser Trp Ala Ile Val Pro Ala Leu Thr Ser Leu Gly
 1 5 10 15

Tyr Leu Ile Ile Leu Val Val Ser Ile Phe Pro Phe Trp Val Arg Leu
 20 25 30

Thr Asn Glu Glu Ser His Glu Val Phe Phe Ser Gly Leu Phe Glu Asn
 35 40 45

Cys Phe Asn Ala Lys Cys Trp Lys Pro Arg Pro Leu Ser Ile Tyr Ile
 50 55 60

Ile Leu Gly Arg Val Phe Leu Leu Ser Ala Val Phe Leu Ala Phe Val
 65 70 75 80

Thr Thr Phe Ile Met Met Pro Phe Ala Ser Glu Phe Phe Pro Arg Thr
 85 90 95

Trp Lys Gln Asn Phe Val Leu Ala Cys Ile Ser Phe Phe Thr Gly Ala
 100 105 110

Cys Ala Phe Leu Ala Leu Val Leu His Ala Leu Glu Ile Lys Ala Leu
 115 120 125

Arg Met Lys Leu Gly Pro Leu Gln Phe Ser Val Leu Trp Pro Tyr Tyr
 130 135 140

Val Leu Gly Phe Gly Ile Phe Leu Phe Ile Val Ala Gly Thr Ile Cys
 145 150 155 160

Leu Ile Gln Glu Met Val Cys Pro Cys Trp His Leu Leu Ser Thr Ser
 165 170 175

Gln Ser Met Glu Glu Asp His Gly Ser Leu Tyr Leu Asp Asn Leu Glu
 180 185 190

Ser Leu Gly Gly Glu Pro Ser Ser Val Gln Lys Glu Thr Gln Val Thr
 195 200 205

Ala Glu Thr Val Ile Xaa
 210

<210> 225

<211> 109

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

Glu Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr
 85 90 95
 Leu Lys Thr Lys Leu Asp Pro Trp Ser Ser Phe Ser Val Leu Gln Ser
 100 105
 Pro Val Trp His Phe Ala Ala Gln Thr Pro Ala Asp Ile Val Ser Pro
 115 120 125
 Asp Ser His Phe Met Leu Ser Thr Gln Gly Met Ser Trp Ala Gln Leu
 130 135 140
 Val Phe Leu Leu Pro Ala Ser Arg Pro Gly Asn Ser Gln Asp Lys Arg
 145 150 155 160
 Arg Lys Lys Ala Ser Ala Trp Glu Arg Asn Leu Val Tyr Pro Ala Val
 165 170 175
 Met Val Leu Leu Ile Glu Thr Ser Ile Ser Val Leu Leu Val Ala
 180 185 190
 Cys Asn Ile Leu Cys Leu Leu Val Asp Glu Thr Ala Met Pro Lys Gly
 195 200 205
 Thr Arg Gly Pro Gly Ile Gly Asn Ala Ser Leu Ser Thr Phe Gly Phe
 210 215 220
 Val Gly Ala Ala Leu Glu Ile Ile Leu Ile Phe Tyr Leu Met Val Ser
 225 230 235 240
 Ser Val Val Gly Phe Tyr Ser Leu Arg Phe Phe Gly Asn Phe Thr Pro
 245 250 255
 Lys Lys Asp Asp Thr Thr Met Thr Lys Ile Ile Gly Asn Cys Val Ser
 260 265 270
 Ile Leu Val Leu Ser Ser Ala Leu Pro Val Met Ser Arg Thr Leu Gly
 275 280 285
 Leu His Lys Leu His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala
 290 295 300
 Lys Pro Ser Val Asn Gly His Gln Lys Ala Leu Xaa
 305 310 315
 <210> 227
 <211> 116
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (116)
 <223> Xaa equals stop translation
 <400> 227

Met Leu Ala Leu Ser Ser Ser Phe Leu Val Leu Ser Tyr Leu Leu Thr
 1 5 10 15
 Arg Trp Cys Gly Ser Val Gly Phe Ile Leu Ala Asn Cys Phe Asn Met
 20 25 30
 Gly Ile Arg Ile Thr Gln Ser Leu Cys Phe Ile His Arg Tyr Tyr Arg
 35 40 45
 Arg Ala Pro Thr Gly Pro Trp Leu Ala Cys Thr Tyr Arg Gln Ser Cys
 50 55 60
 Ser Gly His Leu Pro Ser Val Val Gly Leu Leu Leu Phe Arg Arg Tyr
 65 70 75 80
 Ser Ser Ala Val Ser Arg Ala Gly Gln Pro Asp Trp His Thr Leu Leu
 85 90 95
 Trp Gly Pro Ser Val Trp Glu Gln Leu Ser Gly Gln His Ser Ser Gln
 100 105 110
 Arg Pro Ser Xaa
 115
 <210> 228
 <211> 107
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (107)
 <223> Xaa equals stop translation
 <400> 228
 Met Cys Val Gly Trp Trp Trp Trp Leu Val Val Leu Gly Leu Gly Met
 1 5 10 15
 Gly Gly Thr Leu Gly Cys Asp Gly Phe Leu Ser Gln Arg Trp Cys Phe
 20 25
 Thr Ala Gly Lys Tyr Leu Glu Leu Gly Gly Gly Leu Ser Arg His Gln
 35 40 45
 Ala Asp Phe Ile Phe Ser Gln Thr Lys Ala Thr Phe Thr Ser Lys Gly
 50 55 60
 Lys Thr Gln Asn Thr Lys Ile Glu Thr Ser Met Pro Pro His Leu Phe
 65 70 75 80
 Arg Gln Gln Glu Pro Pro Gly Gln Arg Val Phe Leu Thr Leu Arg Val
 85 90 95
 Thr Leu Thr Ser His Leu Val Ser Cys Gly Xaa
 100 105

<400> 231
Met Glu Leu Ser Leu Ala Val Leu Glu Ala Val Cys Gln Cys Leu Leu
1 5 10 15

Gly Leu Trp Leu Leu Phe Trp Leu Asp Lys Glu Val Ala Val Phe Val
20 25 30

Leu Leu Leu Trp Leu Phe Thr Asp Leu Thr Asp Val Thr Gly Asp Glu
35 40 45

Cys Arg Xaa
50

<210> 232
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 232
Met Lys Leu Leu Phe Cys Leu Arg Tyr Tyr Met Leu Leu Ser Val Val
1 5 10 15

Val Lys Ala Thr Ser Thr Ile Pro Ser Asn Ile Glu Ile Thr Ser Leu
20 25 30

Ser Trp Val Cys His Asn Ser Thr Xaa
35 40

<210> 233
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 233
Met Arg Leu Val Ser Pro Gly Phe Trp Trp Val Leu Pro Leu Arg Leu
1 5 10 15

Gly Glu Ala Leu Pro Gly Arg Arg Gln Gln Pro Pro Gly Ala Met
20 25 30

Lys Thr Leu Arg Leu Arg Glu Val Lys Xaa
35 40

<210> 234
<211> 48

<210> 229
<211> 38
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals stop translation

<400> 229
Met Ser Ser Phe Thr Leu Gly Leu Leu Phe Leu Phe Ile Phe Thr Thr
1 5 10 15

Ala Glu Asn Tyr Leu Ile Leu Phe Gln Arg Lys Tyr Cys Leu Val Ile
20 25 30

Phe Trp Gly Glu Phe Xaa
35

<210> 230
<211> 68
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (68)
<223> Xaa equals stop translation

<400> 230
Met Gln Thr Ser Gln Gln Leu Cys Cys Leu Ala Ile Ser Ile Leu Ala
1 5 10 15

Thr Leu Leu Pro Ser Gly Ala Ser Glu Glu Arg Ser Gly Leu Arg Pro
20 25 30

Gly Met Arg Leu Gln Glu Arg Glu Gln Arg Arg Ala Thr Phe Gly Ala
35 40 45

Ser Val His Ser Ser Phe Ile Ser Phe Cys Leu Leu His Gly Val Leu
50 55 60

Asn Lys Phe Xaa
65

<210> 231
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (48)
 <223> Xaa equals stop translation

<400> 214
 Met Trp Gly Pro Phe Cys Pro Phe Leu Phe Leu Phe Ser Arg Leu Ser
 1 5 10 15

Asn Ser Leu Thr Lys Asp Ser Met Asn Ile Lys Ala His Ile His Met
 20 25 30

Leu Leu Glu Val Arg Ala Ala His Pro Thr Thr Arg Leu Cys Val Xaa
 35 40 45

<210> 235
 <211> 40
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (40)
 <223> Xaa equals stop translation

<400> 235
 Met Phe Ile Leu Ala Ile Trp Asn Phe Phe Ile Leu Tyr Leu Phe Ser
 1 5 10 15

Thr Val Ala Gly Leu Val Cys Lys Ser Leu Cys Gln Asn Gln Thr Ile
 20 25 30

Phe Lys Thr Ala Leu Cys Phe Xaa
 35 40

<210> 236
 <211> 64
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (64)
 <223> Xaa equals stop translation

<400> 236
 Met Leu Arg Gly Trp Ala Leu Ser Thr Phe Leu Val Cys Ile Leu Gln
 1 5 10 15

Trp Val Arg Ser Leu Thr Ile Arg Leu Ala Ser Ala Leu Ser Val Arg

20 25 30
 Gly Pro Ser Ser Ile Pro Ala Ser Leu Ala Ile Ile Tyr Thr Leu Phe
 35 40 45
 Ile Phe Ser Phe Lys Phe Leu Lys Ile Val Lys Ser Ile Tyr Ile Xaa
 50 55 60

<210> 237
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (61)
 <223> Xaa equals stop translation

<400> 237
 Met Arg Lys Val Thr Ile Ser Lys Lys His Ala Leu Leu Cys Phe
 1 5 10 15

Gln Leu Phe Arg Cys Leu Leu Ser Met Tyr Ile Tyr Ile Thr Phe Val
 20 25 30

Leu Asp Gly Ser Cys Gly Ile His Cys Ser Leu Lys Pro Val Ser Phe
 35 40 45

Pro Cys Thr Tyr His Ser Val His Ser Ser Thr Ser Xaa
 50 55 60

<210> 238
 <211> 63
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (63)
 <223> Xaa equals stop translation

<400> 238
 Met Cys Ala Leu Gly Val Phe Leu Leu Val Pro Tyr Tyr Gly Tyr
 1 5 10 15

Leu Val Leu Leu Phe Phe Pro Cys Val Ala Phe Ser Val Val Ser Gly
 20 25 30

Phe Phe Leu Cys Asn Asp Ser Lys Arg Thr Leu His Ser Cys Ala Leu
 35 40 45

Cys Leu Cys Ala Gly Ile Cys Phe Pro Tyr Met Phe Leu Phe Xaa
 50 55 60

<210> 239

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 239

Met Met Leu His Xaa Lys Leu Leu Leu Phe Xaa Glu Ala Leu Trp Tyr
1 5 10 15Tyr Gly Gly Ala Phe Leu Cys Cys Ala Gly Ser Val Pro Thr Asp
20 25 30Cys Tyr Phe Gly Gly Leu Asp Gln Arg Arg Leu Val Xaa Asp Lys Cys
35 40 45

Thr Glu Lys Ser Thr Gly Leu Leu Xaa

50 55

<210> 240

<211> 182

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (182)

<223> Xaa equals stop translation

<400> 240

Met Thr Val Ile Leu Ile Ile Leu Ile Val Val Met Ala Arg Tyr Cys
1 5 10 15Arg Ser Lys Asn Lys Asn Gly Tyr Glu Ala Gly Lys Lys Asp His Glu
20 25 30Asp Phe Thr Pro Gln Gln His Asp Lys Ser Lys Lys Pro Lys Lys
35 40 45Asp Lys Lys Asn Lys Lys Ser Lys Gln Pro Leu Tyr Ser Ser Ile Val
50 55 60Thr Val Glu Ala Ser Lys Pro Asn Gly Gln Arg Tyr Asp Ser Val Asn
65 70 75 80Glu Lys Leu Ser Asp Ser Pro Ser Met Gly Arg Tyr Arg Ser Val Asn
85 90 95Gly Gly Pro Gly Ser Pro Asp Leu Ala Arg His Tyr Lys Ser Ser Ser
100 105 110Pro Leu Pro Thr Val Gln Leu His Pro Gln Ser Pro Thr Ala Gly Lys
115 120 125Lys His Gln Ala Val Gln Asp Leu Pro Pro Ala Asn Thr Phe Val Gly
130 135 140Ala Gly Asp Asn Ile Ser Ile Gly Ser Asp His Cys Ser Glu Tyr Ser
145 150 155 160Cys Gln Thr Asn Asn Lys Tyr Ser Lys Gln Met Arg Leu His Pro Tyr
165 170 175Ile Thr Val Phe Gly Xaa
180

<210> 241

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals stop translation

<400> 241

Met His Met Tyr Val Trp Val Arg Ala His Leu Val Phe Tyr Leu Phe
1 5 10 15Val Cys Leu Ser Glu Ser Ser Ala Gly Gln Arg Leu Pro Leu Asp Cys
20 25 30Cys Cys Ser Gly Asp Glu Lys Asp Glu Glu Ser Ala Gly Lys Arg Gly
35 40 45Gly Val Gln Glu His Gly Gly His Leu Gly Pro Ser Phe Trp His Thr
50 55 60Lys Pro Glu Phe Ser Cys Xaa
65 70

<210> 242
 <211> 62
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals stop translation

<400> 242
 Met Trp Arg Val Met Leu Ala Trp Leu Ala Met Val Asn Ser Pro Met
 1 5 10 15

Ala Met Glu Ser Gln Val Gly His Ile Ile Ala Val Lys Asp Thr Leu
 20 25 30

Thr Gln Met Thr Leu Pro Gly Ala Arg Ile Glu Pro Val Arg Lys Glu
 35 40 45

Ser Lys Ala Gly Ser Ala Gly Lys Arg Glu Gly Phe Cys Xaa
 50 55 60

<210> 243
 <211> 35
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (35)
 <223> Xaa equals stop translation

<400> 243
 Met Ile Ala Asp Trp Met Phe Phe Val Tyr Ala Leu Cys Ile Asp Val
 1 5 10 15

Thr Ala Asn Glu Phe Cys Leu Thr Leu Thr Phe Leu Thr Ser Lys Val
 20 25 30

Ser Lys Xaa
 35

<210> 244
 <211> 47
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (47)
 <223> Xaa equals stop translation

<400> 244
 Met Glu Pro Val Ala Leu Leu Gln Pro Thr Trp Trp Leu Leu Asn Val
 1 5 10 15

Thr Leu Pro Leu Val Ala Trp Ser Gly Pro Leu Ile Cys Arg Pro Leu
 20 25 30

Leu His Gly Glu Gly Arg Gln Gly Ala Ala Cys Leu Gln Gly Xaa
 35 40 45

<210> 245
 <211> 51
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals stop translation

<400> 245
 Met His Phe Lys Arg Thr Gln Asn His Leu Asn Ile Val Thr Trp Leu
 1 5 10 15

Leu Gln Val Met Ile Ile Val Met Leu Ile Ile Met Arg Ile Ser Cys
 20 25 30

Thr His Gln Pro Val Glu Ser Lys Lys Phe Pro Phe Arg Asn Phe Leu
 35 40 45

Ser Cys Xaa
 50

<210> 246
 <211> 51
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals stop translation

<400> 246
 Met Thr Tyr His Val Val Cys Ala Phe Leu Ile Val Val Leu Lys Lys
 1 5 10 15

Gln Phe Ile Leu Ala Leu Gln Thr Ile Ser Thr Ser Leu Arg Ser Lys
 20 25 30

Gln Ile Leu Met Val Leu Ser Ser Thr Ile Ile Ala Asp Ser Thr Phe
 35 40 45

Tyr Tyr Xaa
 50

<210> 247
 <211> 33

<212> PRT
<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals stop translation

<400> 247

Met Pro Val Pro Leu Trp Leu Val Leu Trp Phe Cys Phe Leu Leu Tyr
1 5 10 15

Val Ala Ser Arg Arg Thr Phe Gly Leu Ala Asn Tyr Met Pro Leu Pro
20 25 30

Xaa

<210> 248

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 248

Met Leu Ile Cys Arg Leu Val Leu Leu Ala Asp Pro Gly Pro Val Asn
1 5 10 15

Phe Met Val Arg Leu Phe Val Ile Val Met Phe Ala Trp Ser Ile
20 25 30

Val Gly Lys Tyr Val Leu Ile Ser Thr Ile Thr Glu Gln Thr Lys Thr
35 40 45

Xaa

<210> 249

<211> 116

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (116)

<223> Xaa equals stop translation

<400> 249

Met Ile Asn Val Tyr Phe Ser Gly Pro Gly Val Leu Thr Pro Leu Asp
1 5 10 15

Asp Gln Gly Ser Pro Cys Pro Pro Ala Pro Phe Ala Ala Leu His Pro

20 25 30

Cys Pro His Pro Ala Gly Ser Gly Val Leu Cys Cys Cys Pro Leu Arg
35 40 45

Leu Cys Arg Pro Cys Arg Ile Leu Phe Thr Gly Pro Leu Leu Thr
50 55 60

Leu His His Leu Leu Cys Glu Thr Ser Pro Ser Gly Ile Gly Val Gly
55 70 75 80

Asn Ile Val Pro Gly Ala Arg Pro Leu Gly Val Asn Pro Val Phe Pro
85 90 95

Ile Ser Ser Cys Asp Leu Gly Gln Val Ala Glu Pro Leu Leu Val Thr
100 105 110

Ile Ser Ser Xaa
115

<210> 250

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 250

Met Thr Asn Val Tyr Ser Leu Asp Gly Ile Leu Val Phe Gly Leu Leu
1 5 10 15

Phe Val Cys Thr Cys Ala Tyr Phe Lys Lys Val Pro Arg Leu Lys Thr
20 25 30

Trp Leu Leu Ser Glu Lys Lys Gly Val Trp Gly Val Phe Tyr Lys Ala
35 40 45

Ala Val Ile Gly Thr Arg Leu His Ala Ala Val Ala Ile Ala Cys Val
50 55 60

Val Met Ala Phe Tyr Val Leu Phe Ile Lys Xaa
65 70 75

<210> 251

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (63)
 <223> Xaa equals stop translation

<400> 251

Met Pro Thr Leu Arg Val Pro Val Leu Ser Val Trp Leu Leu Arg Trp
 1 5 10 15

Trp Arg Val Leu Gly Ala Gly Arg Val Leu Pro Asp Ser Leu Ser Leu
 20 25 30

Ser Pro Pro Pro Thr Gly Cys Gln Thr Lys Pro Glu Arg Gly Trp
 35 40 45

Gly Ser Gln Pro Pro Ser Val Leu Xaa Pro Gln Ala Pro Val Xaa
 50 55 60

<210> 252

<211> 73

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (73)

<223> Xaa equals stop translation

<400> 252

Met Val Tyr Tyr Leu Asn Arg Ala Leu Arg Ala Thr Phe Ser Ile Leu
 1 5 10 15

Phe Ser Val Val Cys Leu Leu Phe Leu Gly Ser Ile Val Asn Cys Phe
 20 25 30

Leu Asn Asp Val Phe Lys Pro Leu Thr Leu Asn Phe Ser Thr Ala Leu
 35 40 45

Ser Ala Trp Arg Lys Glu Ser Ser Ala Trp Asn Ser Leu Gly Leu Leu
 50 55 60

Pro Pro Thr Asp Glu Tyr Pro Thr Xaa
 65 70

<210> 253

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 253

Met Val Val Asn Asp Arg Leu Val Ser Thr Cys Ile Leu Cys Thr Leu

1 5 10 15
 His Ile Pro Leu Phe Phe Leu Ile Phe Leu Val Tyr Glu Val His Leu
 20 25 30

Val Phe Gln Ile Val Ala Asn Leu Gln Lys Ile Phe Gln Tyr Ile Tyr
 35 40 45

Xaa

<210> 254

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> Xaa equals stop translation

<400> 254

Met Ile Ile Leu His Ile Val Val Cys Leu Phe Thr Ile Ser Ile Ile
 1 5 10 15

Glu Glu Gln Lys Glu Glu Ile Leu Cys Ser Thr Lys Ser Gln Ala Glu
 20 25 30

Lys Thr Val Thr His Ile Glu Gln Xaa
 35 40

<210> 255

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals stop translation

<400> 255

Met Thr Leu Ser Val Leu Phe Ala Phe Pro Ile Trp Leu Lys Tyr Leu
 1 5 10 15

Asn Leu Asn Ile Phe Phe Leu Ala Leu Lys Ile Phe Trp Val Ile Leu
 20 25 30

Ser Phe Cys Thr Ser Cys Thr Ser Trp Tyr Ser Gly Ala Arg Val Ile
 35 40 45

Phe Phe Gln Ile Ile Xaa
 50

<210> 256

<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 256
Met Cys Arg Arg Ile Gln Arg Leu Arg Ala Met Leu His Met Leu Leu
1 5 10 15
Val Ser Met Leu Pro Thr Val Gly Lys Pro Asn Met Tyr Gln Pro Pro
20 25 30
Gln Asn Tyr Asp Ile Leu Leu Gln Xaa
35 40

<210> 257
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 257
Met Ala Leu Ala Phe Leu His Leu Asn Ile Ser Xaa Ser Gln Ala Leu
1 5 10 15
Thr Leu Cys Lys Glu Leu Glu Lys Pro Lys Leu Glu Lys Asn Lys Gly
20 25 30
Gly Pro Ala Leu Glu Lys Leu Val Val Xaa
35 40

<210> 258
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 258
Met Ser Gly Thr Thr Trp Thr Ala Ile His Leu Thr Ser Asn Leu Phe
1 5 10 15 20 25 30 35 40 45 50
Gly Ile Leu Ala Leu Pro Gly Asn Gln Ser Ser Gly Ser Asn Ile Glu
20 25 30
Gln Leu Cys Thr Ser Ser Arg Glu Ala Thr Asn Arg Leu Pro Cys Val
35 40 45
Asp Val Gly Ser Xaa
50

<210> 259
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 259
Met Phe Tyr Pro Cys Pro Phe Phe Pro Gln Leu Cys Phe Cys Ile
1 5 10 15
Phe Phe Leu Gly Lys Cys Lys Leu Ser Leu Ser Phe Met Thr Cys Glu
20 25 30
Ile Ser Val Ser Leu Glu Phe Val Arg Arg Arg Gly Asn His Ala Xaa
35 40 45

<210> 260
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 260
Met Asn Ser Trp Ile Leu Asn Met Arg Val Arg Phe Thr Phe Leu Ser
1 5 10 15
Gln Leu Leu Thr Leu Ile Pro Arg Thr Ser His Ser Ala Thr Ser Val
20 25 30
Gly Asn Ser Gln Ile Glu Leu Pro Arg Glu Lys His His Met Thr Tyr
35 40 45
Trp Glu Asn Gly Xaa
50

<210> 261
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 261
 Met Phe Ile Val Ile Cys Lys Ile Leu Leu Phe Leu Ile Leu Val Ala
 1 5 10 15

Arg Pro Phe Arg Thr His Ser Cys Ile Lys Tyr Phe Ala Leu Phe Lys
 20 25 30

Glu Thr His Met Asp Glu Val Arg Met Cys Asn Met Met Ala Ser Gln
 35 40 45

Cys Ser Ser Leu Tyr Leu Xaa
 50 55

<210> 262
 <211> 38
 <212> PRT
 <213> Homo sapiens

<400> 262
 Met Lys Asn Met Asn Ser Arg Tyr Tyr Leu Arg Ala Ile Phe Cys Leu
 1 5 10 15

Tyr Thr Leu Ala Cys Ile Leu Phe Leu Gln Ile Ile Leu Lys Ala Arg
 20 25 30

Cys Gly Gly Ser Arg Leu
 35

<210> 263
 <211> 24
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (24)
 <223> Xaa equals stop translation

<400> 263
 Met Pro Pro Leu Phe Leu Gly Ser Phe Leu Val Leu Trp Leu Gly Gly
 1 5 10 15

Val Val Leu Cys Thr Gly Gly Xaa
 20

<210> 264
 <211> 47
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (47)
 <223> Xaa equals stop translation

<400> 264
 Met Val Cys Ala Leu Gly Val Tyr Val Cys Xaa Ser Ala Pro Thr Ala
 1 5 10 15

Ala Val Pro Lys Pro Ala Lys Gly Thr Ile Cys Leu Lys Met Leu Ser
 20 25 30

Gly Ala Asn Cys Ala Cys Gln Gly Gln Val Thr Arg Gln His Xaa
 35 40 45

<210> 265
 <211> 115
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (115)
 <223> Xaa equals stop translation

<400> 265
 Met Ala Gly Pro Arg Ala Ser Thr Gly Pro Arg Pro Xaa Cys Leu Val
 1 5 10 15

Leu Phe Leu Phe Asn Phe Ile Phe Cys Phe Met Ser Val Cys Pro Pro
 20 25 30

Thr Pro Thr Pro Phe Ser Val Lys Trp Gly Ala Leu Gly Gln Ser Leu
 35 40 45

Leu Pro Pro Ser Leu Ser Gln Asp Leu Pro Pro Arg His Gln Pro Ser
 50 55 60

Leu Trp Thr Arg Gln Arg Ala Asp Arg Val Gly Arg Gly Leu Arg Val
 65 70 75 80

Ala Arg Ala Ser Pro Pro Ala Asn Gly Pro Leu Leu Arg Pro Pro Val
85 90 95

Ser Pro Cys Pro Phe Leu Lys Gln Asn Ala Leu Val Cys Lys Pro Leu
100 105 110

Asp Ala Xaa
115

<210> 266

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (166)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (248)

<223> Xaa equals stop translation

<400> 266

Met His Leu Ala Arg Leu Val Gly Ser Cys Ser Leu Leu Leu Leu
1 5 10 15

Gly Ala Leu Ser Gly Trp Ala Ala Ser Asp Asp Pro Ile Glu Lys Val
20 25 30

Ile Glu Gly Ile Asn Arg Gly Leu Ser Asn Ala Glu Arg Glu Val Gly
35 40 45

Lys Ala Leu Asp Gly Ile Asn Ser Gly Ile Thr His Ala Gly Arg Glu
50 55 60

Val Glu Lys Val Phe Asn Gly Leu Ser Asn Met Gly Ser His Thr Gly
65 70 75 80

Lys Glu Leu Asp Lys Gly Val Gln Gly Leu Asn His Gly Met Asp Lys
85 90 95

Val Ala His Glu Ile Asn His Gly Ile Gly Gln Ala Gly Lys Glu Ala
100 105 110

Glu Lys Leu Gly His Gly Val Asn Asn Ala Ala Gly Gln Ala Gly Lys
115 120 125

Glu Ala Asp Lys Ala Val Gln Gly Phe His Thr Gly Val His Gln Ala
130 135 140

Gly Lys Glu Ala Glu Lys Leu Gly Gln Gly Val Asn His Ala Ala Asp
145 150 155 160

Gln Ala Gly Lys Glu Xaa Glu Lys Leu Gly Pro Ser Ala His His Ala

165 170 175

Ala Gly Gln Ala Gly Lys Glu Leu Gln Asn Ala His Asn Gly Val Asn
180 185 190

Gln Ala Ser Lys Glu Ala Asn Gln Leu Leu Asn Gly Asn His Gln Ser
195 200 205

Gly Ser Ser Ser His Gln Gly Ala Thr Thr Thr Pro Leu Ala Ser
210 215 220

Gly Ala Ser Val Asn Thr Pro Phe Ile Asn Leu Pro Ala Leu Trp Arg
225 230 235 240

Ser Val Ala Asn Ile Met Pro Xaa
245

<210> 267

<211> 178

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (155)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (178)

<223> Xaa equals stop translation

<400> 267

Met Leu Phe Leu Phe Leu Tyr Cys Leu Leu Val Val Leu Pro Phe Lys
1 5 10 15

Leu Thr Pro Lys His Ser Ala Glu Val Leu Leu Ser Ile His Lys Ser
20 25 30

Lys Lys Tyr Leu Cys Lys Val Lys Ala Ala Cys Lys Ile Gln Ala Trp
35 40 45

Tyr Arg Cys Trp Arg Ala His Lys Glu Tyr Leu Ala Ile Leu Lys Ala
50 55 60

Val Lys Ile Ile Gln Gly Cys Phe Tyr Thr Lys Leu Glu Arg Thr Arg
65 70 75 80

Phe Leu Asn Val Arg Ala Ser Ala Ile Ile Ile Gln Arg Lys Trp Arg
85 90 95

Ala Ile Leu Pro Ala Lys Ile Ala His Glu His Phe Leu Met Ile Lys
100 105 110

Arg His Arg Ala Ala Cys Leu Ile Gln Ala His Tyr Arg Gly Tyr Lys
115 120 125

Gly Arg Gln Val Phe Leu Arg Gln Lys Ser Ala Ala Leu Ile Ile Gln
130 135 140
Lys Tyr Ile Arg Ala Arg Glu Ala Gly Lys Xaa Glu Arg Ile Lys Tyr
145 150 155 160
Ile Glu Phe Lys Asn Leu Gln Leu Ser Tyr Lys His Trp Cys Val Val
165 170 175

Gly Xaa

<210> 268
<211> 79
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (79)
<223> Xaa equals stop translation

<400> 268
Met Arg Pro Leu Leu Gly Leu Leu Leu Val Phe Ala Gly Cys Thr Phe
1 5 10 15

Ala Leu Tyr Leu Leu Ser Thr Arg Leu Pro Arg Gly Arg Arg Leu Gly
20 25 30

Ser Thr Glu Glu Ala Gly Arg Ser Leu Trp Phe Pro Ser Asp Leu
35 40 45

Ala Glu Leu Arg Glu Leu Ser Glu Val Leu Arg Glu Tyr Arg Lys Glu
50 55 60

His Gln Ala Tyr Val Phe Leu Leu Phe Cys Gly Ala Tyr Leu Xaa
65 70 75

<210> 269
<211> 81
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (81)
<223> Xaa equals stop translation

<400> 269
Met Lys Leu Ser Gly Met Phe Leu Leu Ser Leu Ala Leu Phe Cys
1 5 10 15

Phe Leu Thr Gly Val Phe Ser Gln Gly Gln Val Asp Cys Gly Glu
20 25 30

Phe Gln Asp Thr Lys Val Tyr Cys Thr Arg Glu Ser Asn Pro His Cys
35 40 45

35 40 45
Gly Ser Asp Gly Gln Thr Tyr Gly Asn Lys Cys Ala Phe Cys Lys Ala
50 55 60
Ile Val Lys Ser Gly Gly Lys Ile Ser Leu Lys His Pro Gly Lys Cys
65 70 75 80
Xaa

<210> 270
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 270
Met Asp Ala Ala Met Pro Val Cys Pro Cys Leu Ile Cys Val Cys Phe
1 5 10 15

Val Leu Arg Leu Gln Ser Gly Val Ala Gly Thr Glu Thr Glu Arg Pro
20 25 30

Pro His Gly Ala Ala Ser Leu His Gln Asp Arg Gly Ala Thr Leu Arg
35 40 45

Leu Cys Phe Phe Pro Ser Gly Val Gly Phe Leu Leu Phe Leu Ser Ile
50 55 60

Leu Pro Trp Ser Xaa
65

<210> 271
<211> 131
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (131)
<223> Xaa equals stop translation

<400> 271
Met Asn Phe Arg Gln Arg Met Gly Trp Ile Gly Val Gly Leu Tyr Leu
1 5 10 15

Leu Ala Ser Ala Ala Phe Tyr Tyr Val Phe Glu Ile Ser Glu Thr
20 25 30

Tyr Asn Arg Leu Ala Leu Glu His Ile Gln Gln His Pro Glu Glu Pro
35 40 45

Leu Glu Gly Thr Trp Thr His Ser Leu Lys Ala Gln Leu Ser
50 55 60

Leu Pro Phe Trp Val Trp Thr Val Ile Phe Leu Val Pro Tyr Leu Gln
65 70 75 80

Met Phe Leu Phe Leu Tyr Ser Cys Thr Arg Ala Asp Pro Lys Thr Val
85 90 95

Gly Tyr Cys Ile Ile Pro Ile Cys Leu Ala Val Ile Cys Asn Arg His
100 105 110

Gln Ala Phe Val Lys Ala Ser Asn Gln Ile Ser Arg Leu Gln Leu Ile
115 120 125

Asp Thr Xaa
130

<210> 272

<211> 85

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (85)

<223> Xaa equals stop translation

<400> 272

Met Trp Val Phe Phe Leu Pro Phe Ser Ile Leu Phe Lys Ile Cys
1 5 10 15

Trp Cys Ile Ser Leu Ser Gln Thr Lys Glu Lys Gln Ser Ser Asn Leu
20 25 30

Met Phe Tyr Phe Phe Cys Ile Cys Thr Tyr Glu Arg Arg Lys Lys
35 40 45

Glu Met Arg Arg Gly Glu Lys Lys Arg Ser Phe Cys Leu Ile Gly Leu
50 55 60

Xaa Gln His Met Ile Ala Val Gln Ala Trp Phe His Glu Gln His Gln
65 70 75 80

Ile Gln Ile Ser Xaa
85

<210> 273

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals stop translation

<400> 273

Met Gln Trp Pro Phe Leu Cys Val Leu Pro Leu Leu Pro Gln Val Trp
1 5 10 15

Arg Ala Gly Ser Leu Leu Arg Ala Leu Glu Leu Tyr Ser Val Leu Leu
20 25 30

Ser His Phe Leu Trp Glu Met Trp Thr Met Ser Leu Lys Glu Pro Glu
35 40 45

Leu Leu Leu Ser Thr Lys Ser Leu Thr Val Trp Arg Xaa Arg Glu Pro
50 55 60

Leu Ser Glu Ile Gly Cys Arg Leu Asn Asn Glu Gly Thr Xaa
65 70 75

<210> 274

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals stop translation

<400> 274

Met Phe Cys Phe Asn Trp Leu Leu Cys Phe Leu Phe Pro Arg Phe Pro
1 5 10 15

Ile Leu Val Cys Arg Lys His Gln Phe Cys Val Tyr Leu Leu Val
20 25 30

Leu Lys Leu Arg Thr Leu Tyr Ala Glu Leu Ile Asp Leu His Leu Cys
35 40 45

Ala Ser Ile Leu Gly Xaa
50

<210> 275

<211> 155

<212> PRT

<213> Homo sapiens

<220>
 <221> SITE
 <222> (150)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (155)
 <223> Xaa equals stop translation

<400> 275
 Met Ala Arg His Gly Leu Pro Leu Leu Pro Leu Leu Ser Leu Leu Val
 1 5 10 15

Gly Ala Trp Leu Lys Leu Gly Asn Gly Gln Ala Thr Ser Met Val Gln
 20 25 30

Leu Gln Gly Gly Arg Phe Leu Met Gly Thr Asn Ser Pro Asp Ser Arg
 35 40 45

Asp Gly Glu Gly Pro Val Arg Glu Ala Thr Val Lys Pro Phe Ala Ile
 50 55 60

Asp Ile Phe Pro Val Thr Asn Lys Asp Phe Arg Asp Phe Val Arg Glu
 65 70 75 80

Lys Lys Tyr Arg Thr Glu Ala Glu Met Phe Gly Trp Ser Phe Val Phe
 85 90 95

Glu Asp Phe Val Ser Asp Glu Leu Arg Asn Lys Ala Thr Gln Pro Met
 100 105 110

Lys Ser Val Leu Trp Trp Leu Pro Val Glu Lys Ala Phe Trp Arg Gln
 115 120 125

Pro Ala Gly Pro Gly Ser Gly Ile Arg Glu Arg Leu Glu His Pro Val
 130 135 140

Leu His Val Ser Trp Xaa Asp Ala Arg Ala Xaa
 145 150 155

<210> 276
 <211> 129
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids
 <220>

<221> SITE
 <222> (103)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (104)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (112)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (114)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (124)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals stop translation

<400> 276
 Met Ala Tyr Arg His Phe Trp Met Leu Val Leu Phe Val Ile Phe Asn
 1 5 10 15

Ser Leu Gln Gly Leu Tyr Val Phe Met Val Tyr Phe Ile Leu His Asn
 20 25 30

Gln Met Cys Cys Pro Met Lys Ala Ser Tyr Thr Val Glu Met Asn Gly
 35 40 45

His Pro Gly Pro Ser Thr Ala Phe Phe Thr Pro Gly Ser Gly Met Pro
 50 55 60

Pro Ala Gly Xaa Glu Ile Ser Lys Ser Thr Gln Asn Leu Asn Arg Trp
 65 70 75 80

Tyr Gly Gly Arg Cys His Leu Thr Gly Arg Glu His Pro Ser Lys Gln
 85 90 95

Gly Xaa Gln Gly Gln Pro Xaa Xaa Lys Ala Lys Ser Thr Lys Trp Xaa
 100 105 110

His Xaa Pro Val Leu Trp Arg Ile Trp Pro Gly Xaa Thr Asp Ser Arg
 115 120 125

Xaa

<210> 277
 <211> 84
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (84)
 <223> Xaa equals stop translation

<400> 277

Met Ala Ser Pro Gly Trp His Leu Ser Cys Arg Pro Thr Gly Leu Val
 1 5 10 15

Ser Ile Phe Leu Leu Cys Ala Pro Ala Tyr Leu His Ser Phe Val Met
 20 25 30

Thr Ser Ile Thr Leu Ile Ser Thr Lys Ile Cys Ser Pro Thr Lys Leu
 35 40 45

Arg His Arg Thr His Phe Leu Tyr Gly Ser Ile Met Glu Leu Tyr Pro
 50 55 60

Thr Leu Thr Phe Pro Met Thr Thr Asp Val Glu Asn Leu Asn Leu Asp
 65 70 75 80

Ser Ser Arg Xaa

<210> 278
 <211> 86
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (86)
 <223> Xaa equals stop translation

<400> 278

Met Gly Cys Arg Gly Asn Lys Leu Phe Val Leu Ser Tyr Cys Thr Cys
 1 5 10 15

Leu Thr Trp Leu Leu Gly Thr Lys Ser Gln Lys Asn Pro Phe Gln Val
 20 25 30

Cys Met Ser Gly Gly Trp Ala Val Ser Arg Leu Glu Thr Gly Phe Gln
 35 40 45

Ala Leu His Asp Gly Arg Ala Ser Ser Pro Leu Ser Ala Ala Cys Val
 50 55 60

Leu Asp Arg Thr Val Ala Arg Arg Trp Lys Pro Pro Ser Val Pro Leu
 65 70 75 80

Ala His His Thr Lys Xaa
 85

<210> 279
 <211> 96
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (96)
 <223> Xaa equals stop translation

<400> 279

Met Pro Trp Leu Thr Ile Leu Arg Phe Leu Gln Ala Ser Gly His Val
 1 5 10 15

Arg Ala Gln Asp Leu Ala Leu Leu Gly Asp Thr Ser Val Cys Ile Arg
 20 25 30

Cys Gly Cys Gly Gly Cys Ser Leu Ser Ile Ala Asn Tyr Glu Trp Val
 35 40 45

Pro Leu Arg Arg Lys Asp Cys Lys Arg Tyr Glu Thr Ser Glu Lys Thr
 50 55 60

Ser Cys Leu Leu Leu Pro Ser Ala Cys Ser Arg Gln Asn Ala Val Gly
 65 70 75 80

Phe Ser Arg Leu Pro Val Pro Lys Leu Ser Cys Leu Leu His Gly Xaa
 85 90 95

<210> 280
 <211> 98
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (70)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (98)
 <223> Xaa equals stop translation

<400> 280

Met Ile Leu Leu Phe Leu Leu Ser Leu Ser Leu Leu Ser Leu
 1 5 10 15

Ser Leu Ser Phe Ser Pro Leu Asn Cys Leu Phe Ser Phe Trp Gly Ser
 20 25 30

Pro Pro Thr Arg Cys Ser Trp Cys Arg Leu Gly Ser Gln Gly Glu Ala

35 40 45
 Trp Trp Pro Gly Leu Gly Arg Gly Thr Leu Ser Leu Ala Lys Ala Glu
 50 55 60
 Ser Glu Ile Val Val Xaa Leu Cys Lys Ser Tyr Phe Gln Tyr Phe Leu
 65 70 75 80
 Ala Ala Ser Glu Val Ser Leu Thr Pro Cys Arg Ala Leu Leu Leu
 85 90 95
 Ser Xaa

<210> 281
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 281
 Met Ser Val Trp Pro Arg Ser Thr Leu Leu Phe Cys Leu Leu Ser Leu
 1 5 10 15

Ser Thr Gly Leu Phe Leu Asp Lys Leu Gly Ile Ile Ile Pro Ile Leu
 20 25 30

Leu Cys Gly Trp Lys Leu Asn Val Ile Met Met Cys Val Arg Cys Leu
 35 40 45

His Ser Ala Trp Arg Tyr Xaa
 50 55

<210> 282
 <211> 72
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (72)
 <223> Xaa equals stop translation

<400> 282
 Met Arg Ile His Phe Lys Ile Leu Val Leu Val Ile Tyr Phe Ile Leu
 1 5 10 15

Leu Gly Ser Phe Ser Asp Arg Cys Ser Leu Leu Asp Cys Lys Ser Arg
 20 25 30

Ile Gln Arg Ile Phe Ile Cys Asn Ile Leu Asn Leu Ser Leu Val Ser
 35 40 45

Cys His Leu Cys Arg Tyr Ser Phe Asp Cys Leu Thr Arg Gly Lys Cys
 50 55 60
 Phe Pro Leu Ser Phe Pro Ala Xaa
 65 70

<210> 283
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 283
 Met Tyr Ala Ala Ala Leu Ser Thr Ala Pro Ser Leu Phe Phe Leu His
 1 5 10 15

Leu Cys Leu Leu Lys Thr Leu Ile Leu Phe Ser Leu Ser Ser Ile Pro
 20 25 30

Leu Pro Pro Leu Leu Tyr Ser Tyr Asp Leu His Xaa
 35 40 45

<210> 284
 <211> 56
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (56)
 <223> Xaa equals stop translation

<400> 284
 Met Leu Pro Ser Asn Trp Ser Gly Thr Trp Ala Leu Ile Gln Leu Ser
 1 5 10 15

Ile Pro Phe Thr Leu Ala Phe His Gln Pro Asn Lys Asn Gln Leu Thr
 20 25 30

Gln Lys Lys Arg Lys Ala Pro Gln Gly Ser Phe Asp Pro Asp Ile Tyr
 35 40 45

Ile Asp Ala Ile Gly Val Pro Xaa
 50 55

<210> 285
 <211> 49
 <212> PRT
 <213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 285

Met Ser Thr Leu Arg Arg Met Ala Leu Leu Tyr Ile Glu Thr Pro Leu
1 5 10 15Leu Arg Ala Leu Met Val Gln Gly Pro Arg Leu Val Ser Val Arg Ala
20 25 30Ala Met His Gly Lys Cys Gly Gly Arg Ala Leu Trp Ala Leu Trp Gln
35 40 45

Xaa

<210> 286

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 286

Met Val Cys Val Arg Cys Val Trp Tyr Val Trp His Val Phe Gly Val
1 5 10 15Tyr Gly Asn Ile Leu Trp Ile Arg Thr Cys Gly Leu Phe Lys Asp Leu
20 25 30Ser Phe Cys Ala Leu Lys Ser Glu Met Xaa
35 40

<210> 287

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 287

Met Arg His Val Ala Ile Val Thr Met Ile Val Val Leu Ser Pro Pro
1 5 10 15Val Leu Ala Ser Ser Leu Lys Pro Pro Leu Phe Ile Asp Thr Tyr Phe
20 25 30

Met Phe Gly Lys Arg Cys Ser Arg Trp Asp Thr Pro Ala Cys Ser Lys

35 40 45

Xaa

<210> 288

<211> 110

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (110)

<223> Xaa equals stop translation

<400> 288

Met Trp Ala Glu Leu Lys Leu Ser Trp Gly Arg Ala Ala Ile Ala
1 5 10 15Val Trp Val Cys Leu Arg Arg Val Val Arg Gly Gly His Ser Pro Pro
20 25 30Ala Gly Gln Gly Gly Gln Gly Val Lys Val Gln Trp Gly Val Gln
35 40 45Gly Ser Gly Ser Gly Gln Pro Glu Asp Met Arg Trp Glu Lys Leu His
50 55 60Val Arg Ile Leu Met Gln Gly Met His Gly Ala Pro Gln Asp Asp Ile
65 70 75 80Arg Ser Val His Gly Ser Thr Ala Phe Pro Asp Cys Leu His Leu Pro
85 90 95Cys Arg Pro Thr Cys Pro Gly Val Ser Phe Gly Ser Gly Xaa
100 105 110

<210> 289

<211> 64

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals stop translation

<400> 289

Met Leu Leu Val Ser Cys Phe Met Ser Ile Tyr Phe Leu Ser Pro Leu
1 5 10 15Leu Leu Pro Leu His Gly Ser Pro His Pro His Ser Tyr Leu Cys Phe
20 25 30Ala Val Cys Arg Thr Ser Trp Ser Leu Ser Glu Lys Thr Cys Asn Phe
35 40 45

Pro Asn Glu Met Leu Gln Leu Pro Ile Phe Leu Lys Ser Ile Tyr Xaa
50 55 60

<210> 290
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 290
Met Gly Leu Leu Leu Leu Leu Gly Cys Trp Thr His Ile Phe
1 5 10 15
Phe Thr Asn Gly Met Ile Tyr Trp Tyr Leu Glu Gly His Pro Ile Leu
20 25 30
Asn Glu Ile Leu Phe Ile Leu His Phe Xaa
35 40

<210> 291
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 291
Met Ile Asn Cys Val Cys Val His Ala Cys Val Arg Ala Cys Gly Leu
1 5 10 15
Leu His Ser Leu Val Leu Leu Leu Ser Leu Ser Leu Ser Ala Leu
20 25 30

Phe Ile Pro Trp Asp Thr Glu Ile Phe Lys Xaa
35 40

<210> 292
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)

<223> Xaa equals stop translation

<400> 292
Met Leu Phe Phe Cys Leu Leu Met Lys Met Leu Gly Pro Ser Arg Leu
1 5 10 15

Pro Phe Leu Ala Leu Thr Leu Cys Arg Phe Ile Leu Tyr Phe Gln Phe
20 25 30

Cys Tyr Leu Ile Ser Asp Ser Ser Pro Asp His Ser Xaa
35 40 45

<210> 293
<211> 57
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (57)
<223> Xaa equals stop translation

<400> 293
Met Cys Phe Thr Gln Phe Ser Arg Ile Phe Phe Leu Thr Ser Ser Leu
1 5 10 15
Thr Leu Ala Ala Cys Ala Asn His Ile Leu Ala Ala Tyr Ser Ser Ser
20 25 30
Leu Ala Asp Arg Cys Val Gly Glu Lys Ser Leu Ile Val Ile Val Pro
35 40 45

Glu Arg Ser Phe Gln Thr His Phe Xaa
50 55

<210> 294
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (75)
<223> Xaa equals stop translation

<400> 294
Met Met Tyr Val Gln Ser Ala Ile Met Ser Leu Gln His Leu Leu Val
1 5 10 15
Leu His Arg Val Ile Ile Ile Ser Met His Phe Ala Phe Gly Asn Gly
20 25 30

Cys Thr Phe Lys Ile Leu Val Gln Cys Ala Ile Arg Lys Tyr Thr Ser
35 40 45

Lys Met Ile Ser Arg Ile Ile Gln Met Tyr Leu Thr Thr Met Asp Leu

50 55 60

Phe His Pro Met Lys Leu Gln Arg Lys Leu Xaa 75
65 70

<210> 295

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 295

Met Ile Ile Pro Lys Phe Tyr Leu Phe Lys Leu Leu Leu Leu Gln 15
1 5 10

Lys Ile Thr His Phe Ile Cys Gly Lys Thr Leu Asn Asn Leu Asn Phe 30
20 25

Arg Cys Glu Ser Tyr Phe Leu Phe Leu Tyr Cys Ala Tyr Ile 45
35 40

Leu Tyr Xaa 50

<210> 296

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 296

Met Thr Gln Glu Ile Leu Val Phe Ser Ile Gln Val Leu Ser Ser 15
1 5 10

Leu Arg Leu Leu Gly Leu Trp Phe Phe Met Glu Asn Arg Leu Cys Ser 30
20 25

Gly Ile Val Glu Gln Arg Arg Leu Leu His Leu Asn Xaa 45
35 40

<210> 297

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 297

Met Pro Thr Leu Gly Asp Ala Leu Ile Leu Tyr Leu His Leu Val Leu 15
1 5 10

Gly Val Ala Gly Val Leu Gln Pro Pro Gly Pro Arg Pro Ser Gln Ala 30
20 25

Leu Gly Pro Thr Gly Asp Arg Ala Pro Gly Lys Trp Asn Arg Ser Xaa 45
35 40

<210> 298

<211> 55

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals stop translation

<400> 298

Met Ala Trp Cys Leu Leu Ser Val Phe Leu Arg Ala Leu Cys Ala 15
1 5 10

His Ser Ser Thr Ala Tyr Lys Cys Val Leu Cys Ser Pro Arg Ser Pro 30
20 25

Trp Leu Val Glu Ala Asn Phe Trp Leu Asp Phe Tyr Gly Lys Ser Tyr 45
35 40

Phe Met Ser Pro Lys His Xaa 55
50

<210> 299

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals stop translation

<400> 299

Met Gln Met Thr Val Val Trp Tyr Val Ile Thr Ala Ile Ile Trp Trp 15
1 5 10

Arg Met Ser Met Cys Glu Ala Leu Ser Gln Asn Cys Phe Xaa 30
20 25

<210> 300
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation
<400> 300
Met Pro Leu Gly Val Val Pro Arg Ala Val Trp Ser Thr Leu Ala Trp
1 5 10 15
Val Cys Ile Ile Leu Gln Thr Leu Lys Thr Ser Leu Phe Cys Gln Thr
20 25 30
Thr Phe Cys Gly Gln Pro Gln Asp Ser Gly Phe Phe Gln Gly Ile Leu
35 40 45
Asp Val Cys Val Leu Val Lys Gln Ala Val Ile Arg Leu Asn His Asn
50 55 60
Pro Gln Asp Leu Leu Asp Ser Asp Xaa
65 70
<210> 301
<211> 37
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (37)
<223> Xaa equals stop translation
<400> 301
Met Leu Arg Leu Gln Val Leu Leu Leu Phe Ser Lys Val Thr Asp
1 5 10 15
Gln Ile Ile Thr Gln Ile Ile Gln Gln Asn Arg Ser Gln Ile Lys Asn
20 25 30
Asn Ile Ile Phe Xaa
35
<210> 302
<211> 49
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 302
Met Arg Pro Val Leu Arg Arg Thr Phe Leu Leu Thr Leu Phe Ser Val
1 5 10 15
Ile Ala Leu Thr Lys Ile Lys His Asp Phe Phe Ile Met Cys Ser His
20 25 30
Met Gln Cys Ile Pro Arg Val Phe Leu Lys His Gln Phe Asn Asn Ile
35 40 45
Xaa

<210> 303
<211> 42
<212> PRT
<213> Homo sapiens
<400> 303
Met Phe Tyr Thr Thr Leu Cys Lys Met Phe Gln Tyr Leu His Ile Leu
1 5 10 15
Ser Leu Ser Phe Cys Phe Ala Leu Ile Trp Trp Ser Gln Ser Phe Leu
20 25 30
Trp Leu Ser Asn Leu Val Arg Leu Arg His
35 40

<210> 304
<211> 54
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation
<400> 304
Met Ile Leu Leu Ile Ser Gln Cys Pro Leu Ser Ile Phe Ala Pro
1 5 10 15
Phe Ala Leu Pro Pro Lys Gly His Cys Gly Ser Phe Ser Asp Phe His
20 25 30
Ser Gln Val Thr Leu His Lys Asn Ser Lys Leu Ile Phe Arg Ser His
35 40 45
Lys Ser Ile Leu Leu Xaa
50

<210> 305
<211> 76
<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals stop translation

<400> 305

Met Leu Ala Ala Glu Leu Ile Cys Cys Pro Ser Leu His Ile Phe Phe
1 5 10 15

Phe Ala Ala Phe Ser Leu Trp Gln Cys Thr Val Leu Thr Met Pro Phe
20 25 30

Lys Asn Val Pro Tyr Cys Ile Ser Ile Leu Arg Arg Asp Arg Thr Lys
35 40 45

Lys Tyr Ile Ala Gln Ile Ile Phe Tyr Phe Ile Asp Asn Asp Lys Glu
50 55 60

Tyr Phe Leu Asn Pro Ile Lys Ile Asp Phe Asn Xaa
65 70 75

<210> 306

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (63)

<223> Xaa equals stop translation

<400> 306

Met Phe Phe Arg Met Gln Val Cys Glu His His Gly Phe Trp Val Ile
1 5 10 15

Leu Leu Leu Leu Ser Leu Lys Met Glu Ile Pro Leu Ala Ala Tyr Pro
20 25 30

Thr Ala Glu Tyr Ser Ser Ile Gly Ser Gly Phe Thr Pro Leu His Pro
35 40 45

Ser Arg Thr Phe Thr Gln Ala Ser Pro Leu Pro Ser Ile Phe Xaa
50 55 60

<210> 307

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals stop translation

<400> 307

Met Asn Val Phe Val Gly Pro Leu Ser Val Ala Ile Val Ile Phe Cys
1 5 10 15

Trp Ile Thr Met Tyr Trp Val Ser Ile Val Met Gly Gln Gly Arg Gly
20 25 30

Gln Tyr Thr Trp Arg Thr Ile Leu Ser Thr Ser Thr Pro Ser Val Cys
35 40 45

Ser Xaa

50

<210> 308

<211> 103

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (103)

<223> Xaa equals stop translation

<400> 308

Met Glu His Trp Ile Pro Pro Glu Val Pro Leu Ala Gly Leu Arg Arg
1 5 10 15

Leu Leu Leu Asp Arg Leu Val Phe Ala Pro Ala Phe Leu Met Leu Phe
20 25 30

Phe Leu Ile Met Asn Phe Leu Glu Gly Lys Asp Ala Ser Ala Phe Ala
35 40 45

Ala Lys Met Arg Gly Gly Phe Trp Pro Ala Leu Arg Met Asn Trp Arg
50 55 60

Val Trp Thr Pro Leu Gln Phe Ile Asn Ile Asn Tyr Val Pro Leu Lys
65 70 75 80

Phe Arg Val Leu Phe Ala Asn Leu Ala Ala Leu Phe Trp Tyr Ala Tyr
85 90 95

Leu Ala Ser Leu Gly Lys Xaa
100

<210> 309

<211> 45

<212> PRT

<213> Homo sapiens

<400> 309

Met Arg Phe Ile Ser Gln Gln Ser Cys Glu Cys Val Arg Pro Cys Met
1 5 10 15

Asp Val Tyr Val Cys Val Tyr Ile Ser Ile His Val Tyr Met Asp Ala
20 25 30

His Val Tyr Leu Cys Arg Ile Cys Lys Thr Asn Met Arg
35 40 45

<210> 310

<211> 53

<212> PRT

<213> Homo sapiens

<400> 310

Arg Ile Leu Arg Trp Val Asn Cys Met Ala Cys Asp Leu Tyr Leu Asn
1 5 10 15

Lys Ala Val Ser Val Cys Ala His Val Trp Met Cys Met Cys Val Tyr
20 25 30

Ile Ser Leu Tyr Met Tyr Thr Trp Met Pro Met Cys Ile Tyr Val Gln
35 40 45

Tyr Val Lys Gln Thr
50

<210> 311

<211> 59

<212> PRT

<213> Homo sapiens

<400> 311
Asn Pro Gln Asn Gln Leu Gln Ile Ser Phe Pro Pro Arg Arg Gln Lys
1 5 10 15

Met Lys Leu Thr Leu Asp Leu Gln Val Ser Gln Ser Ser Leu Val His
20 25 30

Ser Leu Leu Ser Ser Asp Phe Phe Ser Val Ser Lys Gln Gly Cys Leu
35 40 45

Trp Lys Pro Ile Leu Leu Pro Ser His Phe Leu
50 55

<210> 312

<211> 47

<212> PRT

<213> Homo sapiens

<400> 312
Leu Gln Thr Gln Ile Ser Asn Tyr Leu Met Phe Val Leu His Ile Leu
1 5 10 15

His Arg Tyr Thr Trp Ala Ser Met Tyr Thr Cys Ile Gln Ile Tyr Thr
20 25 30

His Thr Tyr Thr Ser Ile His Gly Arg Thr His Ser Gln Leu Cys
35 40 45

<210> 313

<211> 45

<212> PRT

<213> Homo sapiens

<400> 313

Ile His Met Gly Ile His Val Tyr Met Tyr Arg Asp Ile Tyr Thr His
1 5 10 15

Ile His Ile His Thr Trp Ala His Thr Leu Thr Ala Leu Leu Arg Tyr
20 25 30

Lys Ser His Ala Ile Gln Leu Thr His Leu Asn Ile Arg
35 40 45

<210> 314

<211> 41

<212> PRT

<213> Homo sapiens

<400> 314
Met Lys Trp Ile Phe Thr Val Leu Ile Leu Thr Ser Cys Phe Thr
1 5 10 15

Ala Gly Ile Cys Gln Asp Gly Ile Cys Ser Arg Ile Gln Leu Arg Asp
20 25 30

Lys Ile Val Gln Ser Ala Phe Arg Gln
35 40

<210> 315

<211> 81

<212> PRT

<213> Homo sapiens

<400> 315
Lys Pro Cys Cys Pro Ser Val Ser Asn Arg Ser Ser Val Gln Met His
1 5 10 15

Gln Leu Pro Ile Gln Phe Leu Gly Gln Phe Gln Ala His Cys Ile Gly
20 25 30

Phe Cys Arg Ser Phe Leu Gln Thr Phe Tyr Thr His Asp Pro Arg Ala
35 40 45

Met His Ser Phe Leu Ser Ser Ile Ser Ser Pro Ser Leu Pro Phe Gly
50 55 60

Phe Ser Arg Met Thr Ser Gln Ile Asn His Leu His Pro Ser Pro Leu
65 70 75 80

Cys

<210> 316
<211> 21
<212> PRT
<213> Homo sapiens

<400> 316

Ser Val Phe Lys Ile Asn Leu Lys Ser Phe Lys Gln His Glu Pro Trp
1 5 10 15

Trp Pro Asn Arg Ser
20

<210> 317
<211> 135
<212> PRT
<213> Homo sapiens

<400> 317

Gly Thr Arg Ser Phe Ser Val Pro Ser Tyr Leu Arg Leu Thr Gly Ser
1 5 10 15

Leu Met Cys Tyr Leu Leu Leu Leu Ile Gln Thr Ala Glu Leu Leu
20 25 30

Ile His Pro Gln Gly Leu Gln Ala Val Ser Asn Gly Glu Ser Ala Leu
35 40 45

Lys Gly Thr Arg Pro Thr Phe Ser Ser Pro Phe Ile Leu Val Thr Glu
50 55 60

Gly Arg Lys Glu Trp Glu Gly Val Phe Leu Ser Ser Gly Trp Lys Gly
65 70 75 80

Asn Thr Leu Ser Asn Tyr Tyr Ile Ser Leu Val Phe Tyr Tyr Ser Arg
85 90 95

Ile Leu Gln Pro Tyr Phe Tyr Cys Leu Trp Gly Lys Leu Glu Met Val
100 105 110

Thr Leu Ile Arg Ser Val Trp Arg Gly Ile Asn Gly Gly Asp Lys Ile
115 120 125

Ser Val Gly Phe Gly Lys Cys
130 135

<210> 318
<211> 38
<212> PRT
<213> Homo sapiens

<400> 318

Trp Met Glu Arg Lys His Thr Val Lys Leu Leu Tyr Leu Leu Gly Phe
1 5 10 15

Leu Leu Gln Asn Ser Pro Ala Ile Phe Leu Leu Ser Met Gly Glu Val
20 25 30

Gly Asp Gly Asp Leu Asp
35

<210> 319
<211> 23
<212> PRT
<213> Homo sapiens

<400> 319

Ser Asn Gly Glu Ser Ala Leu Lys Gly Thr Arg Pro Thr Phe Ser Ser
1 5 10 15

Pro Phe Ile Leu Val Thr Glu
20

<210> 320
<211> 24
<212> PRT
<213> Homo sapiens

<400> 320

Leu Ser Asn Tyr Tyr Ile Ser Leu Val Phe Tyr Tyr Ser Arg Ile Leu
1 5 10 15

Gln Pro Tyr Phe Tyr Cys Leu Trp
20

<210> 321
<211> 131
<212> PRT
<213> Homo sapiens

<400> 321

Glu Lys Asp Phe Met Gln Gly Ser Asp Ala Gly His Gly Thr His
1 5 10 15

Ile Tyr Arg Ala Leu Val Gln Trp Pro Leu Ala Trp Val Phe Tyr Leu
20 25 30

Ser His Ala Lys Thr His Trp Gly Glu Glu Leu Arg Phe Ser Phe Arg
35 40 45

Arg Lys Asn Leu Arg Leu Arg Glu Ala Met Arg His Glu Thr Cys Gln
50 55 60

Val Thr Gln Leu Val Ala Gly Lys Ala Asp Ser Asn Leu Cys Leu Arg
65 70 75 80

Asp Ser Glu Thr Trp Phe Trp Pro Pro Leu Trp Ala Ala Cys Ser Ser
85 90 95

Leu Gln Ala Thr Ala Cys Arg Leu Ser Ser Pro Ser Lys Gly Leu Gly
100 105 110

Ala Ser Arg Glu Cys Pro Trp Leu Ala Ser Gly Arg Ala Leu Val
115 120 125

Ser Phe Leu
130

<210> 322
<211> 69
<212> PRT
<213> Homo sapiens

<400> 322
Ser Leu Arg Val Lys Gly Arg Lys Pro Arg Leu Leu Tyr His Ser Pro
1 5 10 15

Ala Arg Gly Thr Leu Trp Met Leu Pro Gly Leu Cys Asp Cys Leu Ile
20 25 30

Cys Arg Gln Trp Leu Val Glu Arg Ser Arg Leu Pro Arg Val Gly Ala
35 40 45

Arg Thr Arg Phe Gln Ser Pro Ser Asp Thr Gly Trp Ser Gln Leu Cys
50 55 60

Gln Leu Pro Ala Val
65

<210> 323
<211> 26
<212> PRT
<213> Homo sapiens

<400> 323
Glu Arg Ser Arg Leu Pro Arg Val Gly Ala Arg Thr Arg Phe Gln Ser
1 5 10 15

Pro Ser Asp Thr Gly Trp Ser Gln Leu Cys
20 25

<210> 324
<211> 33
<212> PRT
<213> Homo sapiens

<400> 324
Lys His Ala Phe Leu Met Ala His Gln Phe Cys Val Leu Ser Leu Ala
1 5 10 15

Met Gln Trp Ser Ser Cys Phe Gln Leu Val Ala Leu Pro Tyr Leu Ser
20 25 30

Leu

<210> 325
<211> 51
<212> PRT
<213> Homo sapiens

<400> 325
Met Arg Pro Leu Cys Val Leu Leu Pro Trp Pro Cys Trp Gln Trp Gly
1 5 10 15

Gly Leu Gly Ser Ala Ser Pro Ile Arg Pro Gln Ala Pro Pro Gly Gln
20 25 30

Ala Ala His Ala Val Pro Leu Pro Arg Ala Gln His Leu Ala Arg
35 40 45

Ser Arg Gln
50

<210> 326
<211> 52
<212> PRT
<213> Homo sapiens

<400> 326
Ala Arg Gly Leu Arg Ser Pro His Gly Ala Ala Gly Val Val Arg Gly
1 5 10 15

Asp Gly Gly Gly Lys Lys Gly Glu Asp Pro Tyr Ser Pro Ile Leu Phe
20 25 30

Gln Ser Glu Arg Ile Pro Arg Leu Ile Tyr Leu Pro Val Ile Ser Ser
35 40 45

Glu Glu Asn Ser
50

<210> 327
<211> 57
<212> PRT
<213> Homo sapiens

<400> 327
Lys Ser Leu Ser Cys Ser Phe Leu Phe Leu Ala Phe Trp Leu Arg Arg
1 5 10 15

Met Gly Gln Thr Met Cys Val Cys Val Cys Val Cys Val Cys
20 25 30

Val Arg Thr Trp Val Tyr Leu Tyr Glu Pro Val Lys Phe Arg Ser Pro
35 40 45

Leu Ile Tyr Val Asn Leu Leu Pro Thr Ser
50 55

<210> 328

<211> 80
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 328

Lys Leu Gly Phe Thr Met Leu Ala Arg Leu Val Ser Asn Ser Xaa Thr
1 5 10 15

Ser Gly Asp Leu Pro Ser Ser Ala Ser Gln Asn Ala Gly Ile Lys Gly
20 25 30

Met Ser Tyr Arg Ala Trp Pro Tyr Ser Tyr Phe Leu Ile Arg Lys Asn
35 40 45

Lys Gln Thr Asn Lys Gln Thr Lys Thr Asn Pro Gln Leu Gly Glu Asn
50 55 60

Lys His Cys Arg Asn Leu Lys Val Ser Trp Ser Lys Asn Tyr Phe Leu
65 70 75 80

<210> 329
<211> 27
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 329
Glu Arg Gly Gln Gly Gly Ser Ser Arg Asn Val Ala Gly Ser Asp Leu
1 5 10 15

Val Phe Pro Ala Val Phe Val Ser Xaa Leu Cys
20 25

<210> 330
<211> 166
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (90)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (113)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (126)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (150)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 330
Gly Ser Pro Gln Gly Pro Ser Val Ala Leu Gly Ser Arg Gln Cys Trp
1 5 10 15

Ser Arg Pro Leu Arg Arg Gly Gly Arg Gly Ala Ala Val Glu Met Trp
20 25 30

Arg Gly Pro Thr Trp Cys Phe Arg Pro Ser Leu Cys Leu Cys Cys Val
35 40 45

Cys Gly Val Ser Phe Gly Leu Tyr Val Pro His Gly Phe Ser Leu Ser
50 55 60

Met Cys Val Ser Ala Pro Gly Ser Ala Trp Leu Ser Leu Val Tyr Ser
65 70 75 80

Ile Cys Leu Ala Arg Gly Ser Met Ser Xaa Arg Xaa Ser Ser Arg Xaa
85 90 95

Ser Leu Val Ala Ser Gly Ala Ser Val Leu Leu Val Cys Phe Trp Val
100 105 110

Xaa Ala Asp Pro Gly Val Gly Val Ser Val Pro Arg Ala Xaa Val Ser
115 120 125

Gly Leu Trp Trp Cys Val Ser Pro Ser Ala Cys Leu Xaa Leu Ala Pro
130 135 140

Thr Lys Pro Pro Xaa Leu Ser Phe Ser Leu Ser Ile Phe Pro Phe

145 150 155 160
Ser Ser Asn Pro Ser Lys
165

<210> 331
<211> 118
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 331
Thr Ile Ala Ser Leu Gln Pro Thr Ala Leu Asn His Leu Ile Trp Arg
1 5 10 15

Gly Trp Lys Arg Lys Gly Arg Leu Arg Glu Arg Lys Arg Gly Xaa Gly
20 25 30

Gly Ala Trp Leu Gly Pro Xaa Arg Gly Arg Gln Met Asp Ser His Thr
35 40 45

Thr Arg Asp Gln Arg Gln Xaa Leu Gly Glu Gln Arg His Pro Leu Leu
50 55 60

Gly Leu Xaa Ala Pro Arg Ser Lys Pro Thr Lys Gln Met Pro Gln Met
65 70 75 80

Gln Pro Gly Xaa Pro Glu Lys Lys Xaa Xaa Leu Thr Trp Asn His Gly
85 90 95

Leu Asp Arg Trp Asn Thr Gln Gly Thr Ala Arg Gln Ser Leu Gly Gln
100 105 110

Lys His Thr Trp Arg Asp
115

<210> 332
<211> 21
<212> PRT
<213> Homo sapiens

<400> 332
Ala Arg Gly Pro Gly Thr Glu Gly Cys Glu Pro Trp Leu Gln Gln
1 5 10 15

Asp Arg Arg Glu Arg
20

<210> 333
<211> 59
<212> PRT
<213> Homo sapiens

<400> 333
Met Ser Ser Gly Thr Asn Ser Phe Phe Thr Leu Met Ala Leu Asn Ser
1 5 10 15

Pro Thr Gly Asp Ser Gly Ser Arg Ile Thr Val Ser Pro Arg Val
20 25 30

His Pro Val Lys Ser Gly Arg Gly Arg Ala Ser Asp Leu Leu Thr
35 40 45

Arg Phe Leu Ala Pro Arg Ser Ala Leu Trp Ser
50 55

<210> 334
<211> 26
<212> PRT
<213> Homo sapiens

<400> 334
His Glu Tyr His Leu Leu Ser Ser Arg His Ile Leu Gly Ser Val Leu
1 5 10 15

Arg Leu Asp Val Cys Ser Ala Leu Trp Ser
20 25

<210> 335
<211> 82
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 335
Phe Ile Leu Phe Ile Leu Glu Tyr Asp Met Leu Trp Lys Ser Leu Tyr
1 5 10 15

Thr Asn Ser Ser Ala Tyr Gly Tyr Val Ile Ala Ser Tyr Phe Cys Leu
20 25 30

Leu Gly Ile Lys Leu Leu Val Lys Gln Lys Lys Xaa Lys Lys Lys Thr
35 40 45

Arg Gly Gly Ala Arg Xaa Pro Ile Arg Pro Xaa Val Glu Ser Tyr Tyr
50 55 60

Lys Ser Xaa Ala Val Val Leu Leu Gln Arg Arg Gly Leu Gly Lys Asn Leu
65 70 75 80

Gly Gly

<210> 336
<211> 102
<212> PRT
<213> Homo sapiens

<400> 336
Arg Val Ser Ser His Leu Phe Arg Leu Phe Gly Gly Leu Ile Leu Asp
1 5 10 15

Ile Lys Arg Lys Ala Pro Phe Phe Leu Ser Asp Phe Lys Asp Ala Leu
20 25 30

Ser Leu Gln Cys Leu Ala Ser Ile Leu Phe Leu Tyr Cys Ala Cys Met
35 40 45

Ser Pro Val Ile Thr Phe Gly Gly Leu Leu Gly Ala Thr Glu Gly
50 55 60

Arg Ile Val Ser Thr Lys Ile Gly Ser Gly Gln Ala Phe Ser Ser Ser
65 70 75 80

Glu Ala Ser Val Cys Met His Leu Ser His Tyr Ser Tyr Phe Tyr Leu
85 90 95

Lys Ser Leu Pro Thr Ala
100

<210> 337
<211> 24
<212> PRT
<213> Homo sapiens

<400> 337
Phe Arg Leu Phe Gly Gly Leu Ile Leu Asp Ile Lys Arg Lys Ala Pro
1 5 10 15

Phe Phe Leu Ser Asp Phe Lys Asp
20

<210> 338
<211> 23
<212> PRT
<213> Homo sapiens

<400> 338
Phe Leu Tyr Cys Ala Cys Met Ser Pro Val Ile Thr Phe Gly Gly Leu
1 5 10 15

Leu Gly Glu Ala Thr Glu Gly
20

<210> 339
<211> 22
<212> PRT
<213> Homo sapiens

<400> 339
Ser Ser Ser Glu Ala Ser Val Cys Met His Leu Ser His Tyr Ser Tyr
1 5 10 15

Phe Tyr Leu Lys Ser Leu
20

<210> 340
<211> 106
<212> PRT

<213> Homo sapiens

<400> 340

Pro Cys Leu Gln Val Ile Gly Ile Asp Phe Cys Arg Leu Leu Met
1 5 10 15

Cys Leu Val Leu Lys Arg Asn Leu Thr Val Pro Phe Ser Ser Tyr Ser
20 25 30

Pro Leu Lys Thr Ile Thr Cys Ile Thr Ser Glu Gln Ile Ala Val Val
35 40 45

Ser Asn Phe Phe Arg Gln Lys Leu Gly Val Arg Ala Lys Phe Gln
50 55 60

Gly Ala Cys Leu His Thr Ser Lys Val Val Ile Cys Leu Asn Leu Pro
65 70 75 80

Ile Ile Ser Ile Gln Arg Ala Asp Ile Arg Met Trp Trp Leu Val Val
85 90 95

Asn Thr Pro Tyr Ala Arg Gly Val Asn Asn
100 105

<210> 341

<211> 21

<212> PRT

<213> Homo sapiens

<400> 341

Val Val Ser Val Cys Val Leu Glu Thr Gly Gln Leu Gly Pro Ala Ala
1 5 10 15

Leu Cys Arg Ser Val
20

<210> 342

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (85)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (90)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 342

Asn Ile Ser Val His Gly Phe Pro Val Pro Cys Leu Arg Gln Leu
1 5 10 15

Gln Gly Pro Cys His Pro Lys Cys Cys Pro His Xaa Ile Ser Ser Gly
20 25 30

Lys Pro Arg Ser Ser Phe Ser Pro Ser Ser Tyr His Cys Lys Phe Ser
35 40 45

Arg Asn Ala Thr Leu Leu Val Val Pro Asn Ile Phe Ser Tyr Met Gln
50 55 60

Ser Ser Phe Leu Ile Pro Gln Thr Ser Lys Tyr Tyr Ile Leu Xaa Pro
65 70 75 80

Tyr Ala Xaa Thr Xaa Arg Pro Ile Lys Xaa Ile Phe Lys Gln Ala Lys
85 90 95

Gln

<210> 343

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 343

Ile Tyr Asn Asp Met Met Met Glu Lys Lys Lys Thr Glu Val Tyr Gln
1 5 10 15

Lys Arg Xaa Ser Gly Asp Asn Thr Trp Gly Gly Lys Gly Leu Val Ala
20 25 30

Phe Val Ser Ser Met Met Glu Gln Gly Ile His Val Gln Arg Cys Phe Ile
35 40 45

Ala Asn Leu Lys Phe Ser Ser Pro Gly Val
50 55

<210> 344

<211> 93
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 344
 Tyr Asp Asp Gly Glu Lys Glu Asp Arg Gly Leu Pro Glu Glu Met Xaa
 1 5 10 15

Trp Gly Gln His Leu Gly Trp Gln Gly Pro Cys Ser Leu Cys Leu Lys
 20 25 30

His Gly Thr Gly Asn Pro Cys Thr Glu Met Phe Tyr Cys Gln Phe Lys
 35 40 45

Ile Phe Ile Ser Trp Cys Leu Ile Pro Leu Val Phe Ala Arg Leu Gly
 50 55 60

Asp Phe Arg Asp Arg Pro Gly Trp Ile Phe Ser Trp Arg Tyr His Leu
 65 70 75 80

Lys His Thr Val Trp Gly Gly Tyr Asn Ile Ile Met Leu
 85 90

<210> 345
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 345
 Thr Pro Gly Asp Glu Asn Phe Lys Leu Ala Ile Lys His Leu Cys Thr
 1 5 10 15

Trp Ile Pro Cys Ser
 20

<210> 346
 <211> 34
 <212> PRT
 <213> Homo sapiens

<400> 346
 Ile Arg His Glu Ile Phe Leu Thr Thr Ile Glu Ser Phe Cys Pro Ser Ala
 1 5 10 15

Pro Arg Gly Glu Asp Asp Asn Leu Leu Arg Thr Ser Arg Val Pro
 20 25 30

Asp Ile

<210> 347
 <211> 160
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (126)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (130)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 347
 Ile Arg Gly Ser Ile Pro Gly His Lys Lys Met His Leu Ser Phe Asn
 1 5 10 15

Val Ala Ala Gln Trp Ser Leu Leu Lys Pro Leu Val Leu Arg Glu Glu
 20 25 30

Gly Ala Leu Phe Leu Thr His Asp Gln Leu Glu Ser Lys Asn Ser Trp
 35 40 45

Thr Leu Ser Ile Gly Pro Arg Val Pro Tyr Thr Tyr Val Val Thr
 50 55 60

Trp Ser Ser Ala Leu Trp Asp Leu Pro Asn Gln Pro Leu Ala Gly Arg
 65 70 75 80

Lys Glu Ser Gly Gly Ser Tyr Gly Pro Ile Ser Val Thr Gln Ser Pro
 85 90 95

His Gln Ala Ala Leu Lys Trp Phe Ala Lys Lys Lys Gly Lys Gln Ser
 100 105 110

His Ser Thr Val Gln Leu Ala Asn Ile Leu His Val Phe Xaa Ala Pro
 115 120 125

Asp Xaa Tyr His Phe Val Asn Thr Ser Leu Gln Leu Phe Leu Glu Tyr
 130 135 140

Thr Val Met Cys Met Leu Cys Glu Asn Lys Gln Lys Thr Leu Gly Arg
 145 150 155 160

<210> 348
 <211> 135
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 348

Glu Pro Glu Val Thr Gln Val Xaa Ser Xaa Glu Leu Thr Phe Gln Pro
1 5 10 15

Arg Lys Ala Gly Ala Lys Val Thr Ala Gly Lys Ser His His Gln Val
20 25 30

Ile His Trp Glu Phe Glu Ile Met Leu Ser Ser Tyr Ser Thr Asp Val
35 40 45

Pro Leu Trp Phe Leu Lys Phe Phe Ser Ser Asn Leu Pro Gln Thr Tyr
50 55 60

Phe Pro His Ser Gly Val Lys Lys Trp Gly Ser Cys Phe Ser Leu Pro
65 70 75 80

Trp Arg Asp Ser Pro Pro Leu Thr Phe Ile Ser Leu Leu Ser Ser His
85 90 95

Leu Thr Thr Phe His Leu Tyr His Leu His His Gly Ile Ile Cys Leu
100 105 110

Gly Phe Ser Val Tyr Phe His Arg Ala Tyr Thr Ser Leu Cys Ile Leu
115 120 125

Glu Thr Ala Val Gly Ser Tyr
130 135

<210> 349

<211> 25

<212> PRT

<213> Homo sapiens

<400> 349

Trp Ser Leu Leu Lys Pro Leu Val Leu Arg Glu Glu Gly Ala Leu Phe
1 5 10 15

Leu Thr His Asp Gln Leu Glu Ser Lys
20 25

<210> 350

<211> 22

<212> PRT

<213> Homo sapiens

<400> 350

Trp Phe Ala Lys Lys Lys Gly Lys Gln Ser His Ser Thr Val Gln Leu
1 5 10 15

Ala Asn Ile Leu His Val
20

20

<210> 351

<211> 25

<212> PRT

<213> Homo sapiens

<400> 351

Ala Gly Lys Ser His His Gln Val Ile His Trp Glu Phe Glu Ile Met
1 5 10 15

Leu Ser Ser Tyr Ser Thr Asp Val Pro
20 25

<210> 352

<211> 26

<212> PRT

<213> Homo sapiens

<400> 352

His Gly Ile Ile Cys Leu Gly Phe Ser Val Tyr Phe His Arg Ala Tyr
1 5 10 15

Thr Ser Leu Cys Ile Leu Glu Thr Ala Val
20 25

<210> 353

<211> 19

<212> PRT

<213> Homo sapiens

<400> 353

Lys Arg Leu Thr Ile Asn Ala Arg Val His Leu Trp Thr Leu Lys Ser
1 5 10 15

Val Pro Leu

<210> 354

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 354

Glu Tyr Val Phe Asn Met Xaa Xaa Tyr Ser Lys Ser Arg Ala Ile Ser
1 5 10 15Pro Leu Ser Gly Pro Tyr Thr Pro Arg Gly Thr Thr Pro Leu Pro Ile
20 25 30Ile Pro Glu Pro Gly Ala Arg Gln Arg Asp His Pro Ala Ser Leu Lys
35 40 45Tyr Ala Lys Ile Ile Gln Thr Lys Leu Phe Ala Leu Pro Tyr Pro Lys
50 55 60Glu Thr Ser Met Lys Ala Val Ala
65 70

<210> 355

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 355

Glu Thr Val Pro Pro Arg Ser Ser Gln Phe Leu Lys Ile Thr Xaa Gly
1 5 10 15Pro Ala Arg Ser Met Ser Leu Ile Xaa Xaa Ala Ile Gln Asn Pro Glu
20 25 30Pro Tyr Leu Leu Tyr Leu Ala Leu Ile Pro Gln Glu Ala Leu Leu Leu
35 40 45Tyr Leu Ser Ser Gln Ser Gln Val Pro Gly Asn Glu Thr Thr Pro Pro
50 55 60

Val

65

<210> 356

<211> 101

<212> PRT

<213> Homo sapiens

<400> 356

Asn Glu Val Ser Phe Ser Leu Ser Leu Gly Phe Ser Pro Arg Glu Phe
1 5 10 15Ala Arg Trp Lys Val Asn Asn Leu Ala Leu Glu Arg Lys Asp Phe Phe
20 25 30Ser Leu Pro Leu Pro Leu Ala Pro Glu Phe Ile Arg Asn Ile Arg Leu
35 40 45Leu Gly Arg Arg Pro Asn Leu Gln Gln Val Thr Glu Asn Leu Ile Lys
50 55 60Lys Tyr Gly Thr His Phe Leu Leu Ser Ala Thr Leu Gly Gly Lys Gln
65 70 75 80His His Asn Pro Lys Leu Ile Gly Cys Gln Thr Thr Ile Gly Asn Asn Val
85 90 95

Lys Thr Arg Val Ala

100

<210> 357

<211> 75

<212> PRT

<213> Homo sapiens

<400> 357

Val Pro Tyr Phe Leu Ile Arg Phe Ser Val Thr Cys Arg Leu Gly
1 5 10 15Leu Leu Pro Arg Arg Arg Met Phe Arg Ile Asn Ser Gly Ala Arg Gly
20 25 30Asn Gly Lys Leu Lys Lys Ser Phe Leu Ser Arg Ala Lys Leu Phe Thr
35 40 45Phe Gln Arg Ala Asn Ser Leu Gly Glu Lys Pro Arg Asp Lys Glu Lys
50 55 60Leu Thr Ser Phe Gln Ser Lys Arg His Lys Ile
65 70 75

<210> 358

<211> 63

<212> PRT

<213> Homo sapiens

<400> 358

Glu Met Ser Ala Val Leu Phe Asn Gln Ile Phe Cys Asn Leu Leu Gln
1 5 10 15Ile Gly Ser Pro Ser Lys Glu Ala Asn Val Pro Asp Lys Leu Trp Gly
20 25 30

Lys Arg Gln Trp Gln Thr Glu Val Leu Pro Phe Gln Ser Gln Val
35 40 45
Val His Leu Pro Thr Gly Lys Leu Pro Gly Gly Lys Ala Lys Gly
50 55 60

<210> 359
<211> 99
<212> PRT
<213> Homo sapiens

<400> 359
His Tyr His Gly Ser Gly Phe Leu Ile Lys Glu Phe Gly Ser Phe Leu
1 5 10 15
Ser Leu Leu Cys Met Leu Ser Cys Pro Tyr Val Phe Cys His Gly Met
20 25 30

Leu Glu Gln Glu Val Pro Ser Ser Val Val Ser Pro Ser Thr Leu Asp
35 40 45
Phe Pro Thr Ser Arg Thr Val Asn Lys Phe Leu Phe Lys Leu Pro Ser
50 55 60

Leu Trp Tyr Ser Val Ile Ala Thr Gln Asn Gly Leu Lys Gln Lys Ile
65 70 75 80
Arg Glu Thr Phe Leu Phe Val Gln Phe Ser Gln Met Pro Arg Trp His
85 90 95

Lys Leu Glu

<210> 360
<211> 48
<212> PRT
<213> Homo sapiens

<400> 360
Phe Cys Lys His Asn Gly Ser Lys Asn Val Phe Ser Thr Phe Arg Thr
1 5 10 15

Pro Ala Val Leu Phe Thr Gly Ile Val Ala Leu Tyr Ile Ala Ser Gly
20 25 30
Leu Thr Gly Phe Ile Gly Leu Glu Val Val Ala Gln Leu Phe Asn Cys
35 40 45

<210> 361
<211> 139
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 361
Met Pro Lys Pro Gly Ala Ala Thr Gln Arg Thr Leu Leu Cys Leu Pro
1 5 10 15

Arg Leu His Pro Ala Ser Gly Pro Pro Leu Pro Xaa Ala Gly Pro Leu
20 25 30

Arg Gly Leu Arg Gln Leu Pro Ala Leu Pro Val Pro Ala Ala Ser Cys
35 40 45

Arg Arg Arg Pro Ala Pro Arg Leu Cys Ala Ala Gly Pro Cys Thr Val
50 55 60

Gly Pro Ala Ala Ser Pro His Ala Pro Pro His Gly Cys Pro Pro Pro
65 70 75 80

Ala Ser Leu Ala His Val Ala His Arg Gln Ser Val Ser Gly Thr Val
85 90 95

Cys Leu Gly Leu Arg Asp Gly His Val Arg Gly Gly Cys Ala Ala Val
100 105 110

Arg Gly Xaa Ala Ala Leu Pro Trp Asp Ala Ala Ala Gly Pro Asp
115 120 125

His Met Gly Val Gly Ser Gly Pro Ala Leu Leu
130 135

<210> 362
<211> 35
<212> PRT
<213> Homo sapiens

<400> 362
Met Trp Gly Gln Pro Arg Pro Val Asp Ser Val Trp Ser Ser Ser Ile
1 5 10 15

Pro Lys Lys Ser Val Glu Ser Asn Asp Asn Lys Ser His Leu His Lys
20 25 30

Arg Glu His
35

<210> 363
<211> 26

<212> PRT
<213> Homo sapiens

<400> 363

Met Thr Thr Lys Ala Ile Phe Thr Lys Gly Asn Ile Asp Ser Leu Ser
1 5 10 15

Phe Lys Ser Asn Met Trp Ser Val Tyr Ile
20 25

<210> 364

<211> 26

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 364

Asp Ser Xaa Leu Asp Arg Arg Pro Ser Gly Pro Asp Val Lys Phe Leu
1 5 10 15

Ser Asn Lys His His Phe Ser Met Val Cys
20 25

<210> 365

<211> 84

<212> PRT

<213> Homo sapiens

<400> 365

Cys Leu Ala Glu Ala Val Ser Val Ile Gln Ser Ile Pro Ile Phe Asn
1 5 10 15

Glu Thr Gly Arg Phe Ser Phe Thr Leu Pro Tyr Pro Val Lys Ile Lys
20 25 30

Val Arg Phe Ser Phe Phe Leu Gln Ile Tyr Leu Ile Met Ile Phe Leu
35 40 45

Gly Leu Tyr Ile Asn Phe Arg His Leu Tyr Lys Lys Gln Arg Arg Arg
50 55 60

Tyr Gly Gln Lys Lys Lys Arg Ser Thr Lys Lys Lys Asp Leu Asp Gly
65 70 75 80

Phe Leu Pro Val

<210> 366

<211> 62

<212> PRT

<213> Homo sapiens

<400> 366

Leu Cys Ser Thr Pro Val Pro Thr Leu Phe Cys Pro Arg Ile Val Leu
1 5 10 15

Glu Val Leu Val Val Leu Arg Ser Ile Ser Glu Gln Cys Arg Arg Val
20 25 30

Ser Ser Gln Val Thr Val Ala Ser Glu Leu Arg His Arg Gln Trp Val
35 40 45

Glu Arg Thr Leu Arg Ser Arg Gln Arg Gln Asn Tyr Leu Arg
50 55 60

<210> 367

<211> 48

<212> PRT

<213> Homo sapiens

<400> 367

Ala Arg Gly Glu Thr Ala Tyr Asp Gly Ala Ala Val Glu Phe Gln Glu
1 5 10 15

Pro Leu Ser Ser Cys Leu Phe Ser Ser Leu Asn Pro His His Trp Pro
20 25 30

Thr Leu Gly Val Gly Arg Pro Val Met Leu Thr Leu Glu Asp Lys Asp
35 40 45

<210> 368

<211> 200

<212> PRT

<213> Homo sapiens

<400> 368

Glu Leu Leu Gln Cys Gln Met Leu Glu Ala Ser Thr Leu Ile His Leu
1 5 10 15

His His Pro Arg Pro Gly Phe Pro Ala Leu Cys Ser Phe Leu Gly Phe
20 25 30

Arg His His Leu His His Asp Ala Leu Cys Ile Arg Val Leu Pro Glu
35 40 45

Asp Leu Glu Ala Lys Leu Cys Val Ser Leu His Gln Leu Leu His Arg
50 55 60

Gly Leu Cys Leu Pro Gly Phe Gly Ala Ala Cys Pro Gly Asp Gln Gly
65 70 75 80

Ser Glu Asp Glu Ala Arg Pro Pro Ala Val Leu Arg Ala Val Ala Leu
85 90 95

Leu Arg Ala Gly Leu Arg His Leu Ser Val His Ser Gly Trp Tyr His
 100 105 110
 Leu Pro His Ser Arg Asn Gly Leu Pro Leu Leu Ala Leu Val Val His
 115 120 125
 Phe Pro Glu Tyr Gly Gly Gly Pro Arg Glu Pro Val Pro Gly Gln Ser
 130 135 140
 Gly Glu Phe Gly Arg Arg Thr Glu Leu Ser Thr Lys Gly Asp Thr Gly
 145 150 155 160
 Asp Ser Arg Asn Ser His Leu Ala Gln Asp Met Ala Ser Leu Pro Phe
 165 170 175
 Phe Lys Pro Cys Glu Cys Thr His Val Ala Val Cys Ser Pro Pro His
 180 185 190
 Pro Leu Cys Gln Tyr Leu Cys Leu
 195 200
 <210> 369
 <211> 28
 <212> PRT
 <213> Homo sapiens
 <400> 369
 Leu Gln Cys Gln Met Leu Glu Ala Ser Thr Leu Ile His Leu His His
 1 5 10 15
 Pro Arg Pro Gly Phe Pro Ala Leu Cys Ser Phe Leu
 20 25
 <210> 370
 <211> 31
 <212> PRT
 <213> Homo sapiens
 <400> 370
 His Gln Leu Leu His Arg Gly Leu Cys Leu Pro Gly Phe Gly Ala Ala
 1 5 10 15
 Cys Pro Gly Asp Gln Gly Ser Glu Asp Glu Ala Arg Pro Pro Ala
 20 25 30
 <210> 371
 <211> 27
 <212> PRT
 <213> Homo sapiens
 <400> 371
 Leu Ala Leu Val Val His Phe Pro Glu Tyr Gly Gly Gly Pro Arg Glu
 1 5 10 15
 Pro Val Pro Gly Gln Ser Gly Glu Phe Gly Arg

20 25
 <210> 372
 <211> 30
 <212> PRT
 <213> Homo sapiens
 <400> 372
 Gln Ser Trp Thr Ala Pro Ala Ala Arg Leu Pro Met Ala Leu Pro Gln
 1 5 10 15
 Met Cys Asp Gly Ser His Leu Ala Ser Thr Leu Arg Tyr Cys
 20 25 30
 <210> 373
 <211> 190
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (32)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (47)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 373
 Gln Ser Ala Ala Gln Trp Phe Trp Trp Pro Gly Arg Ser Ala Ser Leu
 1 5 10 15
 Gly Gly Ala Lys Gly Met Gln Pro Pro Ser Leu Ala Ser Trp Pro Xaa
 20 25 30
 Pro Arg Ser Ile Arg Cys Leu Arg Ala Pro Ala Pro Cys Ser Xaa Pro
 35 40 45
 Ser Ala Ser Ser Ala Ala Val Gln Val Ala Cys Cys Cys Ser Leu Ala
 50 55 60
 Cys Cys Gly Pro Ser Arg Pro Ala Ser Gln Gly His Leu Arg Trp Asp
 65 70 75 80
 Pro Tyr His Leu Ser Arg Asp Leu Tyr Tyr Leu Thr Val Glu Ser Ser
 85 90 95
 Glu Lys Glu Ser Cys Arg Thr Pro Lys Val Val Asp Ile Pro Thr Tyr
 100 105 110
 Glu Glu Ala Val Ser Phe Pro Val Ala Glu Gly Pro Pro Thr Pro Pro
 115 120 125
 Ala Tyr Pro Thr Glu Glu Ala Leu Glu Pro Ser Gly Ser Arg Asp Ala
 130 135 140

Leu Leu Ser Thr Gln Pro Ala Trp Pro Pro Ser Tyr Glu Ser Ile
145 150 155 160

Ser Leu Ala Leu Asp Ala Val Ser Ala Glu Thr Thr Pro Ser Ala Thr
165 170 175

Arg Ser Cys Ser Gly Leu Val Gln Thr Ala Arg Gly Gly Ser
180 185 190

<210> 374

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 374

Gly Ser Thr Gly Leu Trp Arg Gly Asp Arg Gly Pro Ile Glu Gly Gly
1 5 10 15

Pro Gly Met Leu Ala Leu Thr Asp His Ser Arg Pro Met Ser Ser Ser
20 25 30

Arg Pro Pro Ala Pro Gln Gln Thr Lys Leu Thr Asp Leu Ser Arg Gly
35 40 45

Leu Gly Pro Ser Gly Thr Gly Tyr Ser Val Xaa Gly Ala Ser Trp Pro
50 55 60

Gly Trp Ala Val Ala Ser Pro Ser Leu His Gln Ala Lys Gln Ser Val
65 70 75 80

Pro Ala Thr Arg Thr Thr Val Pro Leu Thr Val Met Gln
85 90

<210> 375

<211> 27

<212> PRT

<213> Homo sapiens

<400> 375

Gln Trp Phe Trp Trp Pro Gly Arg Ser Ala Ser Leu Gly Gly Ala Lys
1 5 10 15

Gly Met Gln Pro Pro Ser Leu Ala Ser Trp Pro
20 25

<210> 376

<211> 29

<212> PRT

<213> Homo sapiens

<400> 376
Ser Ser Ala Ala Val Gln Val Ala Cys Cys Ser Leu Ala Cys Cys
1 5 10 15

Gly Pro Ser Arg Pro Ala Ser Gln Gly His Leu Arg Trp
20 25

<210> 377

<211> 32

<212> PRT

<213> Homo sapiens

<400> 377

Val Ser Phe Pro Val Ala Glu Gly Pro Pro Thr Pro Pro Ala Tyr Pro
1 5 10 15

Thr Glu Glu Ala Leu Glu Pro Ser Gly Ser Arg Asp Ala Leu Leu Ser
20 25 30

<210> 378

<211> 26

<212> PRT

<213> Homo sapiens

<400> 378

Arg Val Ser Phe Pro Val Ala Glu Gly Pro Pro Thr Pro Pro Ala Tyr
1 5 10 15

Pro Thr Glu Glu Ala Leu Glu Pro Ser Gly
20 25

<210> 379

<211> 95

<212> PRT

<213> Homo sapiens

<400> 379

Ser Asn Glu Ile Leu Leu Ser Phe Pro Gln Asn Tyr Tyr Ile Gln Trp
1 5 10 15

Leu Asn Gly Ser Leu Ile His Gly Leu Trp Asn Leu Ala Ser Leu Phe
20 25 30

Ser Asn Leu Cys Leu Phe Val Leu Met Pro Phe Ala Phe Phe Leu
35 40 45

Glu Ser Glu Gly Phe Ala Gly Leu Lys Lys Gly Ile Arg Ala Arg Ile
50 55 60

Leu Glu Thr Leu Val Met Leu Leu Leu Ala Leu Leu Ile Leu Gly
65 70 75 80

Ile Val Trp Val Ala Ser Ala Leu Ile Asp Asn Asp Ala Ser
85 90 95

<210> 380
<211> 33
<212> PRT
<213> Homo sapiens

<400> 380
Pro Thr Arg Pro Val Leu Leu Ala Ile Asn Gly Val Thr Glu Cys
1 5 10 15

Phe Thr Phe Ala Ala Met Ser Lys Glu Glu Val Asp Arg Tyr Asn Phe
20 25 30

Val

<210> 381
<211> 93
<212> PRT
<213> Homo sapiens

<400> 381
Asn Asp Lys Lys Leu Leu Phe Leu Lys Gly Phe Thr Ser Ser Leu Lys
1 5 10 15

Asn Glu Thr Pro Pro His Phe Arg Leu Arg Met Val Thr Gly Val
20 25 30

Ser Cys Ser Gly Thr Leu Trp Cys Leu Ile Ser Gly Val Ala Val Thr
35 40 45

Pro Leu Glu Ser Pro Glu Trp Gly Ser Tyr Thr Glu Cys Val Pro Pro
50 55 60

Thr Glu Leu Pro Ile Ala Gly Pro Gly Ala Ser Gly Val Glu Ala Ser
65 70 75 80

Leu Lys Ser Arg His Phe Val Ser Ala Ser Gly His Thr
85 90

<210> 382
<211> 65
<212> PRT
<213> Homo sapiens

<400> 382
Ser Glu Asn Arg Ile Tyr Arg Asn Gly Leu Glu Lys Met Arg Arg Glu
1 5 10 15

Val Thr Ile Gly Arg Ser Ser Ile Cys Leu Asp Glu Glu Val Lys
20 25 30

Ala Gly Asn Ala Val His His Glu Trp Leu Lys Tyr Val Cys Trp Met
35 40 45
Val Val Val Val Gly Gly Ser Gly Val Gly Asp Gly Gly Asn Leu Gly
50 55 60

Met
65

<210> 383
<211> 129
<212> PRT
<213> Homo sapiens

<400> 383
Asn Trp Ser Ser Gly Arg Arg Leu Arg Met Trp Pro Ser Ala Ala Leu Ser
1 5 10 15

Pro Ala Val Ser Ser Pro Ala Leu Ala Leu Thr Ser Pro Pro Lys Pro
20 25 30

Leu Lys Gly Glu Val Trp Leu Arg Trp Lys Leu Leu Gly Ser Arg Ala
35 40 45

Val Gly Leu Phe Ala Phe Ile Ala Leu Gly Thr Glu Ser Pro Leu Leu
50 55 60

His Arg Ala Cys Leu Pro Val Arg Glu Ser Trp Gly Cys Ser Glu His
65 70 75 80

Lys Ala Tyr Pro Ile Leu Arg Leu Glu Pro Asp Leu Glu Thr Glu Val
85 90 95

Gly Pro Gly His Gly Val Asn Trp Asp Leu Arg Thr Glu Ile Arg Thr
100 105 110

Ile Gly Glu Leu Gly Gly Asp Gly Gly Cys Ser Glu Met Arg Pro Leu
115 120 125

Phe

<210> 384
<211> 123
<212> PRT
<213> Homo sapiens

<400> 384
Asn Leu Phe Ser Thr Pro Cys Lys Arg Glu Lys Leu Ile Lys Leu Glu
1 5 10 15

Trp Thr Glu Ala Pro Asn Val Ala Leu Arg Cys Ser Leu Ser Cys Ser
20 25 30

Leu Ile Pro Gly Leu Ser Pro Asp Leu Ser Ser Glu Ala Pro Glu Gly
35 40 45

Arg Ser Val Ala Lys Met Glu Ile Ala Arg Gln Ser Cys Trp Leu
50 55 60

Val Cys Ile Tyr Cys Phe Arg Asn Pro Glu Ser Thr Leu Ala Pro Gly
65 70 75 80

Leu Pro Ala Cys Glu Ala Glu Leu Gly Leu Arg Ala Gln Gly Leu
85 90 95

Pro His Pro Ala Ser Pro Ala Arg Leu Gly Asn Thr Gly Gly Ala Trp
100 105 110

Pro Arg Ser Lys Leu Gly Ser Gln Asn Thr Asn
115 120

<210> 385

<211> 26

<212> PRT

<213> Homo sapiens

<400> 385

Ser Ser Pro Ala Leu Ala Leu Thr Ser Pro Pro Lys Pro Leu Lys Gly
1 5 10 15

Glu Val Trp Leu Arg Trp Lys Leu Leu Gly
20 25

<210> 386

<211> 28

<212> PRT

<213> Homo sapiens

<400> 386

Glu His Lys Ala Tyr Pro Ile Leu Arg Leu Gln Pro Asp Leu Glu Thr
1 5 10 15

Gln Val Gly Pro Gly His Gly Val Asn Trp Asp Leu
20 25

<210> 387

<211> 28

<212> PRT

<213> Homo sapiens

<400> 387

Ala Leu Arg Cys Ser Leu Ser Cys Ser Leu Ile Pro Gly Leu Ser Pro
1 5 10 15

Asp Leu Ser Ser Glu Ala Pro Glu Gly Arg Ser Val
20 25

<210> 388

<211> 73

<212> PRT
<213> Homo sapiens

<400> 388

Leu Ala Pro Glu Cys Cys Gly Ser Val Thr Tyr Pro Arg Ala Leu
1 5 10 15

Val Pro Arg Pro Cys Cys Pro Glu Pro Arg Ala Pro Leu Gln Leu Thr
20 25 30

Leu Gly Leu Phe Ser Ala Asn Pro Val Asn Ala Ser Pro Trp Gly Arg
35 40 45

Cys Arg Ser Arg Arg Gly Arg Asn Leu Pro Leu Gly His Pro Val
50 55 60

Ser Thr Ala Phe Ser Ser Gly Asp Ser
65 70

<210> 389

<211> 102

<212> PRT

<213> Homo sapiens

<400> 389

Asn Thr Leu His Ser Lys Leu Val Pro Ser Val Tyr His Ser Thr Glu
1 5 10 15

Lys Ser Cys Leu Val Cys Phe Gly Met Cys Pro Ser Ile Tyr Lys Lys
20 25 30

Met Lys Ser Val Leu Leu Ile Gly Thr Arg Met Leu Leu Trp Leu Ser
35 40 45

His Ile Ser Gln Gly Pro Arg Pro Glu Ala Val Leu Pro Arg Ala Pro
50 55 60

Ser Pro Ser Ala Ala His Pro Trp Leu Val Phe Arg Lys Pro Gly Lys
65 70 75 80

Arg Lys Pro Leu Gly Gln Met Gln Lys Lys Arg Glu Gly Lys Pro
85 90 95

Ala Ser Gly Ser Pro Cys
100

<210> 390

<211> 25

<212> PRT

<213> Homo sapiens

<400> 390

Tyr Pro Arg Ala Leu Val Pro Arg Pro Cys Cys Pro Glu Pro Arg Ala
1 5 10 15

Pro Leu Gln Leu Thr Leu Gly Leu Phe

20

25

<210> 391

<211> 27

<212> PRT

<213> Homo sapiens

<400> 391

Val Leu Leu Ile Gly Thr Arg Met Leu Leu Trp Leu Ser His Ile Ser
1 5 10 15

Gln Gly Pro Arg Pro Glu Ala Val Leu Pro Arg
20 25

<210> 392

<211> 61

<212> PRT

<213> Homo sapiens

<400> 392

Trp Ile Ile Val Met Phe Gly Lys Val Leu Lys Ile Lys Asp Phe Met
1 5 10 15

Ser Thr Tyr Ser His Thr Tyr Thr His Thr His Met His Ala His Thr
20 25 30

His Thr His Thr Leu Thr Leu Ser Leu Leu Gln Asn Val Leu Thr Leu
35 40 45

Val Ala Ile Ser Asp Ser Asp Lys Ala Leu Leu Ile Phe
50 55 60

<210> 393

<211> 69

<212> PRT

<213> Homo sapiens

<400> 393

Met Thr Leu Leu Ile Ala Glu Lys Thr Trp Arg Arg Pro Trp Pro Cys
1 5 10 15

Gln Trp Gly Tyr Leu Gly Ala Glu Gly Asp Arg His Leu Glu Gly Arg
20 25 30

Ser Leu Ser Leu Arg His Leu Gln Gly Ala Glu Thr Pro Val Leu Asn
35 40 45

Pro Asp Leu Gln Leu Pro Ser His Ile Gly Lys Gln Ala Trp Ser His
50 55 60

Ala Leu Gly Ser Leu
65

<210> 394

<211> 27

<212> PRT

<213> Homo sapiens

<400> 394

Met Ser Thr Tyr Ser His Thr Tyr Thr His Thr His Met His Ala His
1 5 10 15

Thr His Thr His Thr Leu Thr Leu Ser Leu Leu
20 25

<210> 395

<211> 23

<212> PRT

<213> Homo sapiens

<400> 395

Gly Ala Glu Gly Asp Arg His Leu Glu Gly Arg Ser Leu Ser Leu Arg
1 5 10 15

His Leu Gln Gly Ala Glu Thr
20

<210> 396

<211> 133

<212> PRT

<213> Homo sapiens

<400> 396

Val Val Glu Pro Gly Leu Lys Ala Ser Leu Gly Ala Met Ser Thr Leu
1 5 10 15

Phe Pro Ser Leu Phe Pro Arg Val Thr Glu Thr Leu Trp Phe Asn Leu
20 25 30

Asp Arg Pro Cys Val Glu Glu Thr Glu Leu Gln Gln Gln Gln
35 40 45

His Gln Ala Trp Leu Gln Ser Ile Ala Glu Lys Asp Asn Asn Leu Val
50 55 60

Pro Ile Gly Lys Pro Ala Ser Glu His Tyr Asp Asp Glu Glu Glu
65 70 75 80

Asp Asp Glu Asp Asp Glu Asp Ser Glu Glu Asp Ser Glu Asp Glu
85 90 95

Asp Met Gln Asp Met Asp Glu Met Met Asn Asp Tyr Asn Glu Ser Pro Asp
100 105 110

Asp Gly Glu Val Asn Glu Val Asp Met Glu Gly Asn Glu Gln Asp Gln
115 120 125

Asp Gln Trp Met Ile
130

<210> 397

<211> 23

<212> PRT

<213> Homo sapiens

<400> 397

Leu Phe Pro Arg Val Thr Glu Thr Leu Trp Phe Asn Leu Asp Arg Pro
1 5 10 15Cys Val Glu Glu Thr Glu Leu
20

<210> 398

<211> 23

<212> PRT

<213> Homo sapiens

<400> 398

Tyr Asn Glu Ser Pro Asp Asp Gly Glu Val Asn Glu Val Asp Met Glu
1 5 10 15Gly Asn Glu Gln Asp Gln Asp
20

<210> 399

<211> 101

<212> PRT

<213> Homo sapiens

<400> 399

Met Gly Phe Asp Ile His Gly Val Leu Gly Glu Ala Val Ala Glu Pro
1 5 10 15Arg Glu Lys Lys Gln Glu Arg Ala Lys Trp Ala Pro His Asp Tyr Asp
20 25 30Asp Pro Ser Leu Ser Leu Gln Asp Leu Leu Ile Ser Trp Met Ile Ser
35 40 45Thr Trp Leu Ile Pro Met Trp Lys Cys Gln Ala Thr Ile Trp Phe Ser
50 55 60Leu Ile Gln Arg Leu Leu Asn Ala Tyr Cys Met Pro Gly Asn Phe Arg
65 70 75 80His Trp Glu Ile Ala Ala Asn Thr Thr Asn Lys Thr Pro Gly Leu Met
85 90 95Asp Phe Lys Phe Leu
100

<210> 400

<211> 27

<212> PRT

<213> Homo sapiens

<400> 400

Glu Pro Arg Glu Lys Lys Gln Glu Arg Ala Lys Trp Ala Pro His Asp
1 5 10 15Tyr Asp Asp Pro Ser Leu Ser Leu Gln Asp Leu
20 25

<210> 401

<211> 24

<212> PRT

<213> Homo sapiens

<400> 401

Met Pro Gly Asn Phe Arg His Trp Glu Ile Ala Ala Asn Thr Thr Asn
1 5 10 15Lys Thr Pro Gly Leu Met Asp Phe
20

<210> 402

<211> 100

<212> PRT

<213> Homo sapiens

<400> 402

Gln Ser Val Pro Ser Pro Pro Leu Ala Pro Pro Leu Pro Pro Ser Leu
1 5 10 15Pro Ser Phe Leu Phe Thr Glu Thr Arg Ser His Tyr Val Ala Arg Leu
20 25 30Val Ser Asn Ser Trp Ala Gln Met Ile Leu Leu Pro Trp Pro Leu Lys
35 40 45Val Leu Gly Leu Asp Val Ser His Cys Ala Trp Pro Lys Ser Val Phe
50 55 60Leu Gln Ala Met Glu Glu Ile Ala Asp Phe Cys Leu Phe Ser Val Lys
65 70 75 80Tyr Gln Val Ser Ser Met Thr Cys Phe Asp Arg Thr Ser Tyr Met Lys
85 90 95Asn Thr Tyr Leu
100

<210> 403

<211> 27

<212> PRT

<213> Homo sapiens

<400> 403

Leu Phe Thr Glu Thr Arg Ser His Tyr Val Ala Arg Leu Val Ser Asn

1 5 10 15
Ser Trp Ala Gln Met Ile Leu Leu Pro Trp Pro
20 25

<210> 404
<211> 159
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 404
Ser Gln Ile Lys Ser Glu Lys Lys His Ile Gly Lys Ala Tyr Thr Cys
1 5 10 15

Thr Gln Thr Gln Ser Thr Gly Met Gln Ser Thr Leu Thr Ile Val Ala
20 25 30

Lys Lys Lys Ser Arg Asn His Thr Glu Ser Tyr Thr Arg Lys Lys Gln
35 40 45

Glu Asn Gln Ile Val Leu Ile Pro Trp His Gln Lys Lys His Pro Glu
50 55 60

Gly Thr His Thr Cys Ser His Ser Leu Arg Arg Asp Thr Asn Thr Ala
65 70 75 80

Ala Asp Thr Gln Arg Lys Ile Arg Ala His Arg Tyr Thr Tyr Arg Arg
85 90 95

Asp Lys Tyr Ser Asp Thr Leu Val Thr His Asp His Tyr Lys Gly Asp
100 105 110

Lys His Pro Ser Asn Thr His Thr Gln Pro Arg Xaa Glu Phe Leu Gln
115 120 125

Pro Gly Gly Ser Thr Asn Ser Arg Ala Ala Pro Arg Xaa Ser Ser
130 135 140

Ser Phe Cys Pro Phe Ser Glu Gly Tyr Ser Ser Trp Gly Tyr His
145 150 155

<210> 405
<211> 26
<212> PRT
<213> Homo sapiens

<400> 405
Gly Met Gln Ser Thr Leu Thr Ile Val Ala Lys Lys Ser Arg Asn
1 5 10 15
His Thr Glu Ser Tyr Thr Arg Lys Lys Gln
20 25

<210> 406
<211> 24
<212> PRT
<213> Homo sapiens

<400> 406
Lys Lys His Pro Glu Gly Thr His Thr Cys Ser His Ser Leu Arg Arg
1 5 10 15

Asp Thr Asn Thr Ala Ala Asp Thr
20

<210> 407
<211> 24
<212> PRT
<213> Homo sapiens

<400> 407
Arg Arg Asp Lys Tyr Ser Asp Thr Leu Val Thr His Asp His Tyr Lys
1 5 10 15

Gly Asp Lys His Pro Ser Asn Thr
20

<210> 408
<211> 91
<212> PRT
<213> Homo sapiens

<400> 408
Lys His Leu Pro Leu Lys Ala Pro Ile Asp Leu Asp Asn Lys Ser
1 5 10 15

Cys Met Phe Cys Ser Arg Asp Ile Phe Cys Arg Phe His Ser Thr
20 25 30

Ala Trp Leu Phe Leu Gly Arg Ile Thr Asp Arg Ile Leu Gly Leu His
35 40 45

His Tyr Leu Ile Arg Tyr Gln Phe Glu Ile Glu Asn Leu Cys Leu Met
50 55 60

Lys Ile Val Ile Pro Val Val Ser Met Lys Thr Asn Cys Gln Phe Asp
65 70 75 80

Phe Leu Gly Gln Leu Lys Gln Asn Leu Tyr His
85 90

<210> 409
<211> 28
<212> PRT
<213> Homo sapiens

<400> 409
Ile Glu Asn Leu Cys Leu Met Lys Ile Val Ile Pro Val Val Ser Met
1 5 10 15

Lys Thr Asn Cys Gln Phe Asp Phe Leu Gly Gln Leu
20 25

<210> 410
<211> 21
<212> PRT
<213> Homo sapiens

<400> 410
Ala Pro Ile Asp Leu Asp Asn Lys Asn Ser Cys Met Phe Cys Ser Arg
1 5 10 15

Asp Ile Phe Cys Arg
20

<210> 411
<211> 53
<212> PRT
<213> Homo sapiens

<400> 411
Gly Thr Ser Val Asn Glu Ser Val Ser Asn Ala Thr Ala Ile Asp Ser
1 5 10 15

Gln Ile Ala Arg Ser Leu His Ile Pro Leu Thr Gln Asp Ile Ala Gly
20 25 30

Asp Pro Ser Tyr Glu Ile Ser Lys Gln Arg Leu Ser Ile Val Ile Gly
35 40 45

Val Val Ala Gly Ile
50

<210> 412
<211> 220
<212> PRT
<213> Homo sapiens

<400> 412
Pro Lys Ile Lys Met Ala Met Lys Pro Ala Lys Lys Ile Thr Lys Thr
1 5 10 15

Phe Leu His Pro Asn Ser Met Thr Asn Leu Lys Ser Leu Lys Arg Thr
20 25 30

Arg Lys Thr Lys Asn Leu Ser Ser Leu Ser Thr Ala Ala Leu Ser Leu
35 40 45

Trp Arg Leu Leu Ser Gln Met Asp Arg Gly Met Ile Val Ser Met Arg
50 55 60

Ser Cys Gln Thr Ala Gln Ala Trp Gly Asp Thr Gly Pro Leu Met Val
65 70 75 80

Gly Pro Ala Val Leu Thr Trp Gln Gly Ile Thr Asn Leu Val Pro His
85 90 95

Cys Leu Leu Phe Ser Phe Ile Pro Ser His Gln Leu Gln Glu Lys Asn
100 105 110

Thr Arg Pro Tyr Lys Ile Tyr His Gln Pro Thr His Leu Trp Glu Gln
115 120 125

Glu Thr Thr Phe Gln Leu Asp Gln Ile Thr Ala Leu Ser Thr Ala Val
130 135 140

Lys Pro Ile Thr Ser Thr Ala Asn Arg Cys Val Tyr Ile His Thr Leu
145 150 155 160

Leu Cys Leu Ala Glu Phe His Ser Asn Met Met Leu His Tyr Ala Pro
165 170 175

Tyr Cys Asp Leu Ser Thr Pro Lys Pro Ala Gly Ala Cys Pro Trp
180 185 190

Pro Trp Gly Val Ser Gln Ser Leu Leu Val Pro Leu Val Val His Phe
195 200 205

Ile Phe Glu Ser Phe Ser Phe Ser Tyr Thr Glu Lys
210 215 220

<210> 413
<211> 55
<212> PRT
<213> Homo sapiens

<400> 413
Cys Ser Ile Met His His Thr Val Met Thr Phe Leu Leu Arg Asn Leu
1 5 10 15

Leu Glu Pro Ala Leu Gly Arg Gly Val Ser Ala Asn His Cys Leu Phe
20 25 30

His Leu Leu Tyr Ile Leu Phe Leu Ser Leu Phe Leu Ser His Ile Gln
35 40 45

Lys Asn Ser Met Lys Ile Lys
50 55

<210> 414
<211> 29

<212> PRT
<213> Homo sapiens

<400> 414
Thr Ala Ile Asp Ser Gln Ile Ala Arg Ser Leu His Ile Pro Leu Thr
1 5 10 15

Gln Asp Ile Ala Gly Asp Pro Ser Tyr Glu Ile Ser Lys
20 25

<210> 415
<211> 21
<212> PRT
<213> Homo sapiens

<400> 415
Tyr Cys Arg Ser Lys Asn Lys Asn Gly Tyr Glu Ala Gly Lys Lys Asp
1 5 10 15

His Glu Asp Phe
20

<210> 416
<211> 21
<212> PRT
<213> Homo sapiens

<400> 416
Gly Pro Gly Ser Pro Asp Leu Ala Arg His Tyr Lys Ser Ser Ser Pro
1 5 10 15

Leu Pro Thr Val Gln
20

<210> 417
<211> 25
<212> PRT
<213> Homo sapiens

<400> 417
Leu Pro Pro Ala Asn Thr Phe Val Gly Ala Gly Asp Asn Ile Ser Ile
1 5 10 15

Gly Ser Asp His Cys Ser Glu Tyr Ser
20 25

<210> 418
<211> 119
<212> PRT
<213> Homo sapiens

<400> 418
Gly Thr Ser Asn Ala Ser Val Ser Pro Thr Ile Cys Ile Cys Met Cys
1 5 10 15

Gly Tyr Val His Ile Trp Phe Phe Ile Cys Leu Cys Val Tyr Leu Lys
20 25 30

Val Leu Gln Gly Ser Ala Cys Pro Trp Ile Ala Ala Val Val Met
35 40 45

Arg Arg Met Arg Lys Val Gln Glu Lys Gly Glu Val Phe Arg Asn Met
50 55 60

Ala Ala Thr Trp Ala Leu Arg Ser Gly Ile Gln Ser Leu Asn Ser Leu
65 70 75 80

Val Ser Ser Ala Phe Phe Thr Ile Phe Met Thr Leu Gly Ser Ser Trp
85 90 95

Asn Leu Ile Val Ser Leu Ser Ser Leu Val Asn Trp Thr Gly Leu Phe
100 105 110

Ser Phe Tyr Phe Ser Arg Asn
115

<210> 419
<211> 28
<212> PRT
<213> Homo sapiens

<400> 419
Cys Leu Cys Val Tyr Leu Lys Val Leu Gln Gly Ser Ala Cys Pro Trp
1 5 10 15

Ile Ala Ala Val Val Met Arg Arg Met Arg Lys
20 25

<210> 420
<211> 26
<212> PRT
<213> Homo sapiens

<400> 420
Thr Ile Phe Met Thr Leu Gly Ser Ser Trp Asn Leu Ile Val Ser Leu
1 5 10 15

Ser Ser Leu Val Asn Trp Thr Gly Leu Phe
20 25

<210> 421
<211> 58
<212> PRT
<213> Homo sapiens

<400> 421
Gln Pro Asp Ile Pro Val Leu Pro Val Gly Phe Ser Gln Asn Cys Ser
1 5 10 15

Phe Lys Val Ser Gly Cys Trp Lys Gly Gly Leu Ile Ala Glu Lys Val
20 25 30

Gly Thr Leu Gly Thr Pro Lys Gly Arg Ala Trp Pro Glu Thr Glu
35 40 45

Phe Phe Arg Phe Leu Glu Pro Gly Leu Pro
50 55

<210> 422

<211> 131

<212> PRT

<213> Homo sapiens

<400> 422

Arg Gly Phe Arg Met Ala Gln Pro Leu Val Asn Thr Phe Gln Val Ala
1 5 10 15

Val Pro Val Glu Asp Leu Ala Pro Gln Gln Asn Pro Ser Arg Phe Pro
20 25 30

Ala Asp Pro Ala Leu Leu Ser Phe Leu Thr Gly Ser Ile Leu Ala Pro
35 40 45

Gly Lys Val Ile Trp Val Asn Val Ser Phe Thr Ala Ile Ile Trp Pro
50 55 60

Thr Trp Asp Ser Met Ala Ile Gly Glu Leu Thr Ile Ala Ser His Ala
65 70 75 80

Ser Met Thr Leu His Ile Gly Arg Pro Gly Ser Arg Lys Arg Lys Asn
85 90 95

Ser Val Ser Gly His Ala Arg Leu Pro Phe Gly Val Pro Ser Val Pro
100 105 110

Thr Phe Ser Ala Ile Ser Pro Pro Phe Gln Gln Pro Glu Thr Leu Lys
115 120 125

Glu Gln Phe
130

<210> 423

<211> 24

<212> PRT

<213> Homo sapiens

<400> 423

Glu Asp Leu Ala Pro Gln Gln Asn Pro Ser Arg Phe Pro Ala Asp Pro
1 5 10 15

Ala Leu Leu Ser Phe Leu Thr Gly
20

<210> 424

<211> 29
<212> PRT
<213> Homo sapiens

<400> 424

Thr Trp Asp Ser Met Ala Ile Gly Glu Leu Thr Ile Ala Ser His Ala
1 5 10 15

Ser Met Thr Leu His Ile Gly Arg Pro Gly Ser Arg Lys
20 25

<210> 425

<211> 71

<212> PRT

<213> Homo sapiens

<400> 425

Val Ser Pro Gln Leu Met Gly Ile Lys Arg Glu Pro Ser Ala Ala Gln
1 5 10 15

Leu Ser Val Gly Glu Glu His Thr Leu Asp Arg Glu Gly Arg Glu Leu
20 25 30

Val Asp Leu Pro Gly Gln Pro Ser Gln Lys Ile Lys Ile Lys Asn Lys
35 40 45

Ser Ser Leu His Pro Gly Leu Ile Ile Pro Pro Ala His Tyr Lys Thr
50 55 60

Ala Thr Thr Thr Asn Leu Phe
65 70

<210> 426

<211> 21

<212> PRT

<213> Homo sapiens

<400> 426

Pro Ser Ala Ala Gln Leu Ser Val Gly Glu Glu His Thr Leu Asp Arg
1 5 10 15

Glu Gly Arg Glu Leu
20

<210> 427

<211> 23

<212> PRT

<213> Homo sapiens

<400> 427

Asn Cys Asp His Asp Phe Ile Gln Pro Leu His Thr Pro Met Ser Ala
1 5 10 15

Leu Phe Gln Ser Glu Phe Ser
20

<210> 428
<211> 107
<212> PRT
<213> Homo sapiens

<400> 428
Ser Ile Leu Asn Met Gly Leu Phe Thr Gln Gln Arg Pro Trp Pro Ala
1 5 10 15

Ala Ala Arg Cys Ala Arg Gln Ser Thr Val Ala Gly Ala Ile Arg Arg
20 25 30

Ala Arg Gly Thr Val Thr Met Trp Gln Val Ala Gly Ala Ala Trp Ala
35 40 45

Ser Pro Asp Arg Arg Ala Lys Val His Pro Cys Arg His Ala Ala Pro
50 55 60

Cys Leu Pro Ser Pro Cys Arg Arg Gly Leu Gln Met Ser Gly Pro Leu
65 70 75 80

Gln Ala Thr Arg Gly Arg Val Thr Leu Arg Ser His Gln Val Gly Cys
85 90 95

Lys Arg Ala Thr Gly Ser Ile Gln Asn Ser Leu
100 105

<210> 429
<211> 114
<212> PRT
<213> Homo sapiens

<400> 429
Gln Lys Ser Lys Gly Ser Pro Leu Gln Thr Cys Cys Ser Leu Pro Thr
1 5 10 15

Leu Pro Met Gln Gln Arg Pro Ala Asp Gln Trp Ser Thr Pro Gly Asp
20 25 30

Gln Gly Lys Ser Tyr Ile Lys Lys Pro Pro Gly Gly Leu Gln Lys Gly
35 40 45

His Arg Leu His Arg Lys Leu Thr Leu Lys Gln Gly Arg His Arg Gly
50 55 60

Val Gln Gly Leu Asn Gln Ile Met Val Thr Val Leu Lys Gln Gln Phe
65 70 75 80

Pro Val Ser Lys Pro Gly Leu Asn Val Leu Pro Thr Phe His Arg His
85 90 95

His Gln Cys Tyr Gln His Gly Met Asn Leu Thr Ala Arg Ile Ser Val
100 105 110

Val Ser 1

<210> 430
<211> 25
<212> PRT
<213> Homo sapiens

<400> 430
Ala Arg Gln Ser Thr Val Ala Gly Ala Ile Arg Arg Ala Arg Gly Thr
1 5 10 15

Val Thr Met Trp Gln Val Ala Gly Ala
20 25

<210> 431
<211> 25
<212> PRT
<213> Homo sapiens

<400> 431
Pro Cys Arg Arg Gly Leu Gln Met Ser Gly Pro Leu Gln Ala Thr Arg
1 5 10 15

Gly Arg Val Thr Leu Arg Ser His Gln
20 25

<210> 432
<211> 26
<212> PRT
<213> Homo sapiens

<400> 432
Leu Pro Met Gln Gln Arg Pro Ala Asp Gln Trp Ser Thr Pro Gly Asp
1 5 10 15

Gln Gly Lys Ser Tyr Ile Lys Lys Pro Pro
20 25

<210> 433
<211> 23
<212> PRT
<213> Homo sapiens

<400> 433
Asn Val Leu Pro Thr Phe His Arg His His Gln Cys Tyr Gln His Gly
1 5 10 15

Met Asn Leu Thr Ala Arg Ile
20

<210> 434
<211> 40
<212> PRT

<213> Homo sapiens

<400> 434

Ile Asn Val Leu Tyr Cys Ser Arg Asp Ser Leu Met Gly Arg Thr Ile
1 5 10 15

Met Glu Ser Ser Asp Tyr Ile Lys Lys Gly Ala Asn Val Ser Pro Val
20 25 30

Leu Gly Val Arg Gln Gln Ala Val
35 40

<210> 435

<211> 28

<212> PRT

<213> Homo sapiens

<400> 435

Ser Leu Leu Met Tyr Phe Val Phe Lys Ile Phe Phe Gln Ser Leu Cys
1 5 10 15

Val Leu Gly Tyr Cys Ile Leu Pro Leu Thr Val Ala
20 25

<210> 436

<211> 50

<212> PRT

<213> Homo sapiens

<400> 436

Arg Leu Trp Met Thr Lys Ala His Pro Ala Leu Arg His Leu Leu Leu
1 5 10 15

Leu Phe Thr Leu Ala Leu Thr Leu Leu Ala Gln Gly Cys Cys Ala Val
20 25 30

Ala Pro Ser Gly Cys Ala Asp Leu Ala Gly Phe Cys Ser Leu Gly His
35 40 45

Ser Cys

50

<210> 437

<211> 48

<212> PRT

<213> Homo sapiens

<400> 437

Arg Thr Cys Thr Pro Trp Met Gly Phe Trp Cys Leu Val Cys Ser Leu
1 5 10 15

Phe Ala Pro Val Pro Thr Ser Arg Lys Tyr Leu Val Ser Lys Pro Gly
20 25 30

Cys Tyr Gln Arg Arg Arg Val Phe Gly Val Cys Phe Thr Lys Pro Leu

35 40 45

<210> 438

<211> 8

<212> PRT

<213> Homo sapiens

<400> 438

Trp Leu Leu Ser Glu Lys Lys Gly
1 5

<210> 439

<211> 10

<212> PRT

<213> Homo sapiens

<400> 439

Gly Val Phe Tyr Lys Ala Ala Val Ile Gly
1 5 10

<210> 440

<211> 45

<212> PRT

<213> Homo sapiens

<400> 440

Cys Lys Thr Ser Pro Leu Pro Lys Glu Gly Gln Ser Ala Val Ser Val
1 5 10 15

Pro Val Ser Ser His Phe Leu Ala His Ser Ala Pro Leu Ser Gly Gly
20 25 30

His Ala His Val Phe Ala Arg Asp Gly Ala Thr Gly Leu
35 40 45

<210> 441

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 441

Leu Gly Arg Gly Ser Gly Glu Arg Lys Thr Pro Val Ser Cys Phe Ala
1 5 10 15

Gln Ile Ser Lys Ser Arg Gly Glu Arg Ser Lys Ser Leu Thr His Leu
20 25 30

Cys Thr His Thr His Thr Gln Val Thr Glu Leu Asp Val Arg Met Ser
35 40 45

His Gly Cys Leu Arg Xaa Gln His Ala Gly Arg Leu Ala Pro Pro Pro
50 55 60

Pro Leu Arg Phe Cys Leu Thr Ala Cys Trp Gly Arg Arg Gly Glu Ala
65 70 75 80

Glu Thr Val Trp Lys Asp Pro Ala Ser Ser Gln His Pro Pro Ser
85 90 95

Glu Lys Pro His Arg Gln Asp Arg His Pro Glu Arg Trp His Gln Pro
100 105 110

Gly Gly Pro Ile Pro Gly Lys His Met Arg Val Ser Pro Gly Gln Arg
115 120 125

Gly Arg Val Cys Gln Glu Met Gly Arg Asn Arg Asn
130 135 140

<210> 442

<211> 102

<212> PRT

<213> Homo sapiens

<400> 442

Phe Cys Leu Arg Asp Phe Lys Ile Trp Arg Gly Arg Leu Glu Ala Gly
1 5 10 15

Arg Thr Glu Gly Arg Leu Ala Gly Glu Arg Phe Gly Gly Glu Glu Asp
20 25 30

Pro Ser Phe Leu Phe Cys Ser Asp Phe Lys Val Glu Gly Trp Ala Phe
35 40 45

Glu Ile Ser His Ser Leu Val His Thr His Thr Gly His Gly
50 55 60

Ala Gly Arg Ala Asp Val Thr Arg Val Pro Ala Gly Thr Ala Arg Trp
65 70 75 80

Glu Ala Gly Ser Pro Thr Pro Ser Pro Val Leu Phe Asp Ser Leu Leu
85 90 95

Gly Ala Ala Gly Arg Gly
100

<210> 443

<211> 28

<212> PRT

<213> Homo sapiens

<400> 443

Ala Gln Ile Ser Lys Ser Arg Gly Gly Arg Ser Lys Ser Leu Thr His

Leu Cys Thr His Thr His Thr Gln Val Thr Glu Leu
20 25

<210> 444

<211> 26

<212> PRT

<213> Homo sapiens

<400> 444

Glu Lys Pro His Arg Gln Asp Arg His Pro Glu Arg Trp His Gln Pro
1 5 10 15

Gly Gly Pro Ile Pro Gly Lys His Met Arg
20 25

<210> 445

<211> 26

<212> PRT

<213> Homo sapiens

<400> 445

Gly Arg Leu Glu Ala Gly Arg Thr Glu Gly Arg Leu Ala Gly Glu Arg
1 5 10 15

Phe Gly Gly Glu Glu Asp Pro Ser Phe Leu
20 25

<210> 446

<211> 23

<212> PRT

<213> Homo sapiens

<400> 446

Val Thr Arg Val Pro Ala Gly Thr Ala Arg Trp Glu Ala Gly Ser Pro
1 5 10 15

Thr Pro Ser Pro Val Leu Phe
20

<210> 447

<211> 31

<212> PRT

<213> Homo sapiens

<400> 447

Asp Glu Gly Val Gln Gly Glu Arg Leu Phe Arg Ile Leu Arg Ile Asn
1 5 10 15

Gly Glu Lys Pro Tyr Asn Phe Val Asp Tyr Phe His Cys Glu Tyr
20 25 30

<210> 448
<211> 111
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (62)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (66)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 448
Lys Val Val Arg Ile Asp Asn Gly Ile Leu Cys Ser His Lys Lys Thr
1 5 10 15

Glu Ile Met Ser Leu Gln His Gly Trp Ile Trp Arg Pro Tyr Leu
20 25 30

Lys Gln Thr Asn Thr Gly Thr Glu Asn Gln Ile Pro His Thr Leu Thr
35 40 45

Tyr Lys Trp Glu Leu Asn Phe Glu Tyr Ile Xaa Thr Gln Xaa Arg Gly
50 55 60

Xaa Xaa Asp Ser Glu Ala Tyr Leu Lys Val Glu Gly Gly Arg Arg Glu
65 70 75 80

Gly Ile Gln Lys Leu Pro Ile Arg Tyr Tyr Val Tyr Tyr Leu Gly Asp
85 90 95

Lys Ile Ile Cys Thr Ser Ser Cys Ser Met His Leu Leu Met
100 105 110

<210> 449
<211> 21
<212> PRT
<213> Homo sapiens

<400> 449
His Lys Asp Thr Cys Met Ser Met Phe Thr Ala Ala Leu Phe Thr Ile
1 5 10 15

Ala Lys Thr Trp Asn

20

<210> 450
<211> 14
<212> PRT
<213> Homo sapiens

<400> 450
Met Pro Ile Asn Asp Arg Leu Asp Phe Lys Arg Trp Tyr Val
1 5 10

<210> 451
<211> 47
<212> PRT
<213> Homo sapiens

<400> 451
Thr Met Glu Ser Tyr Val Ala Ile Lys Arg Gln Arg Ser Cys Pro Cys
1 5 10 15

Ser Asn Met Val Gly Ser Gly His Ile Leu Ser Lys Leu Thr Gln
20 25 30

Glu Gln Lys Thr Lys Tyr His Ile Leu Ser Leu Ile Ser Gly Ser
35 40 45

<210> 452
<211> 25
<212> PRT
<213> Homo sapiens

<400> 452
Glu Ile Met Ser Leu Gln Gln His Gly Trp Ile Trp Arg Pro Tyr Leu
1 5 10 15

Lys Gln Thr Asn Thr Gly Thr Glu Asn
20 25

<210> 453
<211> 24
<212> PRT
<213> Homo sapiens

<400> 453
Arg Arg Glu Gly Ile Gln Lys Leu Pro Ile Arg Tyr Tyr Val Tyr Tyr
1 5 10 15

Leu Gly Asp Lys Ile Ile Cys Thr
20

<210> 454
<211> 57
<212> PRT

<213> Homo sapiens
 <400> 454
 Leu His Gly Glu Gln Val Pro Ile Tyr Ile Phe Leu Leu Met Gln Pro
 1 5 10 15
 Leu Asn Phe Glu Cys Ile Ser Phe Leu Asn Cys Ile Glu Gln Tyr Ser
 20 25 30
 Val Gly Val Ile His Asn Ser Val Thr Ile Tyr Ala Cys Asp Arg Glu
 35 40 45
 Glu Asn Cys Met Asp Ile Arg Tyr Leu
 50 55
 <210> 455
 <211> 12
 <212> PRT
 <213> Homo sapiens
 <400> 455
 Gly Thr Ser Trp Ala Ser Arg Phe Phe Thr Cys His
 1 5 10
 <210> 456
 <211> 52
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (18)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 456
 Gly Pro Pro Arg Xaa Phe Xaa Pro Lys Lys Ala Ile Leu Gly Xaa Pro

1 5 10 15
 Pro Xaa Gly Arg Val Pro Pro Phe Arg Tyr Arg Ser Arg Asn Ser Arg
 20 25 30
 Gly Arg Pro His Xaa Ser Ala Pro Arg Val Arg Phe Cys Leu Glu Asn
 35 40 45
 Ser Trp Leu Arg
 50
 <210> 457
 <211> 72
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (56)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 457
 Pro Leu Asn Thr Met Met Cys Met Met Cys Lys Met Lys Val Ser Pro
 1 5 10 15
 Lys Ile Phe Ser Lys Leu Lys Arg Lys Tyr Leu Asn Ser Asn Thr Leu
 20 25 30
 Thr Lys Leu Glu Met Gln Thr Val His Leu Glu Ser Ser Leu Ala Ser
 35 40 45
 Cys Ser Pro Asn Lys Ser Gly Xaa Val Gly Arg Thr Arg Gly Val Asp
 50 55 60
 Pro Gly Asn Ser Gly Thr Gly Thr
 65 70
 <210> 458
 <211> 69
 <212> PRT
 <213> Homo sapiens
 <400> 458
 Gly Thr Val Thr Gln Lys Arg Lys Cys Val Phe Gly Lys Tyr Leu Leu
 1 5 10 15
 Ser Thr Cys Ser Leu Met Phe Ser Ser Met His Gly Ala Cys Ser Trp
 20 25 30
 Lys Ala Lys Gln Thr Ser Ser Ala Gly Phe Leu Cys Leu His Val
 35 40 45
 Leu Cys Pro Ala Leu Gln Leu Thr Arg Glu Lys Tyr Lys Thr Trp Pro
 50 55 60
 Trp Pro Ser Phe Ile

65

<210> 459

<211> 69

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 459

Met Lys Glu Gly Gln Gly His Val Leu Tyr Phe Ser Arg Val Asn Cys
1 5 10 15

Lys Ala Gly His Xaa Thr Cys Arg Gln Arg Lys Pro Ala Asp Glu Leu
20 25 30

Val Cys Phe Ala Phe Gln Glu Gln Ala Pro Cys Ile Leu Leu Asn Ile
35 40 45

Arg Leu Gln Val Leu Asn Lys Tyr Leu Pro Asn Thr His Phe Leu Phe
50 55 60

Cys Val Thr Val Pro
65

<210> 460

<211> 69

<212> PRT

<213> Homo sapiens

<400> 460

Thr Met Thr Gly Ile Asp Ser Ser Pro Glu Glu Ile Leu Arg Gln Val
1 5 10 15

Gly Cys Lys Gln Gln Gln Gly Lys Gly Val Glu His Val Glu Gly Ser
20 25 30

Ser Ala Glu Ala Gly Glu Ala Ala Arg Gly Gly Gly Ala Lys Gly Gly
35 40 45

Gly Gly Ala Ala Gly Lys Gly Thr Ser Lys Val Gly Thr Leu Arg Arg
50 55 60

Thr Arg Gly Ser Thr
65

<210> 461

<211> 185

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 461

Ala Gln Arg Glu Ala Gly Ser Arg Pro Arg Arg Arg Lys Ser Leu Lys
1 5 10 15

Ala Val Ala Met Leu Xaa Val Glu Met Gly Gly Cys Arg Gly Ser
20 25 30

Met Gly Pro Gly Pro Gly Tyr Ser Ala Gly Ser Arg Val Cys Arg Gly
35 40 45

Ser Ser Leu Pro Gln Val Ala Pro Phe Asn Pro Ser Arg Ala His Leu
50 55 60

Leu Pro Pro Pro Val Gly Gly Leu Asn Ser Val Trp Leu Ser Gly
65 70 75 80

Val Gln Leu Ser Thr Pro Tyr Ala Asp Trp Glu Gly Val Gly Gln
85 90 95

Ser Pro Gln Pro Arg Gly Pro Trp Met Gly Ser Ser Ser Leu Gly Thr
100 105 110

Val Gly Pro Gly Cys Val Leu Ser Gly Cys Pro Thr Val Lys Ala Asn
115 120 125

Gly Gly Ser Pro Cys Ser Glu Met Leu Gly Glu Arg Arg Leu Glu
130 135 140

Pro Ser Val Gly Pro Val Ser Gly Cys Pro Glu Arg Arg Glu Gly Gly
145 150 155 160

His Gly Ala Arg Gly Ala Ala Gly Val Val Lys Gly His Ala Ser
165 170 175

Val Gln Leu Asn Phe Leu Ser Leu Ile
180 185

<210> 462

<211> 102

<212> PRT

<213> Homo sapiens

<400> 462

Lys Ala Glu Phe Thr Phe Ala Lys Glu Lys Asn Ala Lys Ala Gln Leu
1 5 10 15

Gly Lys Lys Gly Thr Arg Trp Val Lys His Asp Lys Arg Lys Glu Ile
20 25 30

Gln Leu Tyr Gly Cys Val Thr Leu Asn Asp Pro Ser Cys Pro Pro
35 40 45

Cys Pro Val Pro Thr Leu Pro Pro Phe Thr Trp Thr Ala Thr Tyr Gly Ser

50 55 60
His Gly Arg Phe Gln Lys Pro Phe Ser Gln His Leu Arg Ala Gly
65 70 75 80
Gly Ala Pro Val Gly Leu Asp Cys Gly Ala Pro Thr Gln Tyr Ala Ala
85 90 95
Arg Pro His Gly Pro Lys
100
<210> 463
<211> 26
<212> PRT
<213> Homo sapiens
<400> 463
Gly Cys Arg Gly Ser Met Gly Pro Gly Pro Gly Tyr Ser Ala Gly Ser
1 5 10 15
Arg Val Cys Arg Gly Ser Ser Leu Pro Gln
20 25
<210> 464
<211> 22
<212> PRT
<213> Homo sapiens
<400> 464
Gln Pro Arg Gly Pro Trp Met Gly Ser Ser Ser Leu Gly Thr Val Gly
1 5 10 15
Pro Gly Cys Val Leu Ser
20
<210> 465
<211> 21
<212> PRT
<213> Homo sapiens
<400> 465
Gly Ala Ala Gly Val Val Val Lys Gly His Ala Ser Val Gln Leu Asn
1 5 10 15
Phe Leu Ser Leu Ile
20
<210> 466
<211> 94
<212> PRT
<213> Homo sapiens
<400> 466
Gly Lys Pro Leu Ser Ala Ile Phe Pro Ile Cys His Met Met Phe Leu

1 5 10 15
Pro Gly Lys Phe Asn Leu Gly Ile Ser His Arg Cys Arg Met Thr
20 25 30
Ser Pro Trp Asp Lys Arg Gln Gln Leu Arg Gln Glu Cys Lys Ser Asp
35 40 45
Pro His Val Gln Asn Pro Arg Ile His Phe Pro Glu Ser Lys Asn Ser
50 55 60
Phe Pro Ser Ala Tyr Ile Phe Val Ser Glu Gly Asn Gly Val Ser Pro
65 70 75 80
Ser Lys Trp His Cys Ile Tyr Ser Gly Thr Ser Leu Ser His
85 90
<210> 467
<211> 62
<212> PRT
<213> Homo sapiens
<400> 467
Gly Glu Arg Gly Arg Tyr Gln Ser Lys Tyr Ser Ala Thr Trp Met Val
1 5 10 15
Thr Pro His Tyr Leu Gln Thr Gln Arg Cys Lys Leu Arg Glu Met Asn
20 25 30
Ser Trp Ile Gln Gly Asn Glu Phe Leu Asp Ser Glu His Gly Gly Gln
35 40 45
Ile Tyr Ile Pro Val Ser Ile Val Asp Ala Tyr Pro Lys Asp
50 55 60
<210> 468
<211> 107
<212> PRT
<213> Homo sapiens
<400> 468
Ile Ser Ile Arg Gly Arg Ile Leu Tyr Lys Met Ala Tyr Phe Lys Val
1 5 10 15
Cys Val Ile Ile Trp Phe Gln Gln Phe Cys Val Glu Glu Thr Ser Ile
20 25 30
Ile Lys Asn Val Arg Met Leu Thr Ser Glu Phe Gln Asn Ser Tyr Ala
35 40 45
Thr Pro Val Ser Gly Leu Leu Pro Gly Ala Val Ala Trp Arg Gly Gly
50 55 60
Ala Val Tyr Gly Trp Val Arg His Ala Met Gln Val Leu Gln Lys Glu
65 70 75 80

Pro Thr Gln Pro Ser Ser Phe Leu Pro Pro Ser Asp Ala Ala Ser Phe
85 90 95

Trp Gly Pro Glu Ser Arg Leu His Leu Thr Trp
100 105

<210> 469

<211> 86

<212> PRT

<213> Homo sapiens

<400> 469

Lys Pro Phe Ala Phe Ser Ala Arg Asn Phe Pro Thr Met Leu Ser Glu
1 5 10 15

Ala Tyr Phe Gln Asp Pro Arg Met Arg Gln His His Leu Gly Val Glu
20 25 30

Arg Met Thr Val Ala Trp Val Pro Ser Ala Ile Pro Ala Trp Arg Ala
35 40 45

Ser Pro Thr Arg Thr Gln His His Pro Ser Lys Pro Gln His Gln Glu
50 55 60

Gly Ala Gln Lys Gln Gly Trp His Met Asn Ser Gly Ile Leu Met Ser
65 70 75 80

Ala Tyr Glu His Phe Leu
85

<210> 470

<211> 60

<212> PRT

<213> Homo sapiens

<400> 470

His Ser Lys Gln Asn Ile Cys Arg Glu Val Asn Ile Leu Lys Met Phe
1 5 10 15

Leu His Glu Ile Lys Lys Thr Val Thr Asp Asn Ile Ser Thr Gln Arg
20 25 30

Arg Phe Thr Tyr Asn His Gln Pro Gly Ser Val Ser Ile Phe Ser Val
35 40 45

Thr Asp Ile Leu Asp Phe Glu Val Pro Phe Gly Leu
50 55 60

<210> 471

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 471

Lys Val Ile Asp Val Ile Phe Ser Leu Pro Pro Gly Arg Lys Ala Thr
1 5 10 15

Phe Ser Cys Pro Leu Ala Pro Leu Ser Gly Ala Xaa Gly Leu Pro Gly
20 25 30

Gly Gly Ala Asn Arg Pro Gly Pro Phe Leu Pro Cys Ile Gln Pro Trp
35 40 45

Gly Pro Leu Arg Leu Pro Glu Gly Cys
50 55

<210> 472

<211> 80

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 472

Met Ser Ser Ser Leu Cys Pro Gln Gly Lys Pro Pro Ser Leu Ala
1 5 10 15

Pro Trp Pro Leu Cys Gln Gly Pro Xaa Val Cys Arg Val Gly Val Pro
20 25 30

Thr Gly Leu Ala Leu Ser Ser Pro Ala Ser Ser His Gly Lys Cys
35 40 45

Asp Cys Arg Lys Val Ala Trp Leu Val Pro Gly Pro Ala Gln Ala Arg
50 55 60

Gly Arg Ala Ala Trp Phe Tyr Phe Thr Leu Thr Leu Phe Ser Val Leu
65 70 75 80

<210> 473

<211> 26

<212> PRT

<213> Homo sapiens

<400> 473

Leu Ala Leu Ser Ser Pro Ala Ser Ser His Gly Gly Leu Cys Asp Cys
1 5 10 15

Arg Lys Val Ala Trp Leu Val Pro Gly Pro
20 25

<210> 474
 <211> 160
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (124)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 474
 Met Gln Arg Glu Arg Trp Ala Arg Pro Trp Met Ala Ser Thr Val Gln
 1 5 10 15
 Ser Arg Met Pro Gln Gly Lys Trp Arg Arg Phe Ser Thr Asp Leu Ala
 20 25 30
 Thr Trp Gly Ala Thr Pro Ala Arg Ser Trp Thr Lys Ala Ser Arg Gly
 35 40 45
 Ser Thr Thr Ala Trp Thr Arg Leu Pro Met Arg Ser Thr Met Val Leu
 50 55 60
 Asp Lys Gln Glu Arg Lys Gln Arg Ser Leu Ala Met Gly Ser Thr Thr
 65 70 75 80
 Leu Leu Asp Arg Pro Gly Arg Lys Gln Thr Lys Arg Ser Lys Gly Ser
 85 90 95
 Thr Leu Gly Ser Thr Arg Leu Gly Arg Lys Gln Arg Asn Leu Ala Lys
 100 105 110
 Gly Ser Thr Met Leu Leu Thr Arg Leu Glu Arg Xaa Trp Arg Ser Leu
 115 120 125
 Ala Gln Val Pro Thr Met Leu Leu Ala Arg Pro Gly Arg Ser Cys Arg
 130 135 140
 Met Leu Ile Met Gly Ser Thr Lys Pro Ala Arg Arg Pro Thr Ser Cys
 145 150 155 160

<210> 475
 <211> 264
 <212> PRT
 <213> Homo sapiens

<400> 475
 Met Arg Pro Leu Leu Gly Leu Leu Val Phe Ala Gly Cys Thr Phe
 1 5 10 15
 Ala Leu Tyr Leu Leu Ser Thr Arg Leu Pro Arg Gly Arg Arg Leu Gly
 20 25 30

Ser Thr Gln Glu Ala Gly Gly Arg Ser Leu Trp Phe Pro Ser Asp Leu
 35 40 45
 Ala Glu Leu Arg Glu Leu Ser Glu Val Leu Arg Glu Tyr Arg Lys Gln
 50 55 60
 His Gln Ala Tyr Val Phe Leu Leu Phe Cys Gly Ala Tyr Leu Tyr Lys
 65 70 75 80
 Gln Gly Phe Ala Ile Pro Gly Ser Ser Phe Leu Asn Val Leu Ala Gly
 85 90 95
 Ala Leu Phe Gly Pro Trp Leu Gly Leu Leu Cys Cys Val Leu Thr
 100 105 110
 Ser Val Gly Ala Thr Cys Cys Tyr Leu Leu Ser Ser Ile Phe Gly Lys
 115 120 125
 Gln Leu Val Val Ser Tyr Phe Pro Asp Lys Val Ala Leu Leu Gln Arg
 130 135 140
 Lys Val Glu Glu Asn Arg Asn Ser Leu Phe Phe Phe Leu Leu Phe Leu
 145 150 155 160
 Arg Leu Phe Pro Met Thr Pro Asn Trp Phe Leu Asn Leu Ser Ala Pro
 165 170 175
 Ile Leu Asn Ile Pro Ile Val Gln Phe Phe Phe Ser Val Leu Ile Gly
 180 185 190
 Leu Ile Pro Tyr Asn Phe Ile Cys Val Gln Thr Gly Ser Ile Leu Ser
 195 200 205
 Thr Leu Thr Ser Leu Asp Ala Leu Phe Ser Trp Asp Thr Val Phe Lys
 210 215 220
 Leu Leu Ala Ile Ala Met Val Ala Leu Ile Pro Gly Thr Leu Ile Lys
 225 230 235 240
 Lys Phe Ser Gln Lys His Leu Gln Leu Asn Glu Thr Ser Thr Ala Asn
 245 250 255
 His Ile His Ser Arg Lys Asp Thr
 260

<210> 476
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 476
 Asp Ile Met Pro Ala Ser Val Ile Phe Leu Ile Cys Glu Gly Val Leu
 1 5 10 15
 Tyr Gly Val Gln Gly
 20

35

<210> 479
 <211> 131
 <212> PRT
 <213> Homo sapiens

<400> 479
 Ala Arg Ala Leu Pro Glu Ile Lys Gly Ser Arg Leu Gln Glu Ile Asn
 1 5 10 15

Asp Val Cys Ala Ile Cys Tyr His Glu Phe Thr Thr Ser Ala Arg Ile
 20 25 30

Thr Pro Cys Asn His Tyr Phe His Ala Leu Cys Leu Arg Lys Trp Leu
 35 40 45

Tyr Ile Gln Asp Thr Cys Pro Met Cys His Gln Lys Val Tyr Ile Glu
 50 55 60

Asp Asp Ile Lys Asp Asn Ser Asn Val Ser Asn Asn Asn Gly Phe Ile
 65 70 75 80

Pro Pro Asn Glu Thr Pro Glu Glu Ala Val Arg Glu Ala Ala Glu
 85 90 95

Ser Asp Arg Glu Leu Asn Glu Asp Asp Ser Thr Asp Cys Asp Asp Asp
 100 105 110

Val Gln Arg Glu Arg Asn Gly Val Ile Gln His Thr Gly Ala Ala Ala
 115 120 125

Gly Arg Ile
 130

<210> 480
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 480
 Phe Ser Thr Gln Ala Gln Gln Leu Glu Glu Phe Asn Asp Asp Thr Asp
 1 5 10 15

<210> 481
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 481
 Arg Leu Gln Glu Ile Asn Asp Val Cys Ala Ile Cys Tyr His Glu Phe
 1 5 10 15

<210> 477
 <211> 180
 <212> PRT
 <213> Homo sapiens

<400> 477
 Gly Thr Ala Phe Gln His Ala Phe Ser Thr Asn Asp Cys Ser Arg Asn
 1 5 10 15

Val Tyr Ile Lys Lys Asn Gly Phe Thr Leu His Arg Asn Pro Ile Ala
 20 25 30

Gln Ser Thr Asp Gly Ala Arg Thr Lys Ile Gly Phe Ser Glu Gly Arg
 35 40 45

His Ala Trp Glu Val Trp Trp Glu Gly Pro Leu Gly Thr Val Ala Val
 50 55 60

Ile Gly Ile Ala Thr Lys Arg Ala Pro Met Gln Cys Gln Gly Tyr Val
 65 70 75 80

Ala Leu Leu Gly Ser Asp Asp Gln Ser Trp Gly Trp Asn Leu Val Asp
 85 90 95

Asn Asn Leu Leu His Asn Gly Glu Val Asn Gly Ser Phe Pro Gln Cys
 100 105 110

Asn Asn Ala Pro Lys Tyr Gln Ile Gly Glu Arg Ile Arg Val Ile Leu
 115 120 125

Asp Met Glu Asp Lys Thr Leu Ala Phe Glu Arg Gly Tyr Glu Phe Leu
 130 135 140

Gly Val Ala Phe Arg Gly Leu Pro Lys Val Cys Leu Tyr Pro Ala Val
 145 150 155 160

Ser Ala Val Tyr Gly Asn Thr Glu Val Thr Leu Val Tyr Leu Gly Lys
 165 170 175

Pro Leu Asp Gly
 180

<210> 478
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 478
 Ala Arg Ala Phe Gln His Leu Met Val Ala Asp His Ser His Phe His
 1 5 10 15

Arg Thr Leu Ile Lys Gln Pro Ser Met Ile Pro Asn Ala Thr Phe Tyr
 20 25 30

His Ile Phe

Thr Thr Ser Ala Arg Ile
20

<210> 482

<211> 20

<212> PRT

<213> Homo sapiens

<400> 482

Leu Tyr Ile Gln Asp Thr Cys Pro Met Cys His Gln Lys Val Tyr Ile
1 5 10 15

Glu Asp Asp Ile
20

<210> 483

<211> 21

<212> PRT

<213> Homo sapiens

<400> 483

Val Ser Asn Asn Asn Gly Phe Ile Pro Pro Asn Glu Thr Pro Glu Glu
1 5 10 15

Ala Val Arg Glu Ala
20

<210> 484

<211> 26

<212> PRT

<213> Homo sapiens

<400> 484

Asp Asp Ser Thr Asp Cys Asp Asp Val Gln Arg Glu Arg Asn Gly
1 5 10 15

Val Ile Gln His Thr Gly Ala Ala Gly
20 25

<210> 485

<211> 141

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 485

Val Ala Gly Ile Thr Gly Ala His His His Ala Gln Leu Ile Phe Val
1 5 10 15

Leu Leu Val Glu Met Gly Phe His His Val Gly Gln Ala Gly Leu Lys
20 25 30

Leu Leu Thr Ser Asp Asn Pro Arg Thr Ser Ala Ser Gln Ser Ala Gly
35 40 45

Ile Thr Gly Met Ser Xaa Gly Arg Arg Ile Thr Cys Gly Gln Glu Phe
50 55 60

Lys Thr Ala Val Ser Tyr Asn Cys Thr Thr Ala Leu Gln Pro Asp Arg
65 70 75 80

Ala Lys Leu Cys Phe Leu Phe Lys Lys Lys Lys Ile Ser Ile Gln
85 90 95

Arg Thr Leu Pro Gly Ile Lys Arg Val Ile Tyr Asn Tyr Glu Arg Val
100 105 110

Asp Ser Ser Lys Gly His Asn Ser Gln Val Gln Trp Ala His Ala Cys
115 120 125

Asn Pro Ser Thr Leu Gly Gly Arg Gly Gly Gln Ile Val
130 135 140

<210> 486

<211> 22

<212> PRT

<213> Homo sapiens

<400> 486

Ala Gly Ile Thr Gly Ala His His His Ala Gln Leu Ile Phe Val Leu
1 5 10 15

Leu Val Glu Met Gly Phe
20

<210> 487

<211> 27

<212> PRT

<213> Homo sapiens

<400> 487

Arg Val Ile Tyr Asn Tyr Glu Arg Val Asp Ser Ser Lys Gly His Asn
1 5 10 15

Ser Gln Val Gln Trp Ala His Ala Cys Asn Pro
20 25

<210> 488

<211> 106

<212> PRT

<213> Homo sapiens

<400> 488

Ala Gly Ala Glu Val Val Met Leu Phe Leu Leu Thr Thr Ser Ser His

1 His Gln His Glu Cys Val Arg Arg Ala Phe Glu Cys Gly Asp Cys His
20 25 15
Ile Leu Leu Asp Asn Asn Val Leu Gly Val Asp Cys His Gly Ala Gly
35 40 45
Glu Arg Ala Val His Leu Glu Asp His Phe Val His Ile Asp Thr Ile
50 55 60
Ser Leu Leu Leu Glu Asp Ala Leu Glu Tyr Ser Ala Leu Ile Ala Gly
65 70 75 80
His Pro Lys Ser Asp Leu Pro Pro Gly Leu Ser Arg Cys Arg Pro Trp
85 90 95
Glu His His Trp Pro Ile Ser Tyr Thr Gly
100 105

<210> 489
<211> 64
<212> PRT
<213> Homo sapiens

<400> 489
Thr Ile Ser Tyr Leu Cys Asn Asn Val Ser Tyr Met Gln Leu Gln Lys
1 5 10 15
Leu Val Gly Lys Ser Met Ile Phe Leu Pro Tyr Ser Leu Pro Ile His
20 25 30
Leu Pro Gly Asn His Arg Leu Leu Pro Arg Val Gly Met Arg Leu
35 40 45
Arg Gly Cys Cys Phe Ser Pro Tyr Ile Ile Thr Asp Phe Lys Trp Cys
50 55 60




<210> 490
<211> 58
<212> PRT
<213> Homo sapiens

<400> 490
Glu Met Gly Gln Trp Cys Ser Gln Gly Leu His Leu Asp Ser Pro Gly
1 5 10 15
Gly Lys Ser Asp Phe Gly Cys Pro Ala Ile Asn Ala Glu Tyr Ser Arg
20 25 30
Ala Ser Ser Lys Ser Arg Leu Met Val Ser Met Trp Thr Lys Trp Ser
35 40 45

Ser Arg Cys Thr Ala Leu Ser Pro Ala Pro
50 55
<210> 491
<211> 25
<212> PRT
<213> Homo sapiens
<400> 491
Arg Ala Phe Glu Cys Gly Asp Cys His Ile Leu Leu Asp Asn Val
1 5 10 15
Leu Gly Val Asp Cys His Gly Ala Gly
20 25
<210> 492
<211> 23
<212> PRT
<213> Homo sapiens
<400> 492
Leu Val Gly Lys Ser Met Ile Phe Leu Pro Tyr Ser Leu Pro Ile His
1 5 10 15
Leu Pro Gly Asn His Arg Leu
20

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>212</u> , line <u>N/A</u> .					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution American Type Culture Collection ("ATCC")					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit 25 SEPTEMBER 1997	Accession Number 209229				
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
DNA Plasmid No. PS062					
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
<table border="0"> <tr> <td>For receiving Office use only</td> <td>For International Bureau use only</td> </tr> <tr> <td> <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division  </td> <td> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer </td> </tr> </table>		For receiving Office use only	For International Bureau use only	<input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division 	<input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
For receiving Office use only	For International Bureau use only				
<input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division 	<input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer				

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 215, line N/A	
B. IDENTIFICATION OF DEPOSIT <input checked="" type="checkbox"/> Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 25 SEPTEMBER 1997	Accession Number 209300
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA Plasmid No. PS063 In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application	
For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer Sonya Bernas PCT International Division	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Registrations), or has been finally decided upon by the National Board of Patents and Registrations without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 220, line N/A	
B. IDENTIFICATION OF DEPOSIT <input checked="" type="checkbox"/> Further deposits are identified on an additional sheet	
Name of depository institution American Type Culture Collection	
Address of depository institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 02 OCTOBER 1997	Accession Number 209324
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <input type="checkbox"/> This information is contained on an additional sheet	
DNA Plasmid No. PS064	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer Sonya Barnes PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

DENMARK


The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

A. The indications made below relate to the microorganism referred to in the description on page <u>225</u> line <u>NA</u>	
B. IDENTIFICATION/DEPOSIT	Further deposit is identified on an additional sheet <input type="checkbox"/>
Name of depository institution American Type Culture Collection ("ATCC")	
Address of depository institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit: <u>09 OCTOBER 1997</u>	Accession Number: <u>209346</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	This information is continued on an additional sheet <input type="checkbox"/>
DNA Plasmid No. PS065	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Sonya Barnes PCT International Division	Authorized officer
	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 3 IF(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23376

A. CLASSIFICATION OF SUBJECT MATTER

IPC(9) : Please See Extra Sheet.
US CL. : Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 33623.5, 23.1; 439220.1, 440, 232.3, 69.1, 7.1; 530250, 387.1; 514/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (Name of data base and, where practicable, search terms used)

Please See Extra Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
-----------	--	-----------------------

A	ADAMS et al. Complementary DNA sequencing: Expressed sequence tags and the human genome project. Science. 21 June 1991, Vol. 252, pages 1651-1656, see entire document.	1-22
---	---	------

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*+ User documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention seems to be a further development of the invention
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention seems to be a further development of the invention
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (see specification)	*Y* document of particular relevance; the claimed invention seems to be a further development of the invention
O document referring to an oral disclosure, use, exhibition or other means	*Y* document of particular relevance; the claimed invention seems to be a further development of the invention
P document published prior to the international filing date but later than the priority date claimed	*A* document number of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 JANUARY 1999

03 FEB 1999

Name and mailing address of the ISAUS
Committee of Patents and Trademarks
Box 101
Washington, D.C. 20531
Facsimile No. (703) 305-3230Authorized Officer
JAMES MARTINELL
Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23376

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:2. ☒ Claims Nos.: 23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 23 is directed to a product of the process of claim 20, claim 20 is not a process for the production of a product, but a process for the detection of a substance. Hence, no meaningful search can be carried out.3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(c).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/2376

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

G01N 33/68, 33/53; C07K 16/00; C12N 15/11, 15/12, 15/00, 15/63; A61K 38/17, 38/16; C12P 21/02

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

536/23.5, 23.1; 435/320.1, 440, 252.3, 69.1, 7.1; 530/330, 387.1; 514/12

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, MPSCRCH (SEQ ID NOs 11 and 160 only). One nucleotide sequence and one amino acid sequence have been searched. It is not clear which sequences are embraced by the claims because the claims refer to sequences X and Y. The table beginning after page 209 contains many sequences X and Y, yet the claims refer to X and Y in the singular. If the claims are to embrace more than one X and more than one Y, it is not clear whether each X always requires the corresponding sequence Y. Additionally, the claims are in improper format in referring to the description (see PCT Rule 6.2(e)). Accordingly, the first X nucleotide sequence disclosed and the first Y amino acid sequence mentioned in the claims were searched.